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Kurzfassung 
 
 Diese Arbeit beschäftigt sich mit der Totalsynthese makrocyclischer Histondeacetylase-
inhibitoren (HDACi), welche interessante Zielstrukturen zur Behandlung von Krebs und anderen 
schweren Erkrankungen darstellen. Diese Inhibitoren spielen eine zentrale Rolle bei der Untersu-
chung epigenetischer Prozesse und tragen entscheidend zum Wissen über histonmodifizierende 
Enzyme bei. 
In der vorliegenden Arbeit wird die Synthese der natürlich vorkommenden HDACi Trapo-
xin A und Cyl-1 beschrieben. Diese wurden aufgrund ihrer außergewöhnlichen Struktur als inte-
ressante Zielverbindungen ausgewählt. Als Schlüsselschritte können der stereoselektive Aufbau 
der nicht-proteinogenen Aminosäuren wie etwa (2S,9S)-2-Amino-9,10-epoxy-8-oxodecansäure 
(Aoe) sowie die Makrocyclisierung zum 12-gliedrigen Ringsystem betrachtet werden. Die stereo-
selektive Einführung der α-Epoxyketonseitenkette erfolgte mittels Peptidmodifizierungen wie bei-
spielsweise Palladium-katalysierter allylischer Alkylierung im Falle von Trapoxin A und Es-
terenolat-Claisenumlagerung bei Cyl-1. Letztere erlaubte neben der Synthese des Naturstoffes 
auch den Zugang zu Derivaten hiervon durch Variation der eingesetzten Allylester. Die so erhal-
tenen Derivate wurden u.a. durch Thiol-En Klickreaktionen weiter modifiziert. 
 
 
Abstract 
 
 This work aims to develop a synthetic approach towards macrocyclic histone deacetylase 
inhibitors (HDACi), which show extraordinary activities against several cancer cell lines and are 
potential candidates for the treatment of severe diseases. They play a crucial role in the study of 
epigenetic functions and contribute to the field of histone-modifying enzymes. 
This dissertation describes the synthesis of trapoxin A and Cyl-1. They were found to be 
challenging targets due to their extraordinary structure. A peptide modification approach utilizing 
palladium-catalyzed allylic alkylation and ester enolate Claisen rearrangement was envisioned to 
be suitable to introduce the non-proteinogenic (2S,9S)-2-amino-9,10-epoxy-8-oxodecanoic acid 
(Aoe) side chain. Furthermore, a synthetic access to pipecolinic acid-containing dipeptides was 
realized and methods to perform the challenging macrolactamization were evaluated. The peptide 
modification approach also allowed for the construction of Cyl-1 derivatives through esterification 
of different allylic alcohols with a common precursor. The obtained derivatives were further mod-
ified through thiol-ene click and other reactions. 
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1. Introduction 
 The search for new efficient treatments against severe diseases is a race against time.       
Scientific research makes key contributions to provide humanity with enhanced therapies to tackle 
these diseases. For instance, the fight against cancer involves many research fields that comple-
ment each other. Although advances have been made to address this serious health issue, the fight 
is not over. The World Health Organization (WHO) lists cancer as second most common cause of 
death worldwide, resulting in a total of 8.8 million deaths in 2015.[1] The most abundant cancers 
are those of lung (~ 1.7 million deaths per year), liver (~ 790 k), colorectal (~ 775 k), stomach      
(~ 750 k) and breast (~ 570 k). Besides the appallingly high mortality rate, cancer is an immense 
economic factor with annual costs of $ 1.16 trillion in 2010. New chemical entities to treat acute 
diseases are needed to improve the living conditions of many people around the world. Efforts to 
achieve this goal are made throughout academia and industry. On this account, natural products 
have always played a major role in the drug discovery and development process, a large number 
of anticancer drugs are natural products or natural product derived structures.[2] They often serve 
as lead structures for the discovery of new drugs and inspire the drug development process.[3] 
Nevertheless, many actual natural products are approved as anticancer agents like paclitaxel (mar-
keted as Taxol), romidepsin and doxorubicin (figure 1.1). 
 
 
Figure 1.1: Natural products approved as anticancer drugs.[2] 
 
 The exceptional structure of paclitaxel has been the focus of many total synthesis efforts, 
culminating in nine reported total syntheses so far. In general, natural products have always 
tempted synthetic chemists as challenging targets to develop and assess new chemical methods. 
Many natural products have been in the spotlight of intensive synthetic studies, which led to re-
markable achievements in the field of organic chemistry. Famous examples are Woodward’s first 
total synthesis of strychnine,[4] an alkaloid from Strychnos nux-vomica, reported in 1954 or Nico-
laou’s synthesis of the cyclic polyether brevetoxin B in 123 steps.[5] Other stunning natural prod-
ucts like vitamin B12 and epothilone A have also been in the spotlight of total synthesis approaches 
(figure 1.2).[6] These contributions clearly paved the way for a variety of remarkable synthetic 
approaches. Total synthesis has emerged as key research area to develop and evaluate new syn-
thetic methods. Besides providing material for exhaustive biological testing, since the isolated 
amounts are often not sufficient for this purpose, total synthesis contributes to structure elucidation 
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and verification of a given natural product. Furthermore, total synthesis facilitates access to several 
derivatives of a natural product, for e.g. structure-activity relationship studies, through chemical 
synthesis from a common precursor.[7] 
 
 
Figure 1.2: Natural products as total synthesis targets. 
 
 Among natural products, peptidic structures have entered the limelight due to their extraor-
dinary biological activities.[8] Often found as secondary metabolites for self-defense in different 
microorganisms, peptidic natural products are assembled by non-ribosomal peptide synthetases 
(NRPS).[9] Incorporation of non-proteinogenic and unusual amino acids makes them compelling 
targets for synthetic approaches. Macrocyclic peptides are pervasive throughout this class of nat-
ural products and often show improved stability against proteolytic digest and metabolic pro-
cesses.[10] Furthermore, cyclization generally helps to fix the active conformation of a peptide 
needed to interact with the respective cellular target. Besides peptidic structures like trapoxin B 
(figure 1.3), depsipeptides account for a large number of biologically active secondary metabolites. 
They are generally synthesized via a combination of NRPS and polyketide synthases (PKS). For 
example, the cyclic depsipeptide chondramide C shows strong binding to F-actin and has been the 
target of several total synthesis.[11,12] The structure of peptidic natural products can further be al-
tered through modifying enzymes as seen for vancomycin. This antibiotic peptide inhibits bacterial 
cell wall synthesis and undergoes several modifications including glycosylation and cross-link-
ing.[13] 
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Figure 1.3: Structure of (depsi)peptidic natural products. 
 
 Our group is interested in the synthesis of biologically active peptides. Especially struc-
tures with antibiotic and antitumor activities have been in the focus of recent studies. Secondary 
metabolites from myxobacteria like chondramides[14] and pretubulysin[15] were targets of total syn-
thesis approaches. Natural histone deacetylase inhibitors (HDACi) like trapoxins have aroused our 
interest as potential synthetic targets due to their chemical structure and their ability to affect can-
cer cells by epigenetic regulation. Naturally occurring macrocyclic HDACi show high structure 
analogy, which makes them interesting targets for both natural product synthesis and the develop-
ment of synthetic derivatives through peptide modification reactions developed in our group like 
chelate enolate Claisen rearrangement and transition metal catalyzed allylic substitutions. 
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2. State of Knowledge 
2.1 HDACs and HDAC inhibitors 
Histones are proteins found in eukaryotic cells which are responsible for packaging of 
DNA into nucleosomes. Two of each histone protein H2A, H2B, H3 and H4 form an octameric 
structure and the DNA double strand is wrapped around this octamer to built a nucleosome core, 
which gets further packed into higher-ordered chromatin (figure 2.1).[16] Histones contain many 
basic residues like e.g. lysine. These basic proteins are protonated within the cytosol and therefore 
strongly interact with the negatively charged DNA backbone.[17] Packaging of DNA into chroma-
tin limits access of transcription factors and is responsible for transcriptional regulation. Conse-
quently, histones and histone-modifying enzymes play a vital role in gene expression and are in-
volved in epigenetic processes.[18] 
 
 
Figure 2.1: Crystal structure of the nucleosome core.[16] 
 
2.1.1 Epigenetic background 
 Epigenetics is derived from the ancient Greek words “epi” (= above, upon) and “genesis” 
(= origin). Introduced by Conrad Waddington in the 1940s, epigenetics studies the regulation of 
genes and their effects on the phenotype.[19] Epigenetics refers to changes in the genome beyond 
the base sequence of the DNA. The DNA sequence acts as a blueprint for the proteins that are 
decoded by a particular gene. Epigenetics on the other hand is responsible for regulation of gene 
expression. During the cell cycle, different genes need activation to maintain the cell’s function. 
DNA is packed with histones into chromatin.[20] Generally, two types of chromatin are distin-
guished: 1) transcriptionally active and lightly packed euchromatin and 2) heterochromatin, tightly 
packed and not transcripted. The process of making DNA accessible for transcription factors, 
which are responsible for transcription of DNA into RNA, is called chromatin remodeling.[18] It 
occurs through different covalent modifications to the histone core. Acetylation of lysine residues 
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within the N-terminal histone tails proceeds through the action of histone acetylases (HATs) and 
interrupts the interaction between histones and DNA.[17] The unwrapped DNA can be accessed by 
transcription factors and is transcriptionally active. Acetylation of lysine residues is not limited to 
histones but is an important posttranslational modification and an essential epigenetic tool.[21] En-
zymes that install a covalent group to histones are generally called “writers”. Their cellular coun-
terparts, the histone deacetylases (HDACs or generally “erasers”), are in charge of restoring the 
DNA-histone interaction by deacetylation of histone lysines once transcription is completed. As 
pointed out for HATs, histone deacetylases act not only on histones but on many non-histone tar-
gets including transcription factors and proteins that regulate cell proliferation, migration and 
death.[22,23] Bromodomains, or “readers”, recognize acetylated lysine residues and complement the 
epigenetic toolbox. Together they are involved in active gene regulation and transcriptional con-
trol. Malfunction of HDAC activity is linked to several diseases including cancer. Aberrant HDAC 
expression is found in leukemias, lymphomas and solid tumors.[22–24] Therewith, HDACs are im-
portant pharmocological targets for the treatment of several diseases. 
 
2.1.2 Classes of HDACs and mode of action 
 Eighteen different HDAC enzymes are known so far, and they are divided into four classes 
based on structural homology with yeast proteins (table 2.1).[25] Class I and II enzymes differ in 
terms of catalytic domain, size and location within the cell.[20,26] While class I enzymes are ubiq-
uitously expressed and confined to the nucleus, the multidomain class II enzymes undergo tissue-
selective expression and are further divided into class IIa and IIb. While the active site is highly 
conserved in the HDAC family, class IIa enzymes show a tyrosine to histidine mutation.[27,28] They 
are less active on standard acetylated substrates since histidine differs structurally too much from 
tyrosine for efficient substrate binding (figure 2.2). Class III enzymes are known as sirtuins due to 
their homology to Sir2 enzymes found in yeast.[29] While class I, II and IV enzymes contain Zn2+ 
within the active site, sirtuins (class III) are NAD+-dependent and are therefore not affected by 
typical Zn2+-binding HDAC inhibitors (HDACi). 
 
Table 2.1: Classes of histone deacetylase enzymes.[25] 
classification enzymes mode of action 
class I HDAC1, -2, -3, -8 Zn2+-dependent 
class IIa HDAC4, -5, -7, -9 Zn2+-dependent 
class IIb HDAC6, -10 Zn2+-dependent 
class III sirtuins 1-7 NAD+-dependent 
class IV HDAC11 Zn2+-dependent 
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The mode of action of HDAC enzymes was explained based on the crystal structure of 
HDLP (HDAC-like protein), solved by Pavletich et al. in 1999.[30] HDLP shares sequence homol-
ogy with human HDAC1 and shows identity within the active site. The central Zn2+-cation is co-
ordinated by two asparaginic acid residues, a histidine and one molecule of water. Cocrystalliza-
tion with the natural HDACi trichostatin A (figure 2.3) gave insight into the mechanism of Zn2+-
dependent HDACs (figure 2.2).[31,32] 
 
 
Figure 2.2: Mode of action of Zn2+-dependent HDACs.[30,32] 
 
 Acetylated lysine entering the cavity of the active site gets coordinated to Zn2+ and subse-
quently attacked by water to form a tetrahedral intermediate. This intermediate is stabilized by Tyr 
297, underlining its importance to maintain catalytic activity. Dissociation of the intermediate lib-
erates lysine and one molecule of acetic acid. 
Most HDAC inhibitors act as substrate mimics and contain a zinc-binding motif. They 
competitively interact with the HDACs to form stable intermediates and therewith block the active 
site. In fact, the first HDAC enzyme was isolated by affinity chromatography with a HDAC inhib-
itor, trapoxin, immobilized on a stationary phase by Schreiber and co-workers.[33] The isolated 
enzyme from human Jurkat T cells was called HDAC1 and these findings emphasize the im-
portance of HDAC inhibitors for the development of this research area. 
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2.1.3 Natural HDAC inhibitors 
 Many naturally occurring HDAC inhibitors are known to date.[34] Acyclic molecules like 
trichostatin A (TSA, figure 2.3) were among the first isolated HDAC inhibitors. Isolated in 1976 
from Streptomyces hygroscopicus by Tsuji et al.,[35] TSA played an important role in rationalizing 
the mode of action of HDACs.[30] Trichostatin contains a hydroxamic acid as zinc-binding motif, 
what inspired the design of several synthetic HDACi. It shares the common pharmacophores found 
in most natural HDAC inhibitors (figure 2.3). The essential Zn2+-binding group is attached to a 
non-polar linker, delivering it inside the cavity through a narrow channel. The cap region is re-
sponsible for interactions with residues on the rim of the active site.[31] The length of the linker is 
important to attain biological activity. It was shown for derivatives of natural HDACi that 5-6 
methylene units are most beneficial.[17] The cap region of acyclic HDAC inhibitors is generally 
small, resulting in non-specific interactions with the different HDAC isoforms. It is understandable 
that larger cap groups would be needed to reach selectivity towards the different enzyme classes. 
Therefore, macrocyclic HDAC inhibitors have more and more become the focus of attention. 
 
 
Figure 2.3: Common pharmacophore model of acyclic and macrocyclic HDACi. 
 
More diverse cap regions are found in macrocyclic HDAC inhibitors (figure 2.4). They 
contain a peptidic or depsipeptidic backbone and generally show higher biological activities and 
greater selectivities between the different isoforms than acyclic inhibitors.[36] Macrocyclic HDACi 
also reveal more distinct zinc-binding motifs. The first isolated natural macrocyclic HDACi was 
HC-toxin, produced by Helminthosporium carbonum.[37] Its peptidic backbone contains both (S)- 
and (R)-alanine, (R)-proline and a non-proteinogenic amino acid, (2S,9S)-2-amino-9,10-epoxy-8-
oxodecanoic acid (Aoe). This combination of at least one D-configured and one cyclic amino acid 
is found in most of the natural macrocyclic HDACi. Many of them also contain one aromatic 
amino acid residue. The unusual Aoe with its α-epoxyketone motif is wide-spread among this 
compound class, as it is present in the trapoxins, Cyl-1 & -2, chlamydocin and many others.[34] 
The α-epoxyketone is isosteric to an acetylated lysine residue, which makes it a mimic of HDACs 
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natural substrate.[17] Although α-epoxyketones and hydroxamic acids show high affinities towards 
Zn2+, other chelating groups are also found in natural products including ketones (apicidin, micro-
sporin A), carboxylic acids (azumamide C,E), α-hydroxy ketones (FR235222) or thioesters (lar-
gazole). In fact, many naturally occurring HDACi contain sulfur moieties like e.g. disulfides or 
thioesters. They seem to lack a decent zinc-chelating group at first sight. However, the disulfide 
or thioester acts as a prodrug and is reduced in vivo to liberate the free thiol, a strong Zn-binding 
group.[38,39] Romidepsin contains a disulfide bridge and has been the subject of many clinical trials 
for the treatment of lymphoma and other cancers.[40] Other well established inhibitors are largazole 
and its derivatives, which helped to gain detailed insight into the binding mode and to assess the 
influence of the spacer on biological activity. They will be discussed in the section about HDACi 
derivatives (chapter 2.1.6). 
 
 
Figure 2.4: Structure of macrocyclic HDAC inhibitors. 
 
 Trapoxin A and B were first isolated in 1990 by Itazaki et al. from Helicoma ambiens RF-
1023 strains.[41] The natural products differ only in their peptidic backbone with trapoxin A having 
a (R)-configured pipecolinic acid incorporated while trapoxin B has (R)-proline as cyclic amino 
acid component. (2S,9S)-2-amino-9,10-epoxy-8-oxodecanoic acid (Aoe) delivers the essential 
zinc-binding motif, as found in many other natural HDACi like WF3161, HC-toxin and phoeni-
statin. Analogues of trapoxin B played an important role in the isolation of the first human HDAC 
enzyme.[33] Both natural products show detransformation activity against sis oncogene-trans-
formed NIH3T3 fibroblast cells while having no effect on human red blood cell even at higher 
concentrations (figure 2.5).[41] It is a general observation for HDACi that they selectively induce 
cell death in cancer cells at concentrations that do not affect normal cells.[42] Reduction of the 
epoxide in trapoxin A diminished the transformation activity drastically, leading to the conclusion 
that the α-epoxyketone is crucial to retain biological activity. Trapoxin A shows irreversible 
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inhibition of mammalian histone deacetylases, in contrast to other HDACi like trichostatin A, 
which is a reversible inhibitor under the same conditions.[43,44] Irreversible inhibition of HDAC1 
and -8 led to the hypothesis that trapoxin A alkylates the HDACs through attack at the reactive 
epoxy group.[44,45] Porter and Christianson recently resolved the structure of a trapoxin A-HDAC8 
cocrystal (figure 2.6).[46] They could show that trapoxin A is an irreversible inhibitor of this class 
I enzyme and acts as a substrate mimic. Nucleophilic attack of water at the ketone forms a geminal 
diol that mimics the tetrahedral intermediate of the natural substrate. The epoxy group was shown 
to be intact in the cocrystal, ruling out a covalent inhibition. Nevertheless, the epoxy group is 
essential for irreversible inhibition. Apicidin, which lacks this group, shows reversible inhibition 
of HDAC8. In contrast, trapoxin A shows reversible inhibition of HDAC6, which can be rational-
ized by an energetically unfavored conformation of the epoxide as seen for the HC-toxin-HDAC6 
cocrystal. The different binding modes of trapoxin A, together with the high selectivity towards 
class I enzymes over class IIb enzymes (table 2.5),[45] makes it a promising pharmaceutical com-
pound for the treatment of cancer and other diseases. 
 
 
Figure 2.5: Effect of trapoxin A on sis oncogene-transformed NIH3T3 cells. On the left: cells after 
treatment with trapoxin A. On the right: untreated cells.[41] 
 
 
Figure 2.6: Co-crystal structure and binding mode of trapoxin A and HDAC8.[46] 
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 Cyl-1 and -2 have been first reported by Suzuki and co-workers in 1973 and 1984, respec-
tively.[47,48] Isolated from Cylindrocladium scoparium, both natural products show inhibitory ac-
tivity on root growth of lettuce seedlings. Structure elucidation revealed the presence of an α-
epoxyketone moiety along with a (R)-configured O-methylated tyrosine. Cyl-2 has been reported 
to have excellent selectivity towards class I HDACs over class IIb enzymes with up to 57.000-fold 
higher activity against HDAC1 in comparison to HDAC6 (table 2.5).[45] Although Cyl-1 is gener-
ally referred to as HDACi, no biological activities of the natural product have been reported so far. 
The classification as HDAC inhibitor can be substantiated due to the structural similarity to several 
known inhibitors. Anyway, several derivatives of Cyl were synthesized with regard to altered pep-
tide backbone configurations and zinc-binding motifs (see chapter 2.1.6). The high selectivities 
seen for Cyl-2 and the fact that little is known about the natural Cyl-1 makes the Cyl family an 
interesting target for both natural product synthesis and derivatization efforts. 
Both natural and synthetic HDAC inhibitors play an important role in the development of 
new drugs for the treatment of cancer and other diseases including sickle cell anemia[49] and rheu-
matoid arthritis.[50] Four HDAC inhibitors are currently approved by the FDA as anticancer drugs 
(figure 2.7). SAHA (suberanilohydroxamic acid) was developed by Breslow and Marks and 
showed therapeutical benefit in the treatment of cutaneous T cell lymphoma.[25,51] It has excellent 
selectivity towards malignant over normal cells resulting in little to no toxicity. It contains a hy-
droxamic acid as zinc-binding moiety, a functional group often considered as undruggable due to 
low stability and potential toxicity.[17,52] Along with belinostat[53] and panobinostat[54], they are 
synthetic panHDAC inhibitors. In contrast, romidepsin is a macrocyclic natural HDACi, isolated 
from Chromobacterium violaceum.[55,56] It acts as a prodrug, allowing stability for use in vivo, and 
shows selectivity towards class I HDACs. 
 
 
Figure 2.7: FDA-approved HDAC inhibitors. 
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2.1.4 Biosynthesis of natural HDAC inhibitors 
 Non-ribosomal peptides, produced by microbes as secondary metabolites, account for a 
variety of natural products including important pharmaceuticals like cyclosporin[57] or epothi-
lone.[58] Structural diversity is achieved by incorporation of hundreds of unusual building blocks, 
in comparison to the 20 proteinogenic amino acids used in ribosomal peptide synthesis. Although 
structurally diversified, non-ribosomally produced peptides share a common mode of synthe-
sis.[10,59] Non-ribosomal peptide synthetases (NRPSs), assembly lines for non-ribosomal peptides, 
show a modular organization. Each module is responsible for the incorporation of an amino acid 
and is further divided into different domains. Each domain catalyzes a certain reaction leading to 
the formation of structurally diverse peptides: 
♦ Adenylation domain (A-domain): The A-domain (specifically) recognizes and activates an 
amino acid by catalyzing the condensation reaction of the carboxylic acid of the amino acid with 
Mg2+-ATP. This forms an adenylated amino acid and PPi. The activated amino acid then undergoes 
nucleophilic attack by a free thiol of an adjacent thiolation domain. 
♦ Thiolation domain (T-domain or PCP): The thiolation domain is responsible for the transport of 
an activated amino acid to the catalytic centers. Binding of the adenylated amino acid to a cys-
teamine residue of its ppan (4’-phosphopantetheinyl) cofactor leads to formation of an amino acid 
thioester bound to the peptidyl carrier protein (PCP). 
♦ Condensation domain (C-domain): Nucleophilic attack of a downstream-bound amino acid at 
the PCP-bound thioester of an upstream-bound amino acid leads to formation of a peptide bond 
and is catalyzed by the C-domain. 
The combination of CAT forms an elongation module and is crucial for the subsequent growth of 
the peptide chain. To increase diversity of the natural product, additional editing domains are in-
tegrated in the assembly line: 
♦ Epimerization domain (E-domain): Since almost every NRPS synthesized peptide contains D-
amino acids, epimerization domains play an important part in the production of non-ribosomal 
peptides. Epimerization occurs at the α-center of the PCP-bound amino acid or peptide. Alterna-
tively, L-amino acids get epimerized by external racemases or epimerases and get recognized and 
activated by the A-domain. 
♦ N-Methylation domain (N-Mt-domain): N-methylation of the α-amino group of the PCP-bound 
thioester increases the stability of the secondary metabolite against proteolytic digest. Methylation 
is performed by transfer of a methyl group from S-adenosyl methionine (SAM). 
Other domains present in NRPSs perform oxidations (Ox-domain), reductions (R-domain) or het-
erocyclizations (Cy-domain). To liberate the final product from the NRPS complex, cleavage of 
the thioester is required: 
♦ Thioesterase domain (TE-domain): The thioesterase domain is located in the termination module 
and terminates the peptide elongation by nucleophilic attack of a serine residue at the thioester to 
form an acylated enzyme. Subsequent hydrolysis or intramolecular attack releases a linear or cyclic 
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peptide. Cyclization often occurs to fix the biologically active conformation of a peptide. Cleavage 
can also occur reductively to release an aldehyde- or alcohol-containing natural product. 
 The biosynthesis of the natural HDAC inhibitor apicidin was studied in great detail and 
will be discussed exemplarily for the synthesis of other macrocyclic HDACi.[60] The gene that 
encodes the non-ribosomal peptide synthetase responsible for the biosynthesis of apicidin was 
called apicidin synthetase gene 1 (APS1). It is located in a 63 kb region and is surrounded by other 
genes involved in the synthesis of apicidin. The function of every gene was determined by indi-
vidual depletion and examination of their role in the biosynthesis. The proposed biosynthesis of 
apicidin is shown in scheme 2.1. The NRPS encoded by APS1 assembles the tetrapeptidic back-
bone and catalyzes the macrocyclization to form the 12-membered ring. The only proteinogenic 
amino acid in apicidin is (S,S)-isoleucine. (S)-tryptophan is oxidized and converted to (S)-9-N-
methoxytryptophan by an O-methyltransferase encoded by APS6. The pipecolinic acid moiety 
present in apicidin is synthesized from (S)-lysine.[61,62] Cyclization to Δ1-pyrroline-6-carboxylate 
(P6C) and subsequent reduction to (S)-pipecolinic acid is catalyzed by a reductase encoded from 
APS3. The presence of (R)-pipecolinic acid in apicidin suggested the incorporation of an epi-
merase domain in APS1. In contrast, an external racemase was found in the biosynthesis of HC-
toxin that epimerizes (S)-alanine.[63] The unusual amino acid (S)-2-amino-8-oxo-decanoic acid 
(Aoda) is build up by a fatty acid synthase (FAS) encoded by APS5. Decanoic acid is formed from 
Acetyl-CoA and Malonyl-CoA. Hydroxylation to 2-hydroxydecanoic acid and subsequent oxida-
tion gives a β-keto ester. An aminotransferase converts the β-keto ester into (S)-2-amino-decanoic 
acid. APS7 converts it to (2S,8S)-2-amino-8-hydroxydecanoic acid and APS9 further oxidizes it 
to Aoda. APS1 shows low substrate specificity, therefore, Aoda is recognized and activated by an 
A-domain of the NRPS encoded by APS1. The modular peptide synthesis starts with activation of 
(S)-pipecolinic acid, which gets epimerized by an E-domain on the NRPS complex. Subsequent 
condensations with the downstream bound amino acids gives a linear tetrapeptide. After binding 
to the TE-domain via serine, intramolecular cyclization leads to liberation of the cyclic apicidin. 
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Scheme 2.1: Biosynthesis pathway of apicidin.[60] 
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2.1.5 Synthesis of natural HDAC inhibitors 
 Several total syntheses of natural HDAC inhibitors have been accomplished so far. Olsen 
et al. published a comprehensive review on the synthesis of naturally occurring and synthetic 
HDACi.[34] In general, construction of the non-proteinogenic amino acid (2S,9S)-2-amino-9,10-
epoxy-8-oxodecanoic acid (Aoe) is one of the main challenges regarding this compound class. 
Several attempts were made towards this interesting amino acid scaffold including enzymatic res-
olution,[64] Sharpless epoxidation,[65] radical reactions[66] and epoxidation/oxidation.[67] As re-
ported in the synthesis of several macrocyclic HDACi, the macrolactamization to form the 12-
membered ring is the key challenge to access these natural products. Different cyclization methods 
were evaluated including activation as Pfp ester,[68] NHS-active ester[65] or use of diphenyl phos-
phoryl azide.[69] Besides that, choosing a proper position to perform ring closure is crucial to obtain 
the macrocycle in reasonable yield and without severe epimerization, as impressively pointed out 
by Schmidt et al. in their synthesis of WF-3161.[68] They synthesized a model tetrapeptide and 
alternated the ring closing position. While 70 % yield were obtained at the optimal position, the 
yield dropped significantly (down to no product formation at all) and epimerization was observed 
for other macrolactamization positions. 
 Schreiber et al. published their synthesis of trapoxin B in 1996 along with derivatives used 
to identify the molecular target of HDACi.[67] Their analogues of trapoxin B played a major role 
in the isolation and characterization of the first HDAC enzyme.[33] The total synthesis of trapoxin 
B starts with TIPS-protected 2,3-O-isopropylidine-L-threitol A, which was oxidized under Swern 
conditions and subsequently treated with Wittig’s ylide B to give compound C in 74 % yield over 
two steps (scheme 2.2). Hydrogenation of the double bond in C and benzyl ether cleavage gave 
the free alcohol, which was brominated using Appel’s protocol to access D. Formation of Grignard 
reagent, transmetalation to copper with CuBr·DMS and addition to β-lactone E gave Aoe precur-
sor F in 40 % yield. This approach was inspired by Vederas’ method to construct α-chiral amino 
acids using this β-lactone.[70] 
 
 
Scheme 2.2: Schreiber’s synthesis of Aoe precursor F.[67] 
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 With Aoe precursor F at hand, coupling to tripeptide G and full deprotection gave the linear 
tetrapeptide H, which was used for cyclization (scheme 2.3). Several cyclization methods were 
tested including Schmidt’s Pfp ester method utilized in the synthesis of chlamydocin.[71] While 
this method failed in the synthesis of trapoxin B, performing the macrocyclization with BOP and 
DMAP in DMF under high dilution afforded the cyclic tetrapeptide I in 51 % yield after TIPS-
deprotection with TBAF. Macrocycle I was used to finish the synthesis of trapoxin B through 
installation of the epoxide via the tosylated intermediate and subsequent Moffatt oxidation with 
DCC/DMSO. [3H]-labeled trapoxin B was synthesized through oxidation of I with DMP and re-
duction with NaB[3H]4. The labeled natural product was liberated after the same reaction cascade 
as described for trapoxin B. 
 
 
Scheme 2.3: Synthesis of trapoxin B and [3H]-labeled trapoxin B.[67] 
 
 By replacing the phenylalanine residue adjacent to Aoe with lysine, Schreiber et al. were 
able to immobilize this trapoxin B analogue and identify the molecular target of this HDAC inhib-
itor through affinity chromatography. The target was later recognized as the first isolated human 
histone deacetylase, which was therefore called HDAC1.[33] 
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Ma and coworkers reported the first total synthesis of FR235222 (figure 2.8), a cyclic 
HDACi containing several interesting amino acid moieties including 4-methylproline, isovaline 
and (2S,9R)-2-amino-9-hydroxy-8-oxodecanoic acid (Aoh).[72] The major challenges are the con-
struction of the trans-4-methylproline residue as well as the synthesis of the non-proteinogenic 
Aoh. 
 
 
Figure 2.8: Structure of the macrocyclic HDACi FR235222. 
 
The unusual (2R,4S)-4-methylproline was synthesized starting from (R)-pyroglutamic acid 
A (scheme 2.4). TiCl4-mediated aldol addition of A to formaldehyde and subsequent TBS-protec-
tion gave compound B along with a separable diastereomer. The (2R,4R)-diastereomer was re-
duced with DIBAL-H and Et3SiH/BF3 to afford pyrrolidine C. TBS-deprotection with TBAF, me-
sylation and subsequent defunctionalization with Zn/NaI gave (2R,4S)-4-methylproline D in ex-
cellent yield. 
 
 
Scheme 2.4: Synthesis of (2R,4S)-4-methylproline by Ma and coworkers.[72] 
 
 Construction of the Aoh moiety was accomplished by TBDPS-protection of methyl (R)-
lactate E, followed by ester saponification and formation of Weinreb’s amide F with N,O-dime-
thylhydroxylamine and EDC (scheme 2.5). Addition of 3-butenylmagnesium bromide gave ketone 
G, which was subjected to olefin cross metathesis using Grubbs II catalyst. Hydrogenation of the 
newly formed double bond in H gave Aoh precursor I in 94 % yield. 
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Scheme 2.5: Synthesis of Aoh precursor I.[72] 
 
 The synthesis of FR235222 was completed by coupling of Fmoc-protected isovaline with 
H-(S)-Phe-OBn using EDC/HOBt (scheme 2.6). Dipeptide J was hydrogenated and coupled with 
Boc-deprotected D in 79 % yield. Fmoc-deprotection in K and coupling to Aoh precursor I gave 
a linear tetrapeptide L suitable for macrolactamization. Removal of the benzyl ester in L, followed 
by activation of the carboxylic acid as Pfp ester and Boc-deprotection gave 56 % of cyclic M after 
biphasic ring closure. Finally, TBDPS-deprotection with TBAF liberated the natural product in 
84 % yield. 
 
 
Scheme 2.6: Synthesis of FR235222.[72] 
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 Quirin and Kazmaier accomplished the total synthesis of chlamydocin.[64] Although several 
synthetic routes towards this interesting natural product have been reported earlier, their approach 
is based on a chelated ester enolate Claisen rearrangement to build up the Aoe scaffold present in 
chlamydocin. The synthesis starts with THF-derivative A, which was treated with phosphoric acid 
to obtain the corresponding linear dialdehyde. Subsequent addition of vinylmagnesium bromide 
afforded diallylic alcohol B (scheme 2.7). Mono-protection with TBSCl, followed by enzymatic 
kinetic resolution gave enantiomerically enriched acetate C with good stereoselectivities. Saponi-
fication of C and esterification with Boc-Gly-OH gave allyl ester D, which was used to perform 
the key step of the synthesis: a chelated ester enolate Claisen rearrangement of amino acid ester 
D. Subsequent methylation of the rearranged acid gave Aoe precursor E in 92 % yield and 90 % 
ee. TBS-deprotection with pTosOH in E gave allylic alcohol F, which was again subjected to 
enzymatic kinetic resolution with Novozyme 435, a lipase from Candida antarctica. The resolved 
allylic alcohol G was saponified and coupled with the corresponding tripeptide H in 95 % yield. 
Linear tetrapeptide I was a suitable precursor for cyclization. 
 
 
Scheme 2.7: Synthesis of the linear tetrapeptide of chlamydocin via ester enolate Claisen rear-
rangement.[64] 
2. State of Knowledge 
 
 
19 
 The synthesis of chlamydocin was finished by saponification of I, followed by activation 
of the carboxylic acid as Pfp ester J (scheme 2.8). Boc-deprotection under standard conditions and 
subsequent cyclization under biphasic conditions afforded cyclic peptide K in 65 % yield. Vana-
dium catalyzed epoxidation gave the desired epoxyalcohol in 90 % yield and 72 % ds, while no 
product formation was observed under Sharpless conditions, even after prolonged reaction times. 
Hydrogenation of the double bond in L and subsequent Dess-Martin oxidation gave chlamydocin 
in 70 % yield. 
 
 
Scheme 2.8: Synthesis of chlamydocin by Quirin and Kazmaier.[64] 
 
 Although many other total synthesis of naturally occurring HDAC inhibitors have been 
published over the last decades, containing many striking synthetic approaches towards this com-
pound class, the selected total syntheses underline the synthetic efforts made towards these natural 
scaffolds. 
 
2.1.6. Derivatives of natural HDAC inhibitors 
 Natural HDAC inhibitors were isolated from a variety of different organisms and were the 
subject of many total synthesis approaches. Nevertheless, intensive studies towards derivatives of 
these naturally occurring inhibitors were undertaken. Derivatization was performed in order to 
improve the selectivity of a given HDACi towards the different isoforms, to introduce new zinc-
binding motifs or to examine structure-activity relationships (SAR). The zinc-binding motifs found 
in natural inhibitors often fail in in vivo studies either due to rapid inactivation (α-epoxyketone)[73] 
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or toxicity (hydroxamic acid)[17,52]. Introduction of new zinc-binding motifs could therefore im-
prove both pharmacokinetics and toxicity profiles of established HDACi. 
 Intensive SAR studies were performed for the sulfur-containing macrocyclic depsipeptide 
largazole (figure 2.4). Not only has it been target of 13 stunning total syntheses (so far) but also 
the lead compound for the development of several derivatives with altered zinc-binding motifs,[74] 
spacer lengths[75] or amino acid backbones.[74] It was shown for largazole that the thioester acts as 
a prodrug and that the thiol is the active zinc-binder. Luesch et al. provided inhibitory data against 
HDAC1 (class I) and HDAC6 (class IIb) for both largazole and the unveiled thiol (table 2.2).[76] 
These data impressively demonstrate not only the selectivity towards the different isoforms but 
the effect of thiol as active zinc-binding motif. 
 
Table 2.2: Comparison between largazole and largazole thiol as HDACi.[76] 
 Ki [nM] 
compound HDAC1 HDAC6 
largazole 25 5700 
largazole thiol 2.5 380 
 
 Further studies confirmed the hypothesis that largazole acts as a prodrug and gets reduced 
within the cytosol. When both compounds were applied to malign melanoma cell lines, largazole 
showed superior inhibitory activities due to better cell permeability.[77] The impact of the peptide 
configuration on the biological activity was rationalized by the synthesis of several epimers. Brad-
ner and co-workers compared the inhibitory activities of largazole thiol with both the C-2 epimer 
(valine) and the enantiomer (table 2.3).[74] While the activity dropped by the factor 10 for the C-2 
epimer, the enantiomer showed 1000-fold higher IC50-values. These results underline the im-
portance of a certain peptide configuration and therewith conformation to attain biological activity. 
 
Table 2.3: Influence of the peptide backbone configuration on inhibitory activity of largazole.[74] 
 IC50 [nM] 
compound HDAC1 HDAC2 HDAC3 HDAC6 
largazole thiol 1.2 3.5 3.4 49 
C-2 epimer 30 82 84 680 
enantiomer 1200 3100 1900 2200 
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The linker in largazole was found to be ideally composed of four atoms between the peptide 
backbone and the thiol moiety. Modifying the linker length led to reduced activities against HDAC 
as well as reduced inhibition of HCT-116 cell growth (human colon carcinoma).[75] Substitution 
of the thioester by an anilide or thioacetamide moiety did not improve activity, but the selectivity 
profile changed significantly.[74] While the anilide selectively inhibited class I enzymes, thio-
acetamide IIIb showed high selectivity towards HDAC6 (table 2.4). 
 
Table 2.4: Largazole derivatives with modified linkers and zinc-binding motifs.[74,75] 
 
 IC50 [nM] GI50 [nM] 
Compound HDAC1 HDAC6 HeLa HCT-116 
largazole 7.6 1800 32 6.8 
Ia - - > 20000 > 10000 
Ib 690 > 10000 7600 620 
Ic 1900 > 10000 4100 2500 
 IC50 [nM] 
Compound HDAC1 HDAC2 HDAC3 HDAC6 
IIa 270 4100 4100 > 30000 
IIb 23000 29000 14000 > 30000 
IIIa 670 1600 960 700 
IIIb 1000 1900 1500 240 
 
 Similar investigations were undertaken for cyclic tetrapeptide analogues derived from 
trapoxin, chlamydocin, Cyl-1 &-2. The focus of these works was on replacing the α-epoxyketone 
by a hydroxamic acid moiety. While the inhibitory activity against class I enzymes was not signif-
icantly affected by this modification, the selectivity towards the different isoforms decreased im-
mensely (table 2.5).[45] 
 Komatsu and co-workers developed derivatives of several natural HDACi by altering the 
amino acid sequence along with replacement of the α-epoxyketone motif and epimerization of 
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different amino acid residues (table 2.6).[78] It is worth noting that derivatives with two D-amino 
acids incorporated showed similar or even better inhibition of HDAC than the natural backbone. 
Additionally, epimerization of proline in the Cyl-1 derivatives seemed to have no impact on the 
biological activity of these compounds. These results are somehow in contrast to what was ob-
served from the above presented largazole derivatives, where the epimeric compound revealed 
significantly lower biological activity. Substitution of isoleucine with alanine also seemed to have 
no influence as had depletion of the methyl ether in the tyrosine residue. 
 
Table 2.5: Hydroxamic acid-containing natural product derivatives.[45] 
  IC50 [nM]  
compound Zn2+-binding motif HDAC1 HDAC6 
selectivity 
(HDAC6/HDAC1) 
trapoxin A α-epoxyketone 0.82 524 640 
trapoxin B α-epoxyketone 0.11 360 3300 
Cyl-2 α-epoxyketone 0.70 40000 57000 
chlamydocin α-epoxyketone 0.15 11000 7300 
trapoxin A deriv. hydroxamic acid 6.1 150 25 
trapoxin B deriv. hydroxamic acid 1.9 19 10 
Cyl-1 deriv. hydroxamic acid 4.4 110 25 
Cyl-2 deriv. hydroxamic acid 1.2 36 30 
chlamydocin deriv. hydroxamic acid 0.44 38 86 
 
Table 2.6: Biological activities of derivatives of natural HDACi.[78] 
derivative of sequence HDAC* IC50 [nM] 
trapoxin A cyclo((S)-Asu(NHOH)-(R)-Phe-(S)-Phe-(R)-Pip) 2.91 
trapoxin A cyclo((S)-Asu(NHOH)-(S)-Phe-(S)-Phe-(R)-Pip) 4.78 
trapoxin A cyclo((S)-Asu(NHOH)- R)-Phe-(S)-Phe-(S)-Pip) 4.18 
Cyl-1 cyclo((S)-Asu(NHOH)-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro) 3.31 
Cyl-1 cyclo((S)-Asu(NHOH)-(R)-Tyr(Me)-(S,S)-Ile-(R)-Pro) 3.32 
Cyl-1 cyclo((S)-Asu(NHOH)-(R)-Tyr(Me)-(S)-Ala-(R)-Pro) 3.38 
Cyl-1 cyclo((S)-Asu(NHOH)-(R)-Tyr-(S,S)-Ile-(R)-Pro) 3.38 
*prepared from B16/BL6 cells. 
2. State of Knowledge 
 
 
23 
 In summary, derivatization of natural HDACi can be performed in manifold ways and can 
improve potency, selectivity or (in vivo) stability of a given natural compound. The insights from 
these derivatizations clearly influenced the development of synthetic HDACi. 
 
2.1.7 Synthetic HDAC inhibitors 
 Over the past decades, several synthetic HDAC inhibitors have been developed. Among 
the most famous is SAHA, which was developed by Ronald Breslow and Paul Marks. They pub-
lished a review article about the stunning development of SAHA, a FDA-approved drug for the 
treatment of cutaneous T-cell lymphoma.[25] SAHA shows structural similarity to trichostatin A, 
one of the first reported natural HDACi. One of the main advantages of SAHA over other thera-
peutics is its low toxicity along with high selectivity towards transformed cells over non-trans-
formed ones. While growth arrest is observed for both cell types, cell death is only noticed for the 
transformed cells.[42] The track record of SAHA clearly influenced the development of other syn-
thetic HDAC inhibitors that show the common features shared by all HDACi. In general, these 
synthetic HDACi are simplified structures that can be regarded more druggable. Manal et al. sum-
marized the efforts made so far towards these analogues.[79] Noteworthy, even macrocyclic com-
pounds which do not fit the pharmacophore model of common HDACi were shown to act as in-
hibitors including macrolides[80] and cyclodextrins.[81] 
 Hansen and co-workers were able to develop HDAC6 selective inhibitors by a multicom-
ponent synthesis approach.[82] The design of selective inhibitors was rationalized by recent insights 
into the characteristics of HDAC6 in comparison to other enzymes of this class. Structural dispar-
ities of HDAC6 allow for bulky cap groups, and a specific substrate recognition mechanism makes 
the development of selective inhibitors attractive.[83] They synthesized a library of potential 
HDACi via the three compound Groebke-Blackburn-Bienayme reaction. The mechanism of the 
reaction is displayed in scheme 2.9.[84] Condensation of an aldehyde with 2-aminopyridine forms 
an imine, which undergoes protonation and nucleophilic attack by an isonitrile. Subsequent intra-
molecular cyclization of the intermediate leads to formation of a dihydroimidazo[1,2-a]pyridine, 
which undergoes 1,3-H shift to give the imidazo[1,2-a]pyridine core. 
 
 
Scheme 2.9: Mechanism of the Groebke-Blackburn-Bienayme reaction.[84] 
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 The authors demonstrated the synthesis of 13 imidazo[1,2-a]pyridines and reported their 
inhibitory activities against HDAC1 and -6, respectively (scheme 2.10 and table 2.7). The selec-
tivities towards inhibition of HDAC6 over HDAC1 are remarkable given the structural simplicity 
and straightforward synthesis of these synthetic HDACi. 
 
 
Scheme 2.10: Synthesis of imidazo[1,2-a]pyridine-based HDACi.[82] 
 
Table 2.7: Biological activities and selectivities of imidazo[1,2-a]pyridine-based HDACi.[82] 
  IC50 [µM]  
R1 R2 HDAC1 HDAC6 
selectivity 
HDAC1/HDAC6 
p-NMe2-Ph- H 0.13 0.050 3 
Ph- H 0.89 0.074 12 
p-F-Ph- H 0.51 0.051 10 
3,5-tBu-Ph- H > 3.333 1.33 > 3 
H H 0.84 0.076 11 
H 7-Me 1.01 0.069 15 
nC3H7- H 2.20 0.058 38 
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2.2 Amino acid and peptide modifications 
 Amino acids and the peptides they form are ubiquitously found in all biological systems. 
While the 20 proteinogenic amino acids account for ribosomally produced peptides and proteins, 
many non-proteinogenic amino acids are widespread among living systems and often show inter-
esting biological activities. The latter are incorporated in secondary metabolites of microorganisms 
by the action of non-ribosomal peptide synthetases, e.g. in the biosynthesis of apicidin (section 
2.1.4). Almost all naturally occurring HDACi contain at least one unusual amino acid residue, 
which needs to be addressed in the synthesis of these compounds. Furthermore, derivatization of 
a given natural product is unthinkable without the application of certain peptide modification re-
actions. To address this issue of adding non-proteinogenic amino acids to the synthetic toolbox, 
various methods for the construction and modification of unusual amino acids and peptide moieties 
have been developed over the last decades. In the context of this work, modified Claisen rear-
rangements, transition metal catalyzed allylic substitutions and thiol-ene click reactions were cho-
sen as representative examples of these modification reactions. 
 
2.2.1 Ester enolate Claisen rearrangements 
 The [3,3]-sigmatropic rearrangement of allyl aryl and allyl vinyl ethers was first discovered 
by Ludwig Claisen in 1912.[85] Thermal rearrangement of allyl phenyl ethers gave C-allyl phenols, 
while allyl vinyl ethers afforded γ,δ-unsaturated carbonyls. Since its seminal publication, several 
versions of the latter transformation have been development with altered reaction conditions. Car-
roll reported the thermal rearrangement of in situ generated β-keto esters, which subsequently un-
derwent decarboxylation to afford γ,δ-unsaturated ketones.[86] Application of this transformation 
is limited due to the harsh reaction conditions. Similarly, addition of allylic and benzylic alcohols 
to N,N-dimethylacetamide diethyl acetal and following rearrangement afforded unsaturated am-
ides as reported by Eschenmoser and co-workers.[87,88] Utilization of orthoesters in this reaction 
gave rise to unsaturated esters and is referred to as Johnson-Claisen rearrangement.[89] In contrast 
to Eschenmoser’s version, Johnson rearrangement needs the addition of catalytic amounts of acids 
to proceed readily.[90] The use of allyl esters in this reaction has been reported by Ireland[91] and 
Baldwin,[92] respectively. Ireland et al. generated ester enolates through α-deprotonation to form 
Li-enolates. Subsequent reaction with TMSCl formed silyl ketene acetals, which readily under-
went rearrangement upon heating. In contrast, Baldwin used α-halo esters to generate Zn-enolates 
after zinc insertion in the C-X bond, wherefore this version is referred to as Reformatsky Claisen 
rearrangement. Both rearrangements proceed under mild basic to neutral conditions and generate 
γ,δ-unsaturated carboxylic acids. An overview of the discussed Claisen rearrangements is given in 
scheme 2.11. 
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Scheme 2.11: The Claisen rearrangement and its versions.[85–87,89,91,92] 
 
 The reaction is generally considered to proceed via a chair-like transition state.[93] The ste-
reochemical outcome of the rearranged product depends on the double bond geometry in both the 
allyl and vinyl fragment.[94,95] Detailed mechanistic studies were carried out by Ireland et al. for 
the rearrangement of ester enolates and silyl ketene acetals.[94] The two isomeric crotyl esters A 
and B were treated with LDA in either THF or THF/HMPA to selectively form the (Z)- or (E)-
enolate (scheme 2.12). In THF, Li is coordinated to the carbonyl group and deprotonation presum-
ably proceeds via a chair-like transition state to form the (Z)-enolate selectively. In contrast, addi-
tion of HMPA results in chelation of Li and generation of a stronger amide base. Therefore, an 
acyclic transition state is preferred to give the corresponding (E)-enolate. Upon rearrangement, 
either erythro- or threo-C were obtained in moderate selectivity. In most cases, rearrangement of 
the silyl ketene acetals proceeded more readily and with higher yields. This results could be ra-
tionalized given the tendency of unstabilized ester enolates to undergo condensation reactions 
above –78 °C.[91,96] 
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Scheme 2.12: Influence of the olefin and enolate geometry on the rearrangement of allyl esters.[94] 
 
 A different method to stabilize ester enolates which subsequently underwent [3,3]-sigma-
tropic rearrangement has been reported by Kazmaier.[97] Utilization of glycine allyl esters in the 
reaction should allow for the construction of γ,δ-unsaturated amino acids. While the corresponding 
Li-enolates derived from crotyl ester A only gave decomposition products upon warming to room 
temperature, several chelating metals provided the rearranged product B in good yield and high 
diastereoselectivity (scheme 2.13, A). The driving force was speculated to be the formation of a 
chelate enolate, which is stable at temperatures needed to facilitate rearrangement. The best results 
were generally obtained with zinc chloride as chelating agent. Consequently, this metal salt was 
used to study the influence of the olefin geometry and the degree of substitution on the stereo-
chemical outcome of the reaction. Glycine esters C were treated with LDA and ZnCl2 at –78 °C 
to form the corresponding (Z)-enolates, which then underwent rearrangement upon warming to 
room temperature. It was shown that (E)-configured olefins preferably afforded syn-D, while (Z)-
olefins gave anti-D selectively (scheme 2.13, B). The high diastereoselectivity was a result of the 
fixed enolate geometry through chelation. The (Z)-enolate formed rearranged via a chair-like tran-
sition state to afford the product in a diastereoselective manner. However, the NH-function was 
found to be crucial for chelation and subsequent rearrangement since substrates without this func-
tion failed to give the rearranged product. 
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Scheme 2.13: Chelate enolate rearrangement developed by Kazmaier.[97] 
 
Addition of chiral ligands to the chelate enolate solution enabled an asymmetric version of 
this rearrangement.[98] The rearrangement of TFA-protected glycine crotyl ester A in presence of 
different chiral ligands and metal salts was investigated (scheme 2.14, A). Bidentate ligands in 
combination with Al(OiPr)3 have proven beneficial, while the best results were obtained with the 
cinchona alkaloids quinine and quinidine. The chiral ligand presumably shields one side of the 
ester enolate, resulting in rearrangement via one of the two enantiomeric chair-like transition states 
preferably. Different glycine allyl esters C were exploited in this transformation under optimized 
conditions to afford the corresponding γ,δ-rearranged amino acids D with good enantio- and ex-
cellent diastereoselectivity (scheme 2.14, B). 
 
 
Scheme 2.14: Asymmetric chelate enolate Claisen rearrangement.[98] 
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 The chelation concept is not limited to ester enolates derived from amino acids but can also 
be utilized for peptide ester enolates. With further amino acids attached to the chelate enolate, 
chiral complexes are formed and the stereochemical outcome of the newly formed α-center can in 
general be controlled by the peptide backbone. Kazmaier and Maier reported the rearrangement of 
dipeptide crotyl esters A in presence of manganese salts. The corresponding γ,δ-unsaturated di-
peptide acids B were afforded in good yields, albeit modest diastereoselectivities (scheme 2.15, 
A).[99] Improved results were obtained with other metal salts like NiCl2 or SnCl2 (C → D, scheme 
2.15, B).[100] Noteworthy, Tos-protected peptides gave the best results both in terms of yield and 
diastereoselectivity and even allowed for the rearrangement of Li-enolates. Di-, tri- and even 
tetrapeptides were shown to rearrange readily and with unlike diastereoselectivity, meaning that 
(S)-configured amino acids adjacent to the chelate enolate control the new stereogenic center in 
favor of the (R)-isomer.[100] This could be envisioned by formation of a chiral chelate complex 
where the amino acid side chains shield one side of the ester enolate. Rearrangement then takes 
place from the unlike side preferably (scheme 2.15, C). While no influence of the number of adja-
cent amino acids in the peptide chain on the diastereoselectivity was observed, rearrangement of 
tetrapeptides containing a secondary amine or sarcosine subunit resulted in epimeric mixtures of 
the newly formed α-stereocenter. For instance, rearrangement of tetrapeptide allyl ester E with tin 
chloride afforded F as a 1:1 diastereomeric mixture (scheme 2.15, D). This effect probably resulted 
from an interrupted chelation of the peptide backbone due to the missing NH-functionality of the 
proline residue. 
 
 
Scheme 2.15: Chelate enolate Claisen rearrangement of peptide enolates.[99,100] 
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 Chelate enolate Claisen rearrangements have been reported to be powerful tools in the 
construction of non-proteinogenic and unusual amino acids. Varghese and Hudlicky utilized this 
transformation in their total synthesis of dihydrocodeine and hydrocodone.[101] Reduction of diol 
A, followed by silyl protection and esterification with Boc-protected glycine gave cyclic allyl ester 
B in moderate yield (scheme 2.16). Subsequent ester enolate Claisen rearrangement afforded 
amino acid ester C after methylation in 65 % yield as a 2:1 mixture of diastereomers. The modest 
diastereoselectivity was speculated to result from rearrangement via both chair- and boat-like tran-
sition states as reported by Ireland et al. for cyclohexenyl derivatives.[102] The targeted dihydro-
codeine was obtained from C after 15 consecutive steps. 
 
 
Scheme 2.16: Chelate enolate Claisen rearrangement in the synthesis of dihydrocodeine.[101] 
 
2.2.2 Transition metal catalyzed allylic alkylations 
 Allylic substitutions catalyzed by transition metals are of outstanding importance to the 
construction of C-C, C-N and even C-O bonds. While it has been known that palladium-olefin 
complexes undergo nucleophilic attack by hydroxide anion[103], amines[104] or acetate anion[105], 
studies undertaken by Tsuji et al. in 1965 found that malonates react with palladium-π-allyl chlo-
ride to form mono- and dialkylated products (scheme 2.17).[106,107] Trost and co-workers expanded 
the scope of the reaction tremendously by introducing phosphine ligands.[108] Reactions of pre-
formed Pd-π-allyl complexes with malonates did occur readily upon addition of tri-
phenylphosphine to afford a mixture of regioisomeric allylation products (scheme 2.17). Further-
more, addition of phosphines triggered the development of stereoselective versions of this reaction 
by utilizing chiral ligands.[109] Synthetical importance was gained through development of a cata-
lytic version of the allylic substitution by employing olefins bearing a leaving group in allyl posi-
tion.[110] These substrates react spontaneously with Pd(0) to form the crucial Pd-π-allyl complex 
and allow the intermediately formed Pd(0) species to reenter the catalytic cycle through oxidative 
addition. The transition metal catalyzed allylic alkylation is nowadays referred to as Tsuji-Trost 
reaction. 
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Scheme 2.17: Allylic substitutions developed by Tsuji[107] and Trost[108]. 
 
 Detailed mechanistic studies were conducted in the last decades to rationalize the (stereo-
chemical) outcome of the reaction. The course of the reaction can be depicted using a catalytic 
cycle (scheme 2.18, A).[111] A suitable Pd(0) precursor A undergoes dissociative ligand exchange 
under formation of a catalytically active 16e- complex B, which allows for coordination of an 
olefinic substrate. The coordinated Pd complex C undergoes ionization to form Pd-π-allyl complex 
D, which subsequently undergoes nucleophilic attack by either a C-, N-, O- or another nucleophile. 
Dissociation of the newly formed olefin from complex E liberates the allylated product and sim-
ultaneously regenerates the active catalyst B. The stereochemical outcome can be envisioned uti-
lizing chiral allylic substrates F, which undergo nucleophilic attack of the TM species under ste-
reoinversion (scheme 2.18, B).[112] The newly formed TM-π-allyl complex G can then undergo 
nucleophilic attack in two different ways; soft nucleophiles (pKa-value of corresponding acid < 
25) directly attack at the allyl scaffold of complex G (“outer sphere”), while hard nucleophiles 
(pKa-value of corresponding acid > 25) initially attack the transition metal center and form the 
product after reductive elimination (“inner sphere”). Attack of soft nucleophiles happens from the 
opposite side than the transition metal is located and with double inversion of the stereogenic cen-
ter. The allylation product H shows total retention, meaning that the conformation of both starting 
material and product is the same. In contrast, an inner sphere mechanism performed by hard nu-
cleophiles results in total stereoinversion (F → I) since reductive elimination proceeds under ste-
reoretention from the same side than the transition metal. Another effect that was shown to influ-
ence the stereochemical outcome of the Tsuji-Trost reaction is π-σ-π isomerization of the TM-allyl 
complex (scheme 2.18, C). The η3 π-allyl complex formed after ionization can change its hapticity 
under formation of a η3 (σ+π)-enyl complex and finally a η1 σ-allyl complex, which allows free 
rotation around the C-M bond. This can have drastic consequences for the regio- and stereoselec-
tivity of the reaction and influences the double bond geometry of the allylation product. The ten-
dency to undergo π-σ-π isomerizations depends on the transition metal employed in the reaction. 
Palladium is known to rapidly isomerize and undergo nucleophilic attack preferably at the 
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sterically less hindered position of the Pd-π-allyl complex. Other transition metals like Rh,[113] 
Ru[114] and Ir[115,116] have also been reported to perform allylic substitutions and generally show 
different stereochemical courses of the reaction. For instance, allylic substitutions catalyzed by 
Wilkinson’s catalyst were shown to proceed under preservation of absolute configuration via a 
(σ+π)-enyl complex.[117] 
 
 
Scheme 2.18: Mechanistic and stereochemical considerations of the transition metal catalyzed al-
lylic substitution.[111,112] 
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 The Tsuji-Trost reaction proved to be a powerful tool in the modification of glycine and 
peptide enolates. Kazmaier and Zumpe reported the use of chelated glycine ester enolates in Pd-
catalyzed allylic substitutions.[118] Differently N-protected glycine tert-butyl esters A were depro-
tonated with LHMDS and treated with zinc chloride to form a chelate enolate complex (as seen 
for ester enolate Claisen rearrangements). These enolates performed nucleophilic attack on a Pd-
π-allyl complex formed in situ from allyl ethyl carbonate and [allylPdCl]2. The reaction proceeded 
readily at –78°C to afford α-allylated glycine esters B (scheme 2.19, A). Furthermore, utilization 
of 1,3-disubstituted allyl carbonate C showed that the allylic alkylation of chelated glycine esters 
proceeded in a highly diastereoselective manner (scheme 2.19, B). In contrast to reflections about 
the stereochemical outcome of the ester enolate Claisen rearrangement, Pd-catalyzed allylic sub-
stitution gave rise to the anti-diastereomer D with excellent diastereoselectivity. Therewith, TM-
catalyzed allylic substitutions and ester enolate Claisen rearrangements complement each other in 
terms of diastereoselective formation of γ,δ-unsaturated amino acid esters. Employing chiral al-
lylic carbonate E in the reaction afforded the allylated amino acid F not only with high diastere-
oselectivity but also excellent enantioselectivity (scheme 2.19, C). The stereogenic information 
was transfer from the allylic substrate via a Pd-π-allyl complex. 
 
 
Scheme 2.19: Chelated glycine enolates in the Pd-catalyzed allylic alkylation.[118] 
 
 These initial studies revealed that the stereogenic information of chiral 1,3-disubstituted 
allylic substrates could be transferred to the allylation product effectively.[118] The reason for the 
observed regio- and stereoselectivity can be rationalized by a chiral Pd-π-allyl complex that un-
dergoes nucleophilic attack from the chelate enolate in such a way, that the bulky tert-butyl group 
stands trans to the larger substituent at the allyl fragment. Furthermore, nucleophilic attack pref-
erably occurs from the opposite side than the Pd coordination (outer sphere) and at the least 
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hindered allylic position, leading to the formation of the corresponding allylation product with 
high regio- and stereoselectivity (scheme 2.20). 
 
 
Scheme 2.20: Proposed mechanism for the allylic alkylation of chelated glycine enolates.[118] 
 
 As pointed out in the mechanistic reflections (scheme 2.18), π-σ-π isomerization can have 
a dramatic influence on the stereochemical outcome of the reaction. The stereogenic information 
of enantiomerically pure allylic substrates generally cannot be transferred via a terminal Pd-π-allyl 
complex due to rapid isomerization and therewith racemization via the σ-allyl complex.[119] How-
ever, chelated glycine enolates were shown to be very reactive nucleophiles, allowing transfor-
mations at low temperatures (–78 °C), where π-σ-π isomerization seemed to be suppressed. These 
findings resulted in the observation of unusual allylation products.[119] Kazmaier and Zumpe 
showed that (Z)-configured allylic substrate A could be transformed into the corresponding allyla-
tion product B bearing a (Z)-double bond (scheme 2.21, A). It was hypothesized that suppressed 
π-σ-π isomerization of the intermediately formed anti/syn complex led to formation of the ob-
served product. The obtained regioselectivity was in accordance to previously reported results (see 
scheme 2.20). Moreover, symmetrically substituted (Z)-configured allylic substrate C was used to 
determine the relative reactivity of the syn- and anti-position to undergo nucleophilic attack 
(scheme 2.21, B). By ruling out the influence of sterics on the product formation, the attained 
product D allowed for conclusions about the intrinsic reactivity of the respective positions. The 
obtained results clearly indicated that the anti-position is more reactive in symmetrically substi-
tuted π-allyl complexes since only the (E)-configured product D was observed. 
 A characteristic of the Pd-catalyzed allylic substitution is that nucleophilic attack prefera-
bly occurs at the sterically less hindered position of the allyl moiety. Consequently, a terminal Pd-
π-allyl complex gives rise to the linear allylation product with high selectivity. Luckily, this trans-
formation is not limited to Pd-catalysis, but also other transition metals have been reported to 
effectively facilitate the allylic substitution. Ruthenium-catalyzed reactions have gained ground 
since their initial discovery by Tsuji and co-workers.[114] The observed regioselectivity in the Ru-
catalyzed process depends more on the metal’s ligand system than on the utilized allylic sub-
strate.[120] This led to the development of catalysts with selectivities for either linear[121] or 
branched[120,122] products, regardless of the starting allylic substrate. On the contrary, Kawatsura 
et al. reported allylic substitutions under regioretention, meaning that branched allylic substrates 
afforded the branched products preferably, while linear allylic substrates gave the corresponding 
linear products.[121,123] The observed “memory effect” with the utilized [p-cymeneRuCl2]2 complex 
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could be rationalized via formation of a (σ+π)-enyl complex, as discussed for the Rh-catalyzed 
process.[117] 
 
 
Scheme 2.21: Utilization of (Z)-configured allylic substrates in isomerization-free allylic substitu-
tions.[119] 
 
Outstanding results with the [p-cymeneRuCl2]2/PPh3 catalyst system were obtained by 
Bayer and Kazmaier.[124,125] The memory effect of the utilized Ru-complex was exploited to syn-
thesize branched glycine allyl esters B from the corresponding allylic substrates A bearing a ter-
minal olefin (scheme 2.22, A). Thus, Ru-catalyzed allylic alkylation supplements the scope of the 
Pd-catalyzed reaction in terms of the employed allylic substrates as well as the attained products. 
Another peculiarity of this catalyst system was the observed lack of π-σ-π isomerization. When 
(Z)-configured allylic substrate C was used, the obtained product D also contained a (Z)-double 
bond, indicating the configurational stability of the intermediately formed anti-complex (scheme 
2.22, B). These observations, together with the fact that the stereogenic information can be trans-
ferred via a terminal allyl complex, underlined the hypothesis of an intermediate (σ+π)-enyl com-
plex (scheme 2.22, C). 
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Scheme 2.22: Ru-catalyzed allylic alkylations of chelated glycine enolates.[124,125] 
 
Seebach and co-workers reported the regio- and stereoselective modification of linear[126] 
and cyclic peptides[127] that underwent substitution with various electrophiles at glycine or sarco-
sine subunits. The observed regioselectivity could be rationalized by the lithiation state of a given 
peptide. While peptidic NH-groups prevented an adjacent amino acid’s α-H from deprotonation, 
glycines or sarcosines next to secondary or N-Me amino acids could be modified. Seebach et al. 
impressively demonstrated the regio- and stereoselective modification of cyclosporin A, a cyclic 
undecapeptide (scheme 2.23). Treatment of cyclosporin A with LDA presumably afforded the 
hexalithiated compound A, which readily underwent nucleophilic substitution with methyl iodide 
or other suitable electrophiles. The stereochemical outcome of the reaction was controlled by the 
peptide backbone. 
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Scheme 2.23: Regio- and stereoselective modification of cyclosporin A.[127] 
 
 The concept of selective peptide modifications could be expanded to transition metal cat-
alyzed allylic alkylations of chelated peptide enolates. Kazmaier and co-workers reported the dia-
stereoselective allylic alkylation of dipeptides under Pd-catalysis[128]. These initial studies focused 
on modifications of C-terminal glycine moieties. Deprotonation of A with LHMDS and chelation 
with ZnCl2 afforded stabilized dipeptide enolates, that performed nucleophilic attack at Pd-π-allyl 
complexes derived from allylic carbonates (scheme 2.24, A). Remarkably, the adjacent amino acid 
was able to control the stereochemical outcome of the newly formed α-stereogenic center in B. In 
accordance to reflections about the stereocontrol during peptide ester enolate Claisen rearrange-
ment, the already present side chain shielded one side of the nucleophile and delivered the product 
with high selectivities for the (S,R)-diastereomer. 
 
 
Scheme 2.24: Pd-catalyzed allylic alkylation of chelated peptide enolates.[128] 
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Interestingly, even internal peptide enolates could be successfully transformed via the 
aforementioned peptide modification reaction. To guarantee effective α-deprotonation and chela-
tion, the modified glycine must contain a secondary amine in C-direction as seen in the selective 
modification of cyclosporin A. Proline-containing tripeptides C were shown to effectively undergo 
Pd-catalyzed allylic substitutions (scheme 2.24, B). 
 The selective modification of internal tripeptide enolates is not restricted to Pd-
catalyzed allylic alkylations. Transformations of these substrates under Ru-catalysis were shown 
to proceed quite effectively and in a highly regio- and stereoselective manner.[129] Furthermore, N-
methylated amino acids could also be utilized to achieve selective enolization of adjacent glycine 
residues and (Z)-configured allylic substrates allowed the introduction of the corresponding (Z)-
olefins into a given peptide chain (scheme 2.25). These results demonstrated the synthetic useful-
ness of transition metal catalyzed allylic substitutions for the selective modification of amino acids 
and peptides. 
 
 
Scheme 2.25: Ru-catalyzed selective peptide modifications.[129] 
 
2.2.3 Thiol-ene click reactions 
 The allylic side chain introduced by either ester enolate Claisen rearrangement or transition 
metal catalyzed allylic alkylation allows for a range of diverse modifications of the olefin moiety. 
Olefins are among the most versatile starting materials to introduce new functional groups into a 
given structure. Several transformations involving olefins have been developed over the past dec-
ades including Sharpless’ asymmetric dihydroxylation,[130,131] Brown hydroboration,[132] Heck re-
action,[133] and so on. Applying the developed methods to functionalized amino acids and peptides 
should allow for the construction of highly complex biomolecules with interesting properties. 
 Sharpless and co-workers have made great contributions to the field of olefin modifications 
by introducing the “click chemistry” concept. They envisioned that nature has a preference for 
making C-X bonds over C-C bonds.[134] Base of this concept was to provide a set of powerful and 
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reliable chemical transformations to perform C-X bond formations in a selective manner and to 
focus on the function of a synthesized molecule instead of its chemical structure. Sharpless et al. 
defined the parameters that a reaction has to meet in order to be considered a “click reaction”. This 
includes high yields, simple reaction conditions, no or mild solvents and simple product isolations 
as key requirements. Furthermore, high thermodynamic driving forces are demanded in order to 
give full and rapid conversion of the starting materials. They initially focused their work on gen-
eration and opening of small ring electrophiles like epoxides and aziridines (scheme 2.26) 
 
 
Scheme 2.26: “Click chemistry” as developed by Sharpless and co-workers.[134] 
 
 The click concept was expanded to further transformations involving olefins under for-
mation of C-X bonds. The addition of thiols to olefins has been known for over a century and was 
resurrected in the light of these new developments.[135] The radical reaction of thiols with terminal 
olefins was found to meet the criteria of a classical click reaction. Hoyle and Bowman described 
the addition of thiols to alkenes as high yielding, simple to execute and rapidly proceeding without 
formation of side products.[136] Radical formation can be initiated by light and the reaction tolerates 
a large scope of olefin substrates and thiols. Thiol-ene click reactions can generally be conducted 
in presence of air and moisture and proceed with nearly quantitative formation of the correspond-
ing thioether in a regioselective manner.[137] The radical thiol-ene click reaction was broadly ap-
plied to polymer and material synthesis by performing post-polymerization modifications or sur-
face modification reactions.[136,137] 
 Due to the neutral reaction conditions, the reaction was shown to perform well in modifi-
cation reactions of carbohydrates[138,139] and amino acids.[138,140] However, intramolecular H-radi-
cal shift led to racemization of the α-center of amino acids in some cases.[141] Karmann and Kaz-
maier reported the thiol-ene click reaction of allylglycine and unsaturated peptides containing ter-
minal alkenes.[142] Boc-protected allylglycine A reacted with a series of different thiols under irra-
diation in good to excellent yields (scheme 2.27, A). While terminal olefins underwent radical 
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thiol addition rapidly, utilization of internal alkenes failed, meaning that no reaction was observed 
(scheme 2.27, B). Besides steric aspects, the addition of thiols to olefins is a reversible process and 
product formation is observed preferably with terminal alkenes.[143] Epimerization via internal rad-
ical 1,3-H shift was observed with Boc-protected allylglycine (S)-A. Addition of thiol B led to a 
slight drop in enantiomeric excess (scheme 2.27, C). These findings were in accordance to the 
above-mentioned observations by Broxterman and co-workers.[141] Interestingly, even unsaturated 
peptides could successfully be employed in the reaction giving the desired thioethers in good yield 
and most notably without epimerization of the α-center (scheme 2.27, D). 
 
 
Scheme 2.27: Light-induced thiol-ene click reaction of amino acids and peptides.[142] 
 
Although radical thiol-ene additions normally occur rapidly and with high yields of the 
desired product, rise of side reactions and moderate yields were observed with substrates bearing 
O-allyl and O-benzyl moieties.[144,145] The in situ formed thiyl radicals can cause H-abstraction in 
allyl- or benzyl position, resulting in undesired side reaction and chain termination processes 
(scheme 2.28, A).[146] Furthermore, large excess of thiol was needed in some cases to afford the 
addition products with these substrates.[147,148] To overcome these limitations, Renaud et al. re-
ported an improved protocol for the radical thiol-ene click reaction with anomeric O-allyl sugar 
derivatives.[146] They found that a combination of triethylborane and catechol is suitable to “repair” 
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the radical chain process. Triethylborane is known to form ethyl radicals through reaction with 
oxygen and its use as radical initiator has been reported.[149,150] Addition of catechol leads to for-
mation of a borinic ester, which is able to transfer H-radicals to O-allyl and O-benzyl radicals and 
therewith prevents termination processes (scheme 2.28, B). 
 
 
Scheme 2.28: “Repair” mechanism in the BEt3-mediated thiol-ene click reaction.[146] 
 
 While stochiometric amounts of both triethylborane and catechol were required in the 
aforementioned thiol-ene modification of sugar derivatives, Gorges and Kazmaier could show that 
catalytic amounts of BEt3 are sufficient to efficiently perform the addition of thiols to amino acids 
and peptide derivatives (scheme 2.29, A).[151] Moreover, BEt3-initiated thiol-ene click reaction 
proved to be an improvement of the light-induced version due to the fact that no large excess of 
thiol was needed and even photolabile substrates could be transformed under the reaction condi-
tions used. O-allyl ethers were employed in the reaction to evaluate the presence of a H-abstraction 
mechanism. Interestingly, high yields were obtained for all kinds of substrate including O-allyl 
ethers and esters as well as N-allyl amides. Most striking was the selective modification of the 
natural product soraphen A, a cyclic polyketide from Sorangium cellulosum.[152] Treatment of so-
raphen A with allyl bromide afforded allyl ether A. Subsequent addition of thioacetic acid gave 
the desired thioester B in 81 % yield (scheme 2.29, B). 
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Scheme 2.29: BEt3-initiated thiol-ene click reactions of unsaturated compounds.
[151] 
 
 In conclusion, selective modifications of amino acids and peptides are powerful tools for 
the construction of unusual, non-proteinogenic amino acid residues, which are often incorporated 
in biologically active compounds. This large toolbox furthermore triggers the development of nat-
ural product derivatives essential for the study of biological function and evaluation of structure-
activity relationships. 
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3. Aim of this work 
 The main goal of this dissertation was to synthesize natural HDAC inhibitors and develop 
a flexible protocol to get access to both the natural products and derivatives thereof. For this pur-
pose, Cyl-1 and trapoxin A were identified as striking targets. The first natural HDACi, Cyl-1, was 
isolated from Cylindrocladium scoparium and was recognized as a HDACi due to its chemical 
structure.[47] However, no biological activities have been reported so far for Cyl-1, which made it 
an attractive goal for total synthesis. Together with the fact that its structural analogue Cyl-2 shows 
extraordinary selectivity towards the different HDAC isoforms (see chapter 2.1.6), Cyl-1 was 
noted as a promising core structure for the development of several derivatives. The second natural 
product, trapoxin A, was first isolated from Helicoma ambiens RF-1023 in 1990.[41] While trapoxin 
B, a structural analogue, was the target of a total synthesis shortly after its isolation, no synthetic 
access towards trapoxin A has been accomplished yet. Furthermore, trapoxin A evinced a peptide 
backbone which was found to be ideal to demonstrate the power of peptide modification reactions 
to incorporate unusual amino acids into a given peptide chain. 
 To establish a straightforward protocol for the synthesis of Cyl-1, construction of the non-
proteinogenic (2S,9S)-2-amino-9,10-epoxy-8-oxodecanoic acid (Aoe) was crucial. Therefore, the 
main goal in the synthesis of Cyl-1 was to exploit an elegant access towards the Aoe scaffold. This 
amino acid should be accessible through ester enolate Claisen rearrangement of a suitable precur-
sor. These rearrangements generally proceed with high yield and excellent transfer of stereogenic 
information to the newly formed α-stereocenter. The stereogenic information of the corresponding 
allylic ester should be derived from natural sources, e.g. tartaric acid (scheme 3.1, A). 
 The synthesis of derivatives of Cyl-1 should be accomplished by incorporation of an al-
lylglycine into the macrocyclic core structure. This would allow for manifold derivatization reac-
tion like thiol-ene click reactions in order to introduce new zinc-binding motifs. This strategy was 
chosen since the Cyl-core structure already shows high isoform selectivity (determined by the 
peptidic backbone) and introduction of new zinc-binders should alter the pharmacological proper-
ties (especially pharmacokinetics). While the focus of this work clearly lied on the derivatization 
of this allylglycine moiety, access towards this non-proteinogenic amino acid containing macro-
cycle was essential. Thus, a flexible synthetic route was needed that would allow for the incorpo-
ration of other side chains through peptide modification reactions (scheme 3.1, B). 
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Scheme 3.1: Synthesis of Cyl-1 and its derivatives. 
 
 For trapoxin A, synthetic routes towards the two non-proteinogenic amino acids Aoe and 
(R)-pipecolinic acid needed to be developed. While Aoe was also targeted in the synthesis of Cyl-
1, the pipecolinic acid moiety should be accessible through Mitsunobu cyclization of a suitable 
precursor. With this amino acids in hand, the natural product should by accessible by gradual 
peptide coupling and following macrolactamization (scheme 3.2, A). 
On the other hand, the structure of trapoxin A was compelling in terms of peptide modifi-
cation reactions. Performing the macrolactamization between Aoe and Phe should leave a linear 
tetrapeptide backbone with a (S)-(S)-(R)-(S)-combination that would allow for subsequent intro-
duction of both the pipecolinic acid precursor as well as the Aoe precursor via transition metal 
catalyzed allylic alkylations. Finally, Mitsunobu cyclization within the peptide chain and subse-
quent macrolactamization should give the natural product. This synthetic protocol should also 
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allow access to several derivatives through altering the allylic substrates in the allylic alkylation 
step (scheme 3.2, B). 
 
 
Scheme 3.2: Synthesis of trapoxin A. 
 
 As outlined before, macrolactamization to form the 12-membered ring system was always 
a crucial step in the synthesis of these natural compounds and the optimal ring closing position 
needed evaluation in most cases. Consequently, a highly flexible approach towards these natural 
HDACi and their derivatives was needed that would allow for the straightforward synthesis of 
regioisomeric tetrapeptides with the developed methods. 
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4. Results and Discussion 
4.1 Synthesis of Cyl-1 
 The key steps in the synthesis of the macrocyclic HDAC inhibitor Cyl-1 were the construc-
tion of the non-proteinogenic Aoe moiety and the challenging macrolactamization to form the 
12-membered ring system. From a retrosynthetical point of view, the α-epoxyketone present in 
Cyl-1 should be accessible through epoxidation and oxidation (scheme 4.1).[67] Macrolactamiza-
tion between proline and Aoe should give a linear tetrapeptide that could further be disjointed into 
an Aoe precursor and a tripeptide. The carboxylic acid A should be directly accessible through 
ester enolate Claisen rearrangement of allyl ester B without further modifications. The correspond-
ing allylic alcohol C needed for esterification with N-protected glycine should be derived from a 
suitable precursor through olefination. This precursor D could be synthesized via McMurry ho-
mocoupling of aldehydes, whose stereogenic information were obtained from L-tartaric acid. The 
outlined strategy is straightforward in terms of step count since no further derivatization of the 
rearranged carboxylic acid A is required before incorporation into the linear tetrapeptide. Subse-
quent cyclization and construction of the α-epoxyketone moiety should access the natural product 
Cyl-1. 
 
4.1.1 Synthesis of the Aoe precursor 
 The stereogenic information for the construction of Aoe precursor A should be derived 
from naturally occurring, chiral starting materials like tartaric acids. This so called chiral pool 
synthesis allows for the construction of various natural products and is well described in litera-
ture.[153,154] 2,3-O-isopropylidene-L-threitol was synthesized following literature procedure[155] 
and monoprotection of the L-threitol derivative gave alcohols 1a-c (table 4.1).[67,156] While 1a and 
1b were obtained along with the corresponding double-protected compounds, alcohol 1c was 
formed in 99 % yield when 0.9 eq. TIPSCl were used in the reaction. 
 
Table 4.1: Monoprotection of 2,3-O-isopropylidene-L-threitol. 
 
entry 1 PG conditions Y 
1 a Bz NaH, BzCl, THF, 0 °C – rt 62 % 
2 b Bn NaH, BnBr, DMF, –40 °C – rt 71 % 
3 c TIPS NaH, TIPSCl, THF, 0 °C 99 % 
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Scheme 4.1: Retrosynthetical analysis of Cyl-1. 
 
 Alcohols 1a-c were then oxidized under Swern conditions to the corresponding alde-
hydes.[157] These aldehydes proved to be unstable and sensitive towards epimerization of the α-ste-
reogenic center. The isolated aldehydes decomposed quickly even when stored at –20 °C. There-
fore, crude aldehydes were immediately subjected to Mukaiyama/McMurry conditions to undergo 
subsequent homocoupling.[158,159] In general, TiCl4 was dissolved in a solvent, treated with zinc 
dust and heated to reflux for up to two hours. The crude aldehydes were then added at temperatures 
ranging from –45 °C to 85 °C and reflux was continued. Latter reflux was required to eliminate 
TiO2 from the intermediately formed pinacol.
[158] Performing the reaction with aldehyde derived 
from 1a in THF gave no olefinic product, although TLC control of the reaction mixture showed 
full consumption of the aldehyde. Instead, reduction to the corresponding alcohol was observed. 
In order to increase the temperature during TiCl4 reduction and aldehyde coupling, DME was used 
rather than THF. However, only decomposition products were formed in DME during the course 
of the reaction. Switching the protective group from benzoyl to benzyl yielded only undefined 
decomposition products. The use of zinc-copper couple has been reported by McMurry et al. to 
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efficiently improve both yield and reproducibility of the coupling.[160] Unfortunately, only ketal 
cleavage was observed with aldehyde derived from 1b. To avoid side reactions of the acid-labile 
groups initiated by partial hydrolysis of TiCl4, pyridine was added to the reaction mixture. Lenoir 
described the use of TiCl4/Zn/Py for efficient ketone coupling.
[161] However, neither benzyl- nor 
TIPS-protected substrates gave any product. Since TiCl4 was rather difficult to handle under an-
hydrous conditions, commercially available TiCl4·2THF complex was used instead. This complex 
was used for successful McMurry coupling of an aldehyde containing a ketal, although not in 
adjacency to the affected aldehyde.[162] Analysis of the crude product indicated ketal cleavage but 
no formation of olefinic product. The less Lewis-acidic tin (IV) chloride has been reported to per-
form McMurry type couplings after reduction.[163] Subjecting alcohol 1b in the oxida-
tion/McMurry cascade with SnCl4/Zn in THF led to reisolation of the intermediate aldehyde. 
 Considering that no olefinic product was formed under any reaction conditions tested gave 
rise to questions about the general eligibility of aldehydes with potential leaving groups in α-posi-
tion. Although McMurry couplings have been used in the literature to build up complex natural 
products,[164] almost no examples of aldehydes with leaving groups in near proximity have been 
reported.[165] To prove this hypothesis, C2-prolonged aldehydes were synthesized starting from 1c 
(scheme 4.2). Oxidation under Swern conditions gave crude aldehydes, which were transformed 
with the corresponding Wittig ylide into the α,β-unsaturated ester 2c in an one-pot protocol.[166,167] 
Despite the NMR spectra of 2c appeared clean after column chromatography, a second chromato-
graphic purification was needed before subsequent hydrogenation. Formation of elemental sulfur 
was sometimes observed during hydrogenation if the starting material was only purified once. 
However, hydrogenation of 2c under 10 bar of H2 with palladium on carbon gave saturated ester 
3c in 96 % yield. Ester 3c was reduced with DIBAL-H in toluene at –78 °C to the corresponding 
aldehyde 4c, which was then subjected to McMurry conditions. But as described before, only ketal 
cleavage and consumption of the aldehyde was observed, and no olefinic product was obtained. 
Alcohol 1b was subjected to the same transformations as described for 1c. Hydrogenation of the 
α,β-unsaturated ester 2b was performed in the presence of 10 mol% n-BuNH2 to prevent benzyl 
ether cleavage.[168] Various amines were shown to prevent O-debenzylation from occurring under 
hydrogenolysis conditions.[169] Subsequent reduction of 3b with DIBAL-H gave aldehyde 4b, 
which was utilized at a later stage of the synthesis. 
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Scheme 4.2: Synthesis of C2-prolonged aldehydes 4. 
 
 Since the McMurry approach provided no improvable results, other methods to derivatize 
the previously prepared aldehydes were tested. Alcohol 1b was transformed into the corresponding 
iodide 5b and subsequently heated with PPh3 to 80 °C to form the corresponding Wittig salt 6 
(scheme 4.3).[170] This phosphonium salt was treated with different bases (LHMDS, LDA, n-BuLi) 
in a variety of solvents (THF, DME, PhMe) to form the corresponding Wittig ylene. Subsequent 
addition of aldehydes derived from 1a-c led to no product formation under any reaction conditions 
tested. To rule out steric hinderance of the Wittig ylene, benzaldehyde was added to the in situ 
formed ylene. However, no product was observed from this reaction either. It was therefore spec-
ulated that deprotonation of the Wittig salt led to rapid decomposition of the substrate. The obser-
vation of various side reactions in both the McMurry approach as well as the Wittig approach 
called for another synthetic strategy to construct a suitable allylic alcohol C for introduction of the 
Aoe side chain. 
 
 
Scheme 4.3: Synthesis of Wittig salt 6. 
 
 The stereogenic center in allylic alcohol C (scheme 4.1) could either be controlled during 
the addition of organometallic reagents to aldehydes 4, or the allylic alcohol could be enzymati-
cally resolved afterwards. Knochel et al. developed methods for the synthesis of diorganozinc 
compounds[171] and reported catalytic, enantioselective additions of these zinc organyls to alde-
hydes in the presence of chiral bissulfonamides and Ti(OiPr)4.
[172] A similar approach was utilized 
to access chiral allylic alcohols 7 (table 4.2). Unfortunately, the reaction typically showed no full 
conversion (entry 1) or poor diastereoselectivities (entries 2-4). While Knochel et al. only used 
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dialkylzinc reagents, divinylzinc is required to access allylic alcohols through stereoselective car-
bonyl addition. The preparation and purification of divinylzinc proved to be challenging. While 
literature procedures are available for the preparation of divinylzinc, obtaining the product in pure 
form and avoiding extremely hazardous materials (e. g. mercury organyls) was difficult.[173] The 
poor diastereoselectivities probably resulted from incomplete separation of magnesium salts and -
organyls. 
 
Table 4.2: Stereoselective addition of divinylzinc to aldehydes 4. 
 
 
entry PG 4 solvent T Y dr* 
1 Bn b PhMe –40 °C - –25 °C 11 % > 99:1 
2 TIPS c PhMe –40 °C - –25 °C 56 % 60:40 
3 TIPS c PhMe –40 °C - 0 °C 33 % 60:40 
4 TIPS c THF –78 °C - rt 54 % 70:30 
*determined by 1H-NMR 
 
Since the stereoselective carbonyl addition of divinylzinc proved to be a non-trivial issue, 
enzymatic resolution of alcohol 7c seemed to be the more convenient choice to access diastereo-
merically pure (3S)-7c. Enzymatic dynamic kinetic resolutions (DKR) were found to be an elegant 
way to gain access to the corresponding acetate. During the course of the reaction, the allylic al-
cohol is epimerized by a Ru(II) complex, while one epimer is permanently removed from the equi-
librium through the action of the lipase. Several catalysts, like Shvo’s catalyst,[174] are known to 
effectively perform this racemization reaction. Bäckvall et al. developed several enzymatic dy-
namic kinetic resolutions of simple alcohols utilizing (Ph5Cp)Ru(CO)2Cl and other Ru com-
plexes.[175,176] Racemization of the alcohol proceeds through Ru-catalyzed dehydrogenation, leav-
ing a carbonyl and a Ru-hydride species. Subsequent re-addition of Ru-H leads to racemization of 
the alcohol.[177] Unfortunately, utilizing the reported reaction conditions for (Ph5Cp)Ru(CO)2Cl 
with allylic alcohol 7c as substrate failed (table 4.3, entries 1-2). While enzymatic resolution pro-
ceeded readily to give acetate 8, epimerization of the allylic alcohol seemed not to occur. There-
with, both acetate 8 and alcohol (3R)-7c were obtained in good yields and excellent diastereose-
lectivities. The absolute configuration of acetate 8 and the remaining alcohol (3R)-7c can be ra-
tionalized by the Kazlauskas rule for lipases.[178]  
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Table 4.3: Enzymatic (dynamic) kinetic resolution of 7c. 
 
 
entry additives R t 
Y 
((3R)-7c) 
Y (8) 
dr* 
((3R)-7c) 
dr* (8) 
1 
(Ph5Cp)Ru(CO)2Cl 
Na2CO3, KOtBu 
vinyl 64.5 h 45 % 41 % > 99:1 > 99:1 
2 
(Ph5Cp)Ru(CO)2Cl 
Na2CO3, KOtBu 
isopro-
penyl 
22 h 50 %c 50 %c > 99:1 > 99:1 
3 - vinyl 24 h 81 % 15 % 60:40 > 99:1 
4 - vinyl 40 h 65 % 34 % 73:27 > 99:1 
5 - vinyl 66 h 62 % 33 % 75:25 > 99:1 
6 Na2CO3 vinyl 24 h 49 % 50 % > 99:1 > 99:1 
7 KOtBu vinyl 24 h 47 % 49 % > 99:1 > 99:1 
8 Na2CO3 vinyl 6 h 49 % 46 % > 99:1 > 99:1 
c: conversion, *determined by 1H-NMR. 
 
Since no epimerization seemed to proceed under DKR-conditions, substrate 7c was sub-
jected to an enzymatic kinetic resolution under standard conditions. Allylic alcohol 7c was there-
fore dissolved in vinyl acetate at room temperature and treated with 5 w% Novozyme 435 (Lipase 
from Candida antarctica) for several hours. After 24 h, only 15 % of the corresponding acetate 
was obtained, although with excellent diastereoselectivity (table 4.3, entry 3). Performing the re-
action for 40 h increased the yield of acetate 8 to 34 % (entry 4). However, further prolonged 
reaction times neither changed conversion nor diastereoselectivity, indicating the termination of 
the reaction. Since full conversion was achieved in the dynamic kinetic resolution, the role of the 
added base was examined. Checking the literature revealed that addition of base can accelerate 
enzymatic kinetic resolutions through deprotonation of acylated enzyme intermediates.[179,180] 
Therefore, 1.0 eq. sodium carbonate or 5 mol% KOtBu were added to the reaction mixture (entries 
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6 and 7). Almost quantitative yields of both acetate and alcohol were obtained after 24 h. Sodium 
carbonate was preferred over KOtBu since it can be removed from the reaction mixture through 
simple filtration. The reaction was further adjusted to give 46 % of acetate 8 and 49 % alcohol 
(3R)-7c with excellent diastereoselectivities after only 6 h. For the construction of (S)-configured 
Aoe via ester enolate Claisen rearrangement, allylic alcohol (3S)-7c was needed. Transesterifica-
tion of acetate 8 with potassium carbonate in aq. MeOH gave the corresponding alcohol. 
Other acyl donors were also exploited in the enzymatic kinetic resolution of 7c. Using 
glycine esters as acyl donors would directly access glycine allyl esters, which could be subjected 
to ester enolate Claisen rearrangement. Although methods for the synthesis of amino acid vinyl 
esters are available,[181,182] p-Cl-phenol esters could easily be synthesized and have been used in 
DKR reactions before.[183] Furthermore, esterifications of p-nitro-phenol and trifluoroethanol with 
Cbz-Gly-OH were performed to alter the reactivity of the acyl donor.[184,185] With these active 
esters in hand, enzymatic kinetic resolutions were performed under optimized conditions and in 
toluene as solvent. At room temperature and with glycine p-Cl-phenol ester, only 17 % conversion 
to the corresponding glycine allyl ester was observed. Increasing the reaction temperature to 40 °C 
gave 34 % conversion. Similar results were obtained with the p-NO2-phenol ester and the trifluo-
roethanol ester. Although the diastereomeric ratios were excellent, separation of the newly formed 
glycine allyl ester and alcohol 7c couldn’t be accomplished. Additionally, p-NO2-phenol, formed 
as byproduct during the reaction, could not be removed from the reaction mixture. The obtained 
results clearly demonstrated the general applicability of other acyl donors in enzymatic kinetic 
resolutions. Due to difficulties regarding separation of the products, this approach was not contin-
ued further. 
 
4.1.2 Synthesis of a linear tetrapeptide and cyclization 
 With allylic alcohol (3S)-7c in hand, Steglich esterification[186] with Cbz-protected glycine 
gave the corresponding allyl ester 9, which was then subjected to ester enolate Claisen rearrange-
ment (scheme 4.4, A). These rearrangements were shown to proceed with excellent yield and 
transfer of stereogenic information via a chair-like transition state. The enolate geometry is fixed 
by formation of a five-membered chelate complex and therefore, excellent transfer of stereogenic 
information from the allyl ester to the α-center of the amino acid is achieved. Indeed, chelate eno-
late Claisen rearrangement of allyl ester 9 afforded carboxylic acid 10 in excellent yield and as a 
single diastereomer. This Aoe precursor should subsequently be coupled to tripeptides to obtain 
linear tetrapeptides suitable for cyclization towards the Cyl-1 scaffold. 
Coupling of PG-(R)-Tyr(Me)-OH with (HCl) H-(S,S)-Ile-(S)-Pro-OR to tripeptides 11 pro-
ceeded well and without side reaction for both methyl and tert-butyl esters (scheme 4.4, B). The 
use of tert-butyl esters in this coupling was exploited since preliminary results with proline dipep-
tide methyl esters indicated formation of side products. Luckily, this drawback was overcome by 
performing the coupling with the hydrochloride salt and IBCF at –20 °C. Hydrogenative cleavage 
of the Cbz-group in 11 gave amines 12. Carboxylic acid 10 was then coupled with 12a using TBTU 
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(scheme 4.4, C). Unfortunately, saponification of methyl ester 13 lacked from full conversion and 
gave the free carboxylic acid 14 in only moderate yield along with unreacted starting material. 
Subsequent activation of carboxylic acid 14 as Pfp ester gave compound 15 with almost full con-
version. 
 
 
Scheme 4.4: Synthesis of linear tetrapeptide 14 and activation as Pfp ester. 
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Amine 12b was also coupled with carboxylic acid 10 to investigate the selective cleavage 
of tert-butyl esters in the presence of acid labile groups. Unfortunately, cleavage of the tert-butyl 
ester in this linear tetrapeptide under standard conditions (TFA, DCM) resulted in the cleavage of 
the silyl ether and ketal group, respectively. Subjecting this ester to basic conditions with KOtBu 
in THF led to decomposition of the tetrapeptide.[187] Esterases from porcine liver (PLE) are known 
to cleave esters in various substrates.[188] Performing the reaction in phosphate buffer at rt showed 
no conversion of the starting material. Finally, heating in acetonitrile with CeCl3 and NaI led to 
ketal cleavage rather than tert-butyl ester cleavage.[189] The results of these investigations were 
important for the synthesis of trapoxin A and are discussed in detail there. 
 To access the macrocyclic scaffold of Cyl-1, Pfp ester 15 was subjected to macrolactami-
zation under hydrogenative conditions in THF with Pd on carbon as catalyst. Interestingly, even 
at 10 bar H2 pressure, Cbz-deprotection seemed to occur very slowly. No product was formed after 
24 h and the starting material could be reisolated. At 80 °C in dioxane, Cbz-cleavage occurred, but 
no cyclized product was found in the crude reaction mixture. These results led to the conclusion 
that the conformation of 15 apparently did not allow for rapid Cbz-cleavage and subsequent cy-
clization. 
 
4.1.3 Synthesis of a regioisomeric tetrapeptide and synthesis of Cyl-1 
 Several total synthesis of natural macrocyclic HDAC inhibitors revealed that the ring clos-
ing position can have a dramatic effect on the overall yield and epimerization rate during cycliza-
tion.[68,190] Since macrocyclization of 15 failed under any reaction conditions tested, the construc-
tion of a regioisomeric tetrapeptide was required. Therefore, it was important to develop a syn-
thetic strategy that would allow for rapid changes in the ring closing position. 
 With such a strategy at hand, the synthesis of a regioisomer of 15 was performed rapidly 
and with high yields. Methylation of carboxylic acid 10 and hydrogenative cleavage of the Cbz-
group made amine 17 available (scheme 4.5, A). The tripeptide building block needed was derived 
from protected tripeptide esters 11 after saponification and tert-butyl ester cleavage, respectively 
(scheme 4.5, B). Similar to the synthesis of tetrapeptide 13, the free amine 17 was coupled with 
18a using TBTU to get tetrapeptide 19 in excellent yield as a single diastereomer (scheme 4.5, C). 
Saponification of the methyl ester and activation as Pfp ester gave the desired substrate for mac-
rolactamization. Noteworthy, Pfp ester 21 formed two stable rotamers (rotameric ratio ~ 3:1) 
which could be separated on an analytical column (Phenomenex Luna). NMR spectra recorded at 
elevated temperature (DMSO-d6, 100 °C) excluded severe epimerization of the Pfp ester and the 
diastereomeric ratio was analyzed to be 97:3. 
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Scheme 4.5: Synthesis of a regioisomeric linear tetrapeptide for Cyl-1. 
 
 Tetrapeptide 21 was treated with H2/Pd/C in THF with alternation of H2 pressure and dilu-
tion (table 4.4). Applying 20 bar H2 pressure and addition of HOAc to the reaction mixture yielded 
27 % of macrocycle 22 with a diastereomeric ratio of 95:5 (entry 1). Interestingly, acetic acid 
apparently did not lead to ammonium salt formation as the free amine cyclized readily. At atmos-
pheric pressure, longer reaction times were required, which gave slightly higher yield albeit with 
more epimerization (entry 2). Higher dilution under otherwise same conditions gave better yields 
but surprisingly also more epimerization (entries 3-6). When the reaction was performed at 80 °C 
in dioxane with a continuous H2 passage through the reaction mixture,
[191] 75 % of the desired 
macrocycle were obtained but with severe epimerization (entry 7). In summary, prolonged reaction 
times and high temperatures led to progressive epimerization of the activated Pfp ester. 
Due to the fact that Pfp esters were prone to epimerize under the reaction conditions, other 
cyclization methods were evaluated. Since epimerization of the Pfp ester 21 was caused by long 
reaction times during hydrogenative cleavage of the Cbz-group, utilizing the free tetrapeptide for 
macrocyclization should remedy this drawback. Consequently, hydrogenation of carboxylic acid 
20 at 20 bar H2 pressure gave the free tetrapeptide, which was then subjected to diverse ring closing 
conditions. Using a literature protocol (PyBOP, DIPEA, DMF) for the construction of 12-mem-
bered ring systems developed by Schreiber et al.,[67] macrocycle 22 was obtained in 66 % yield 
containing several impurities. Irritatingly, these impurities could not be separated by any means to 
access the pure product. 
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Table 4.4: Optimization of the macrocyclization of 21. 
 
 
entry conditions Y dr* 
1 20 bar, HOAc, THF (50 mM), rt, 18 h 27 % 95:5 
2 1 bar, THF (1 mM), rt, 48 h 32 % 85:15 
3 5 bar, THF (50 mM), rt, 40 h 21 % > 99:1 
4 5 bar, THF (10 mM), rt, 40 h 28 % 94:6 
5 10 bar, THF (1 mM), rt, 23 h 32 % 88:12 
6 10 bar, THF (10 mM), rt, 24 h 16 % 93:7 
7 continuous H2 passage, dioxane (1 mM), 80 °C, 5.5 h 75 % 68:32 
*determined by 1H-NMR and LCMS 
 
Furthermore, treatment of the free tetrapeptide with PfTU under different reaction condi-
tions afforded only minor amounts of product or a complex mixture of compounds. PfTU should 
react with the carboxylic acid to form an intermediate Pfp ester, which should then readily undergo 
nucleophilic attack from the free amine. Apparently, PfTU was not suitable for this challenging 
macrocyclization, although it performed well in standard peptide couplings of test substrates. It 
was easily synthesized in two steps from tetramethylurea.[192] 
 With macrocycle 22 at hand, attempts to complete the total synthesis of natural Cyl-1 were 
undertaken Deprotection of silyl ether and following treatment with TosCl gave tosylate 23 
(scheme 4.6). Cleavage of the ketal proceeded readily at 40 °C and the corresponding diol was 
further treated with DBU in MeOH to give epoxyalcohol 24. Final oxidation with Dess-Martin 
periodinane in DCM gave natural Cyl-1 in 40 % yield. The epimers formed during Pfp ester acti-
vation and cyclization could be partially separated in all steps, so the natural product was isolated 
as a single diastereomer along with a diastereomeric mixture. The recorded NMR spectra were in 
accordance to previously reported data (see appendix).[47] Unfortunately, no complete data set or 
spectra were published for Cyl-1. 
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Scheme 4.6: Synthesis of Cyl-1. 
 
4.2 Synthesis of Cyl-1 derivatives 
 With a straightforward synthesis of Cyl-1 accomplished, efforts towards derivatives of this 
natural product were undertaken. Consequently, the synthesis started with the construction of a 
suitable allylglycine precursor to be incorporated into linear tetrapeptides fit for subsequent cy-
clization. 
The stereogenic information for this allylglycine moiety was again derived from L-tartaric 
acid. Thus, mono-O-allylation of the L-threitol derivative under similar conditions as reported be-
fore for monobenzylation gave alcohol 1d (scheme 4.7). Iodination and subsequent elimination of 
the iodide with zinc dust and acetic acid in THF gave allylic alcohol 25 as a single enantiomer. 
Esterification of this alcohol with Boc-protected glycine gave allyl ester 26, which was rearranged 
via a chelated ester enolate to give carboxylic acid 27 in 99 % yield. Noteworthy, the rearranged 
product was obtained as a single enantiomer and was then coupled with tripeptide amine 12a via 
mixed anhydride. Linear tetrapeptide 28 was saponified and subsequently activated as Pfp ester. 
Boc-deprotection gave a crude ammonium salt, which was subjected to a biphasic ring closure.[64] 
Although acceptable yield was obtained, the product appeared to be the corresponding cyclodimer, 
which consisted of two tetrapeptides forming a 24-membered ring. This indicated that ring closure 
between proline and the allylglycine precursor was not apt for the construction of the desired cyclic 
tetrapeptide. As discussed for tetrapeptide 15, the conformation of this derivative apparently pre-
vented cyclization. 
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Scheme 4.7: Attempts towards derivatives of Cyl-1. 
 
4.2.1 Ester enolate Claisen rearrangement of linear tetrapeptides 
 The obtained results underlined previous observations made in the synthesis of Cyl-1. Fur-
thermore, the effect of the ring closing position on the obtained product and the yield/epimerization 
rate during the reaction was emphasized. As a result, a different approach was tested, that would 
allow not only for the synthesis of derivatives but also the natural product from a common precur-
sor (scheme 4.8). Macrolactamization between allylglycine and (R)-Tyr(Me) should leave a linear 
tetrapeptide E. The side chain of the C-terminal amino acid should be introduced via ester enolate 
Claisen rearrangement of a chelated tetrapeptide. The corresponding allyl ester F needed for this 
transformation should be accessible through esterification of a linear tetrapeptide G with suitable 
allylic alcohols. This would allow for the incorporation of different side chains at a late stage of 
the synthesis. In general, allylic alcohols (3S)-7c or 25 could be introduced to either access the 
natural product or its derivatives. 
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Scheme 4.8: Retrosynthetical analysis of Cyl-1 derivatives. 
 
 An effortless approach towards such a linear tetrapeptide G arose from the coupling of two 
dipeptides. Unfortunately, coupling of Cbz-(R)-Tyr(Me)-(S,S)-Ile-OH with HCl·H-(S)-Pro-Gly-
OMe failed by any means. Either no conversion was observed, or the product could not be purified 
or showed severe epimerization of the isoleucine residue. Therewith, stepwise coupling of the four 
amino acids seemed to be the more advantageous approach. Cbz-(S,S)-Ile-OH was coupled with 
H-(S)-Pro-Gly-OtBu using TBTU as coupling reagent (scheme 4.9). In general, TBTU was the 
preferred coupling reagent for proline since the latter is known to form urethanes when coupled 
via mixed anhydrides and is generally prone to form diketopiperazines.[193,194] In addition, the use 
of tert-butyl esters could suppress diketopiperazine formation in proline-containing dipeptides.[195] 
The resulting tripeptide 30 was hydrogenated and coupled with Cbz-(R)-Tyr(Me)-OH to give lin-
ear tetrapeptide 31 in good yields. Cleavage of the tert-butyl ester gave carboxylic acid 32, which 
should then be coupled with allylic alcohols. The resulting tetrapeptide allyl esters could then be 
transformed further via ester enolate Claisen rearrangements. 
However, esterification of 32 with allylic alcohol 25 proved to be rather challenging. Under 
standard conditions (EDC, DMAP), only 30 % conversion was observed. Activation of 32 as acid 
chloride led to complete decomposition. Addition of DIPEA to the EDC coupling slightly in-
creased conversion and with DCC under Steglich conditions, 49 % of the desired product were 
obtained. Nevertheless, the obtained ester was contaminated with the corresponding N-acyl urea 
formed during the reaction. This clearly indicated that addition of alcohol 25 to the activated car-
boxylic acid was restricted. Additionally, activation as acid fluoride with DAST resulted in no 
conversion at all. Performing the reaction in DMF with TBTU and DBU has been described in 
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literature for challenging esterifications,[196] but no conversion was observed either. EDC coupling 
in DMF revealed the formation of multiple side products, which weren’t characterized further. 
Since low conversions and poor yields for a simple esterification were not acceptable at this stage 
of the synthesis, a different approach towards the tetrapeptidic allyl esters for Cyl-1 and its deriv-
atives was chosen. 
 
 
Scheme 4.9: Stepwise synthesis of a linear tetrapeptide for Cyl-1 derivatives. 
 
Incorporation of an allylglycine moiety in the linear tetrapeptide required a different syn-
thetic strategy. Since esterification of the linear tetrapeptide 32 was not an option, different glycine 
allyl esters were synthesized and subsequently coupled with linear tripeptides to the corresponding 
tetrapeptide allyl esters. Therefore, glycine allyl ester 26 was Boc-deprotected to give amine 33 as 
hydrochloride salt using a protocol developed by Nudelman et al. (scheme 4.10, A).[197] Steglich 
esterification of allylic alcohol (3S)-7c with Fmoc-Gly-OH was achieved in excellent yield 
(scheme 4.10, B).[186] Subsequent Fmoc-deprotection with Tris(2-aminoethyl)amine gave the free 
amine 35 for incorporation into linear tetrapeptides.[198] The previously synthesized tripeptides 18 
were then coupled with the different amines 33 and 35 to give the desired tetrapeptidic allyl esters 
36a, 36c and 37 in good to excellent yields (scheme 4.10, C). Tetrapeptide 36 was synthesized 
with two different N-protective groups, which both could be cleaved orthogonally to the side chain 
functional groups. Coupling with TBTU proved to be very effective and usually occurred without 
epimerization.[199] Occasionally, 1-2 % of an epimer were found after the reaction, which was 
acceptable given the presence of an activated tripeptide intermediate. 
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Scheme 4.10: Synthesis of linear tetrapeptide allyl esters. 
 
 The different tetrapeptide allyl esters 36 and 37 were subjected to the key step of the syn-
thesis; ester enolate Claisen rearrangement should provide suitable precursors for cyclization to 
access Cyl-1 and its derivatives. Although some efforts were made towards peptide Claisen rear-
rangements, application of this synthetically useful reaction in the synthesis of natural products 
hasn’t been accomplished yet. The peptidic backbone was shown to be able to control the stereo-
chemical outcome of the newly formed C-C bond.[100] On the other hand, proline-containing pep-
tides have also been reported to give epimeric mixtures. This effect is presumably caused by in-
terrupted chelation (figure 4.1). To overcome these limitations, diastereomerically pure tetrapep-
tide allyl esters were used in the synthesis of Cyl-1 and its derivatives to control the stereochemical 
outcome via the configuration of the esterified allylic alcohol. 
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Figure 4.1: Potential transition state for ester enolate Claisen rearrangement of tetrapeptides. 
 
Subjecting allyl ester 36a to the conditions of an ester enolate Claisen rearrangement with 
zinc chloride as chelating metal gave the rearranged product in 33 % yield and a diastereomeric 
ratio of 93:7 (table 4.5, entry 1). The reaction was kept at –45 °C overnight to suppress potential 
epimerization of the peptide. Generally, epimerization is prevented through deprotonation of am-
ide NH-bonds, as argued by Seebach for Li-enolates.[200] Nevertheless, isoleucine was prone to 
epimerize under the reaction conditions due to its vicinity to proline and therewith lack of “pro-
tecting” NH-groups. Since no full conversion was observed in this first attempt, LDA was replaced 
with LHMDS and the reaction was allowed to warm to rt overnight (entry 2). LHMDS is a slightly 
weaker base than LDA and should not deprotonate α-substituted amino acids. However, no full 
conversion was observed either and both yield and diastereomeric ratio were similar to the reaction 
with LDA. Afterwards, allyl ester 37 was subjected to the same reaction conditions as 36a before 
(entries 3-4). Interestingly, no conversion at all was observed for this allylic ester. Starting material 
could be isolated after the reaction and the only byproduct formed was allylic alcohol (3S)-7c. 
Elimination of alcohol from the ester enolate can occur with allylic substrates that undergo rear-
rangement too slowly and partially form ketenes.[201] Boc-protected ester 36c was then treated with 
LHMDS under the evaluated reaction conditions (entry 5). Surprisingly, also no conversion was 
observed for this substrate. Switching the base to LDA gave similar results than for 36a (entry 6). 
Since the reaction seemed to stop after 30-40 % conversion, it was speculated that ester enolate 
chelate complex formation was incomplete due to consumption of the base. For instance, depro-
tonation of tyrosine residues in benzyl position has been reported in the derivatization of miurae-
namides and called for an additional equivalent of base.[202] Therefore, the reaction was repeated 
with 5.5 eq. LDA (entry 7). The rearranged acid was obtained in quantitative yields as crude prod-
uct without the formation of byproducts. Strikingly, the diastereomeric ratios were generally high 
(up to >99:1). The reaction was performed several times giving similar results. Only prolonged 
reaction times (> 18 h) led to epimerization of the rearranged peptide. The rearranged carboxylic 
acid derived from 36c was suitable for cyclization towards Cyl-1 derivatives. Finally, ester 37 was 
subjected to the same reaction conditions (entry 8). Even with 5.5 eq. LDA, no rearranged product 
was obtained. Thus, ester enolate Claisen rearrangement proved to be suitable to incorporate an 
allylglycine precursor but not to access the natural product Cyl-1. 
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Table 4.5: Ester enolate Claisen rearrangements of tetrapeptide allyl esters. 
 
 
entry ester base T Y dr comment 
1 36a 4.8 eq. LDA –45 °C 33 % 93:7a no full conversion 
2 36a 4.8 eq. LHMDS rt 37 % ~ 95:5a no full conversion 
3 37 4.5 eq. LHMDS rt - - no conversion 
4 37 4.5 eq. LDA rt - - no conversion 
5 36c 4.5 eq. LHMDS rt - - no conversion 
6 36c 4.5 eq. LDA rt 34 % 95:5a no full conversion 
7 36c 5.5 eq. LDA rt quant. > 99:1b - 
8 37 5.5 eq. LDA rt - - no conversion 
a: determined by 1H-NMR, b: determined by HPLC of the corresponding methyl ester 
 
4.2.2 Cyclization and derivatization 
 With rearranged tetrapeptide 38c in hand, esterification with PfpOH gave Pfp ester 39, 
which should readily cyclize after Boc-deprotection (scheme 4.11). Treatment with HCl in dioxane 
gave the crude ammonium salt, which was subjected to biphasic ring closure.[64] The hydrochloride 
salt was therefore added dropwise to an emulsion of a saturated NaHCO3 solution in chloroform. 
Macrocycle 40 was obtained in acceptable yield as a diastereomeric mixture (dr 87:13). The dia-
stereomers of 40 could partially be separated by column chromatography. To access the allylgly-
cine motif for further derivatization, cycle 40 was subjected to Grubbs I catalyst in DCM at 45 °C 
to get the desired product 41. While the reaction proceeded well with the cyclic tetrapeptide, com-
pound 41 proved to be highly insoluble, which complicated its purification. This fact also under-
mined later transformations of 41 (vide infra). The removal of Ru-impurities was crucial in order 
to obtain pure derivatives for further transformations and biological testing. An acknowledged 
method for the removal of metathesis catalysts is the formation of Ru-DMSO complexes, which 
do not eluate from a silica column.[203] Additionally, providing sophisticated NMR spectra of 41 
turned out to be a non-trivial issue. The majority of commercially available deuterated solvents 
were tested in order to get good NMR spectra of 41. Recording the NMR spectra in tetrachloro-
ethane-d2 at elevated temperatures (100 °C) led to a clear solution and hence clean NMR spectra. 
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Scheme 4.11: Synthesis of Cyl-1 derivatives. 
 
 It was not clear from the beginning whether the metathesis reaction to obtain the allylgly-
cine moiety works well with the cyclic peptide. To optimize the synthesis of Cyl-1 derivatives and 
minimize the number of steps with the cyclic peptide, Boc-protected allylglycine was treated with 
HCl in dioxane and the hydrochloride salt was coupled with tripeptide 18c using TBTU (scheme 
4.12). Saponification of the obtained tetrapeptide 42 and activation as Pfp ester 44 was performed 
for subsequent macrocyclization. To access allylglycine-containing cycle 41 directly after cycliza-
tion, the corresponding linear tetrapeptide 44 was Boc-deprotected and cyclized in a biphasic ring 
closure. Unfortunately, only 45 % of the cyclic compound was obtained and with nearly complete 
epimerization of the intermediate Pfp ester. Compound 41 still contained 10 % of the correspond-
ing cyclodimer, which could not be separated from the desired product. In situ activation of the 
corresponding free peptide (derived after Boc-deprotection in 43) with PfTU and cyclization under 
the same conditions as before also gave no improved results. Macrocycle 41 was obtained as a 
mixture of diastereomers (dr 56:44) along with 15 % of the cyclodimer. 
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Scheme 4.12: Direct cyclization to allylglycine-containing macrocycle 41. 
 
In order to attach several zinc-binding motifs to Cyl-1’s macrocyclic core, different deri-
vatization reactions were tested. A convenient and powerful method to derivatize terminal alkenes 
as present in 41 is the thiol-ene click reaction. Several investigations into this reaction were un-
dertaken in our group and it was shown that this reaction is in general suitable for complex sub-
strates.[142,151] With this in mind, compound 41 was treated with N-acetylcysteamine in THF. When 
BEt3 and air were used as radical starters, approximately 50 % conversion of the starting material 
was achieved. However, separation of the product from unreacted starting material could not be 
accomplished on a preparative scale. With 2-mercaptoacetic acid, no conversion was observed 
under the reaction conditions. Initiation of radical reactions involving thiols could also be per-
formed with visible light. Therefore, compound 41 was treated again with N-acetylcysteamine, 
suspended in DCM, MeCN or DMF and irradiated. Unfortunately, no conversion of the terminal 
alkene was observed under any of the conditions tested. Finally, a method developed by Renaud 
et al. that utilized catechol to “repair” the thiol-ene click reaction was tested in order to achieve 
full conversion.[146] However, even after 24 h and repeated addition of BEt3, only 10 % conversion 
of the starting material was obtained. 
Since thiol-ene click reactions with macrocycle 41 failed, probably due to its low solubility, 
another access to derivatives of Cyl-1 was envisioned by olefin cross metathesis (CM reaction). 
Previous results demonstrated that 40 reacts readily with either Grubbs I or Grubbs II catalyst in 
an intramolecular ring closing metathesis (RCM) to give allylglycine derivative 41. Consequently, 
addition of a second alkene to the reaction mixture should give rise to the corresponding CM 
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product. Grubbs et al. have developed a general model for selectivity in cross metathesis reac-
tions.[204] Unlike RCM, no entropic driving force is present in cross metathesis. Homodimerization 
of alkenes and consumption of CM products generally lead to side products in cross metathesis. 
Acrylates are among the best alkenes for cross metathesis since they don’t show homodimerization 
and the products formed from CM are stable towards further metathesis reactions. Thus, RCM/CM 
reactions were performed both with compound 40 and 41 in combination with different acrylates. 
Compound 40 was used preferably to overcome the limitations resulting from the poor solubility 
of 41. Treatment of cycle 40 with ethyl acrylate and Grubbs II in DCM at 45 °C in a sealed vessel 
showed the formation of allylglycine derivative 41 but no cross metathesis product. Repetition of 
the experiment in an open vessel under Ar gave a 2:1 mixture of 41 and the desired product. Uti-
lization of benzyl acrylate with Grubbs I in a sealed or open vessel only gave allylglycine deriva-
tive 41. Using 40 or 41 and Grubbs II in degassed DCM also led to no improvement. Bubbling 
argon through the reaction mixture for several hours to expel the forming ethylene gave a conver-
sion of 50-60 %. Unfortunately, separation of the CM product from 41 was a non-trivial issue and 
could not be accomplished on a preparative scale. The low solubility of 41 seemed to be the key 
problem in these transformations, preventing full conversion and therewith simple purification. 
Formation of allylglycine cycle 40 from 41 proceeded readily, clearly demonstrating the activity 
of the metathesis catalyst under the reaction conditions. Although large excess of acrylates (up to 
10 eq.) were used in the reaction, the formation of allylglycine derivative 41 seemed to be preferred 
over the formation of CM product. In particular, precipitation of 41 from the reaction mixture 
undermined further transformations. While the general applicability of CM reactions for these 
substrates was indicated by the displayed results and literature reports,[205] the low solubility in 
combination with incomplete conversion restricted the synthetic use of these transformations. 
 With the so far obtained results at hand, other derivatization reactions were exploited. Due 
to the low solubility of 41 and the better accessibility of 40, the latter was preferred for further 
derivatization. Hence, macrocycle 40 was subjected to an ozonolysis with subsequent Wittig reac-
tion in an one-pot manner (scheme 4.13, A). Performing the ozonolysis in presence of pyridine led 
to immediate reduction of the primary ozonide formed during the reaction.[206] Consequently, no 
PPh3 or Me2S was needed to obtain the crude aldehyde. Subsequent addition of a Wittig ylide gave 
access to macrocycle 42. Unsurprisingly, the newly formed double bond exhibited an E/Z-ratio of 
3:1, which was in accordance to previously performed reactions with this ylide. Compound 45 
contained approximately 30 w% of triphenylphosphine oxide as impurity, which could not be sep-
arated from the product. Although methods have been developed to remove triphenylphosphine 
oxide from polar compounds using ZnCl2 in EtOH, application of these conditions to the potential 
zinc-binder 45 afforded no separation.[207] Hydrogenation of 45 proceeded readily and gave mac-
rocycle 46 in good yield. However, the impurity could not be separated at this stage either. Due to 
the low yield of the ozonolysis/Wittig reaction and the inseparable OPPh3 impurity, no further 
efforts were made towards this derivatization. Unfortunately, using a corresponding phosphonate 
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in a Horner-Wadsworth-Emmons reaction yielded no α,β-unsaturated ester at all. No reaction be-
tween the intermediately formed aldehyde and the phosphonate was observed. 
 Further efforts towards the thiol-ene click reaction were undertaken since solely the low 
solubility of 41 seemed to prevent full conversion. Consequently, compound 40 was used as a 
substrate in thiol-ene click reactions. Since the length of the side chain containing the zinc-binding 
motif is important to retain biological activity,[208] other thiols than before were evaluated. Thio-
acetic acid was treated with 40 and BEt3/air in THF to give 82 % of the thiol-ene click product 
(scheme 4.13, B). Careful analysis of the NMR spectra revealed that the intermediately formed 
radical cyclized in an intramolecular 5-exo trig fashion with the internal double bond to form a 
tetrahydrofuran cycle 47. In contrast, previous efforts to undertake thiol-ene click reactions in 
combination with intramolecular cyclizations to form pipecolinic acid derivatives failed and solely 
addition to the external double bond was observed. The formation of the 5-membered ring system 
seemed to be the driving force for this reaction and could be speculated from research done by 
Beckwith and Schiesser, who showed that 5-exo cyclizations are favored over 6-endo.[209] They 
argued that an efficient overlap of the SOMO with the π*-orbital of the alkene in the transition 
state accounts for the selective formation of 5-membered over 6-membered rings. Beckwith et al. 
also developed guidelines to predict the regioselectivity of radical cyclizations.[210] Furthermore, 
Renaud et al. have also reported thiol-ene click addition-cyclization reactions with simple sub-
strates.[146] In the present case, the formation of four diastereomers made a detailed analysis of the 
constitution via NMR spectroscopy impossible. However, performing the reaction with thioben-
zoic acid likewise gave the expected thiol-ene click product with subsequent cyclization to form 
compound 48 in 67 % yield. 
 
 
Scheme 4.13: Ozonolysis/Wittig reaction and thiol-ene click reactions of macrocycle 40. 
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 In conclusion, formation of thiol-ene click products 47 and 48 substantiated the hypothesis 
that the insolubility of 41 limited its synthetic applicability. The fact that 40 underwent rapid in-
tramolecular cyclization after thiol addition could render further investigations into thiol-ene click 
initiated cyclization reactions with complex substrates. The chain length in 47 and 48 should gen-
erally be suitable for effective HDAC inhibition and the thioester moiety might act as a prodrug 
as seen for the natural HDACi largazole (see state of knowledge). 
 
4.3 Synthesis of trapoxin A 
 A straightforward approach towards the macrocyclic HDACi trapoxin A should arise from 
similar building blocks as used for the synthesis of Cyl-1. As outlined there, epoxidation and oxi-
dation should liberate the natural product from a suitable precursor (scheme 4.14). Macrolactami-
zation between Pip and Aoe should leave a linear tetrapeptide, which could be further divided into 
Aoe precursor A and tripeptide H. Although the corresponding position prevented successful cy-
clization in the synthesis of Cyl-1, the respective position proved beneficial in the synthesis of 
trapoxin B.[67] Tripeptide H could be build up through peptide coupling of phenylalanine and (R)-
pipecolinic acid I. This non-proteinogenic amino acid should be accessible through Mitsunobu 
cyclization of a suitable alcohol J, which in turn could be obtained through ester enolate Claisen 
rearrangement. The stereogenic information should again come from the chiral pool, in this case 
from D-tartaric acid. 
 
 
Scheme 4.14: Retrosynthetical analysis of trapoxin A. 
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4.3.1 Synthesis of a (R)-pipecolinic acid-containing tetrapeptide 
 To target the non-proteinogenic (R)-pipecolinic acid moiety in trapoxin A via ester enolate 
Claisen rearrangement and subsequent Mitsunobu cyclization, a fitting allylic alcohol was needed. 
Starting from D-tartaric acid, 2,3-O-isopropylidene-D-threitol can be obtained in two steps fol-
lowing literature procedure.[155] Monobenzylation of this threitol derivative needed optimization 
to access 1 in reasonable yield. Following a literature protocol using sodium hydride and benzyl 
bromide in DMF gave 50 % of ent-1b, together with the corresponding dibenzylated product.[156] 
While altering solvent and/or temperature didn’t yield better results, replacement of benzyl bro-
mide with benzyl chloride gave an improved yield of 60 % (scheme 4.15). Alcohol ent-1b was 
further transformed into iodide ent-5b in a modified Appel reaction[211] and was then treated with 
zinc dust and acetic acid in THF to form allylic alcohol 49.[212] The enantiomeric ratio in 49 was 
shown to be > 99:1, clearly demonstrating the power of a chiral pool synthesis approach. Esterifi-
cations with N-protected glycines gave allyl esters 50. Choosing a proper solvent for esterification 
under Steglich conditions was crucial in terms of yield. While diethyl ether would allow for quan-
titative removal of urea byproducts by simple filtration, the yields were significantly worse com-
pared to the yields obtained in DCM. To introduce the (R)-configured pipecolinic acid moiety, 
esters 50 were subjected to ester enolate Claisen rearrangements, which proceeded readily with 
both esters 50a and 50b and afforded carboxylic acids 51 in good yields and good to excellent 
enantioselectivities. Towards the synthesis of the pipecolinic acid scaffold, the TFA-protected car-
boxylic acid 51b was transformed into tert-butyl ester 52 with tert-butyl trichloroacetimidate in 
92 % yield.[213] The combination of TFA- and tert-butyl protected amino acid was chosen since 
good results were obtained with these protective groups in previous studies.[214] Hydrogenation of 
this amino acid ester and subsequent Mitsunobu cyclization then gave pipecolinic acid 54 in mod-
erate yields. High dilutions were mandatory for this latter step to form the six-membered ring. 
Nevertheless, elimination of the activated hydroxy group to the corresponding olefin was observed 
even at dilutions as low as 12 mM. Removal of the TFA group was performed with a method 
developed by Weygand and Frauendorfer using sodium borohydride in ethanol.[215] Coupling of 
the crude amine with Cbz-(S)-Phe-OH accessed dipeptide 55 with slight epimerization (dr 94:6). 
Further hydrogenation of 55 and coupling with Cbz-(S)-Phe-OH yielded 82 % of tripeptide 56, 
which was then derivatized to give the linear tetrapeptide. The diastereomeric ratio of tripeptide 
56 was analyzed to be 89:11. The observed epimerization was surprising since the combination of 
TBTU and DIPEA usually performed well in similar couplings. No further investigations into the 
origin of these diastereomers were undertaken at this point of the synthesis since the optimal ring 
closing position needed to be evaluated first. 
4. Results and Discussion 
 
 
70 
 
Scheme 4.15: Synthesis of Pip-containing tripeptide 56. 
 
 Tripeptide 56 was hydrogenated under typical conditions (H2/Pd/C) and coupled with Aoe 
precursor 10 to gain access to linear tetrapeptide 57 (scheme 4.16). TBTU proved to be by far the 
most useful reagent to perform this kind of couplings due to the mild reaction conditions. Selective 
cleavage of tert-butyl esters in presence of acid-labile groups has previously been investigated in 
the synthesis of Cyl-1 (see chapter 4.1.2). Careful analysis of the course of the reaction under 
acidic conditions revealed that decomposition started with cleavage of the TIPS group. However, 
several literature reports were found that utilized TMSOTf or TESOTf for mild cleavage of tert-
butyl esters in complex structures and natural product synthesis.[216] With this in mind, tetrapeptide 
57 was treated with TMSOTf to give a complex mixture of starting material, product, and TIPS-
deprotected compounds. As a result, the silyl ether in 57 was replaced by a tosylate to give 
tetrapeptide 58 and a more convenient and robust three-step protocol for the selective tert-butyl 
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ester cleavage was developed. Ketal cleavage with aq. HCl at 60 °C led to the corresponding diol, 
which was treated with TFA in DCM to obtain the free carboxylic acid. Reinstallation of the ketal 
with pTosOH in boiling acetone gave access to carboxylic acid 59 in 81 % yield without interme-
diate purification steps. Subsequent activation of 59 as Pfp ester did not proceed as readily as 
observed for other substrates, meaning that no full conversion was attained. Following hydrogena-
tive ring closure in dioxane/EtOH at 85 °C afforded the cyclic tetrapeptide 60 in poor yield and 
with almost full epimerization. However, no starting material was reisolated from the reaction 
mixture, indicating that Cbz-cleavage did occur, but the conformation of the macrocycle seemed 
to undermine a successful cyclization. 
 
 
Scheme 4.16: Synthesis of linear tetrapeptide 59 and macrocyclization. 
 
4.3.2 Synthesis of trapoxin A via peptide backbone modifications 
 Macrolactamization between Pip and Aoe failed to afford the macrocyclic core structure 
of trapoxin A in acceptable yield. Consequently, a different approach towards the natural product 
was desired. As envisioned earlier, the structure of trapoxin A should allow for several peptide 
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backbone modification reactions, as outlined in the retrosynthetical analysis (scheme 4.17). Mac-
rocyclization between Aoe and phenylalanine should give a linear tetrapeptide K, which could be 
further disjointed by various peptide modifications. Mitsunobu cyclization to construct the pipe-
colinic acid moiety, together with transition metal catalyzed allylic alkylation to introduce the Aoe 
side chain, were powerful transformations to be considered in the synthesis of natural HDAC in-
hibitors. Linear tetrapeptide K contains a combination of (S)-(S)-(R)-(S)-configured amino acids. 
The (S)-configured Aoe side chain should be introduced via transition metal catalyzed allylic al-
kylation, controlled by the (R)-configured pipecolinic acid precursor in L. Allylic alcohol C should 
be synthesized starting from L-tartaric acid as outlined for Cyl-1. The Pip precursor itself can be 
introduced in a second TM-catalyzed allylic alkylation of tripeptide M, while the adjacent (S)-
phenylalanine should control the stereochemical outcome of the C-C bond formation in favor of 
the (R)-isomer. 
 
 
Scheme 4.17: Retrosynthesis of trapoxin A using peptide modifications. 
 
 Following the retrosynthetical analysis, glycine-containing tripeptides were synthesized 
starting from Cbz-(S)-Phe-(S)-Phe-OMe (scheme 4.18). Both the Cbz- and TFA-protected tripep-
tides were subjected to ruthenium catalyzed allylic alkylations to introduce (Z)-configured allyl 
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side chains. Subsequent transesterification of benzoates formed allylic alcohols in acceptable 
yields.[217] These (Z)-configured allylic alcohols should allow for rapid cyclization and would 
leave a double bond in the six-membered baikiain derivative for further modifications.[214] The 
utilized [BisAllylRuCl2]2 complex (= [(η3:η3-2,7-Dimethylocta-2,6-diene-1,8-diyl)RuCl2]) was 
discovered in earlier works to efficiently catalyze allylic alkylations of glycine enolates.[218] Nev-
ertheless, the diastereomeric ratios obtained in the allylation step were not outstanding and could 
only be determined after transesterification. Before further efforts were made to evaluate other 
reaction conditions or catalysts to remedy this drawback, attempts towards the Mitsunobu cycliza-
tion of these derivatives were undertaken.[219] While cyclizations of N-terminal amino acids bear-
ing electron-withdrawing groups under Mitsunobu conditions have been described in litera-
ture,[214,220] the utilization of internal or C-terminal amino acids in peptides for this purpose has 
not. Therefore, the previously synthesized allylic alcohols were subjected to Mitsunobu conditions 
(scheme 4.18). Unfortunately, in all reactions performed, only substitution of the activated alcohol 
with hydrazine was observed. This led to the conclusion that the pKa-value of peptidic amides was 
not feasible for successful cyclization under the reaction conditions used. 
 
 
Scheme 4.18: Ru-catalyzed allylic alkylation of tripeptides. 
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 These results clearly indicated that another synthetic strategy was needed to construct the 
pipecolinic acid scaffold present in trapoxin A. The requirement of N-terminal amides for success-
ful Mitsunobu cyclization called for a different protocol to introduce the (R)-configured side chain. 
The stereogenic center in the Pip moiety could be introduced via ester enolate Claisen rearrange-
ment as presented earlier (scheme 4.15). Coupling to glycine would give a dipeptide, whose (R)-
configured residue could be used to introduce the (S)-configured Aoe side chain through allylic 
alkylation of a chelated dipeptide enolate. Subsequent Mitsunobu cyclization of the N-terminal 
amino acid should afford a Pip-containing dipeptide. 
Consequently, carboxylic acid 51a was activated with IBCF and coupled with glycine es-
ters to afford dipeptides 61 (scheme 4.19, A). The Cbz-group in 61 was replaced by TFA through 
hydrogenation and subsequent treatment with TFAOMe.[221,222] The obtained dipeptides 61 and 62 
were used to determine the optimal combination of N-protective group and ester for Pd-catalyzed 
allylic alkylation in terms of yield and diastereoselectivity (vide infra). Dipeptide 61c was also 
hydrogenated in presence of aq. HCl and treated with TFAOMe to give the TFA-protected dipep-
tide 63 with a free hydroxy group. Addition of acid to the hydrogenation mixture was crucial since 
the initially formed amine prevented cleavage of the benzyl ether. Under these conditions, 22 % 
of the dehydroxylation product were isolated as side product. Transformation of the desired alco-
hol 63 under Mitsunobu conditions gave rise to the pipecolinic acid-containing dipeptide 64 in 
good yields, proving the applicability of this synthetic strategy (proof of concept). 
 The call for dipeptides with electron-withdrawing N-protective groups for successful 
Mitsunobu cyclization made switching of protective groups necessary. To omit these steps, car-
boxyl acid 51b was coupled with HCl·H-Gly-OtBu under diverse reaction conditions. In general, 
TFA-protected amino acids are known to epimerize after activation and during peptide coupling. 
Epimerization proceeds via intramolecular cyclization of the TFA-amide with the activated car-
boxylic acid and subsequent racemization of the azlactone formed. However, some examples have 
been described in literature to successfully couple TFA-protected amino acids.[223] Activation of 
51b with IBCF to form the mixed anhydride at –20 °C gave dipeptide 61b in 58 % yield and 92 % 
ee (scheme 4.19, B). To improve the yield of the coupling, the reaction was repeated with 
EDC·HCl, HOBt and DIPEA. Under these conditions, 86 % of the dipeptide were obtained. How-
ever, severe epimerization of the activated amino acid (er 76:24) was observed. Repetition of the 
reaction under exact same conditions gave an enantiomeric ratio of 85:15, demonstrating the poor 
reproducibility of the reaction. Omitting the additional base and increasing the equivalents of 
EDC·HCl was also of no advantage. Utilization of other coupling reagents and additives also fell 
short compared to the first attempt. Surprisingly, performing the IBCF coupling at –40 °C gave 
even worse er values than at –20 °C. Thus, the synthetic route via the Cbz-protected dipeptides 
was by far the best choice to construct TFA-protected dipeptides in terms of yields and epimeri-
zation rates. 
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Scheme 4.19: Synthesis of dipeptides for Pd-catalyzed allylic alkylation. 
 
With different suitable dipeptides in hand, the next step in the synthesis towards trapoxin A 
was the introduction of the Aoe side chain. As mentioned above, (R)-configured amino acids con-
trol the stereochemical outcome of the new stereogenic center formed during allylic alkylation in 
favor of the (S)-configured amino acid (and vice versa).[128] One side of the chelated dipeptide 
ester enolate complex is shielded by the side chain of the N-terminal amino acid and attack of the 
dipeptide nucleophile at the Pd-π-allyl complex takes place from the unshielded side preferably. 
This diastereoselective peptide modification reaction was therefore particularly useful for the con-
struction of the peptide backbone present in trapoxin A. To determine the optimal conditions to 
introduce the Aoe side chain, the above prepared dipeptides were reacted with different allylic 
substrates under Pd-catalysis to form the linear allylation products. 
Allylic substrates for the allylic alkylation bearing different leaving groups were derived 
from allylic alcohol 7c (table 4.6). Since a terminal Pd-π-allyl complex was formed in the course 
of the allylation reaction, the stereogenic information from these substrates could not be transferred 
due to rapid π-σ-π isomerization of the Pd-allyl complex (scheme 4.20, path A) or displacement 
of Pd(0), as suggested by Bäckvall et al. (path B).[224] This was no synthetic disadvantage because 
the newly formed stereogenic center should be controlled by the chiral, chelated dipeptide enolate 
complex, anyway. Due to this rapid isomerization, alcohol (3R)-7c could also be utilized in the 
transformation after introduction of a suitable leaving group. Therewith, both diastereomers of 
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alcohol 7c, derived from enzymatic kinetic resolution, could be employed for the synthesis of the 
Aoe scaffold via either ester enolate Claisen rearrangement or Pd-catalyzed allylic alkylation. 
 
Table 4.6: Synthesis of different allylic substrates for Pd-catalyzed allylic alkylation. 
 
 
entry SM conditions Y LG product 
1 7c MeOCOCl, Py, 0 °C 94 % -COOMe 65 
2 7c EtOCOCl, Py, 0 °C - rt 91 % -COOEt 66 
3 7c 
(EtO)2POCl, Py, 4-DMAP, 
DCM, 0 °C – rt 
75 % -PO(OEt)2 67 
4 7c BzCl, Py, 0 °C 99 % -Bz 68 
5 (3R)-7c EtOCOCl, Py, 0 °C - rt 93 % -COOEt (3R)-66 
 
 
Scheme 4.20: Racemization of terminal Pd-π-allyl complexes. 
 
 The investigations into Pd-catalyzed allylic alkylation started with Cbz-protected dipep-
tides 61a and 61c, which gave the desired allylated products but usually lacked full conversion of 
the allylic substrate 65 (table 4.7, entries 1-2). Since TFA-protective groups were needed anyway 
for further transformations (Mitsunobu cyclization), the allylations were in the following per-
formed with the corresponding TFA-protected dipeptides 61b and 62c. Use of LHMDS as base 
for the formation of chelated enolates in combination with methyl- and ethyl chloroformates gave 
the allylation product 69c in 62 % and 80 % yield, respectively (entries 3-4). Afterwards, different 
leaving groups in the allylic substrate were tested in combination with different temperature pro-
files according to their general reactivity (entries 5-8). While incomplete conversion was observed 
for all leaving groups tested, the phosphate group in 67 seemed to be by far the most reactive. 
Benzoate 68 on the other hand gave the best diastereoselectivities. This matched previous results 
since more reactive leaving groups generally tended to give poorer selectivities.[225] Ethyl car-
bonate 66 was further utilized in combination with LDA to give allylation product 69d in 66 % 
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yield (entry 9). Noteworthy, allylations performed with LDA generally showed better reproduci-
bility. Furthermore, reisolation of unreacted dipeptide from the reaction mixture and determination 
of diastereomeric ratios revealed no epimerization of the α-center of the N-terminal amino acid. 
Later experiments with the diastereomerically enriched allylic substrate (3R)-66 in combination 
with dipeptide 61b (entry 10) or 62c (entry 11) gave similar results in terms of yield (87 % and 85 
%) and diastereoselectivity (dr ~ 80:20). These results demonstrated that the presence of a double 
bond in the dipeptide had no effect on the stereochemical outcome of the reaction. 
 
Table 4.7: Pd-catalyzed allylic alkylations of dipeptides to introduce the Aoe side chain. 
 
 
  allylic substrate conditions product 
entry 61/62 LG 65-68 base T Y 69 dr 
1 61c COOMe 65 LHMDS rt 18 % a 77:23a 
2 61a COOMe 65 LHMDS rt 65 % b 75:25b 
3 62c COOMe 65 LHMDS rt 62 % c 84:16b 
4 62c COOEt 66 LHMDS rt 80 % c 89:11a 
5 61b COOEt 66 LHMDS rt 55 % d 86:14c 
6 61b PO(OEt)2 67 LHMDS –65 °C 62 % d 74:26a 
7 61b COOEt 66 LHMDS –60 °C 24 % d 84:16a 
8 61b Bz 68 LHMDS rt 29 % d 92:8a 
9 61b COOEt 66 LDA rt 66 % d 89:11c 
10 61b COOEt (3R)-66 LDA rt 87 % d 79:21b 
11 62c COOEt (3R)-66 LDA rt 85 % c 80:20b 
a: determined by 1H-NMR, b: determined by HPLC, c: determined by 13C-NMR 
 
 The next step in the synthesis was the construction of the pipecolinic acid since this has to 
be accomplished with the N-terminal amino acid residue (as discussed above). The use of methyl 
esters in the synthesis of trapoxin A was exploited, in order to avoid issues later in the synthesis 
during tert-butyl ester cleavage as seen before. Therefore, methyl ester 69b was transformed into 
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the pipecolinic acid-containing dipeptide 72b (scheme 4.21). Hydrogenation of 69b and subse-
quent TFA-protection gave the corresponding dipeptide 70b. To prevent deoxygenation during 
hydrogenation under acidic conditions, the benzyl ether in 70b was cleaved in a second reaction 
to give alcohol 71b, suitable for Mitsunobu cyclization. Luckily, cyclization proceeded well to 
form the Pip-dipeptide 72b in 84 % yield. All attempts to remove the TFA group under basic 
conditions failed, meaning that the crude amine couldn’t be isolated from the reaction mixture. 
Reducing the TFA-group in 72b with NaBH4 gave the corresponding amine. Unfortunately, the 
1H-NMR spectrum revealed additional cleavage of the methyl ester. These findings have also been 
reported by Weygand and Frauendorfer, who stated the incompatibility of their method in presence 
of methyl esters.[215] Therefore, the use of tert-butyl esters to construct the pipecolinic acid moiety 
and reduce the TFA-group was obligatory. 
 
 
Scheme 4.21: Transformation of 69b to Pip-containing dipeptide 72b. 
 
 The reactions were then optimized for the TFA-protected dipeptide tert-butyl esters. Di-
peptides 69c-d were hydrogenated to reduce the double bond(s) and cleave the benzyl ether (table 
4.8). Under standard conditions (1 bar H2/Pd/C, MeOH, rt), neither reduction of the double bond 
nor the benzyl ether was observed (entry 1). Instead, partial cleavage of the ketal in 69c was de-
tected. Changing the solvent to ethyl acetate and rising the pressure to 2 bar led to hydrogenation 
of the double bond, but no benzyl ether cleavage was observed. Subsequent performance of the 
reaction at 20 bar gave 85 % of the desired product 71c (entry 2). In contrast, repeating the reaction 
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with dipeptide 69d showed less reactivity resulting in incomplete double bond hydrogenation at 3 
bar (entry 3) and no benzyl cleavage at 20 bar (entry 4). However, at pressures as high as 50 bar, 
71c was obtained in quantitative yields (entry 5). The solvent was switched to THF, which gener-
ally showed the highest reactivities for benzyl ether cleavage.[226] Indeed, hydrogenation of 69c in 
THF at 20 bar for 24 h gave 82 % of 71c, along with an unknown side product (entry 6). The 
reaction was repeated and no benzyl ether cleavage was observed after 18 h at 20 bar. Catalytic 
amounts of acetic acid were added to facilitate benzyl ether hydrogenolysis and the pressure was 
increased to 30 bar to obtain 99 % of pure 71c (entry 7). Performing the reaction immediately at 
30 bar with catalytic HOAc lowered the yield slightly (entry 8). 
 
Table 4.8: Optimization of the hydrogenation of 69c-d. 
 
 
entry DB conditions Y comment 
1  1 bar, MeOH, 21 h - partial ketal cleavage 
2  2 bar, EtOAc, 3 h, then 20 
bar, EtOAc, 20 h 
85 % no benzyl deprotection at 2 bar 
3 ✓ 3 bar, EtOAc, 6 h - partial DB hydrogenation 
4 ✓ 20 bar, EtOAc, 4 h 71 % no benzyl deprotection 
5  50 bar, EtOAc, 24 h quant. - 
6  20 bar, THF, 24 h 82 % unknown side product 
7  20 bar, THF, 18 h, then cat. 
HOAc, 30 bar, THF, 22 h 
99 % - 
8  30 bar, cat. HOAc, THF, 
24 h 
91 % - 
 
 Having dipeptide 71c at hand, attempts towards the crucial Mitsunobu reaction were un-
dertaken. Under the previously described conditions, Pip-containing dipeptide 72c was obtained 
in excellent yield and the diastereomeric ratio was not influenced by the reaction (scheme 4.22). 
Subsequent reduction of 72c with NaBH4 gave crude amine 73c, leaving the tert-butyl ester unaf-
fected. Unfortunately, coupling with Cbz-(S)-Phe-(S)-Phe-OH and TBTU failed and did not lead 
to formation of the corresponding tetrapeptide 75. Stepwise coupling of amine 73c with 
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Cbz-(S)-Phe-OH to tripeptide 74, followed by hydrogenolysis and immediate second coupling 
with Cbz-(S)-Phe-OH gave the desired tetrapeptide 75 in excellent yield. 
As speculated above, the selective cleavage of tert-butyl esters in presence of acid-sensitive 
groups in 75 was again a non-trivial issue. Performing the reaction under standard conditions (HCl, 
dioxane, rt) as well as at low temperatures (TFA, DCM, –40 °C) gave only decomposition prod-
ucts. Other methods to selectively cleave the tert-butyl ester were examined in the synthesis of 
Cyl-1 and gave no improved results. As pointed out before, decomposition was found to start with 
TIPS-cleavage. Consequently, the silyl ether in 75 was again replaced by a tosylate to give 
tetrapeptide 77 (scheme 4.22). The substitution could either be performed in two steps, with iso-
lation of alcohol 76, or in two subsequent steps without intermediate purification of the alcohol. 
The yields were in a similar range (73 % and 82 % respectively). 
 
 
Scheme 4.22: Mitsunobu cyclization and synthesis of tetrapeptide 77. 
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Noteworthy, tripeptide 74 crystallized spontaneously after column chromatography from a 
mixture of petroleum ether/ethyl acetate. Therefore, the relative configuration of the stereocenters 
in 74 was determined by X-ray diffraction (figure 4.2). Conclusions about the absolute configura-
tion were drawn from the known stereogenic centers derived from starting materials (Cbz-(S)-Phe-
OH and L-tartaric acid). The assumption about stereocontrol during Pd-catalyzed allylic alkylation 
was proven correct since the configuration of the main diastereomer met the expectations. 
 
 
Figure 4.2: X-ray structure of the major diastereomer of tripeptide 74. 
 
 In order to avoid side reaction of the labile ketal in 77 during tert-butyl ester cleavage, acid 
hydrolysis with aq. HCl in THF was attempted to give diol 78 (scheme 4.23). Interestingly, very 
slow conversion of the ketal was observed at room temperature. Thus, hydrolysis was performed 
at 60 °C to afford the free diol in almost quantitative yield. Diol 78 was typically obtained along 
with 10 % of the corresponding carboxylic acid. Further methods were evaluated to suppress this 
side reaction. While Amberlyst 15 has been reported to selectively cleave acetonides in acid-sen-
sitive substrates,[227,228] no conversion of the starting material was observed under the reported 
conditions, not even at 50 °C. Diol 78 was then subjected to a variety of transformations as high-
lighted in scheme 4.22. Due to the fact that the Aoe side chain already needed alteration to cleave 
the tert-butyl ester (switching from -TIPS to -Tos), some attempts were undertaken to install a 
precursor of the α-epoxyketone at this stage of the synthesis. This would account for fewer trans-
formations of the cyclic peptide later in the synthesis. Thus, diol 78 was treated with DBU to form 
the epoxyalcohol under similar conditions than reported in the synthesis of trapoxin B.[67] To sup-
press side reactions of this epoxyalcohol during acidic tert-butyl ester cleavage, like Payne rear-
rangement or epoxide opening, the alcohol function was directly protected as benzyl carbonate 79. 
The Cbz-group could potentially be cleaved during hydrogenative ring closure to give a direct 
precursor of trapoxin A after cyclization. Unfortunately, treatment of carbonate 79 with TFA in 
DCM gave solely decomposition products. Consequently, further options to selectively cleave the 
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tert-butyl ester in 77 were tested. As discussed before, TMSOTf was used to transform tetrapeptide 
77 into the corresponding carboxylic acid 80. Even though 49 % of the carboxylic acid was ob-
tained, the reaction suffered from poor reproducibility and the results could not get improved. 
Reactions with TESOTf and 77 gave none of the desired product. As a result, the beforehand 
developed three-step protocol was utilized. Diol 38 was treated with TFA to give the free carbox-
ylic acid and subsequent reinstallation of the ketal with pTosOH in acetone gave tetrapeptide 80 
in 79 % yield without intermediate purification. This linear tetrapeptide 80 was then used for cy-
clizations to the macrocyclic core of trapoxin A. 
 
 
Scheme 4.23: Transformations of tert-butyl ester 77 and diol 78. 
 
 With tetrapeptide 80 at hand, intensive investigations into the macrocyclization step were 
undertaken. Activation of linear tetrapeptide 80 was performed with pentafluorophenol. The cor-
responding Pfp ester 81 was cyclized under hydrogenative conditions to form the cyclic peptide 
60 (scheme 4.24 and table 4.9). Performing the reaction under elevated pressure with or without 
additional acid showed no conversion (entries 1-4). Addition of acid was thought to suppress cat-
alyst inactivation from gradually formed amine and the ammonium salt should then be cyclized in 
a subsequent step. However, Cbz-deprotection seemed not to occur as the activated Pfp ester 81 
was reisolated from the reaction mixture. Since higher temperatures were sometimes required for 
successful macrolactamization of these derivatives, a solution of Pfp ester 81 was added slowly to 
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a vigorously stirred suspension of Pd/C in dioxane at 80 °C. During the addition, H2 was continu-
ously passed through the reaction mixture. Utilizing this method developed by Schmidt et al. gave 
28 % of macrocycle 60 as a single diastereomer after purification (entry 5).[191] Carboxylic acid 80 
was also hydrogenated at 20 bar H2 pressure to give free peptide 82, which was subsequently 
cyclized according to Schreiber’s trapoxin B synthesis.[67] Herein, similar results were observed 
compared to the hydrogenative ring closure, although with slightly worse diastereoselectivities (dr 
~ 90:10). 
 
 
Scheme 4.24: Macrocyclization with tetrapeptide 80. 
 
Table 4.9: Optimization of the hydrogenative ring closure of 81. 
 
entry conditions T Y dr* comment 
1 
5 bar, THF (5 mM), 18 h, then 
20 bar, 24 h 
rt - - almost no conversion 
2 
5 bar, THF (5 mM), 24 h, then 
20 bar, 20 h 
rt - - 1 % cyclic product 
3 
20 bar, HCl/dioxane, THF (14 
mM), Pd/C + Pd(OH)2/C, 63 h 
rt - - no product detected 
4 
5 bar, THF (5 mM), 18 h, then 
20 bar, cat. HOAc, 24 h 
rt - - no product detected 
5 
continuous H2 induction, diox-
ane (0.6 mM), EtOH 
80 °C 28 % > 99:1 - 
*determined by 1H-NMR and LCMS 
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 To accomplish the first total synthesis of trapoxin A, macrocycle 60 was transformed sim-
ilarly to literature procedures described for trapoxin B (scheme 4.25).[67] Ketal cleavage in 60 with 
aq. HCl proceeded smoothly at rt and subsequent treatment with DBU in MeOH gave epoxyalco-
hol 83. Finally, this alcohol was oxidized with DMP in DCM to give rise to trapoxin A as a single 
diastereomer. The NMR spectra recorded were in accordance to previously reported data of the 
isolated natural product (see appendix).[41] 
 
 
Scheme 4.25: Synthesis of trapoxin A. 
 
 In conclusion, the described peptide modification approach towards the natural product 
trapoxin A proved to be a powerful tool in the construction of both the (R)-configured pipecolinic 
acid and the Aoe scaffold. Allyl alkylation of chelated dipeptides should in general be suitable for 
the synthesis of various derivatives through altering the allylic substrate. Although tert-butyl ester 
cleavage proved to be difficult without altering the initial Aoe side chain precursor, robust methods 
to accomplish this task were developed and could be used in other natural product synthesis. 
 
4.4 Biological evaluation 
 The synthesized natural products, together with their epoxyalcohol precursors and deriva-
tives, were surveyed with regard to their cytotoxicity. Biological testing was performed in coop-
eration with Prof. Dr. R. Müller at Helmholtz Institute for Pharmaceutical Research Saarland 
(HIPS) in Saarbrücken and the experiments were conducted by Viktoria Schmitt and Dr. Jennifer 
Herrmann. The synthesized compounds were incubated with different cancer cell lines in order to 
determine their influence on cell proliferation and viability. Quantification of the concentration-
dependent inhibition of cell growth was achieved using an MTT assay.[229,230] 
 This quantitative colorimetric assay is based on the NADH-dependent transformation of 
the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) to form-
azan (scheme 4.26). Cell-dependent reduction of the pale yellow MTT leads to formation of dark 
blue formazan, which segregates from the assay medium. Formazan is then dissolved with acidi-
fied iso-propanol and colorimetrically quantified at a wavelength of 570 nm. The concentration-
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dependent absorption of formazan is proportional to the number of living cells since only these 
can reduce MTT effectively. 
 
 
Scheme 4.26: NADH-dependent reduction of MTT to formazan. 
 
 To determine the biological activity of the synthesized compounds, incubation with differ-
ent cancer cell lines was performed for five days before MTT was added. Afterwards, the amount 
of produced formazan was measured, which allowed conclusions about the number of living cells 
present after treatment with the substances. The obtained IC50 values are summarized in table 4.10 
and are given in µg/mL and µmol/L, respectively. 
 
Table 4.10: Biological activity of the natural HDACi and their derivatives. 
 IC50 [µg/mL] IC50 [µM] 
compound HCT-116 KB-3.1 U-2 OS HCT-116 KB-3.1 U-2 OS 
24 19.1 - 7.2 32.6 - 12.3 
Cyl-1* 0.007 - 0.0002 0.01197 - 0.00034 
41* > 50 > 50 - > 103.2 >103.2 - 
46*,a > 50 > 50 - > 91.8 >91.8 - 
47 12.3 44.6 - 19.5 70.7 - 
48 > 50 > 50 - > 72.2 >72.2 - 
83 1.4 10.1 - 2.3 16.7 - 
trapoxin A 0.00024 0.052 - 0.00040 0.08627 - 
*not completely soluble; a: triphenylphosphine oxide impurity; HCT-116: human colon cancer cells; KB-3.1: human endocervical adenocarci-
noma cells; U-2 OS: human osteosarcoma cells 
 
Direct comparison between the natural product Cyl-1 and its epoxyalcohol precursor 24 
underlined the importance of the epoxyketone functionality to attain biological activity. An in-
crease in inhibitory activity by 4-5 orders of magnitude was noted after oxidation to the natural 
product. Furthermore, Cyl-1 exhibited a 35-fold higher activity against U-2 OS cells compared to 
the HCT-116 cell line. 
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 Unsurprisingly, the derivatives of Cyl-1 (41, 46, 47 and 48) showed significantly lower 
activity due to their rather simple side chain functionalities. However, thioacetate 47 inhibited 
cellular growth in the µM range, while the corresponding benzoate revealed less pronounced in-
hibitory activity. Since these two compounds only differ in their esterified acid moiety, further 
investigations whether a prodrug mechanism is in place need to be undertaken. 
 Outstanding results were obtained for trapoxin A. Similar to Cyl-1, the epoxyalcohol pre-
cursor 83 showed significantly lower activity due to the missing epoxyketone group. However, the 
natural product showed IC50 values in the low nM range with a 215-fold selectivity in favor of 
HCT-116 over KB-3.1. The origin of this high selectivity towards a certain cancer cell line needs 
further assessment. 
 In summary, the natural HDACi were shown to effectively inhibit cellular growth in the 
nM range. The importance of the ketone functionality for the biological activity was underlined. 
Further zinc-binding motifs were evaluated, while interesting results were obtained for the two 
thioesters 47 and 48. The distinguished selectivity of trapoxin A in favor of one cancer cell line 
over another triggered further investigations. Moreover, inhibition of isolated HDAC enzymes 
needs to be evaluated to allow conclusions about their HDACi-activity and -selectivity profiles. 
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5. Experimental section 
5.1 General remarks 
 All chemicals and solvents were ordered from “Zentrales Chemikalienlager” at Saarland 
University and were occasionally purified and dried using standard techniques. 
 Thin layer chromatography was performed with precoated silica gel plates from Sigma-
Aldrich. Visualization was accomplished with a 254 nm UV lamp, an iodine chamber, a KMnO4 
bath, a ninhydrin bath or a Ce(IV) bath. 
 Column chromatography was done with silica gel (60 Å, 63-200 µm, technical) from 
Macherey-Nagel and a Reveleris® Flash Chromatography System from Grace with RediSep® Rf 
columns from Teledyne Isco. 
 1H-NMR spectra were recorded on a 400 MHz Bruker AC II 400 or a 500 MHz Bruker AV 
500 spectrometer. Chemical shifts are reported in ppm relative to TMS, and the NMR solvent was 
used as internal standard. Analysis of the spectra was performed with NMR Processor Academic 
Edition 12.01 from ACD. 
 13C-NMR spectra were also recorded on a 400 MHz Bruker AC II 400 or a 500 MHz 
Bruker AV 500 spectrometer. The spectra were proton decoupled. The theoretical couplings be-
tween C and H and the actual couplings between C and F, P are given. Chemical shifts are reported 
in ppm relative to TMS, and the NMR solvent was used as internal standard. Analysis of the spec-
tra was performed with NMR Processor Academic Edition 12.01 from ACD. 
 Optical rotations were measured on a PerkinElmer Model 341 in a tempered (20 ± 0.1 °C, 
unless otherwise stated) 1 dm cuvette. A sodium vapor lamp (λ = 589 nm) was used as light source 
and the optical rotation was calculated from the device as function of the concentration. 
 HRMS were recorded with a MAT 95Q from Finnigan or a maXis 4G hr-ToF from Bruker 
Daltonics. 
 For gas chromatography, a Shimadzu (GC-2010, autoinjector AOC-20i, FID-detector) 
with a Varian capillary column CP-Chirasil-Dex CB (25 m x 0.25 mm, 0.25 µm ID) with nitrogen 
as carrier gas was used. 
 HPLC analyses were performed on a Merck Hitachi D-7000 with a Diode Array detector 
L-7455. 
 LCMS analyses were accomplished on a Shimadzu (LC-10At, autoinjector SCL-6B, mass 
spectrometer LCMS-2020). A Phenomenex Luna C18(2) column (50 x 4.6 mm, grain size 3 µm) 
was used as the column. 
 Melting points were measured uncorrected in open glass capillaries with an IA 9100 de-
vice from Electrothermal. 
 For lyophilisation, a lyophilisator Alpha from Christ was used. 
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5.2 Synthesis of compounds 
((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)methanol 
(1c)[67] 
To a suspension of 2.40 g (60.0 mmol) Sodium hydride (60 w% in paraffin) in 350 mL THF abs. 
was added dropwise a solution of 8.92 g (55.0 mmol) (+)-2,3-O-Isopropylidene-L-threitol in 35 
mL THF abs. at 0 °C. The cooling bath was removed and the reaction was stirred at rt for 1 h. 
After cooling to 0 °C, a solution of 10.8 mL (9.84 g, 50 mmol) TIPSCl in 35 mL THF abs. was 
added slowly and the reaction was stirred for 1 h. The reaction was concentrated in vacuo, the 
residue was redissolved in Et2O and water was added. The layers were separated and the aqueous 
phase was extracted three times with diethyl ether. The combined organic layers were dried over 
Na2SO4 and the crude product was purified by column chromatography (silica gel, PE:EA 80:20, 
50:50) to yield 15.8 g (49.6 mmol, 99 %) of compound 1c as a slightly yellow oil. 
Rf (1c) = 0.39 (silica gel, PE:EA 70:30) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.16 (m, 21 H, 1-H, 2-H), 1.40 (s, 3 H, 7-H), 1.42 (s, 3 
H, 7'-H), 2.45 (br s, 1 H, OH), 3.71 – 3.76 (m, 2 H, 3-Ha, 8-Ha), 3.79 (dd, 2J8b,8a = 11.5 Hz, 3J8b,5 
= 4.8 Hz, 1 H, 8-Hb), 3.90 (dt, 
3J5,8 = 7.7 Hz, 
3J5,4 = 3.8 Hz, 1 H, 5-H), 3.97 (dd, 
2J3a,3b = 9.8 Hz, 
3J3a,4 = 4.0 Hz, 1 H, 3-Hb), 4.03 (dt, 
3J4,3 = 7.9 Hz, 
3J4,5 = 4.6 Hz, 1 H, 4-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.0 (q, C-7'), 62.8 
(t, C-8), 64.2 (t, C-3), 78.2 (d, C-5), 80.5 (d, C-4), 109.1 (s, C-6). 
Optical rotation:   [∝]𝐷
20 = +13.0° (c = 1.0, CHCl3) 
 
Methyl 3-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)acry-
late (2c) 
To a solution of 2.70 mL (4.05 g, 31.9 mmol) oxalyl chloride in 75 mL DCM abs. was added a 
solution of 4.30 mL (4.73 g, 60.5 mmol) DMSO abs. in 15 mL DCM abs. in such a way that the 
temperature stayed between –71 °C and –66 °C. After complete addition, the reaction was stirred 
for 5 min before a solution of 6.37 g (20.0 mmol) 1c in 40 mL DCM abs. were added dropwise 
(the temperature must not exceed –65 °C). The reaction was then stirred at –66 °C for 30 min 
before 14.0 mL (10.2 g, 101 mmol) triethylamine were added slowly (T < –60 °C). The cooling 
bath was replaced by an ice bath and the reaction was allowed to warm to 0 °C within 1 h. After-
wards, a solution of 7.07 g (21.2 mmol) methyl 2-(triphenyl-λ5-phosphaneylidene)acetate in 20 
mL DCM abs. was added dropwise and the cooling bath was removed. The reaction was stirred 
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for 1 h at rt. For workup, water was added and the layers were separated. The aqueous phase was 
extracted three times with DCM and the combined organic layers were washed with brine and 
dried over MgSO4. The crude product was purified twice by column chromatography (silica gel, 
n-pentane:Et2O 80:20). 7.45 g (20.0 mmol, E/Z 78:22, quant.) of product 2c were obtained as a 
slightly yellow oil. 
Rf(2c) = 0.57 (silica gel, PE:EA 70:30) 
 
E-Isomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.04 – 1.16 (m, 21 H, 1-H, 2-H), 1.42 (s, 3 H, 7-H), 1.43 (s, 3 
H, 7'-H), 3.74 (s, 3 H, 11-H), 3.83 (m, 1 H, 3-Ha), 3.87 (m, 1 H, 4-H), 3.93 (m, 1 H, 3-Hb), 4.58 
(ddd, 3J5,4 = 7.4 Hz, 
3J5,8 = 5.0 Hz, 
4J5,9 = 1.4 Hz, 1 H, 5-H), 6.14 (dd, 
3J9,8 = 15.7 Hz, 
4J9,5 = 1.6 
Hz, 1 H, 9-H), 6.99 (dd, 3J8,9 = 15.8 Hz, 
3J8,5 = 5.0 Hz, 1 H, 8-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.8 (q, C-7), 26.9 (q, C-7'), 51.6 
(q, C-11), 63.3 (t, C-3), 78.0 (d, C-5), 80.8 (d, C-4), 109.9 (s, C-6), 121.2 (d, C-9), 145.2 (d, C-8), 
166.6 (s, C-10). 
Z-Isomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.44 (s, 3 H, 7-H), 3.71 (s, 3 H, 11-H), 5.44 (ddd, 3J5,4 ≈ 3J5,8 = 
8.1 Hz, 4J5,9 = 0.9 Hz, 1 H, 5-H), 5.93 (dd, 
3J9,8 = 11.7 Hz, 
4J9,5 = 1.1 Hz, 1 H, 9-H), 6.20 (dd, 
3J8,9 
= 11.8 Hz, 3J8,5 = 8.8 Hz, 1 H, 8-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-2), 27.1 (q, C-7), 27.2 (q, C-7'), 51.4 (q, C-11), 64.0 
(t, C-3), 73.7 (d, C-5), 82.3 (d, C-4), 110.0 (s, C-6), 122.4 (d, C-9), 145.7 (d, C-8), 165.7 (s, C-10). 
HRMS (CI):    calculated found 
C19H37O5Si [M+H]
+   373.2405 373.2447 
Optical rotation:   [∝]𝐷
20 = +5.2° (c = 1.0, CHCl3) 
 
Methyl 3-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)propa-
noate (3c) 
A solution of 7.45 g (20.0 mmol) 2c in 40 mL MeOH was treated with 748 mg palladium on 
charcoal (10 w% Pd) and hydrogenated at 10 bar for 3.5 h. The reaction was then filtrated through 
a pad of Celite® and washed with Et2O. The filtrate was concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, PE:EA 80:20) to give 7.18 g (19.2 mmol, 96 
%) of product 3c as a colourless oil.  
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Rf (3c) = 0.49 (silica gel, PE:EA 80:20) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.03 – 1.15 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.86 (m, 1 H, 8-Ha), 2.07 (m, 1 H, 8-Hb), 2.44 (ddd, 
2J9a,9b = 16.1 Hz, 
3J9a,8a = 9.3 Hz, 
3J9a,8b = 6.6 Hz, 1 H, 9-Ha), 2.54 (ddd, 
2J9b,9a = 16.1 Hz, 
3J9b,8a = 9.7 Hz, 
3J9b,8b = 5.9 Hz, 1 H, 9-
Hb), 3.67 (s, 3 H, 11-H), 3.69 – 3.77 (m, 2 H, 4-H, 3-Ha), 3.88 (m, 1 H, 3-Hb), 3.96 (td, 3J5,8 = 7.8 
Hz, 3J5,4 = 3.4 Hz, 1 H, 5-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-2), 17.9 (q, C-1), 27.0 (q, C-7), 27.3 (q, C-7'), 28.6 
(t, C-8 o. C-9), 30.5 (t, C-8 o. C-9), 51.5 (q, C-11), 64.1 (t, C-3), 78.2 (d, C-5), 80.7 (d, C-4), 108.7 
(s, C-6), 173.7 (s, C-10). 
HRMS (CI):    calculated found 
C19H39O5Si [M+H]
+   375.2561 375.2542 
Optical rotation:   [∝]𝐷
20 = –10.0° (c = 1.0, CHCl3) 
 
3-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)propanal (4c) 
380 mg (0.997 mmol) 3c were dissolved in 10 mL toluene abs. and cooled to –78 °C. 1.40 mL 
(1.40 mmol) DIBAL-H (1.0 M in toluene) were added dropwise within 30 min. The reaction was 
stirred for further 15 min at this temperature. The reaction was diluted with DCM at –78 °C and 
hydrolyzed with sat. K-Na-tartrate solution. The reaction was allowed to warm to rt and the layers 
were separated. The aqueous phase was extracted three times with DCM, washed with brine and 
dried over Na2SO4. The crude product was purified by column chromatography (silica gel, PE:EA 
100:0, 90:10) to yield 318 mg (0.923 mmol, 93 %) aldehyde 4c as a colourless oil. 
Rf (4c) = 0.50 (silica gel, PE:EA 70:30) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.04 – 1.15 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.86 (dtd, 2J8a,8b = 14.4 Hz, 
3J8a,9 = 8.1 Hz, 
3J8a,5 = 6.4 Hz, 1 H, 8-Ha), 2.09 (dddd, 
2J8b,8a 
= 14.5 Hz, 3J8b,5 = 10.4 Hz, 
3J8b,9a = 6.6 Hz, 
3J8b,9b = 3.5 Hz, 1 H, 8-Hb), 2.62 (m, 2 H, 9-H), 3.72 
(m, 1 H, 3-Ha), 3.74 (dd, 
2J3b,3a = 14.1 Hz, 
3J3ba,4 = 6.3 Hz, 1 H, 3-Hb), 3.90 (m, 1 H, 4-H), 3.97 
(ddd, 3J5,8b = 11.3 Hz, 
3J5,8a = 5.5 Hz, 
3J5,4 = 3.5 Hz, 1 H, 5-H), 9.80 (t, 
3J10,9 = 1.5 Hz, 1 H, 10-H). 
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13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-2), 17.9 (q, C-1), 25.8 (t, C-8), 27.0 (q, C-7), 27.3 
(q, C-7'), 40.4 (t, C-9), 64.1 (t, C-3), 78.4 (d, C-5), 80.6 (d, C-4), 108.7 (s, C-6), 201.9 (s, C-10). 
HRMS (CI):    calculated found 
C18H35O4Si [M+H]
+   345.2299 345.2306 
Optical rotation:   [∝]𝐷
20 = –6.0° (c = 1.0, CHCl3) 
 
5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-3-ol 
(7c) 
From compound 4c: 
To a solution of 1.07 g (3.11 mmol) aldehyde 4c in 30 mL THF abs. were added 4.70 mL (4.70 
mmol) vinylmagnesium bromide (1.0 M in THF) dropwise at –78 °C. The reaction was allowed 
to warm to rt overnight. For workup, the reaction was diluted with Et2O and water was added. The 
layers were separated and the aqueous phase was extracted three times with Et2O. The combined 
organic layers were washed with brine and dried over Na2SO4. Purification by column chromatog-
raphy (silica gel, PE:EA 100:0, 90:10, 80:20) yielded 804 mg (2.16 mmol, dr 50:50, 69 %) allylic 
alcohol 7c as a slightly yellow oil. 
From compound 3c: 
A solution of 1.87 g (5.0 mmol) ester 3c in 50 mL toluene abs. was cooled to –78 °C before 5.25 
mL (5.25 mmol) DIBAL-H (1.0 M in toluene) were added via syringe pump within 50 min. The 
reaction was stirred for further 10 min at this temperature before 6.25 mL (6.25 mmol) vinyl-
magnesium bromide (1.0 M in THF) were added slowly. The reaction was allowed to warm to rt 
overnight. The reaction was diluted with Et2O and 1 M HCl sol. was added. The layers were sep-
arated and the aqueous phase was extracted three times with Et2O. The combined organic layers 
were washed with brine and dried over Na2SO4. The crude product was purified by column chro-
matography (silica gel, PE:EA 100:0, 90:10). 1.52 g (4.08 mmol, dr 50:50, 82 %) of allylic alcohol 
7c were obtained as a colourless oil. 
Rf (7c) = 0.41 (silica gel, PE:EA 70:30) 
 
(3S)-Diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.03 – 1.16 (m, 21 H, 1-H, 2-H), 1.38 (s, 3 H, 7-H), 1.41 (s, 3 
H, 7'-H), 1.62 – 1.79 (m, 3 H, 8-Ha, 9-H), 1.85 (m, 1 H, 8-Hb), 2.45 (br s, 1 H, OH), 3.72 (m, 1 H, 
4-H), 3.75 (m, 1 H, 3-Ha), 3.89 (dd, 
2J3b,3a = 9.8 Hz, 
3J3b,4 = 3.5 Hz, 1 H, 3-Hb), 3.97 (m, 1 H, 5-
5. Experimental section 
 
 
92 
H), 4.16 (m, 1 H, 10-H), 5.10 (ddd, 3J12a,11 = 10.5 Hz, 
2J12a,12b ≈ 4J12a,10 = 1.4 Hz, 1 H, 12-Ha), 5.24 
(ddd, 3J12b,11 = 17.1 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.6 Hz, 1 H, 12-Hb), 5.87 (ddd, 3J11,12b = 16.6 Hz, 3J11,12a 
= 10.5 Hz, 3J11,10 = 6.0 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-2), 17.9 (q, C-1), 27.0 (q, C-7), 27.3 (q, C-7'), 29.8 
(t, C-8), 34.0 (t, C-9), 64.1 (t, C-3), 73.0 (d, C-10), 79.4 (d, C-5), 80.9 (d, C-4), 108.6 (s, C-6), 
114.5 (d, C-11), 140.9 (t, C-12). 
(3R)-Diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 2.19 (br s, 1 H, OH), 3.87 (dd, 2J3b,3a = 10.3 Hz, 3J3b,4 = 3.8 Hz, 
1 H, 3-Hb), 5.10 (ddd, 
3J12a,11 = 10.4 Hz, 
2J12a,12b ≈ 4J12a,10 = 1.6 Hz, 1 H, 12-Ha), 5.24 (ddd, 3J12b,11 
= 17.2 Hz, 2J12b,12a ≈ 4J12b,10 = 1.6 Hz, 1 H, 12-Hb), 5.88 (ddd, 3J11,12b = 16.3 Hz, 3J11,12a = 10.5 Hz, 
3J11,10 = 5.8 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 28.9 (t, C-8), 33.6 (t, C-9), 64.0 (t, C-3), 72.4 (d, C-10), 79.3 
(d, C-5), 80.9 (d, C-4), 108.6 (s, C-6), 140.8 (t, C-12). 
HRMS (CI):    calculated found 
C20H41O4Si [M+H]
+   373.2769 373.2792 
 
(S)-5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-
3-yl acetate (8) and (R)-5-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-diox-
olan-4-yl)pent-1-en-3-ol ((3R)-7c) 
4.45 g (11.9 mmol) 7c were dissolved in 5.6 mL (5.23 g, 60.8 mmol) vinyl acetate at rt before 1.26 
g (11.9 mmol) Na2CO3 and 221 mg Novozyme 435 were added. The reaction was shaken for 6 h 
at ambient temperature. For workup, the reaction mixture was filtrated. The filtrate was concen-
trated in vacuo and the crude product was purified by column chromatography (silica gel, PE:EA 
100:0, 90:10). 2.27 g (5.47 mmol, dr > 99:1, 46 %) acetate 8 were obtained as a colourless oil and 
2.17 g (5.82 mmol, dr > 99:1, 49 %) alcohol (3R)-7c were obtained as a colourless oil. 
Rf (8) = 0.28 (silica gel, PE:EA 90:10) 
Rf ((3R)-7c) = 0.08 (silica gel, PE:EA 90:10) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.03 – 1.15 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.61 (m, 1 H, 8-Ha), 1.72 (m, 2 H, 9-H), 1.87 (m, 1 H, 8-Hb), 2.05 (s, 3 H, 14-H), 3.70 
(m, 1 H, 4-H), 3.72 (dd, 2J3a,3b = 9.5 Hz, 
3J3a,4 = 6.2 Hz, 1 H, 3-Ha), 3.89 (dd, 
2J3b,3a = 9.6 Hz, 
3J3b,4 
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= 3.5 Hz, 1 H, 3-Hb), 3.93 (td, 
3J5,8 = 7.5 Hz, 
3J5,4 = 3.4 Hz, 1 H, 5-H), 5.17 (d, 
3J12a,11 = 10.5 Hz, 
1 H, 12-Ha), 5.24 (d, 
3J12b,11 = 17.2 Hz, 1 H, 12-Hb), 5.27 (dt, 
3J10,11 ≈ 3J10,9 = 6.2 Hz, 1 H, 10-H), 
5.76 (ddd, 3J11,12b = 17.1 Hz, 
3J11,12a = 10.5 Hz, 
3J11,10 = 6.4 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 21.2 (q, C-14), 27.0 (q, C-7), 27.4 
(q, C-7'), 28.9 (t, C-8), 30.6 (t, C-9), 64.3 (t, C-3), 74.5 (d, C-10), 79.2 (d, C-5), 80.8 (d, C-4), 
108.5 (s, C-6), 116.9 (d, C-11), 136.2 (t, C-12), 170.2 (s, C-13). 
HRMS (CI):    calculated found 
C22H43O5Si [M+H]
+   415.2874 415.2908 
Optical rotation:   [∝]𝐷
20 = –5.1° (c = 1.0, CHCl3) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.03 – 1.15 (m, 21 H, 1-H, 2-H), 1.37 (s, 3 H, 7-H), 1.40 (s, 3 
H, 7'-H), 1.60 – 1.90 (m, 4 H, 8-H, 9-H), 2.19 (br s, 1 H, OH), 3.72 (m, 1 H, 4-H), 3.75 (dd, 2J3a,3b 
= 10.1 Hz, 3J3a,4 = 6.1 Hz, 1 H, 3-Ha), 3.88 (dd, 
2J3b,3a = 10.0 Hz, 
3J3b,4 = 3.8 Hz, 1 H, 3-Hb), 3.96 
(td, 3J5,8 = 7.8 Hz, 
3J5,4 = 3.0 Hz, 1 H, 5-H), 4.18 (dt, 
3J10,11 ≈ 3J10,9 = 5.5 Hz, 1 H, 10-H), 5.11 (d, 
3J12a,11 = 10.5 Hz, 1 H, 12-Ha), 5.24 (d, 
3J12b,11 = 17.2 Hz, 1 H, 12-Hb), 5.88 (ddd, 
3J11,12b = 16.7 
Hz, 3J11,12a = 10.5 Hz, 
3J11,10 = 5.8 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-2), 17.9 (q, C-1), 27.0 (q, C-7), 27.3 (q, C-7'), 28.9 
(t, C-8), 33.6 (t, C-9), 64.1 (t, C-3), 72.4 (d, C-10), 79.3 (d, C-5), 80.9 (d, C-4), 108.6 (s, C-6), 
114.5 (d, C-11), 140.8 (t, C-12). 
HRMS (CI):    calculated found 
C20H41O4Si [M+H]
+   373.2769 373.2766 
Optical rotation:   [∝]𝐷
20 = –4.7° (c = 1.0, CHCl3) 
 
(S)-5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-
3-ol ((3S)-7c) 
To a solution of 725 mg (1.75 mmol) 8 in 15.5 mL MeOH and 2.0 mL H2O were added 267 mg 
(1.93 mmol) K2CO3 at rt. The reaction was stirred for 2.5 h. For workup, the reaction was diluted 
with DCM and water was added. The layers were separated and the aqueous phase was extracted 
three times with DCM. The combined organic layers were dried over Na2SO4 and concentrated in 
vacuo to obtain 646 mg (1.73 mmol, 99 %) alcohol (3S)-7c as a colourless oil. 
Rf((3S)-7c) = 0.11 (silica gel, PE:EA 90:10) 
5. Experimental section 
 
 
94 
 
1H-NMR (400 MHz, CDCl3): δ = 1.04 – 1.15 (m, 21 H, 1-H, 2-H), 1.38 (s, 3 H, 7-H), 1.41 (s, 3 
H, 7'-H), 1.66 (m, 1 H, 8-Ha), 1.71 (m, 2 H, 9-H), 1.85 (m, 1 H, 8-Hb), 2.44 (br s, 1 H, OH), 3.72 
(m, 1 H, 4-H), 3.75 (dd, 2J3a,3b = 9.9 Hz, 
3J3a,4 = 6.1 Hz, 1 H, 3-Ha), 3.89 (dd, 
2J3b,3a = 9.8 Hz, 
3J3b,4 
= 3.6 Hz, 1 H, 3-Hb), 3.97 (td, 
3J5,8 = 7.9 Hz, 
3J5,4 = 3.0 Hz, 1 H, 5-H), 4.14 (dt, 
3J10,11 ≈ 3J10,9 = 
6.0 Hz, 1 H, 10-H), 5.10 (d, 3J12a,11 = 10.4 Hz, 1 H, 12-Ha), 5.25 (d, 
3J12b,11 = 17.2 Hz, 1 H, 12-Hb), 
5.87 (ddd, 3J11,12b = 16.8 Hz, 
3J11,12a = 10.4 Hz, 
3J11,10 = 5.9 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.3 (q, C-7'), 29.7 
(t, C-8), 34.0 (t, C-9), 64.1 (t, C-3), 73.0 (d, C-10), 79.4 (d, C-5), 80.9 (d, C-4), 108.6 (s, C-6), 
114.5 (d, C-11), 140.9 (t, C-12). 
HRMS (CI):    calculated found 
C20H41O4Si [M+H]
+   373.2769 373.2772 
Optical rotation:   [∝]𝐷
20 = –3.4° (c = 1.0, CHCl3) 
 
(S)-5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-
3-yl ((benzyloxy)carbonyl)glycinate (9) 
535 mg (2.56 mmol) Cbz-Gly-OH and 635 mg (1.70 mmol) (3S)-7c were dissolved in 17 mL DCM 
abs. and cooled to 0 °C. 23.5 mg (0.192 mmol) 4-DMAP and 534 mg (2.59 mmol) DCC were 
added subsequently. The reaction was allowed to warm to rt overnight. For workup, the reaction 
was filtrated through a pad of Celite® and washed with DCM. The filtrate was concentrated in 
vacuo. The residue was redissolved in DCM and water was added. The layers were separated and 
the aqueous phase was extracted three times with DCM. The combined organic phases were 
washed with sat. NaHCO3 sol. and dried over Na2SO4. The crude product was purified by column 
chromatography (silica gel, PE:EA 100:0, 90:10). 947 mg (1.68 mmol, 99 %) 9 were obtained as 
a colourless oil. 
Rf (9) = 0.34 (silica gel, PE:EA 80:20). 
 
1H-NMR (400 MHz, CDCl3): δ = 1.03 – 1.14 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.57 (m, 1 H, 8-Ha), 1.67 – 1.78 (m, 2 H, 8-Hb, 9-Ha), 1.91 (m, 1 H, 9-Hb), 3.69 (m, 1 H, 
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4-H), 3.72 (m, 1 H, 3-Ha), 3.88 (dd, 
2J3b,3a = 9.6 Hz, 
3J3b,4 = 3.2 Hz, 1 H, 3-Hb), 3.92 (td, 
3J5,8 = 7.4 
Hz, 3J5,4 = 3.0 Hz, 1 H, 5-H), 3.98 (d, 
3J14,NH = 5.4 Hz, 2 H, 14-H), 5.13 (s, 2 H, 16-H), 5.20 (d, 
3J12a,11 = 10.5 Hz, 1 H, 12-Ha), 5.24 (br s, 1 H, NH), 5.26 (d, 
3J12b,11 = 17.2 Hz, 1 H, 12-Hb), 5.32 
(dt, 3J10,11 ≈ 3J10,9 = 6.4 Hz, 1 H, 10-H), 5.75 (ddd, 3J11,12b = 17.2 Hz, 3J11,12a = 10.4 Hz, 3J11,10 = 
6.7 Hz, 1 H, 11-H), 7.29 – 7.37 (m, 5 H, 18-H, 19-H, 20-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.3 (q, C-7'), 28.8 
(t, C-8), 30.6 (t, C-9), 42.9 (t, C-14), 64.2 (t, C-3), 67.1 (t, C-16), 76.1 (d, C-10), 79.1 (d, C-5), 
80.7 (d, C-4), 108.5 (s, C-6), 117.9 (t, C-12), 128.1 (d, C-18 o. C-20), 128.2 (d, C-18 o. C-20), 
128.5 (d, C-19), 135.4 (d, C-11), 136.2 (s, C-17), 156.1 (s, C-15), 169.2 (s, C-13). 
HRMS (CI):    calculated found 
C30H50NO7Si [M+H]
+   564.3351 564.3381 
Optical rotation:   [∝]𝐷
20 = –4.3° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 90:10, 1 mL/min, 20 °C: 
(3S)-9: tR = 25.9 min (> 99 %). 
 
(S,E)-2-(((Benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)-
methyl)-1,3-dioxolan-4-yl)hept-4-enoic acid (10) 
0.21 mL (149 mg, 1.47 mmol) Di-iso-propylamine were dissolved in 1.5 mL THF abs. before 0.88 
mL (1.41 mmol) n-BuLi (1.6 M in hexanes) were added dropwise at –78 °C. The cooling bath was 
removed and the reaction was stirred at rt for 15 min. 
A solution of 93 mg (0.682 mmol) vacuum-dried zinc chloride in 0.5 mL THF abs. were added to 
a solution of 282 mg (0.500 mmol) 9 in 2.0 mL THF abs. at rt. After cooling to –78 °C, the freshly 
prepared LDA solution was transferred to the amino acid ester/ zinc chloride solution carefully. 
Remaining dry ice was removed from the cooling bath and the reaction was allowed to warm to rt 
overnight. The reaction was diluted with Et2O and NH4OAc/HOAc buffer sol. was added. The 
layers were separated and the aqueous phase was extracted three times with Et2O. The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. The crude product was dried 
by lyophilisation. 281 mg (0.499 mmol, quant.) of acid 10 were obtained as a yellow oil. 
Rf (10) = 0.34 (silica gel, PE:EA 50:50 + 1 % HOAc) 
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1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.15 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.68 (m, 2 H, 8-H), 2.17 (m, 2 H, 9-H), 2.53 (dd, 3J12,11 ≈ 3J12,14 = 5.5 Hz, 2 H, 12-H), 
3.71 (m, 1 H, 4-H), 3.75 (dd, 2J3a,3b = 10.2 Hz, 
3J3a,4 = 6.2 Hz, 1 H, 3-Ha), 3.87 (dd, 
2J3b,3a = 10.2 
Hz, 3J3b,4 = 4.0 Hz, 1 H, 3-Hb), 3.93 (td, 
3J5,8 = 7.8 Hz, 
3J5,4 = 3.4 Hz, 1 H, 5-H), 4.44 (dt, 
3J14,NH = 
7.2 Hz, 3J14,12 = 5.5 Hz, 1 H, 14-H), 5.12 (s, 2 H, 16-H), 5.28 (d, 
3JNH,14 = 7.8 Hz, 1 H, NH), 5.35 
(dt, 3J11,10 = 14.9 Hz, 
3J11,12 = 7.4 Hz, 1 H, 11-H), 5.58 (dt, 
3J10,11 = 14.5 Hz, 
3J10,9 = 7.1 Hz, 1 H, 
10-H), 7.29 – 7.36 (m, 5 H, 18-H, 19-H, 20-H). The signal of -COOH wasn’t observed in the 1H-
NMR spectrum. 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.3 (q, C-7'), 29.0 
(t, C-9), 33.0 (t, C-8), 35.2 (t, C-12), 53.3 (d, C-14), 64.2 (t, C-3), 67.1 (t, C-16), 78.6 (d, C-5), 
80.7 (d, C-4), 108.6 (s, C-6), 123.5 (d, C-11), 128.2 (d, C-18 o. C-20), 128.2 (d, C-18 o. C-20), 
128.5 (d, C-19), 135.4 (d, C-10), 136.1 (s, C-17), 155.9 (s, C-15), 175.3 (s, C-13). 
HRMS (CI):    calculated found 
C30H50NO7Si [M+H]
+   564.3351 564.3354 
Optical rotation:   [∝]𝐷
20 = +10.2° (c = 1.0, CHCl3) 
 
Cbz-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-OMe (11a) 
494 mg (1.5 mmol) Cbz-(R)-Tyr(Me)-OH were dissolved in 15 mL THF abs. and 0.185 mL (170 
mg, 1.65 mmol) NMM were added. The reaction was cooled to –20 °C and 0.22 mL (230 mg, 1.65 
mmol) IBCF were added. After 10 min, further 0.185 mL (170 mg, 1.65 mmol) NMM and 450 mg 
(1.50 mmol) HCl·H-(S,S)-Ile-(S)-Pro-OMe were added and the reaction was allowed to warm to 
rt overnight. For workup, the reaction mixture was filtrated and the filtrate was concentrated in 
vacuo. The residue was redissolved in EA and water was added. The layers were separated and the 
aqueous phase was extracted three times with EA. The combined organic layers were washed with 
sat. NaHCO3 sol. and dried over Na2SO4. The crude product was purified by column chromatog-
raphy (silica gel, PE:EA 100:0, 70:30, 50:50) to obtain 764 mg (1.38 mmol, dr ~ 94:6, 92 %) 
tripeptide 11a as an off-white solid. 
Rf (11a) = 0.25 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.80 (t, 3J12,11 = 6.5 Hz, 3 H, 12-H), 0.87 (m, 1 H, 11-Ha), 0.91 
(d, 3J10,9 = 6.9 Hz, 3 H, 10-H), 1.32 (m, 1 H, 11-Hb), 1.69 (m, 1 H, 9-H), 1.92 – 2.09 (m, 3 H, 4-
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Ha, 5-H), 2.21 (m, 1 H, 4-Hb), 2.99 (d, 
3J15,14 = 6.9 Hz, 2 H, 15-H), 3.64 (dt, 
2J6a,6b = 9.7 Hz, 
3J6a,5 
= 6.9 Hz, 1 H, 6-Ha), 3.70 (s, 3 H, 1-H), 3.77 (s, 3 H, 20-H), 3.82 (dt, 
2J6b,6a = 9.5 Hz, 
3J6b,5 = 6.4 
Hz, 1 H, 6-Hb), 4.40 (m, 1 H, 14-H), 4.48 (dd, 
3J3,4a = 8.4 Hz, 
3J3,4b = 4.7 Hz, 1 H, 3-H), 4.55 (dd, 
3J8,9 = 8.6 Hz, 
3J8,NH = 7.6 Hz, 1 H, 8-H), 5.05 (s, 2 H, 22-H), 5.30 (d, 
3JNH,14 = 7.8 Hz, 1 H, NHb), 
6.47 (d, 3JNH,8 = 7.7 Hz, 1 H, NHa), 6.79 (d, 
3J18,17 = 8.4 Hz, 2 H, 18-H), 7.09 (d, 
3J17,18 = 7.8 Hz, 
2 H, 17-H), 7.27 – 7.36 (m, 5 H, 24-H, 25-H, 26-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.1 (q, C-12), 15.0 (q, C-10), 24.0 (t, C-11), 24.9 (t, C-5), 29.0 
(t, C-4), 37.7 (d, C-9), 38.1 (t, C-15), 47.3 (t, C-6), 52.1 (q, C-1), 54.9 (d, C-8), 55.2 (q, C-20), 
56.4 (d, C-14), 58.9 (d, C-3), 66.9 (t, C-22), 114.1 (d, C-18), 128.0 (d, C-24), 128.1 (s, C-16), 
128.2 (d, C-25 o. C-26), 128.5 (d, C-25 o. C-26), 130.2 (d, C-17), 136.2 (s, C-23), 155.6 (s, C-21), 
158.6 (s, C-19), 170.4 (s, C-13), 170.6 (s, C-7), 172.3 (s, C-2). 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 6.67 (d, 3J18,17 = 8.3 Hz, 2 H, 18-H), 6.95 (d, 3J17,18 = 8.3 Hz, 2 
H, 17-H). 
HRMS (CI):    calculated found 
C30H40N3O7 [M+H]
+   554.2861 554.2858 
Melting point:    56 °C 
Optical rotation:   [∝]𝐷
20 = –43.2° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 9.41 min 
([M+H]+ = 554). 
 
Cbz-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-OtBu (11b) 
1.07 g (3.25 mmol) Cbz-(R)-Tyr(Me)-OH were dissolved in 32.5 mL THF abs. and cooled to –
20 °C before 0.39 mL (359 mg, 3.55 mmol) NMM and 0.47 mL (492 mg, 3.60 mmol) IBCF were 
added subsequently. After 10 min at this temperature, a solution of 930 mg (3.27 mmol) H-(S,S)-
Ile-(S)-Pro-OtBu in 6.5 mL THF abs. was added slowly. The reaction was allowed to warm to rt 
overnight, filtrated and washed with Et2O. The filtrate was concentrated in vacuo, the residue was 
redissolved in EA and water was added. The layers were separated and the aqueous phase was 
extracted three times with EA. The combined organic layers were dried over Na2SO4 and concen-
trated in vacuo. The crude product was purified by column chromatography (silica gel, PE:EA 
100:0, 80:20, 50:50) to give 1.71 g (2.87 mmol, dr 98:2, 88 %) of tripeptide 11b as an off-white 
solid. 
Rf (11b) = 0.05 (silica gel, PE:EA 70:30) 
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1H-NMR (400 MHz, CDCl3): δ = 0.80 (t, 3J19,18 = 7.0 Hz, 3 H, 19-H), 0.82 – 0.90 (m, 1 H, 18-
Ha), 0.92 (d, 
3J13,12 = 6.8 Hz, 3 H, 17-H), 1.35 (m, 1 H, 18-Hb), 1.43 (s, 9 H, 27-H), 1.69 (m, 1 H, 
16-H), 1.87 – 1.97 (m, 2 H, 22-Ha, 23-Ha), 2.03 (m, 1 H, 23-Hb), 2.18 (m, 1 H, 22-Hb), 2.99 (m, 2 
H, 8-H), 3.61 (dt, 2J24a,24b = 9.8 Hz, 
3J24a,23 = 6.8 Hz, 1 H, 24-Ha), 3.77 (s, 3 H, 13-H), 3.80 (dt, 
2J24b,24a = 9.8 Hz, 
3J24b,23 = 6.4 Hz, 1 H, 24-Hb), 4.34 (dd, 
3J21,22a = 8.2 Hz, 
3J21,22b = 4.9 Hz, 1 H, 
21-H), 4.41 (m, 1 H, 7-H), 4.54 (dd, 3J15,NH ≈ 3J15,16 = 8.0 Hz, 1 H, 15-H), 5.05 (s, 2 H, 5-H), 5.29 
(d, 3JNH,7 = 7.5 Hz, 1 H, NHb), 6.52 (d, 
3JNH,7 = 8.3 Hz, 1 H, NHa), 6.79 (d, 
3J11,10 = 8.5 Hz, 2 H, 
11-H), 7.08 (d, 3J10,11 = 7.8 Hz, 2 H, 10-H), 7.27 – 7.36 (m, 5 H, 1-H, 2-H, 3-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.1 (q, C-19), 15.2 (q, C-17), 24.1 (t, C-18), 24.8 (t, C-23), 
27.9 (q, C-27), 29.1 (t, C-22), 37.7 (d, C-16), 38.1 (t, C-8), 47.4 (t, C-24), 54.8 (d, C-15), 55.2 (q, 
C-13), 56.4 (d, C-7), 59.8 (d, C-21), 66.9 (t, C-5), 81.3 (s, C-26), 114.1 (d, C-11), 128.0 (d, C-1 o. 
C-3), 128.1 (d, C-1 o. C-3), 128.2 (s, C-9), 128.5 (d, C-2), 130.2 (d, C-10), 136.2 (s, C-4), 155,6 
(s, C-6), 158,6 (s, C-12), 170,2 (s, C-14 o. C-20 o. C-25), 170,6 (s, C-14 o. C-20 o. C-25), 171,1 
(s, C-14 o. C-20 o. C-25). 
HRMS (CI):    calculated found 
C33H46N3O7 [M+H]
+   596.3330 596.3340 
Melting point:   53-56 °C 
Optical rotation:   [∝]𝐷
20 = –44.2° (c = 1.0, CHCl3) 
HPLC: Chiralcel OD-H, n-hexane:iPrOH 80:20, 1 mL/min, 20 °C: 
tR1 = 6.37 min (2 %), 
tR2 = 7.69 min (98 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 14.5 min 
([M+Na]+ = 618). 
 
Boc-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-OMe (11c) 
1.51 g (5.11 mmol) Boc-(R)-Tyr(Me)-OH were dissolved in 50.0 mL THF abs. and cooled to –
20 °C before 0.62 mL (570 mg , 5.64 mmol) NMM and 0.74 mL (775 mg, 5-67 mmol) IBCF were 
added slowly. After 10 min at this temperature, 1.42 g (5.09 mmol) HCl·H-(S,S)-Ile-(S)-Pro-OMe 
and further 0.62 mL (570 mg, 5.64 mmol) NMM were added slowly. The reaction was allowed to 
warm to rt overnight. For workup, the reaction mixture was filtrated and washed with Et2O. The 
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filtrate was concentrated in vacuo and the residue was redissolved in EA. 1 M HCl sol. was added 
and the layers were separated. The aqueous phase was extracted three times with EA, the combined 
organic phases were washed with sat. NaHCO3 sol. and dried over Na2SO4. The crude product was 
purified by column chromatography (silica gel, PE:EA 100:0, 70:30, 50:50) to give 2.24 g (4.31 
mmol, 85 %) product 11c (containing 2 % iso-butylcarbonate at tyrosine residue) as an off-white 
solid. 
Rf (11c) = 0.19 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.81 (t, 3J12,11 = 7.0 Hz, 3 H, 12-H), 0.91 (m, 1 H, 11-Ha), 0.93 
(d, 3J10,9 = 6.8 Hz, 3 H, 10-H), 1.37 (m, 1 H, 11-Hb), 1.38 (s, 9 H, 23-H), 1.71 (m, 1 H, 9-H), 2.00 
(m, 3 H, 4-Ha, 5-H), 2.23 (m, 1 H, 4-Hb), 2.93 (dd, 
2J15a,15b = 13.9 Hz, 
3J15a,14 = 6.8 Hz, 1 H, 15-
Ha), 3.00 (dd, 
2J15b,15a = 13.9 Hz, 
3J15b,14 = 6.8 Hz, 1 H, 15-Hb), 3.65 (m, 1 H, 6-Ha), 3.70 (s, 3 H, 
1-H), 3.77 (s, 3 H, 20-H), 3.84 (m, 1 H, 6-Hb), 4.32 (m, 1 H, 14-H), 4.47 (dd, 
3J3,4a = 8.7 Hz, 
3J3,4b 
= 5.2 Hz, 1 H, 3-H), 4.56 (dd, 3J8,9 ≈ 3J8,NH = 8.3 Hz, 1 H, 8-H), 4.93 (d, 3JNH,14 = 7.5 Hz, 1 H, 
NHb), 6.50 (d, 
3JNH,8 = 8.0 Hz, 1 H, NHa), 6.80 (d, 
3J18,17 = 8.5 Hz, 2 H, 18-H), 7.08 (d, 
3J17,18 = 
8.5 Hz, 2 H, 17-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.1 (q, C-12), 15.0 (q, C-10), 24.0 (t, C-11), 24.9 (t, C-5), 28.2 
(q, C-23), 29.1 (t, C-4), 37.7 (d, C-9), 37.7 (t, C-15), 47.3 (t, C-6), 52.2 (q, C-1), 54.8 (d, C-8), 
55.2 (q, C-20), 56.0 (d, C-14), 58.9 (d, C-3), 80.0 (s, C-22), 114.0 (d, C-18), 128.4 (s, C-16), 130.1 
(d, C-17), 155.1 (s, C-21), 158.5 (s, C-19), 170.4 (s, C-7), 171.0 (s, C-13), 172.3 (s, C-2). 
HRMS (CI):    calculated found 
C27H42N3O7 [M+H]
+   520.3017 520.3021 
Melting point:   64 °C 
Optical rotation:   [∝]𝐷
20 = –38.6° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 80:20, 1 mL/min, 20 °C: 
tR = 25.4 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 7.49 min 
(98 %, [M+Na]+ = 542), tR2 = 13.4 min (2 %, [M+Na]
+ = 628). 
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H-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-OMe (12a) 
To a solution of 179 mg (0.323 mmol) 11a in 1.6 mL MeOH were added 19 mg palladium on 
charcoal (10 w% Pd) at rt. The reaction was set under a H2-atmossphere and hydrogenated for 2 
h. The reaction mixture was filtrated through a pad of Celite® and washed with MeOH. The filtrate 
was concentrated in vacuo. After lyophilisation, 132 mg (0.315 mmol, dr ~ 92:8, 97 %) of amine 
12a were obtained as a colourless resin. 
Rf (12a) = 0.05 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.88 (t, 3J12,11 = 7.3 Hz, 3 H, 12-H), 1.00 (d, 3J10,9 = 6.7 Hz, 3 
H, 10-H), 1.07 (m, 1 H, 11-Ha), 1.46 (br s, 2 H, NH2), 1.50 (m, 1 H, 11-Hb), 1.83 (m, 1 H, 9-H), 
1.93 – 2.10 (m, 3 H, 4-Ha, 5-H), 2.23 (m, 1 H, 4-Hb), 2.58 (dd, 2J15a,15b = 13.8 Hz, 3J15a,14 = 9.5 Hz, 
1 H, 15-Ha), 3.17 (dd, 
2J15b,15a = 13.8 Hz, 
3J15b,14 = 4.4 Hz, 1 H, 15-Hb), 3.54 (dd, 
3J14,15a = 9.5 Hz, 
3J14,15b = 4.4 Hz, 1 H, 14-H), 3.69 (m, 1 H, 6-Ha), 3.72 (s, 3 H, C-1), 3.78 (s, 3 H, C-20), 3.88 (m, 
1 H, 6-Hb), 4.49 (dd, 
3J3,4a = 8.4 Hz, 
3J3,4b = 5.1 Hz, 1 H, 3-H), 4.59 (dd, 
3J8,NH = 9.0 Hz, 
3J8,9 = 7.9 
Hz, 1 H, 8-H), 6.83 (d, 3J18,17 = 8.6 Hz, 2 H, 18-H), 7.10 (d, 
3J17,18 = 8.6 Hz, 2 H, 17-H), 7.62 (d, 
3JNH,8 = 9.2 Hz, 1 H, NH). 
13C-NMR (100 MHz, CDCl3): δ = 11.1 (q, C-12), 15.2 (q, C-10), 24.4 (t, C-11), 25.0 (t, C-5), 29.1 
(t, C-4), 37.7 (d, C-9), 40.2 (t, C-15), 47.3 (t, C-6), 52.1 (q, C-1), 54.6 (d, C-8), 55.2 (q, C-20), 
56.8 (d, C-14), 58.9 (d, C-3), 114.1 (d, C-18), 130.0 (s, C-16), 130.1 (d, C-17), 158.4 (s, C-19), 
170.8 (s, C-7 o. C-13), 172.4 (s, C-2), 174.2 (s, C-7 o. C-13). 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 0.76 (t, 3J12,11 = 7.2 Hz, 3 H, 12-H), 3.06 (dd, 2J15b,15a = 14.3 Hz, 
3J15b,14 = 4.5 Hz, 1 H, 15-Hb), 4.34 – 4.42 (m, 2 H, 3-H, 8-H), 7.54 (d, 3JNH,8 = 9.2 Hz, 1 H, NH). 
HRMS (CI):    calculated found 
C22H34N3O5 [M+H]
+   420.2493 420.2496 
Optical rotation:   [∝]𝐷
20 = –35.7° (c = 1.0, CHCl3) 
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Methyl ((R)-2-((S,E)-2-(((benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-
propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enamido)-3-(4-methoxyphenyl)propan-
oyl)-L-isoleucyl-L-prolinate (13) 
A solution of 318 mg (0.564 mmol) 10 and 265 mg (0.582 mmol) HCl·12a in 4.5 mL MeCN was 
treated with 181 mg (0.563 mmol) TBTU at rt. Afterwards, 0.21 mL (155 mg, 1.20 mmol) DIPEA 
were added dropwise and the reaction was stirred for 4.5 h. The reaction mixture was then con-
centrated in vacuo and the residue was redissolved in DCM. 1 M HCl sol. was added and the layers 
were separated. The aqueous phase was extracted three times with DCM, the combined organic 
phases were washed with sat. NaHCO3 sol. and dried over Na2SO4. Purification by column chro-
matography (silica gel, PE:EA 100:0, 80:20, 50:50) gave 456 mg (0.472 mmol, dr > 99:1, 84 %) 
tetrapeptide 13 as an off-white solid. 
Rf (13) = 0.30 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.80 (t, 3J12,11= 6.9 Hz, 3 H, 12-H), 0.90 (m, 1 H, 11-Ha), 0.91 
(d, 3J10,9= 6.9 Hz, 3 H, 10-H), 1.01 – 1.13 (m, 21 H, 33-H, 34-H), 1.34 (m, 1 H, 11-Hb), 1.35 (s, 3 
H, 31-H), 1.38 (s, 3 H, 31'-H), 1.59 (m, 1 H, 27-Ha), 1.66 – 1.75 (m, 2 H, 9-H, 27-Hb), 1.92 – 2.11 
(m, 4 H, 5-H, 26-H), 2.18 (m, 2 H, 4-H), 2.30 (ddd, 2J23a,23b = 14.2 Hz, 
3J23a,22 ≈ 3J23a,24 = 7.3 Hz, 
1 H, 23-Ha), 2.42 (ddd, 
2J23b,23a = 14.1 Hz, 
3J23b,22 ≈ 3J23b,24 = 6.4 Hz, 1 H, 23-Hb), 2.97 (m, 2 H, 
15-H), 3.61 – 3.71 (m, 2 H, 29-H, 32-Ha), 3.68 (s, 3 H, 1-H), 3.72 (m, 1 H, 6-Ha), 3.75 (s, 3 H, 20-
H), 3.82 (m, 1 H, 6-Hb), 3.84 (dd, 
2J32a,32b= 10.1 Hz, 
3J32a,29 = 3.9 Hz, 1 H, 32-Hb), 3.91 (td, 
3J28,27 
= 7.8 Hz, 3J28,29 = 3.3 Hz, 1 H, 28-H), 4.08 (dt, 
3J22,23 ≈ 3J22,NH = 6.6 Hz, 1 H, 22-H), 4.48 – 4.53 
(m, 2 H, 3-H, 8-H), 4.67 (m, 1 H, 14-H), 5.06 (d, 2J36a,36b= 12.1 Hz, 1 H, 36-Ha), 5.11 (d, 
2J36b,36a= 
12.0 Hz, 1 H, 36-Hb), 5.28 (dt, 
3J24,25= 14.8 Hz, 
3J24,23 = 7.3 Hz, 1 H, 24-H), 5.37 (d, 
3JNH,22 = 6.1 
Hz, 1 H, NHc), 5.51 (dt, 
3J25,24= 14.6 Hz, 
3J25,26 = 7.1 Hz, 1 H, 25-H), 6.56 (br s, 1 H, NHa), 6.57 
(d, 3JNH,14 = 7.7 Hz, 1 H, NHb), 6.79 (d, 
3J18,17 = 8.4 Hz, 2 H, 18-H), 7.09 (d, 
3J17,18 = 8.1 Hz, 2 H, 
17-H), 7.28 – 7.37 (m, 5 H, 38-H, 39-H, 40-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.0 (q, C-12), 11.8 (d, C-33), 15.0 (q, C-10), 17.9 (q, C-34), 
24.1 (t, C-11), 24.9 (t, C-5), 27.0 (q, C-31), 27.4 (q, C-31'), 29.0 (t, C-4 o. C-26), 29.1 (t, C-4 o. 
C-26), 33.1 (t, C-27), 35.5 (t, C-23), 37.5 (d, C-9), 37.6 (t, C-15), 47.3 (t, C-6), 52.1 (q, C-1), 54.4 
(d, C-14), 54.7 (d, C-22), 55.0 (d, C-8), 55.2 (q, C-20), 58.8 (d, C-3), 64.1 (t, C-32), 67.1 (t, C-36), 
78.6 (d, C-28), 80.8 (d, C-29), 108.4 (s, C-30), 114.1 (d, C-18), 124.4 (d, C-24), 128.1 (d, C-38 o. 
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C-39 o. C-40), 128.1 (d, C-38 o. C-39 o. C-40), 128.3 (s, C-16), 128.5 (d, C-38 o. C-39 o. C-40), 
130.2 (d, C-17), 134.7 (d, C-25), 136.2 (s, C-37), 158.6 (s, C-19), 170.4 (s, C-7 o. C-13), 170.4 (s, 
C-7 o. C-13), 170.8 (s, C-21), 172.3 (s, C-2). The signal of C-35 wasn’t observed in the 13C-NMR 
spectrum. 
HRMS (CI):    calculated found 
C52H81N4O11Si [M+H]
+  965.5666 965.5679 
Melting point:    66 °C 
Optical rotation:   [∝]𝐷
20 = –25.3° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 50:50, 1 mL/min, 20 °C: 
tR = 22.6 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 21.7 min 
([M+H]+ = 966). 
 
((R)-2-((S,E)-2-(((benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsil-
yl)oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enamido)-3-(4-methoxyphenyl)propanoyl)-L-iso-
leucyl-L-proline (14) 
453 mg (0.469 mmol) 13 were dissolved in 4.7 mL dioxane and treated with 516 µL (0.516 mmol) 
NaOH (1 M in H2O) at 0 °C. The cooling bath was removed and the reaction was stirred for 23 h. 
The reaction mixture was concentrated in vacuo and the residue was redissolved in Et2O. Water 
was added and the layers were separated. The etheric phase was discarded and the aqueous phase 
was acidified with 1 M HCl sol. and extracted three times with ethyl acetate. The crude product 
was again dissolved in 2 mL dioxane and treated with 500 µL (0.500 mmol) NaOH (1 M in H2O) 
at rt and the reaction was stirred overnight. For workup, the reaction was diluted with DCM and 1 
M HCl sol. was added. The layers were separated and the aqueous phase was extracted three times 
with DCM. The combined organic phases were dried over Na2SO4. Purification by column chro-
matography (silica gel, DCM:MeOH 100:0, Gradient 95:5) afforded 283 mg (0.297 mmol, 63 %) 
of acid 14 as an off-white solid along with 61.9 mg (64.1 µmol, 14 %) of educt 13. 
Rf (14) = 0.10 (silica gel, DCM:MeOH 95:5) 
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1H-NMR (400 MHz, CDCl3): δ = 0.77 (t, 3J33,32= 7.2 Hz, 3 H, 33-H), 0.90 (m, 1 H, 32-Ha), 0.92 
(d, 3J31,30= 6.7 Hz, 3 H, 31-H), 1.02 – 1.13 (m, 21 H, 18-H, 19-H), 1.26 (m, 1 H, 32-Hb), 1.35 (s, 
3 H, 16-H), 1.38 (s, 3 H, 16'-H), 1.60 (m, 1 H, 12-Ha), 1.65 – 1.77 (m, 2 H, 12-Hb, 30-H), 1.97 (m, 
1 H, 37-Ha), 2.05 – 2.21 (m, 5 H, 11-H, 36-H, 37-Hb), 2.33 (m, 2 H, 8-H), 2.91 (m, 1 H, 22-Ha), 
3.04 (dd, 2J22a,22b= 13.7 Hz, 
3J22a,21 = 7.1 Hz, 1 H, 22-Hb), 3.63 – 3.75 (m, 3 H, 14-H, 17-Ha, 38-
Ha), 3.73 (s, 3 H, 27-H), 3.84 (dd, 
2J17b,17a= 10.2 Hz, 
3J17b,14 = 3.9 Hz, 1 H, 17-Hb), 3.88 (m, 1 H, 
38-Hb), 3.92 (td, 
3J13,12 = 7.7 Hz, 
3J13,14 = 3.4 Hz, 1 H, 13-H), 4.22 (m, 1 H, 7-H), 4.46 (t, 
3J35,36 = 
6.7 Hz, 1 H, 35-H), 4.49 (m, 1 H, 29-H), 4.82 (m, 1 H, 21-H), 5.06 (d, 2J5a,5b= 11.9 Hz, 1 H, 5-Ha), 
5.12 (d, 2J5b,5a= 12.2 Hz, 1 H, 5-Hb), 5.28 (dt, 
3J9,10= 14.6 Hz, 
3J9,8 = 7.2 Hz, 1 H, 9-H), 5.44 – 5.52 
(m, 2 H, 10-H, NHc), 6.76 (d, 
3J25,24 = 8.3 Hz, 2 H, 25-H), 6.93 (br s, 1 H, NHb), 7.06 (d, 
3J24,25 = 
8.3 Hz, 2 H, 24-H), 7.28 – 7.36 (m, 5 H, 1-H, 2-H, 3-H), 7.72 (br s, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.7 (q, C-33), 11.8 (d, C-18), 15.0 (q, C-31), 17.9 (q, C-19), 
24.4 (t, C-32), 25.0 (t, C-37), 27.0 (q, C-16), 27.3 (q, C-16'), 28.5 (t, C-11 o. C-36), 29.1 (t, C-11 
o. C-36), 33.1 (t, C-12), 35.9 (t, C-8), 37.3 (d, C-30), 37.5 (t, C-22), 47.8 (t, C-38), 55.1 (d, C-29), 
55.1 (q, C-27), 59.6 (d, C-35), 64.1 (t, C-17), 67.1 (t, C-5), 78.6 (d, C-13), 80.9 (d, C-14), 108.5 
(s, C-15), 113.8 (d, C-25), 124.2 (d, C-9), 128.1 (d, C-1 o. C-2 o. C-3), 128.2 (s, C-23), 128.5 (d, 
C-1 o. C-2 o. C-3), 130.4 (d, C-24), 134.7 (d, C-10), 136.1 (s, C-4), 158.5 (s, C-26), 170.1 (s, C-
20 o. C-28 o. C-34 o. C-39), 170.9 (s, C-20 o. C-28 o. C-34 o. C-39), 171.3 (s, C-20 o. C-28 o. C-
34 o. C-39), 171.6 (s, C-20 o. C-28 o. C-34 o. C-39). The signals of C-6, C-7 and C-21 weren’t 
observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C51H79N4O11Si [M+H]
+  951.5509 951.5525 
Melting point:    85 °C 
Optical rotation:   [∝]𝐷
20 = –25.8° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 19.2 min 
([M+H]+ = 952). 
 
Perfluorophenyl ((R)-2-((S,E)-2-(((benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-
(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enamido)-3-(4-methoxyphenyl)-
propanoyl)-L-isoleucyl-L-prolinate (15) 
A solution of 266 mg (0.280 mmol) 14 in 2.8 mL DCM abs. was cooled to 0 °C before 66 mg 
(0.359 mmol) pentafluorophenol and 61 mg (0.319 mmol) EDC·HCl were added. The reaction 
was allowed to warm to rt overnight and diluted with DCM. 1 M HCl sol. was added and the layers 
were separated. The aqueous phase was extracted three times with DCM. The combined organic 
layers were washed with sat. NaHCO3 sol. and dried over Na2SO4. 305 mg (0.273 mmol, 98 %) of 
Pfp ester 15 were obtained as an off-white solid after lyophilisation. 
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Rf (15) = 0.43 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.76 (t, 3J33,32= 7.2 Hz, 3 H, 33-H), 0.86 (d, 3J31,30= 6.7 Hz, 3 H, 
31-H), 0.89 (m, 1 H, 32-Ha), 1.02 – 1.13 (m, 21 H, 18-H, 19-H), 1.32 (m, 1 H, 32-Hb), 1.35 (s, 3 
H, 16-H), 1.38 (s, 3 H, 16'-H), 1.60 (m, 1 H, 12-Ha), 1.66 – 1.75 (m, 2 H, 12-Hb, 30-H), 2.05 – 
2.22 (m, 5 H, 11-H, 36-Ha, 37-H), 2.29 (m, 1 H, 8-Ha), 2.36 – 2.47 (m, 2 H, 8-Hb, 36-Ha), 2.98 (d, 
3J22,21 = 5.8 Hz, 2 H, 22-H), 3.65 – 3.75 (m, 3 H, 14-H, 17-Ha, 38-Ha), 3.73 (s, 3 H, 27-H), 3.84 
(dd, 2J17b,17a= 10.2 Hz, 
3J17b,14 = 3.9 Hz, 1 H, 17-Hb), 3.91 (td, 
3J13,12 = 7.9 Hz, 
3J13,14 = 3.5 Hz, 1 
H, 13-H), 3.95 (m, 1 H, 38-Hb), 4.12 (dt, 
3J7,8 ≈ 3J7,NH = 6.9 Hz, 1 H, 7-H), 4.48 (t, 3J29,30 ≈ 3J29,NH 
= 8.3 Hz, 1 H, 29-H), 4.73 (m, 1 H, 21-H), 4.84 (m, 1 H, 35-H), 5.05 (d, 2J5a,5b= 12.1 Hz, 1 H, 5-
Ha), 5.11 (d, 
2J5b,5a= 12.0 Hz, 1 H, 5-Hb), 5.30 (dt, 
3J9,10= 14.7 Hz, 
3J9,8 = 7.2 Hz, 1 H, 9-H), 5.47 
– 5.54 (m, 2 H, 10-H, NHc), 6.70 (br s, 1 H, NHb), 6.77 (d, 3J25,24 = 8.7 Hz, 2 H, 25-H), 6.92 (br s, 
1 H, NHa), 7.09 (d, 
3J24,25 = 8.3 Hz, 2 H, 24-H), 7.29 – 7.36 (m, 5 H, 1-H, 2-H, 3-H). 
13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-33), 11.8 (d, C-18), 14.9 (q, C-31), 17.9 (q, C-19), 
24.2 (t, C-32), 25.1 (t, C-37), 26.9 (q, C-16), 27.4 (q, C-16'), 29.1 (t, C-11), 29.3 (t, C-36), 33.1 (t, 
C-12), 35.6 (t, C-8), 37.3 (d, C-30), 37.7 (t, C-22), 47.4 (t, C-38), 54.2 (d, C-21), 54.6 (d, C-7), 
55.0 (d, C-29), 55.1 (q, C-27), 58.4 (d, C-35), 64.1 (t, C-17), 67.1 (t, C-5), 78.6 (d, C-13), 80.8 (d, 
C-14), 108.4 (s, C-15), 114.0 (d, C-25), 124.5 (d, C-9), 128.1 (d, C-1 o. C-2 o. C-3), 128.2 (d, C-
1 o. C-2 o. C-3), 128.3 (s, C-23), 128.4 (d, C-1 o. C-2 o. C-3), 130.2 (d, C-24), 134.5 (d, C-10), 
136.2 (s, C-4), 158.5 (s, C-26), 168.2 (s, C-20 o. C-28 o. C-34 o. C-39), 170.5 (s, C-20 o. C-28 o. 
C-34 o. C-39), 170.9 (s, C-20 o. C-28 o. C-34 o. C-39). The signals of C-6, C-40 to C-43 as well 
as the signal of one of the carbonyls weren’t observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C57H78F5N4O11Si [M+H]
+  1117.5351 1117.5353 
Melting point:    62 °C 
Optical rotation:   [∝]𝐷
20 = –32.0° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH90:10, 0.6 mL/min, tR = 17.6 min ([M+Na]
+ = 1140). 
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Methyl (S,E)-2-(((benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propyl-si-
lyl)oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enoate (16) 
To a solution of 2.75 g (4.87 mmol) acid 10 in 20.0 mL DMF were added 809 mg (5.85 mmol) 
K2CO3 at rt. After cooling to 0 °C, 0.91 mL (2.07 g, 14.6 mmol) methyl iodide were added and the 
reaction was stirred for 2 h at this temperature. For workup, the reaction mixture was poured into 
15 mL sat. NH4Cl sol. and 80 mL water at rt. After stirring for 30 min, the layers were separated 
and the aqueous phase was extracted three times with Et2O. The combined organic phases were 
washed with brine trice and dried over Na2SO4. After purification by column chromatography 
(silica gel, PE:EA 100:0, 90:10), 2.79 g (4.83 mmol, dr > 99:1, 99 %) 16 were obtained as a 
colourless oil. 
Rf (16) = 0.30 (silica gel, PE:EA 80:20) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.03 – 1.14 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.63 (m, 1 H, 8-Ha), 1.71 (m, 1 H, 8-Hb), 2.15 (m, 2 H, 9-H), 2.48 (dd, 
3J12,11 ≈ 3J12,15 = 
6.1 Hz, 2 H, 12-H), 3.66 – 3.76 (m, 2 H, 3-Ha, 4-H), 3.73 (s, 3 H, 13-H), 3.87 (dd, 2J3b,3a = 10.0 
Hz, 3J3b,4 = 3.7 Hz, 1 H, 3-Hb), 3.91 (td, 
3J5,8 = 7.7 Hz, 
3J5,4 = 3.6 Hz, 1 H, 5-H), 4.41 (dt, 
3J15,NH = 
7.7 Hz, 3J15,12 = 5.7 Hz, 1 H, 15-H), 5.11 (s, 2 H, 17-H), 5.27 (br s, 1 H, NH), 5.31 (dt, 
3J11,10 = 
15.7 Hz, 3J11,12 = 7.3 Hz, 1 H, 11-H), 5.54 (dt, 
3J10,11 = 14.6 Hz, 
3J10,9 = 7.1 Hz, 1 H, 10-H), 7.30 – 
7.36 (m, 5 H, 19-H, 20-H, 21-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.4 (q, C-7'), 29.1 
(t, C-9), 33.0 (t, C-8), 35.4 (t, C-12), 52.3 (q, C-13), 53.5 (d, C-15), 64.2 (t, C-3), 67.0 (t, C-17), 
78.7 (d, C-5), 80.8 (d, C-4), 108.4 (s, C-6), 123.5 (d, C-11), 128.1 (d, C-19 o. C-21), 128.2 (d, C-
19 o. C-21), 128.5 (d, C-20), 135.0 (d, C-10), 136.2 (s, C-18), 155.7 (s, C-16), 172.3 (s, C-14). 
HRMS (CI):    calculated found 
C31H52NO7Si [M+H]
+   578.3508 578.3523 
Optical rotation:   [∝]𝐷
20 = +6.9° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 90:10, 1 mL/min, 20 °C: 
(S)-16: tR = 29.9 min (> 99 %). 
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Methyl (S)-2-amino-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxo-
lan -4-yl)heptanoate (17) 
201 mg (0.348 mmol) amino acid ester 16 were dissolved in 1.75 mL MeOH at rt before 21.1 mg 
palladium on charcoal (10 w% Pd) were added and the reaction mixture was stirred under H2 
atmosphere for 18 h. The reaction was filtrated through a pad of Celite® and washed with MeOH. 
The filtrate was concentrated in vacuo. 151 mg (0.339 mmol, 97 %) of amine 17 were obtained as 
a colourless oil after lyophilisation. 
Rf (17) = 0.18 (silica gel, PE:EA 70:30) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.04 – 1.15 (m, 21 H, 1-H, 2-H), 1.32 – 1.43 (m, 5 H, 9-H, 10-
Ha/10-Hb, 11-Ha/11-Hb), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 H, 7'-H), 1.47 – 1.60 (m, 3 H, 8-Ha, 10-
Ha/10-Hb/11-Ha/11-Hb, 12-Ha), 1.57 (m, 2 H, NH2), 1.62 – 1.75 (m, 2 H, 8-Hb, 12-Hb), 3.43 (dd, 
3J15,12/NH = 7.4 Hz, 
3J15,12/NH = 5.6 Hz, 1 H, 15-H), 3.69 (m, 1 H, 4-H), 3.71 (s, 3 H, 13-H), 3.75 
(dd, 2J3a,3b = 10.3 Hz, 
3J3a,4 = 6.0 Hz, 1 H, 3-Ha), 3.86 (dd, 
2J3b,3a = 10.3 Hz, 
3J3b,4 = 4.0 Hz, 1 H, 
3-Hb), 3.93 (td, 
3J5,8 = 7.7 Hz, 
3J5,4 = 3.7 Hz, 1 H, 5-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-2), 17.9 (q, C-1), 25.6 (q, C-7), 26.0 (q, C-7'), 27.0 
(t, C-10 o. C-11), 27.4 (t, C-10 o. C-11), 29.5 (t, C-9), 33.5 (t, C-8), 34.9 (t, C-12), 51.9 (q, C-13), 
54.4 (d, C-15), 64.2 (t, C-3), 79.1 (d, C-5), 81.0 (d, C-4), 108.3 (s, C-6), 176.7 (s, C-14). 
HRMS (CI):    calculated found 
C23H48NO5Si [M+H]
+   446.3296 446.3296 
Optical rotation:   [∝]𝐷
20 = –5.1° (c = 1.0, CHCl3) 
 
Cbz-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-OH (18a) 
A solution of 1.99 g (3.59 mmol) ester 11a in 35 mL 1,4-dioxane was treated with 3.94 mL (3.94 
mmol) NaOH (1.0 M in H2O) at 0 °C. The cooling bath was removed and the reaction was stirred 
at rt overnight. The reaction was then concentrated in vacuo and the residue was redissolved in 
EA. 1 M HCl sol. was added and the layers were separated. The aqueous phase was extracted three 
times with EA. The combined organic phases were dried over Na2SO4. 1.93 g (3.58 mmol, 99 %) 
of acid 18a were obtained as an off-white solid after lyophilisation. 
Rf (18a) = 0.22 (silica gel, PE:EA 50:50) 
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1H-NMR (400 MHz, CDCl3): δ = 0.74 (t, 3J19,18 = 6.9 Hz, 3 H, 19-H), 0.85 (m, 1 H, 18-Ha), 0.89 
(d, 3J17,16 = 6.5 Hz, 3 H, 17-H), 1.23 (m, 1 H, 18-Hb), 1.68 (m, 1 H, 16-H), 1.97 (m, 1 H, 23-Ha), 
2.04 – 2.21 (m, 3 H, 22-H, 23-Hb), 2.92 (dd, 2J8a,8b = 13.6 Hz, 3J8a,7 = 5.9 Hz, 1 H, 8-Ha), 3.00 (dd, 
2J8b,8a = 13.8 Hz, 
3J8b,7 = 7.1 Hz, 1 H, 8-Hb), 3.65 (m, 1 H, 24-Ha), 3.75 (s, 3 H, 13-H), 3.88 (m, 1 
H, 24-Hb), 4.48 (dd, 
3J21,22a = 7.5 Hz, 
3J21,22b = 5.5 Hz, 1 H, 21-H), 4.53 (dd, 
3J15,NH = 8.9 Hz, 
3J15,16 
= 8.9 Hz, 1 H, 15-H), 4.56 (m, 1 H, 7-H), 5.05 (m, 2 H, 5-H), 5.66 (d, 3JNH,7 = 7.6 Hz, 1 H, NHb), 
6.76 (d, 3J11,10 = 8.6 Hz, 2 H, 11-H), 7.07 (d, 
3J10,11 = 8.6 Hz, 2 H, 10-H), 7.23 – 7.36 (m, 5 H, 1-
H, 2-H, 3-H), 7.50 (d, 3JNH,15 = 7.2 Hz, 1 H, NHa), 9.75 (br s, 1 H, COOH). 
13C-NMR (100 MHz, CDCl3): δ = 10.8 (q, C-19), 14.9 (q, C-17), 24.3 (t, C-18), 24.9 (t, C-23), 
28.6 (t, C-22), 37.4 (d, C-16), 38.3 (t, C-8), 47.8 (t, C-24), 54.8 (d, C-15), 55.1 (q, C-13), 55.7 (d, 
C-7), 59.3 (d, C-21), 67.0 (t, C-5), 113.9 (d, C-11), 128.0 (d, C-3), 128.1 (s, C-9), 128.4 (d, C-1 o. 
C-2), 128.5 (d, C-1 o. C-2), 130.4 (d, C-10), 136.2 (s, C-4), 156.0 (s, C-6), 158.5 (s, C-12), 171.1 
(s, C-14), 171.6 (s, C-20), 173.7 (s, C-25). 
HRMS (CI):    calculated found 
C29H38N3O7 [M+H]
+   540.2704 540.2695 
Melting point:    92 °C 
Optical rotation:   [∝]𝐷
20 = –45.9° (c = 0.5, CHCl3) 
 
Boc-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-OH (18c) 
A solution of 2.14 g (4.12 mmol) 11c in 34 mL dioxane was treated with a solution of 264 mg 
(6.17 mmol) LiOH·H2O in 7 mL water at 0 °C. The reaction was allowed to warm to rt within 7.5 
h. The reaction mixture was then concentrated in vacuo and the residue was redissolved in water. 
The aqueous phase was extracted with EA and the organic phase was discarded. The aqueous 
phase was then acidified with 1 M HCl sol. and extracted three times with EA. The combined 
organic layers of this latter extraction were dried over Na2SO4. After lyophilisation, 2.03 g (4.01 
mmol, 99 %) of acid 18c (containing 3 % iso-Butylcarbonate at tyrosine residue) were obtained as 
an off-white solid. 
Rf (18c) = 0.17 (silica gel, PE:EA 50:50 + 1 % HOAc) 
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1H-NMR (400 MHz, CDCl3): δ = 0.77 (t, 3J11,10 = 7.0 Hz, 3 H, 11-H), 0.88 (m, 1 H, 10-Ha), 0.91 
(d, 3J9,8 = 6.8 Hz, 3 H, 9-H), 1.27 (m, 1 H, 10-Hb), 1.39 (s, 9 H, 22-H), 1.70 (m, 1 H, 8-H), 2.01 
(m, 1 H, 4-Ha), 2.15 (m, 3 H, 3-H, 4-Hb), 2.89 (dd, 
2J14a,14b = 14.0 Hz, 
3J14a,13 = 5.0 Hz, 1 H, 14-
Ha), 3.05 (dd, 
2J14b,14a = 13.6 Hz, 
3J14b,13 = 7.1 Hz, 1 H, 14-Hb), 3.69 (m, 1 H, 5-Ha), 3.76 (s, 3 H, 
19-H), 3.91 (m, 1 H, 5-Hb), 4.52 (m, 3 H, 2-H, 7-H, 13-H), 5.31 (d, 
3JNH,13 = 6.1 Hz, 1 H, NHb), 
6.78 (d, 3J17,16 = 8.6 Hz, 2 H, 17-H), 7.08 (d, 
3J16,17 = 8.6 Hz, 2 H, 16-H), 7.54 (br s, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.8 (q, C-11), 14.9 (q, C-9), 24.3 (t, C-10), 24.9 (t, C-4), 28.2 
(q, C-22), 28.6 (t, C-3), 37.6 (d, C-8), 38.2 (t, C-14), 47.8 (t, C-5), 54.8 (d, C-7), 55.1 (q, C-19), 
59.4 (d, C-2 o. C-13), 60.4 (d, C-2 o. C-13), 80.3 (s, C-21), 113.8 (d, C-17), 128.3 (s, C-15), 130.4 
(d, C-16), 155.6 (s, C-20), 158.5 (s, C-18), 171.4 (s, C-6), 171.6 (s, C-12), 173.6 (s, C-1). 
HRMS (CI):    calculated found 
C26H40N3O7 [M+H]
+   506.2861 506.2864 
Melting point:   98 °C 
Optical rotation:   [∝]𝐷
20 = –48.9° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.6 mL/min, tR1 = 16.5 min 
(95 %, [M+H]+ = 506), tR2 = 18.6 min (3 %, [M+Na]
+ = 614). 
 
Methyl (S)-2-((S)-1-(((R)-2-(((benzyloxy)carbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-
L-isoleucyl)pyrrolidine-2-carboxamido)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)-
oxy)-methyl)-1,3-dioxolan-4-yl)heptanoate (19) 
1.87 g (3.47 mmol) 18a were dissolved in 28 mL MeCN and 1.56 g (3.50 mmol) 17 were added. 
Afterwards, 1.14 g (3.55 mmol) TBTU and 642 µL (475 mg, 3.68 mmol) DIPEA were added and 
the reaction was stirred at rt overnight. The reaction was then concentrated in vacuo and the residue 
was redissolved in DCM. 1 M HCl sol. was added and the layers were separated. The aqueous 
phase was extracted three times with DCM. The combined organic phases were washed with sat. 
NaHCO3 sol. and dried over Na2SO4. Purification by column chromatography (silica gel, PE:EA 
50:50 + 1 % HOAc) yielded 2.70 g (2.79 mmol, dr > 99:1, 80 %) tetrapeptide 19 as an off-white 
solid. 
Rf (19) = 0.36 (silica gel, PE:EA 50:50) 
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1H-NMR (400 MHz, CDCl3): δ = 0.75 (t, 3J19,18 = 6.9 Hz, 3 H, 19-H), 0.85 (d, 3J17,16 = 6.7 Hz, 3 
H, 17-H), 0.86 (m, 1 H, 18-Ha), 1.03 – 1.14 (m, 21 H, 37-H, 38-H), 1.20 – 1.33 (m, 6 H, 18-Hb, 
28-Ha/28-Hb, 29-Ha/29-Hb, 30-Ha/30-Hb), 1.35 (s, 3 H, 35-H), 1.37 (m, 1 H, 28-Ha/28-Hb/29-
Ha/29-Hb/30-Ha/30-Hb), 1.38 (s, 3 H, 35'-H), 1.50 (m, 1 H, 31-Ha), 1.57 – 1.67 (m, 3 H, 16-H, 31-
Hb, 27-Ha), 1.72 (m, 1 H, 27-Hb), 1.87 – 2.02 (m, 2 H, 22-Ha, 23-Ha), 2.10 (m, 1 H, 23-Hb), 2.30 
(m, 1 H, 22-Hb), 2.99 (d, 
3J8,7 = 6.6 Hz, 2 H, 8-H), 3.59 – 3.68 (m, 2 H, 24-Ha, 33-H), 3.71 (s, 3 H, 
40-H), 3.73 (m, 1 H, 36-Ha), 3.76 (s, 3 H, 13-H), 3.83 (m, 1 H, 24-Hb), 3.85 (dd, 
2J36b,36a = 10.3 
Hz, 3J36b,33 = 4.1 Hz, 1 H, 36-Hb), 3.90 (td, 
3J32,31 = 7.9 Hz, 
3J32,33 = 3.5 Hz, 1 H, 32-H), 4.44 (dt, 
3J26,27 ≈ 3J26,NH = 6.6 Hz, 1 H, 26-H), 4.49 (m, 1 H, 15-H), 4.52 (t, 3J7,8/NH = 8.4 Hz, 2 H, 7-H), 
4.61 (d, 3J21,22a = 6.5 Hz, 1 H, 21-H), 5.07 (s, 2 H, 5-H), 5.34 (d, 
3JNH,7 = 7.0 Hz, 1 H, NHc), 6.70 
(br s, 1 H, NHb), 6.78 (d, 
3J11,10 = 8.4 Hz, 2 H, 11-H), 7.08 (d, 
3J10,11 = 7.6 Hz, 2 H, 10-H), 7.27 – 
7.37 (m, 6 H, 1-H, 2-H, 3-H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-19), 11.8 (d, C-37), 15.2 (q, C-17), 17.9 (q, C-38), 
24.1 (t, C-18), 24.9 (t, C-23), 25.3 (t, C-28 o. C-29 o. C-30), 26.0 (t, C-28 o. C-29 o. C-30), 27.0 
(q, C-35), 27.4 (q, C-35'), 27.5 (t, C-22), 29.3 (t, C-28 o. C-29 o. C-30), 32.2 (t, C-27), 33.5 (t, C-
31), 37.6 (d, C-16), 38.3 (t, C-8), 47.8 (t, C-24), 52.5 (q, C-40), 52.5 (d, C-26), 54.9 (d, C-7), 55.1 
(q, C-13), 56.2 (d, C-15), 59.7 (d, C-21), 64.2 (t, C-36), 67.0 (t, C-5), 79.0 (d, C-32), 81.0 (d, C-
33), 108.3 (s, C-34), 114.0 (d, C-11), 128.0 (d, C-3), 128.1 (d, C-1 o. C-2), 128.1 (s, C-9), 128.5 
(d, C-1 o. C-2), 130.2 (d, C-10), 136.2 (s, C-4), 155.6 (s, C-6), 158.6 (s, C-12), 170.7 (s, C-14), 
170.9 (s, C-20 o. C-25), 171.6 (s, C-20 o. C-25), 172.7 (s, C-39). 
HRMS (CI):    calculated found 
C52H83N4O11Si [M+H]
+  967.5822 967.5840 
Melting point:    56 °C 
Optical rotation:   [∝]𝐷
20 = –42.6° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 50:50, 1 mL/min, 20 °C: 
tR = 31.4 min (> 99 %, broad). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 24.5 min 
([M+H]+ = 968). 
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(S)-2-((S)-1-(((R)-2-(((Benzyloxy)carbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-L-iso-
leucyl)pyrrolidine-2-carboxamido)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)-oxy)me-
thyl)-1,3-dioxolan-4-yl)heptanoic acid (20) 
A solution of 2.67 g (2.76 mmol) ester 19 in 25 mL 1,4-dioxane was treated with 3 mL (3.37 
mmol) LiOH (1.12 M in H2O) at 0 °C. The cooling bath was removed and the reaction was stirred 
at rt for 8 h. For workup, the reaction was concentrated in vacuo and the residue was redissolved 
in EA. 1 M HCl sol. was added and the layers were separated. The aqueous phase was extracted 
three times with EA and the combined organic phases were dried over Na2SO4. After lyophilisa-
tion, 2.62 g (2.75 mmol, dr 95:5, quant.) of product 20 were obtained as an off-white solid. 
Rf (20) = 0.10 (silica gel, PE:EA 50:50 + 1 % HOAc) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.77 (t, 3J19,18 = 6.8 Hz, 3 H, 19-H), 0.87 (d, 3J17,16 = 6.7 Hz, 3 
H, 17-H), 0.96 (m, 1 H, 18-Ha), 1.02 – 1.13 (m, 21 H, 37-H, 38-H), 1.24 – 1.39 (m, 6 H, 18-Hb, 
28-Ha/28-Hb, 29-Ha/29-Hb, 30-Ha/30-Hb), 1.34 (s, 3 H, 35-H), 1.37 (s, 3 H, 35'-H), 1.44 (m, 1 H, 
28-Ha/28-Hb/29-Ha/29-Hb/30-Ha/30-Hb), 1.51 (m, 1 H, 31-Ha), 1.57 – 1.72 (m, 3 H, 16-H, 27-Ha, 
31-Hb), 1.78 (m, 1 H, 27-Hb), 1.87 (m, 1 H, 22-Ha), 2.06 (m, 2 H, 23-H), 2.50 (m, 1 H, 22-Hb), 
2.99 (d, 3J8,7 = 5.9 Hz, 2 H, 8-H), 3.60 – 3.68 (m, 2 H, 24-Ha, 33-H), 3.72 (m, 1 H, 36-Ha), 3.75 (s, 
3 H, 13-H), 3.84 (dd, 2J36b,36a = 10.3 Hz, 
3J36b,33 = 4.0 Hz, 1 H, 36-Hb), 3.89 (td, 
3J32,31 = 7.9 Hz, 
3J32,33 = 3.4 Hz, 1 H, 32-H), 3.94 (m, 1 H, 24-Hb), 4.44 – 4.53 (m, 3 H, 7-H, 15-H, 26-H), 4.70 (d, 
3J21,22a/b = 7.3 Hz, 1 H, 21-H), 5.05 (s, 2 H, 5-H), 5.48 (d, 
3JNH,7 = 8.2 Hz, 1 H, NHc), 6.78 (d, 
3J11,10 
= 8.4 Hz, 2 H, 11-H), 7.08 (d, 3J10,11 = 8.6 Hz, 2 H, 10-H), 7.27 – 7.35 (m, 5 H, 1-H, 2-H, 3-H), 
7.63 (d, 3JNH,15 = 8.7 Hz, 1 H, NHb), 7.83 (d, 
3JNH,26 = 6.6 Hz, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.7 (q, C-19), 11.8 (d, C-37), 15.0 (q, C-17), 17.9 (q, C-38), 
24.6 (t, C-18), 25.0 (t, C-23), 25.5 (t, C-28 o. C-29 o. C-30), 26.1 (t, C-28 o. C-29 o. C-30), 26.5 
(t, C-22), 27.0 (q, C-35), 27.4 (q, C-35'), 29.5 (t, C-28 o. C-29 o. C-30), 33.0 (t, C-27), 33.6 (t, C-
31), 37.1 (d, C-16), 38.1 (t, C-8), 48.4 (t, C-24), 53.0 (d, C-26), 55.0 (d, C-7 o. C-15), 55.2 (q, C-
13), 56.0 (d, C-7 o. C-15), 60.4 (d, C-21), 64.1 (t, C-36), 66.7 (t, C-5), 79.0 (d, C-32), 81.0 (d, C-
33), 108.3 (s, C-34), 113.9 (d, C-11), 127.8 (d, C-3), 128.0 (d, C-1 o. C-2), 128.1 (s, C-9), 128.4 
(d, C-1 o. C-2), 130.3 (d, C-10), 136.4 (s, C-4), 155.7 (s, C-6), 158.6 (s, C-12), 169.8 (s, C-25), 
171.7 (s, C-14), 173.4 (s, C-20), 174.1 (s, C-39). 
HRMS (CI):    calculated found 
C51H81N4O11Si [M+H]
+  953.5666 953.5685 
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Melting point:    55-57 °C 
Optical rotation:   [∝]𝐷
20 = –37.5° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 17.9 min 
(95 %, [M+Na]+ = 976) tR2 = 18.5 min (5 %, [M+Na]
+ = 976). 
 
Perfluorophenyl (S)-2-((S)-1-(((R)-2-(((benzyloxy)carbonyl)amino)-3-(4-methoxyphenyl)-
propanoyl)-L-isoleucyl)pyrrolidine-2-carboxamido)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-
propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)heptanoate (21) 
To a solution of 102 mg (0.107 mmol) acid 20 in 1.1 mL DCM abs. were added 27 mg (0.147 
mmol) pentafluorophenol and 24.1 mg (0.126 mmol) EDC·HCl at 0 °C. The reaction was allowed 
to warm to rt overnight and diluted with DCM. 1 M HCl sol. was added and the layers were sepa-
rated. The aqueous phase was extracted three times with DCM and the combined organic phases 
were washed with sat. NaHCO3 sol. and dried over Na2SO4. 120 mg (0.107 mmol, dr ~ 97:3, 
quant.) 21 were obtained as an off-white solid after lyophilisation. 
Rf (21) = 0.31 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (500 MHz, 373K, DMSO-d6): δ = 0.80 (t, 3J19,18 = 7.4 Hz, 3 H, 19-H), 0.88 (m, 3 H, 17-
H), 0.88 (m, 1 H, 18-Ha), 1.02 – 1.14 (m, 21 H, 37-H, 38-H), 1.27 – 1.46 (m, 7 H, 18-Hb, 28-Ha, 
28-Hb, 29-Ha, 29-Hb, 30-Ha, 30-Hb), 1.30 (s, 3 H, 35-H), 1.32 (s, 3 H, 35'-H), 1.53 (m, 1 H, 31-
Ha), 1.57 – 1.65 (m, 2 H, 16-H, 31-Hb), 1.71 – 1.86 (m, 3 H, 22-Ha, 27-H), 1.88 – 2.06 (m, 3 H, 
22-Hb, 23-H), 2.76 (dd, 
2J8a,8b = 13.4 Hz, 
3J8a,7 = 9.6 Hz, 1 H, 8-Ha), 2.95 (dd, 
2J8b,8a = 13.4 Hz, 
3J8b,7 = 9.6 Hz, 1 H, 8-Hb), 3.56 (m, 1 H, 24-Ha), 3.65 (ddd, 
3J33,36a = 7.7 Hz, 
3J33,36b ≈ 3J33,32 = 4.7 
Hz, 1 H, 33-H), 3.74 (s, 3 H, 13-H), 3.76 (m, 1 H, 24-Hb), 3.77 (dd, 
2J36a,36b = 10.8 Hz, 
3J36a,33 = 
4.9 Hz, 1 H, 36-Ha), 3.81 (dd, 
2J36b,36a = 10.7 Hz, 
3J36b,33 = 4.4 Hz, 1 H, 36-Hb), 3.87 (m, 1 H, 32-
H), 4.24 (m, 1 H, 15-H/26-H), 4.33 (m, 1 H, 7-H), 4.41 – 4.49 (m, 2 H, 15-H/26-H, 21-H), 4.96 
(d, 2J5a,5b = 13.2 Hz, 1 H, 5-Ha), 4.99 (d, 
2J5b,5a = 13.2 Hz, 1 H, 5-Hb), 6.80 (d, 
3J11,10 = 8.5 Hz, 2 
H, 11-H), 6.93 (br s, 1 H, NHc), 7.16 (d, 
3J10,11 = 8.5 Hz, 2 H, 10-H), 7.25 – 7.34 (m, 5 H, 1-H, 2-
H, 3-H), 7.62 (br s, 1 H, NH), 7.71 (br s, 1 H, NH). 
13C-NMR (125 MHz, 373K, DMSO-d6): δ = 10.1 (q, C-19), 11.1 (d, C-37), 14.7 (q, C-17), 17.2 
(q, C-38), 23.5 (t, C-18), 24.5 (t, C-23), 24.5 (t, C-28 o. C-29 o. C-30), 24.8 (t, C-28 o. C-29 o. C-
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30), 26.4 (q, C-35), 26.8 (q, C-35'), 28.1 (t, C-22), 30.9 (t, C-28 o. C-29 o. C-30), 31.1 (t, C-27), 
32.4 (t, C-31), 36.2 (d, C-16), 36.7 (t, C-8), 46.7 (t, C-24), 51.5 (d, C-21), 53.9 (d, C-15 o. C-26), 
54.6 (q, C-13), 56.0 (d, C-7), 58.8 (d, C-15 o. C-26), 63.4 (t, C-36), 64.9 (t, C-5), 77.3 (d, C-32), 
80.6 (d, C-33), 107.2 (s, C-34), 113.2 (d, C-11), 126.8 (d, C-1 o. C-2 o. C-3), 127.0 (d, C-1 o. C-2 
o. C-3), 127.6 (d, C-1 o. C-2 o. C-3), 129.2 (s, C-9), 129.6 (d, C-10), 136.6 (s, C-4), 155.0 (s, C-
6), 157.6 (s, C-12), 170.5 (s, C-14 o. C-20 o. C-25 o. C-39), 172.4 (s, C-14 o. C-20 o. C-25 o. C-
39), 172.6 (s, C-14 o. C-20 o. C-25 o. C-39). 
Minor diastereomer: 
1H-NMR (500 MHz, 373K, DMSO-d6): δ = 1.27 (s, 3 H, 35-H), 4.70 – 4.75 (m, 2 H, 15-H/26-H, 
21-H), 6.65 (d, 3J11,10 = 8.2 Hz, 2 H, 11-H), 7.03 (d, 
3J10,11 = 8.5 Hz, 2 H, 10-H), 7.52 (br s, 1 H, 
NH), 7.83 (br s, 1 H, NH). 
13C-NMR (125 MHz, 373K, DMSO-d6): δ = 14.6 (q, C-17), 28.2 (t, C-22), 32.3 (t, C-31), 51.3 (d, 
C-21), 54.1 (d, C-15 o. C-26), 59.1 (d, C-15 o. C-26), 77.3 (d, C-32). 
HRMS (CI):    calculated found 
C57H80F5N4O11Si [M+H]
+  1119.5508 1119.5509 
Melting point:    57 °C 
Optical rotation:   [∝]𝐷
20 = –40.8° (c = 1.0, CHCl3) 
 
(3S,6R,9S,14aS)-9-((S)-sec-Butyl)-3-(5-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)-
methyl)-1,3-dioxolan-4-yl)pentyl)-6-(4-methoxybenzyl)decahydropyrrolo[1,2-a][1,4,7,10]-
tetraazacyclododecine-1,4,7,10-tetraone (22) 
Method A: 
58 mg (51.8 µmol) 21 were dissolved in 50 mL THF and 5.6 mg palladium on charcoal (10 w% 
Pd) were added. The reaction was hydrogenated under atmospheric pressure for 48 h. The reaction 
mixture was filtrated through a pad of Celite and washed with Et2O. The filtrate was concentrated 
in vacuo and the crude product was purified by column chromatography (silica gel, PE:EA 100:0, 
80:20, 50:50). 13.1 mg (16.4 µmol, dr 85:15, 32 %) of the cyclic tetrapeptide 22 were obtained as 
an off-white solid. 
Method B: 
To a solution of 56 mg (50.0 µmol) 21 in 5 mL THF were added 5.6 mg palladium on charcoal 
(10 w% Pd) at rt. The reaction was set under 5 bar H2 and hydrogenated for 40 h at rt. The reaction 
mixture was filtrated through a pad of Celite and washed with Et2O. The filtrate was concentrated 
in vacuo and the crude product was purified by column chromatography (silica gel, PE:EA 100:0, 
80:20, 50:50). 11.3 mg (14.1 µmol, dr 94:6, 28 %) of the cyclic tetrapeptide 22 were obtained as 
an off-white solid. 
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Rf (22) = 0.27 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.70 (t, 3J14,13 = 6.9 Hz, 3 H, 14-H), 0.80 (d, 3J12,11 = 6.4 Hz, 3 
H, 12-H), 0.80 (m, 1 H, 13-Ha), 1.03 (m, 1 H, 13-Hb), 1.03 – 1.15 (m, 21 H, 32-H, 33-H), 1.29 – 
1.41 (m, 5 H, 23-Ha/23-Hb, 24-Ha/24-Hb, 25-Ha/25-Hb), 1.36 (s, 3 H, 30-H), 1.39 (s, 3 H, 30'-H), 
1.46 – 1.58 (m, 2 H, 23-Ha/23-Hb/24-Ha/24-Hb/25-Ha/25-Hb, 26-Ha), 1.60 – 1.69 (m, 2 H, 22-Ha, 
26-Hb), 1.82 – 1.92 (m, 3 H, 11-H, 18-Ha, 22-Hb), 1.98 (m, 1 H, 18-Hb), 2.16 (m, 1 H, 17-Ha), 2.24 
(m, 1 H, 17-Hb), 2.83 (dd, 
2J3a,3b = 13.5 Hz, 
3J3a,2 = 5.3 Hz, 1 H, 3-Ha), 3.21 (dd, 
2J3b,3a = 13.0 Hz, 
3J3b,2 = 10.8 Hz, 1 H, 3-Hb), 3.61 – 3.70 (m, 2 H, 19-Ha, 28-H), 3.69 (s, 3 H, 8-H), 3.72 – 3.78 (m, 
2 H, 19-Hb, 31-Ha), 3.86 (dd, 
2J31b,31a = 10.4 Hz, 
3J31b,28 = 4.0 Hz, 1 H, 31-Hb), 3.91 (dt, 
3J27,26 = 
7.5 Hz, 3J27,28 = 3.4 Hz, 1 H, 27-H), 4.52 (dd, 
3J10,11 ≈ 3J10,NH = 9.8 Hz, 1 H, 10-H), 4.57 (dt, 
3J21,22/NH = 9.3 Hz, 
3J21,22/NH = 7.5 Hz, 1 H, 21-H), 4.63 (ddd, 
3J2,3b = 10.3 Hz, 
3J2,3a ≈ 3J2,NH =  5.4 
Hz, 1 H, 2-H), 4.93 (d, 3J16,17 = 7.0 Hz, 1 H, 16-H), 6.22 (br s, 1 H, NHa), 6.58 (br s, 1 H, NHc), 
6.65 (d, 3J6,5 = 8.2 Hz, 2 H, 6-H), 6.85 (m, 1 H, NHb), 7.01 (d, 
3J5,6 = 8.1 Hz, 2 H, 5-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.3 (q, C-14), 11.9 (d, C-32), 15.9 (q, C-12), 18.0 (q, C-33), 
21.9 (t, C-18), 24.1 (t, C-13), 25.8 (t, C-23 o. C-24 o. C-25), 26.1 (t, C-23 o. C-24 o. C-25), 27.0 
(q, C-30), 27.4 (q, C-30'), 28.2 (t, C-22), 29.5 (t, C-23 o. C-24 o. C-25), 31.6 (t, C-17), 33.4 (t, C-
26), 34.6 (t, C-3), 36.2 (d, C-11), 47.0 (t, C-19), 54.0 (d, C-21), 55.0 (q, C-8), 55.7 (d, C-10), 57.2 
(d, C-2), 61.0 (d, C-16), 64.2 (t, C-31), 79.2 (d, C-27), 81.0 (d, C-28), 108.3 (s, C-29), 113.7 (d, 
C-6), 128.7 (s, C-4), 130.5 (d, C-5), 158.3 (s, C-7), 170.1 (s, C-9), 170.6 (s, C-15), 174.0 (s, C-1 
o. C-20), 174.6 (s, C-1 o. C-20). 
Minor diastereomer: 
1H-NMR (400 MHz, CDCl3): δ =2.93 (m, 1 H, 3-Ha), 3.12 (m, 1 H, 3-Hb). 
HRMS (CI):    calculated found 
C43H73N4O8Si [M+H]
+  801.5192 801.5192 
Melting point:    198 °C 
Optical rotation:   [∝]𝐷
20 = –56.6° (c = 0.5, CHCl3) 
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HPLC: Reprosil, n-hexane:iPrOH 50:50, 1 mL/min, 20 °C: 
tR1 = 7.0 min (minor), 
tR2 = 13.7 min (major). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 20.1 min 
([M+Na]+ = 824). 
 
((4S,5S)-5-(5-((3S,6R,9S,14aS)-9-((S)-sec-Butyl)-6-(4-methoxybenzyl)-1,4,7,10-tetraoxo-
tetra-decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-3-yl)pentyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)methyl 4-methylbenzenesulfonate (23) 
To a solution of 122 mg (152 µmol) 22 in 1.5 mL THF were added 228 µL (228 µmol) TBAF (1.0 
M in THF) at rt. The reaction was stirred for 1.5 h and concentrated in vacuo. The residue was 
redissolved in DCM and water was added. The layers were separated and the aqueous phase was 
extracted three times with DCM. The combined organic layers were dried over Na2SO4. The crude 
product was dissolved in 3.0 mL pyridine abs. and 3.8 mg (31.1 µmol) 4-DMAP were added. 
Afterwards, 64 mg (336 µmol) tosyl chloride were added and the reaction was stirred at rt over-
night before further 23 mg (121 µmol) tosyl chloride were added. Stirring was continued for 4 h 
and the reaction was concentrated in vacuo. The crude product was either purified by preparative 
TLC (silica gel, EA/MeOH 99:1) or reversed phase column chromatography (silica gel C-18, 
H2O:MeCN 50:50, Gradient 10:90) to obtain 5.8 mg (7.26 µmol, 5 % over two steps) of the pure 
tosylate 23 as an off-white solid and 78 mg (97.6 µmol, dr 91:9, 64 % over two steps) of an epi-
meric mixture as an off-white solid. 
Rf (23) = 0.26 (silica gel, PE:EA 50:50) 
 
1H-NMR (500 MHz, CDCl3): δ = 0.71 (t, 3J14,13 = 7.3 Hz, 3 H, 14-H), 0.80 (d, 3J12,11 = 6.6 Hz, 3 
H, 12-H), 0.82 (m, 1 H, 13-Ha), 1.05 (m, 1 H, 13-Hb), 1.25 – 1.36 (m, 5 H, 23-Ha/23-Hb, 24-Ha/24-
Hb, 25-Ha/25-Hb), 1.29 (s, 3 H, 30-H), 1.35 (s, 3 H, 30'-H), 1.43 (m, 1 H, 23-Ha/23-Hb/24-Ha/24-
Hb/25-Ha/25-Hb), 1.51 – 1.55 (m, 2 H, 26-H), 1.67 (m, 1 H, 22-Ha), 1.84 – 1.93 (m, 3 H, 11-H, 18-
Ha, 22-Hb), 1.96 (m, 1 H, 18-Hb), 2.16 (m, 1 H, 17-Ha), 2.24 (m, 1 H, 17-Hb), 2.45 (s, 3 H, 36-H), 
2.83 (dd, 2J3a,3b = 13.4 Hz, 
3J3a,2 = 5.5 Hz, 1 H, 3-Ha), 3.20 (dd, 
2J3b,3a = 13.6 Hz, 
3J3b,2 = 10.1 Hz, 
1 H, 3-Hb), 3.62 (m, 1 H, 19-Ha), 3.70 (s, 3 H, 8-H), 3.74 – 3.83 (m, 3 H, 19-Hb, 27-H, 28-H), 4.05 
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(dd, 2J31a,31b = 10.7 Hz, 
3J31a,28 = 4.4 Hz, 1 H, 31-Ha), 4.10 (dd, 
2J31b,31a = 10.6 Hz, 
3J31b,28 = 4.3 Hz, 
1 H, 31-Hb), 4.52 (dd, 
3J10,11 ≈ 3J10,NH = 9.8 Hz, 1 H, 10-H), 4.57 (dt, 3J21,22/NH = 9.8 Hz, 3J21,22/NH 
= 7.9 Hz, 1 H, 21-H), 4.63 (ddd, 3J2,3b = 10.4 Hz, 
3J2,3a ≈ 3J2,NH =  5.7 Hz, 1 H, 2-H), 4.92 (d, 3J16,17 
= 7.3 Hz, 1 H, 16-H), 6.24 (br s, 1 H, NHa), 6.50 (br s, 1 H, NHc), 6.66 (d, 
3J6,5 = 8.5 Hz, 2 H, 6-
H), 6.83 (d, 1 H, NHb), 7.02 (d, 
3J5,6 = 8.5 Hz, 2 H, 5-H), 7.35 (d, 
3J34,33 = 8.2 Hz, 2 H, 34-H), 7.79 
(d, 3J33,34 = 8.2 Hz, 2 H, 33-H). 
13C-NMR (125 MHz, CDCl3): δ = 11.3 (q, C-14), 15.9 (q, C-12), 21.7 (q, C-36), 21.9 (t, C-18), 
24.1 (t, C-13), 25.6 (t, C-23 o. C-24 o. C-25), 25.7 (t, C-23 o. C-24 o. C-25), 26.7 (q, C-30), 27.3 
(q, C-30'), 28.1 (t, C-22), 29.2 (t, C-23 o. C-24 o. C-25), 31.6 (t, C-17), 32.8 (t, C-26), 34.5 (t, C-
3), 36.3 (d, C-11), 47.0 (t, C-19), 53.9 (d, C-21), 55.0 (q, C-8), 55.7 (d, C-10), 57.2 (d, C-2), 61.0 
(d, C-16), 69.1 (t, C-31), 77.8 (d, C-27 o. C-28), 78.1 (d, C-27 o. C-28), 109.3 (s, C-29), 113.7 (d, 
C-6), 128.0 (d, C-33), 128.7 (s, C-4), 129.9 (d, C-34), 130.5 (d, C-5), 132.7 (s, C-32), 145.0 (s, C-
35), 158.3 (s, C-7), 170.1 (s, C-9), 170.6 (s, C-15), 173.9 (s, C-1 o. C-20), 174.6 (s, C-1 o. C-20). 
HRMS (CI):    calculated found 
C41H59N4O10S [M+H]
+  799.3946 799.3963 
Melting point:    205 °C 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 10.3 min 
(minor, [M+H]+ = 799), tR2 = 11.5 min (major, [M+H]
+ = 799). 
 
(3S,6R,9S,14aS)-9-((S)-sec-butyl)-3-((S)-6-Hydroxy-6-((S)-oxiran-2-yl)hexyl)-6-(4-methoxy-
benzyl)decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone (24) 
A solution of 14.7 mg (18.4 µmol) tosylate 23 in 1 mL THF was treated with 1.0 mL HCl (5 w% 
in H2O) at rt and the reaction was heated to 40 °C for 8 h. Stirring was continued at ambient 
temperature for 1.5 h and the reaction was concentrated in high vacuo. The residue was redissolved 
in DCM and brine was added. The layers were separated and the aqueous phase was extracted 
three times with DCM. The combined organic layers were dried over Na2SO4. The crude product 
was dissolved in 3.6 mL MeOH abs. before 14.0 µL (14.1 µg, 92.6 µmol) DBU were added at 
0 °C. The reaction was allowed to warm to rt within 8.5 h. The reaction mixture was filtrated 
through a pad of silica gel and washed with EA:MeOH 90:10. The filtrate was concentrated in 
vacuo and the crude product was purified by reversed phase column chromatography (silica gel 
C-18, H2O:MeCN 90:10, Gradient 10:90). 6.6 mg (11.2 µmol, 61 % over two steps) of epoxyal-
cohol 24 were obtained as an off-white solid. 
Rf (24) = 0.46 (silica gel, EA:MeOH 95:5) 
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1H-NMR (500 MHz, CDCl3): δ = 0.71 (t, 3J14,13 = 7.2 Hz, 3 H, 14-H), 0.80 (d, 3J12,11 = 6.3 Hz, 3 
H, 12-H), 0.82 (m, 1 H, 13-Ha), 1.06 (m, 1 H, 13-Hb), 1.28 – 1.37 (m, 4 H, 23-H, 25-H), 1.40 (m, 
1 H, 24-Ha), 1.49 (m, 1 H, 24-Hb), 1.57 (m, 2 H, 26-H), 1.67 (m, 1 H, 22-Ha), 1.71 (br s, 1 H, OH), 
1.83 – 1.94 (m, 3 H, 11-H, 18-Ha, 22-Hb), 1.98 (m, 1 H, 18-Hb), 2.16 (m, 1 H, 17-Ha), 2.24 (m, 1 
H, 17-Hb), 2.71 (dd, 
2J29a,29b= 5.0 Hz, 
3J29a,28 = 2.8 Hz, 1 H, 29-Ha), 2.81 (dd, 
2J29b,29a= 4.7 Hz, 
3J29b,28 = 4.0 Hz, 1 H, 29-Hb), 2.84 (dd, 
2J3a,3b = 13.8 Hz, 
3J3a,2 = 5.7 Hz, 1 H, 3-Ha), 2.97 (ddd, 
3J28,27 = 7.2 Hz, 
3J28,29b = 4.4 Hz, 
3J28,29a = 2.8 Hz, 1 H, 28-H), 3.21 (dd, 
2J3b,3a = 13.2 Hz, 
3J3b,2 = 
10.4 Hz, 1 H, 3-Hb), 3.44 (dt, 
3J27,28 ≈ 3J27,26 = 5.9 Hz, 1 H, 27 H), 3.63 (m, 1 H, 19-Ha), 3.70 (s, 3 
H, 8-H), 3.77 (m, 1 H, 19-Hb), 4.52 (t, 
3J10,11 ≈ 3J10,NH = 9.7 Hz, 1 H, 10-H), 4.58 (m, 1 H, 21-H), 
4.64 (ddd, 3J2,3b = 10.4 Hz, 
3J2,3a ≈ 3J2,NH = 5.8 Hz, 1 H, 2-H), 4.95 (d, 3J16,17a/b = 6.9 Hz, 1 H, 16-
H), 6.25 (br s, 1 H, NHa), 6.61 (br s, 1 H, NHc), 6.65 (d, 
3J6,5 = 8.5 Hz, 2 H, 6-H), 6.86 (br s, 1 H, 
NHb), 7.01 (d, 
3J5,6 = 8.5 Hz, 2 H, 5-H). 
13C-NMR (125 MHz, CDCl3): δ = 11.3 (q, C-14), 15.9 (q, C-12), 21.9 (t, C-18), 24.1 (t, C-13), 
25.2 (t, C-24), 25.8 (t, C-23 o. C-25), 28.2 (t, C-22), 29.4 (t, C-23 o. C-25), 31.6 (t, C-17), 34.3 (t, 
C-26), 34.6 (t, C-3), 36.3 (d, C-11), 45.0 (t, C-29), 47.0 (t, C-19), 54.0 (d, C-21), 55.1 (q, C-8), 
55.3 (d, C-28), 55.7 (d, C-10), 57.3 (d, C-2), 61.0 (d, C-16), 71.2 (d, C-27), 113.7 (d, C-6), 128.7 
(s, C-4), 130.5 (d, C-5), 158.3 (s, C-7), 170.2 (s, C-9), 170.6 (s, C-15), 173.9 (s, C-1 o. C-20), 
174.6 (s, C-1 o. C-20). 
HRMS (CI):    calculated found 
C31H47N4O7 [M+H]
+   587.3439 587.3423 
Melting point:    230 °C (decomposition) 
Optical rotation:   [∝]𝐷
20 = –79° (c = 0.1, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.6 mL/min, tR1 = 14.9 min 
(minor, [M+H]+ = 587), tR2 = 15.5 min (major, [M+H]
+ = 587). 
 
Cyl-1[47] 
To a solution of 9.6 mg (16.4 µmol) 24 in 2.0 mL DCM abs. was added 14.3 mg (33.7 µmol) DMP 
at rt and the reaction was stirred for 3 h. The reaction mixture was then filtrated through a pad of 
Celite® and washed with DCM. The filtrate was concentrated in vacuo and the crude product was 
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purified by column chromatography (silica gel C-18, H2O:MeCN 90:10, Gradient 10:90). 1.8 mg 
(3.08 µmol, 19 %) pure Cyl-1 and 2.0 mg (3.42 µmol, dr 81:19, 21 %) of an epimeric mixture of 
Cyl-1 were obtained as off-white solids. 
Rf (Cyl-1) = 0.18 (silica gel, EA) 
 
1H-NMR (500 MHz, CDCl3): δ = 0.71 (t, 3J14,13 = 6.8 Hz, 3 H, 14-H), 0.80 (d, 3J12,11 = 6.5 Hz, 3 
H, 12-H), 0.85 (m, 1 H, 13-Ha), 1.05 (m, 1 H, 13-Hb), 1.24 – 1.33 (m, 4 H, 23-H, 24-H), 1.50 – 
1.66 (m, 3 H, 22-Ha, 25-H), 1.81 – 1.92 (m, 3 H, 11-H, 18-Ha, 22-Hb), 1.99 (m, 1 H, 18-Hb), 2.18 
(m, 2 H, 17-H), 2.25 (m, 1 H, 26-Ha), 2.42 (m, 1 H, 26-Hb), 2.83 (dd, 
2J3a,3b = 13.8 Hz, 
3J3a,2 = 5.8 
Hz, 1 H, 3-Ha), 2.86 (dd, 
2J29a,29b= 5.8 Hz, 
3J29a,28 = 2.5 Hz, 1 H, 29-Ha), 2.99 (dd, 
2J29b,29a= 5.8 Hz, 
3J29b,28 = 4.8 Hz, 1 H, 29-Hb), 3.20 (dd, 
2J3b,3a = 13.5 Hz, 
3J3b,2 = 10.2 Hz, 1 H, 3-Hb), 3.41 (dd, 
3J28,29b = 4.5 Hz, 
3J28,29a = 2.5 Hz, 1 H, 28-H), 3.62 (m, 1 H, 19-Ha), 3.71 (s, 3 H, 8-H), 3.74 (m, 1 
H, 19-Hb), 4.51 (dd, 
3J10,11 ≈ 3J10,NH = 9.8 Hz, 1 H, 10-H), 4.52 (m, 1 H, 21-H), 4.61 (ddd, 3J2,3b = 
10.4 Hz, 3J2,3a ≈ 3J2,NH = 5.5 Hz, 1 H, 2-H), 4.88 (d, 3J16,17a/b = 6.9 Hz, 1 H, 16-H), 6.16 (br s, 1 H, 
NHa), 6.43 (br s, 1 H, NHc), 6.68 (d, 
3J6,5 = 8.5 Hz, 2 H, 6-H), 6.76 (br s, 1 H, NHb), 7.04 (d, 
3J5,6 
= 7.8 Hz, 2 H, 5-H). 
13C-NMR (125 MHz, CDCl3): δ = 11.3 (q, C-14), 15.9 (q, C-12), 21.9 (t, C-18), 22.8 (t, C-25), 
24.1 (t, C-13), 25.6 (t, C-23 o. C-24), 27.9 (t, C-22), 28.7 (t, C-23 o. C-24), 31.6 (t, C-17), 34.5 (t, 
C-3), 36.2 (t, C-26), 36.3 (d, C-11), 46.1 (t, C-29), 47.1 (t, C-19), 53.4 (d, C-28), 53.9 (d, C-21), 
55.1 (q, C-8), 55.7 (d, C-10), 57.1 (d, C-2), 61.1 (d, C-16), 113.7 (d, C-6), 128.7 (s, C-4), 130.4 
(d, C-5), 158.3 (s, C-7), 170.1 (s, C-9), 170.5 (s, C-15), 173.1 (s, C-1 o. C-20), 174.7 (s, C-1 o. C-
20), 207.5 (s, C-27). 
HRMS (CI):    calculated found 
C31H45N4O7 [M+H]
+   585.3283 585.3293 
Melting point:    220 °C (decomposition) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 15.6 min 
(minor, [M+H]+ = 585), tR2 = 16.3 min (major, [M+H]
+ = 585). 
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((4S,5S)-5-((Allyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol (1d) 
2.20 g (55.0 mmol) Sodium hydride (60 w% in paraffin) was placed in a three-necked flask and 
10 mL n-pentane were added. After stirring for a few minutes, the sodium hydride was allowed to 
segregate and the solvent was removed via syringe. The procedure was repeated two times and the 
oil-free NaH was dried in high-vacuo. 
The free sodium hydride was suspended in 35 mL DMF abs. and cooled to –40 °C. A solution of 
8.15 g (50.3 mmol) (+)-2,3-O-Isopropylidene-L-threitol in 45 mL DMF abs. was added carefully 
within 50 min. Afterwards, a solution of 4.46 mL (6.24 g, 51.6 mmol) allyl bromide in 45 mL 
DMF abs. was added dropwise within 20 min at –40 °C and the reaction was allowed to warm to 
0 °C slowly. The solvent was then distilled off in vacuo (0.43 mbar, 30-50 °C oil bath). The residue 
was dissolved in DCM and water was added. The layers were separated and the aqueous phase 
was extracted three times with DCM. The combined organic layers were washed with brine and 
dried over Na2SO4. The crude product was purified by column chromatography (silica gel, PE:EA 
80:20, 70:30). 7.12 g (35.2 mmol, 70 %) of compound 1d were obtained as a colourless oil. 
Rf (1d) = 0.32 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.41 (s, 6 H, 9-H, 9-H'), 2.28 (dd, 3JOH, 7a = 8.2 Hz, 3JOH,7b = 4.6 
Hz, 1 H, OH), 3.52 (dd, 2J4a,4b = 9.9 Hz, 
3J4a,5 = 5.6 Hz, 1 H, 4-Ha), 3.65 (dd, 
2J4b,4a = 9.9 Hz, 
3J4b,5 
= 5.1 Hz, 1 H, 4-Hb), 3.71 (ddd, 
2J7a,7b = 11.9 Hz, 
3J7a,OH = 8.2 Hz, 
3J7a,6 = 4.2 Hz, 1 H, 7-Ha), 3.78 
(ddd, 2J7b,7a = 11.6 Hz, 
3J7b,OH ≈ 3J7b,6 = 4.5 Hz, 1 H, 7-Hb), 3.93 (dt, 3J6,5 = 8.4 Hz, 3J6,7 = 4.2 Hz, 
1 H, 6-H), 4.02 (m, 1 H, 5-H), 4.04 (d, 3J3,2 = 5.5 Hz, 2 H, 3-H), 5.20 (ddt, 
3J1a,2 = 10.4 Hz, 
2J1a,1b 
≈ 4J1a,3 = 1.3 Hz, 1 H, 1-Ha), 5.27 (ddt, 3J1b,2 = 17.2 Hz, 2J1b,1a ≈ 4J1b,3 = 1.6 Hz, 1 H, 1-Hb), 5.89 
(dddd, 3J2,1b = 17.1 Hz, 
3J2,1a = 10.4 Hz, 
3J2,3a = 5.8 Hz, 
3J2,3b = 5.5 Hz, 1 H, 2-H). 
13C-NMR (100 MHz, CDCl3): δ = 26.9 (q, C-9), 26.9 (q, C-9'), 62.4 (t, C-7), 70.4 (t, C-4), 72.6 (t, 
C-3), 76.6 (d, C-5), 79.6 (d, C-6), 109.3 (s, C-8), 117.6 (t, C-1), 134.1 (d, C-2). 
HRMS (CI):    calculated found 
C10H19O4 [M+H]
+   203.1278 203.1283 
Optical rotation:   [∝]𝐷
20 = +3.5° (c = 1.0, CHCl3) 
 
(4S,5R)-4-((Allyloxy)methyl)-5-(iodomethyl)-2,2-dimethyl-1,3-dioxolane (5d) 
To a solution of 7.01 g (34.7 mmol) 1d in 100 mL toluene abs. and 20 mL MeCN abs. was added 
2.95 g (43.3 mmol) imidazole, 9.55 g (36.4 mmol) PPh3 and 9.23 g (36.4 mmol) iodine carefully 
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at rt. The reaction was heated to 60 °C for 2 h. For workup, the reaction was diluted with Et2O and 
washed with sat. Na2S2O3 sol., water and brine. The organic phase was dried over Na2SO4 and 
concentrated in vacuo. Purification by column chromatography (silica gel, n-pentane:Et2O 2:1) 
afforded 10.5 g (33.6 mmol, 97 %) of iodide 5d as a colourless liquid. 
Rf (5d) = 0.25 (silica gel, PE:EA 90:10) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.42 (s, -, 3 H, 9-H), 1.47 (s, -, 3 H, 9'-H), 3.29 (dd, 2J7a,7b = 10.5 
Hz, 3J7a,6 = 5.3 Hz, 1 H, 7-Ha), 3.36 (dd, 
2J7b,7a = 10.5 Hz, 
3J7b,6 = 5.3 Hz, 1 H, 7-Hb), 3.60 (dd, 
2J4a,4b = 10.3 Hz, 
3J4a,5 = 4.9 Hz, 1 H, 4-Ha), 3.64 (dd, 
2J4b,4a = 10.3 Hz, 
3J4b,5 = 5.3 Hz, 1 H, 4-Hb), 
3.85 (dt, 3J6,5 = 7.5 Hz, 
3J6,7 = 5.3 Hz, 1 H, 6-H), 3.95 (dt, 
3J5,6 = 7.5 Hz, 
3J5,4 = 5.3 Hz, 1 H, 5-H), 
4.05 (d, 3J3,2 = 5.6 Hz, 2 H, 3-H), 5.20 (ddt, 
3J1a,2 = 10.4 Hz, 
2J1a,1b = 2.9 Hz, 
4J1a,3 = 1.3 Hz, 1 H, 
1-Ha), 5.28 (ddt, 
3J1b,2 = 17.2 Hz, 
2J1b,1a = 3.3 Hz, 
4J1b,3 = 1.6 Hz, 1 H, 1-Hb), 5.90 (dddd, 
3J2,1b = 
17.3 Hz, 3J2,1a = 10.5 Hz, 
3J2,3a = 5.8 Hz, 
3J2,3b = 5.5 Hz, 1 H, 2-H). 
13C-NMR (100 MHz, CDCl3): δ = 6.3 (t, C-7), 27.3 (q, C-9), 27.3 (q, C-9'), 70.6 (t, C-4), 72.6 (t, 
C-3), 77.6 (d, C-6), 80.1 (d, C-5), 109.8 (s, C-8), 117.4 (t, C-1), 134.3 (d, C-2). 
HRMS (CI):    calculated found 
C10H18IO3 [M+H]
+   313.0295 313.0312 
Optical rotation:   [∝]𝐷
20 = –11.6° (c = 1.0, CHCl3) 
 
(R)-1-(Allyloxy)but-3-en-2-ol (25) 
A solution of 10.5 g (33.6 mmol) 5d in 135 mL THF abs. was treated with 8.78 g (134 mmol) zinc 
dust and 9.60 mL (10.1 g, 168 mmol) acetic acid at rt and the reaction was stirred for 3 h. The 
reaction mixture was filtrated through a pad of Celite® and washed with Et2O. The filtrate was 
concentrated in vacuo and the residue was dissolved in Et2O. Sat. NaHCO3 sol. was added and the 
layers were separated. The aqueous phase was extracted three times with diethyl ether and the 
combined organic layers were dried over Na2SO4. Purification by column chromatography (silica 
gel, PE:EA 80:20, 70:30) gave 3.76 g (29.3 mmol, er > 99:1, 87 %) allylic alcohol 25 as a slightly 
yellow liquid. 
Rf (25) = 0.21 (silica gel, PE:EA 70:30) 
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1H-NMR (400 MHz, CDCl3): δ = 2.65 (br s, 1 H, OH), 3.34 (dd, 2J4a,4b = 9.7 Hz, 3J4a,5 = 7.9 Hz, 
1 H, 4-Ha), 3.51 (dd, 
2J4b,4a = 9.7 Hz, 
3J4b,5 = 3.4 Hz, 1 H, 4-Hb), 4.04 (ddd, 
3J3,2 = 5.8 Hz, 
4J3,1a ≈ 
4J3,1b = 1.3 Hz, 2 H, 3-H), 4.33 (m, 1 H, 5-H), 5.20 (m, 2 H, 1-Ha, 7-Ha), 5.28 (ddt, 
3J1b,2 = 17.3 
Hz, 2J1b,1a = 1.8 Hz, 
4J1b,3 = 1.5 Hz, 1 H, 1-Hb), 5.36 (ddd, 
3J7b,6 = 17.3 Hz, 
2J7b,7a ≈ 4J7b,5 = 1.5 Hz, 
1 H, 7-Hb), 5.84 (ddd, 
3J6,7b = 17.2 Hz, 
3J6,7a = 10.5 Hz, 
3J6,5 = 5.5 Hz, 1 H, 6-H), 5.91 (dddd, 
3J2,1b 
= 17.3 Hz, 3J2,1a = 10.5 Hz, 
3J2,3a = 5.8 Hz, 
3J2,3b = 5.5 Hz, 1 H, 2-H). 
13C-NMR (100 MHz, CDCl3): δ = 71.5 (d, C-5), 72.2 (t, C-3), 73.9 (t, C-4), 116.4 (t, C-7), 117.4 
(t, C-1), 134.3 (d, C-2), 136.5 (d, C-6). 
HRMS (CI):    calculated found 
C7H13O2 [M+H]
+   129.0910 129.0908 
Optical rotation:   [∝]𝐷
20 = –1.6° (c = 1.0, CHCl3) 
GC: CP-Chirasil-Dex CB, column flow 1.25 mL/min, injector 250 °C; 60 °C (5 min), 80 °C 
(1 °C/min), 5 min, 170 °C (6 °C/min), 10 min: 
(R)-25: tR = 31.51 min (> 99 %). 
 
(R)-1-(Allyloxy)but-3-en-2-yl (tert-butoxycarbonyl)glycinate (26) 
990 mg (5.65 mmol) Boc-Gly-OH and 658 mg (5.13 mmol) 25 were dissolved in 20.0 mL DCM 
abs. before 62.4 mg (0.511 mmol) 4-DMAP and 1.18 g (6.16 mmol) EDC·HCl were added at 0 
°C. The reaction was stirred at this temperature for 1 h and afterwards at rt for 30 min. For workup, 
the reaction was diluted with DCM and 1 M HCl sol. was added. The layers were separated and 
the aqueous phase was extracted three times with DCM. The combined organic phases were 
washed with sat. NaHCO3 sol., dried over Na2SO4 and concentrated in vacuo. 1.42 g (4.98 mmol, 
97 %) of ester 26 were obtained as a colourless oil. 
Rf (26) = 0.43 (silica gel, PE:EA 60:40) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.45 (s, 9 H, 12-H), 3.55 (m, 2 H, 4-H), 3.96 (d, 3J9,NH = 5.3 Hz, 
2 H, 9-H), 4.01 (m, 2 H, 3-H), 5.00 (br s, 1 H, NH), 5.19 (ddt, 3J1a,2 = 10.5 Hz, 
2J1a,1b = 1.5 Hz, 
4J1a,3 = 1.3 Hz, 1 H, 1-Ha), 5.27 (m, 2 H, 1-Hb, 7-Ha), 5.34 (ddd, 
3J7b,6 = 17.3 Hz, 
2J7b,7a ≈ 4J7b,5 = 
1.3 Hz, 1 H, 7-Hb), 5.50 (dt, 
3J5,6 = 6.0 Hz, 
3J5,4 = 5.0 Hz, 1 H, 5-H), 5.82 (ddd, 
3J6,7b = 16.8 Hz, 
3J6,7a = 10.5 Hz, 
3J6,5 = 6.3 Hz, 1 H, 6-H), 5.87 (ddt, 
3J2,1b = 17.3 Hz, 
3J2,1a = 10.3 Hz, 
3J2,3 = 5.5 
Hz, 1 H, 2-H). 
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13C-NMR (100 MHz, CDCl3): δ = 28.3 (q, C-12), 42.5 (t, C-9), 71.0 (t, C-4), 72.2 (t, C-3), 74.3 
(d, C-5), 79.9 (s, C-11), 117.4 (t, C-1), 118.6 (t, C-7), 132.7 (d, C-6), 134.3 (d, C-2), 155.6 (s, C-
10), 169.6 (s, C-8). 
HRMS (CI):    calculated found 
C14H24NO5 [M+H]
+   286.1649 286.1652 
Optical rotation:   [∝]𝐷
20 = –3.8° (c = 1.0, CHCl3) 
GC: CP-Chirasil-Dex CB, column flow 1.50 mL/min, injector 250 °C; 130 °C, 175 °C (1 °C/min), 
200 °C (5 °C/min), 10 min: 
(R)-26: tR = 39.27 min (> 99 %). 
 
(S,E)-6-(Allyloxy)-2-((tert-butoxycarbonyl)amino)hex-4-enoic acid (27) 
1.00 mL (710 mg, 7.02 mmol) Di-iso-propylamine was dissolved in 7.0 mL THF abs. and cooled 
to –78 °C before 4.00 mL (6.4 mmol) n-BuLi (1.6 M in hexanes) were added dropwise. The cool-
ing bath was removed and the LDA solution was stirred at rt for 15 min. 
A solution of 571 mg (2.00 mmol) 26 in 10.0 mL THF abs. was added to 330 mg (2.42 mmol) zinc 
chloride (dried in high-vacuo) and the mixture was cooled to –78 °C. The freshly prepared LDA 
solution was added slowly to the amino acid ester/ zinc chloride solution at –78 °C. After complete 
addition, the remaining dry ice was removed from the cooling bath and the reaction was allowed 
to warm to rt overnight. For workup, the reaction was diluted with Et2O and 1 M KHSO4 sol. was 
added. The layers were separated and the aqueous phase was extracted three times with Et2O. The 
combined organic layers were dried over Na2SO4 and concentrated in vacuo. 569 mg (1.99 mmol, 
er > 99:1, 99 %) of acid 27 were obtained as a yellow oil. 
Rf (27) = 0.07 (silica gel, PE:EA 60:40) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.44 (s, 9 H, 12-H), 2.57 (m, 2 H, 7-H), 3.95 – 3.98 (m, 4 H, 3-
H, 4-H), 4.39 (m, 1 H, 8-H), 5.05 (d, 3JNH,8 = 7.1 Hz, 1 H, NH), 5.18 (d, 
3J1a,2 = 10.3 Hz, 1 H, 1-
Ha), 5.27 (dd, 
3J1b,2 = 17.3 Hz, 
2J1b,1a = 1.6 Hz, 1 H, 1-Hb), 5.59 – 5.74 (m, 2 H, 5-H, 6-H), 5.90 
(ddt, 3J2,1b = 17.1 Hz, 
3J2,1a = 10.4 Hz, 
3J2,3 = 5.8 Hz, 1 H, 2 H), 9.33 (br s, 1 H, COOH). 
13C-NMR (100 MHz, CDCl3): δ = 28.3 (q, C-12), 34.9 (t, C-7), 52.8 (d, C-8), 70.2 (t, C-3 o. C-4), 
71.0 (d, C-3 o. C-4), 80.4 (s, C-11), 117.3 (t, C-1), 127.3 (t, C-6), 131.1 (d, C-7), 134.5 (d, C-2), 
155.6 (s, C-10), 175.7 (s, C-9). 
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HRMS (CI):    calculated found 
C14H24NO5 [M+H]
+   286.1649 286.1654 
Optical rotation:   [∝]𝐷
20 = +26.4° (c = 1.0, CHCl3) 
GC: A small amount was derivatized using TMS-diazomethane for GC-analysis. CP-Chirasil-Dex 
CB, column flow 1.50 mL/min, injector 250 °C; 145 °C, 5 min, 180 °C (1 °C/min), 15 min, 200 
°C (20 °C/min), 5 min: 
tR1 = 28.2 min (< 1 %), 
tR2 = 28.95 min (> 99 %), 
tR3 = 29.55 min (< 1 %). 
 
Methyl ((R)-2-((S,E)-6-(allyloxy)-2-((tert-butoxycarbonyl)amino)hex-4-enamido)-3-(4-me-
thoxyphenyl)propanoyl)-L-isoleucyl-L-prolinate (28) 
To a solution of 137 mg (0.480 mmol) 27 in 10.0 mL THF abs. were added 0.06 mL (55 mg, 0.544 
mmol) NMM and 0.07 mL (73 mg, 0.535 mmol) IBCF at –20 °C. After stirring for 10 min at this 
temperature, 195 mg (0.465 mmol) 12a,dissolved in 2.0 mL THF abs., were added dropwise and 
the reaction was allowed to warm to rt overnight. The reaction mixture was then filtrated and 
washed with diethyl ether. The filtrate was concentrated in vacuo, the residue was redissolved in 
EA and 1 M HCl sol. was added. The layers were separated and the aqueous phase was extracted 
three times with EA. The combined organic phases were washed with sat. NaHCO3 sol. and dried 
over Na2SO4. Purification by column chromatography (silica gel, PE:EA 100:0, 70:30, 50:50) gave 
228 mg (0.332 mmol, dr > 99:1, 71 %) of tetrapeptide 28 as an off-white solid. 
Rf (28) = 0.06 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.76 – 0.87 (m, 4 H, 11-Ha, 12-H), 0.90 (d, 3J10,9 = 6.7 Hz, 3 H, 
10-H), 1.30 (m, 1 H, 11-Hb), 1.42 (s, 9 H, 32-H), 1.68 (m, 1 H, 9-H), 1.91 – 2.05 (m, 3 H, 4-Ha, 5-
H), 2.22 (m, 1 H, 4-Hb), 2.35 (ddd, 
2J23a,23b = 14.1 Hz, 
3J23a,22 ≈ 3J23a,24 = 7.0 Hz, 1 H, 23-Ha), 2.49 
(ddd, 2J23b,23a = 13.6 Hz, 
3J23b,22 ≈ 3J23b,24 = 6.5 Hz, 1 H, 23-Hb), 2.94 (dd, 2J15a,15b = 14.1 Hz, 3J15a,14 
= 8.0 Hz, 1 H, 15-Ha), 3.00 (dd, 
2J15b,15a = 13.9 Hz, 
3J15b,14 = 6.4 Hz, 1 H, 15-Hb), 3.63 (m, 1 H, 6-
Ha), 3.69 (s, 3 H, 1-H), 3.75 (s, 3 H, 20-H), 3.82 (m, 1 H, 6-Hb), 3.90 (d, 
3J26,25 = 5.4 Hz, 2 H, 26-
H), 3.92 (d, 3J27,28 = 5.6 Hz, 2 H, 27-H), 4.12 (br s, 1 H, 22-H), 4.46 – 4.53 (m, 2 H, 3-H, 8-H), 
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4.66 (dt, 3J14,15 ≈ 3J14,NH = 7.3 Hz, 1 H, 14-H), 5.13 (m, 1 H, NHc), 5.15 (dd, 3J29a,28 = 10.5 Hz, 
2J29a,29b = 1.0 Hz, 1 H, 29-Ha), 5.25 (dd, 
3J29b,28 = 17.2 Hz, 
2J29b,29a = 1.5 Hz, 1 H, 29-Hb), 5.54 (dt, 
3J24,25 = 14.7 Hz, 
3J24,23 = 7.4 Hz, 1 H, 24-H), 5.62 (dt, 
3J25,24 = 15.5 Hz, 
3J25,26 = 5.6 Hz, 1 H, 25-
H), 5.88 (ddd, 3J28,29b = 16.1 Hz, 
3J28,29a = 10.8 Hz, 
3J28,27 = 5.7 Hz, 1 H, 28-H), 6.52 (br s, 1 H, 
NHa), 6.65 (d, 
3JNH,14 = 7.8 Hz, 1 H, NHb), 6.83 (d, 
3J18,17 = 8.6 Hz, 2 H, 18-H), 7.10 (d, 
3J17,18 = 
8.4 Hz, 2 H, 17-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.0 (q, C-12), 15.0 (q, C-10), 24.1 (t, C-11), 24.9 (t, C-5), 28.3 
(q, C-32), 29.0 (t, C-4), 35.5 (t, C-23), 37.5 (d, C-9), 37.8 (t, C-15), 47.3 (t, C-6), 52.1 (q, C-1), 
53.8 (d, C-22), 54.4 (d, C-14), 55.0 (d, C-3 o. C-8), 55.1 (q, C-20), 58.8 (d, C-3 o. C-8), 70.3 (t, 
C-26), 70.9 (t, C-27), 80.0 (s, C-31), 114.0 (d, C-18), 117.0 (t, C-29), 128.2 (d, C-24), 128.3 (s, C-
16), 130.2 (d, C-17), 130.8 (d, C-25), 134.7 (d, C-28), 158.6 (s, C-19), 170.3 (s, C-7), 170.4 (s, C-
13), 171.0 (s, C-21), 172.3 (s, C-2). The signal of C-30 wasn’t observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C36H55N4O9 [M+H]
+   687.3964 687.3971 
Melting point:   92 °C 
Optical rotation:   [∝]𝐷
20 = –26.9° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 70:30, 1 mL/min, 20 °C: 
tR = 33.3 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 11.0 min 
([M+Na]+ = 710). 
 
((R)-2-((S,E)-6-(Allyloxy)-2-((tert-butoxycarbonyl)amino)hex-4-enamido)-3-(4-methoxy-
phenyl)propanoyl)-L-isoleucyl-L-proline (29) 
192 mg (0.280 mmol) 28 were dissolved in 2.5 mL dioxane and cooled to 0 °C before a solution 
of 19 mg (0.444 mmol) LiOH·H2O in 0.5 mL water was added. The cooling bath was removed 
and the reaction was stirred at rt for 3 h. For workup, the reaction mixture was concentrated in 
vacuo and the residue was redissolved in water. The aqueous phase was acidified with 1 M HCl 
sol. and the aqueous phase was extracted three times with EA. The combined organic phases were 
dried over Na2SO4 and the crude product was dried by lyophilisation to afford 185 mg (0.275 
mmol, 98 %) of compound 29 as an off-white solid. 
Rf (29) = 0.08 (silica gel, PE:EA 50:50 + 1 % HOAc) 
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Major rotamer: 
1H-NMR (400 MHz, CDCl3): δ = 0.77 (t, 3J11,10 = 7.1 Hz, 3 H, 11-H), 0.88 (m, 1 H, 10-Ha), 0.92 
(d, 3J9,8 = 6.5 Hz, 3 H, 9-H), 1.26 (m, 1 H, 10-Hb), 1.41 (s, 9 H, 31-H), 1.72 (m, 1 H, 8-H), 2.01 
(m, 1 H, 4-Ha), 2.08 – 2.26 (m, 3 H, 3-H, 4-Hb), 2.33 (ddd, 2J22a,22b = 14.0 Hz, 3J22a,21 ≈ 3J22a,23 = 
7.0 Hz, 1 H, 22-Ha), 2.46 (m, 1 H, 22-Hb), 2.91 (m, 1 H, 14-Ha), 3.07 (m, 1 H, 14-Hb), 3.69 (m, 1 
H, 5-Ha), 3.74 (s, 3 H, 19-H), 3.90 (m, 1 H, 5-Hb), 3.90 (d, 
3J25,24 = 5.1Hz, 2 H, 25-H), 3.94 (d, 
3J26,27 = 5.6 Hz, 2 H, 26-H), 4.20 (br s, 1 H, 21-H), 4.46 (m, 1 H, 2-H), 4.51 (dd, 
3J7,8 ≈ 3J7,NH = 
8.7 Hz, 1 H, 7-H), 4.83 (dt, 3J13,14 ≈ 3J13,NH = 6.6 Hz, 1 H, 13-H), 5.16 (m, 1 H, NHc), 5.16 (d, 
3J28a,27 = 10.2 Hz, 1 H, 28-Ha), 5.25 (dd, 
3J28b,27 = 17.2 Hz, 
2J28b,28a = 1.5 Hz, 1 H, 28-Hb), 5.45 – 
5.67 (m, 2 H, 23-H, 24-H), 5.88 (ddd, 3J27,28b = 16.0 Hz, 
3J27,28a = 10.8 Hz, 
3J27,26 = 5.6 Hz, 1 H, 
27-H), 6.77 (d, 3J17,16 = 8.6 Hz, 2 H, 17-H), 6.96 (d, 
3JNH,13 = 7.3 Hz, 1 H, NHb), 7.08 (d, 
3J16,17 = 
8.0 Hz, 2 H, 16-H), 7.81 (br s, 1 H, NHa). The signal of -COOH wasn’t observed in the 1H-NMR 
spectrum. 
13C-NMR (100 MHz, CDCl3): δ = 10.8 (q, C-11), 14.9 (q, C-9), 24.4 (t, C-10), 25.1 (t, C-4), 28.3 
(q, C-31), 28.7 (t, C-3), 35.7 (t, C-22), 37.4 (d, C-8), 37.7 (t, C-14), 47.9 (t, C-5), 53.7 (d, C-21), 
53.9 (d, C-13), 55.0 (d, C-7), 55.1 (q, C-19), 59.6 (d, C-2), 70.3 (t, C-25), 71.0 (t, C-26), 80.1 (s, 
C-30), 113.8 (d, C-17), 117.2 (t, C-28), 128.1 (d, C-23), 130.3 (s, C-15), 130.5 (d, C-16), 130.7 (d, 
C-24), 134.6 (d, C-27), 155.5 (s, C-29), 158.5 (s, C-18), 171.5 (s, C-1 o. C-6 o. C-12 o. C-20), 
173.2 (s, C-1 o. C-6 o. C-12 o. C-20). The signal of C-1/C-6/C-12/C-20 wasn’t observed in the 
13C-NMR spectrum. 
Minor rotamer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.48 (s, 9 H, 31-H), 3.78 (s, 3 H, 19-H), 7.12 (d, 3J16,17 = 8.6 Hz, 
2 H, 16-H). 
HRMS (CI):    calculated found 
C35H53N4O9 [M+H]
+   673.3807 673.3809 
Melting point:   82 °C 
Optical rotation:   [∝]𝐷
20 = –30.9° (c = 1.0, CHCl3) 
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LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.6 mL/min, tR = 17.8 min 
([M+Na]+ = 695). 
 
Cbz-(S,S)-Ile-(S)-Pro-Gly-OtBu (30) 
275 mg (1.04 mmol) Cbz-(S,S)-Ile-OH were dissolved in 10.0 mL acetonitrile abs. and 333 mg 
(1.04 mmol) TBTU, 168 mg (1.10 mmol) HOBt and 0.23 mL (170 mg, 1.32 mmol) DIPEA were 
added at rt. Afterwards, a solution of 240 mg (1.05 mmol) H-(S)-Pro-Gly-OtBu in 2.0 mL acetoni-
trile abs. was added dropwise and the reaction was stirred overnight. The reaction mixture was 
diluted with Et2O and 1 M KHSO4 sol. was added. The layers were separated and the aqueous 
phase was extracted three times with Et2O. The combined organic phases were washed with sat. 
NaHCO3 sol. and dried over Na2SO4. Purification by column chromatography (silica gel, PE:EA 
100:0, 80:20, 70:30, 50:50) yielded 437 mg (0.919 mmol, dr > 99:1, 88 %) tripeptide 30 as a 
colourless oil. 
Rf (30) = 0.13 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.88 (t, 3J15,14 = 7.4 Hz, 3 H, 15-H), 0.97 (d, 3J13,12 = 6.8 Hz, 3 
H, 13-H), 1.14 (m, 1 H, 14-Ha), 1.45 (s, 9 H, 1-H), 1.60 (m, 1 H, 14-Hb), 1.78 (m, 1 H, 12-H), 1.87 
– 2.03 (m, 2 H, 7-Ha, 8-Ha), 2.11 (m, 1 H, 8-Hb), 2.37 (m, 1 H, 7-Hb), 3.63 (dt, 2J9a,9b = 8.7 Hz, 
3J9a,8 = 3.8 Hz, 1 H, 9-Ha), 3.76 (dt, 
2J9b,9a ≈ 3J9b,8 = 8.3 Hz, 1 H, 9-Hb), 3.85 (dd, 2J4a,4b = 18.6 Hz, 
3J4a,NH = 5.3 Hz, 1 H, 4-Ha), 3.91 (dd, 
2J4b,4a = 18.6 Hz, 
3J4b,NH = 5.5 Hz, 1 H, 4-Hb), 4.37 (dd, 
3J11,NH = 9.2 Hz, 
3J11,12 = 7.4 Hz, 1 H, 11-H), 4.63 (dd, 
3J6,7a = 7.9 Hz, 
3J6,7b = 2.6 Hz, 1 H, 6-H), 
5.06 (d, 2J17a,17b = 12.3 Hz, 1 H, 17-Ha), 5.11 (d, 
2J17b,17a = 12.3 Hz, 1 H, 17-Hb), 5.44 (d, 
3JNH,11 = 
9.3 Hz, 1 H, NHb), 7.14 (dd, 
3JNH,4a ≈ 3JNH,4b = 4.6 Hz, 1 H, NHa), 7.29 – 7.38 (m, 5 H, 19-H, 20-
H, 21-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.1 (q, C-15), 15.4 (q, C-13), 24.2 (t, C-14), 25.0 (t, C-8), 27.2 
(t, C-7), 28.0 (q, C-1), 37.9 (d, C-12), 42.1 (t, C-4), 47.7 (t, C-9), 56.8 (d, C-11), 59.7 (d, C-6), 
66.9 (t, C-17), 82.0 (s, C-2), 128.0 (d, C-19), 128.1 (d, C-21), 128.5 (d, C-20), 136.3 (s, C-18), 
156.3 (s, C-16), 168.5 (s, C-3), 170.9 (s, C-5 o. C-10), 172.4 (s, C-5 o. C-10). 
HRMS (CI):    calculated found 
C25H38N3O6 [M+H]
+   476.2755 476.2752 
Optical rotation:   [∝]𝐷
20 = –77.1° (c = 1.0, CHCl3) 
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HPLC: Chiralcel OD-H, n-hexane:iPrOH 80:20, 1 mL/min, 20 °C: 
tR = 10.8 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 5.17 min 
([M+Na]+ = 498). 
 
Cbz-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-Gly-OtBu (31) 
1.56 g (3.28 mmol) 30 were dissolved in 33 mL MeOH and treated with 153 mg palladium on 
charcoal (10 w% Pd) at rt. The reaction was set under a H2-atmossphere and hydrogenated over-
night. The reaction mixture was filtrated through a pad of Celite® and the filtrate was concentrated 
in vacuo. 
To a solution of 961 mg (2.92 mmol) Cbz-(R)-Tyr(Me)-OH in 29 mL THF abs. were added 0.35 
mL (322 mg, 3.18 mmol) NMM and the reaction was cooled to –20 °C. 0.42 mL (440 mg, 3.22 
mmol) IBCF were added dropwise and the reaction was stirred for 10 min at this temperature 
before 991 mg (2.90 mmol) of the above prepared H-(S,S)-Ile-(S)-Pro-Gly-OtBu in 6 mL THF abs. 
were added slowly and the reaction was allowed to warm to rt overnight. The reaction mixture was 
filtrated and the filtrate was concentrated in vacuo. The residue was redissolved in EA and water 
was added. The layers were separated and the aqueous phase was extracted three times with EA. 
The combined organic phases were washed with sat. NaHCO3 sol. and dried over Na2SO4. Purifi-
cation by column chromatography (silica gel, PE:EA 100:0, 80:20, 70:30, 50:50) gave 1.65 g (2.53 
mmol, dr ~ 94:6, 87 %) of compound 31 as an off-white solid. 
Rf (31) = 0.05 (silica gel, PE:EA 50:50) 
 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.64 – 0.76 (m, 4 H, 19-H, 18-Ha), 0.88 (d, 3J17,16 = 6.8 Hz, 3 
H, 17-H), 0.97 (m, 1 H, 18-Hb), 1.43 (s, 9 H, 29-H), 1.59 (m, 1 H, 16-H), 1.94 – 2.06 (m, 2 H, 22-
Ha, 23-Ha), 2.13 (m, 1 H, 23-Hb), 2.24 (m, 1 H, 22-Hb), 2.95 (m, 2 H, 8-H), 3.59 – 3.72 (m, 2 H, 
24-Ha, 26-Ha), 3.74 (s, 3 H, 13-H), 3.87 (m, 1 H, 24-Hb), 4.01 (dd, 
2J26b,26a = 18.2 Hz, 
3J26b,NH = 
5.6 Hz, 1 H, 26-Hb), 4.51 (dd, 
3J15,16 ≈ 3J15,NH = 8.8 Hz, 1 H, 15-H), 4.66 – 4.75 (m, 2 H, 7-H, 21-
H), 5.08 (m, 2 H, 5-H), 5.50 (d, 3JNH,7 = 7.5 Hz, 1 H, NHc), 6.75 (d, 
3J11,10 = 8.5 Hz, 2 H, 11-H), 
7.06 (d, 3J10,11 = 8.3 Hz, 2 H, 10-H), 7.28 – 7.38 (m, 6 H, 1-H, 2-H, 3-H, NHb), 7.53 (br s, 1 H, 
NHa). 
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13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-19), 15.2 (q, C-17), 23.9 (t, C-18), 24.7 (t, C-23), 
28.0 (q, C-29), 28.4 (t, C-22), 37.4 (d, C-16), 38.8 (t, C-8), 42.0 (t, C-26), 47.9 (t, C-24), 54.8 (d, 
C-15), 55.1 (q, C-13), 55.6 (d, C-7), 59.6 (d, C-21), 67.0 (t, C-5), 81.9 (s, C-28), 113.9 (d, C-11), 
128.1 (s, C-9), 128.1 (d, C-1), 128.1 (d, C-3), 128.5 (d, C-2), 130.2 (d, C-10), 136.2 (s, C-4), 155.7 
(s, C-6), 158.5 (s, C-12), 168.7 (s, C-27). The signals of C-14, C-20 and C-25 weren’t observed in 
the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 0.82 (d, 3J17,16 = 6.8 Hz, 3 H, 17-H), 1.44 (s, 9 H, 29-H), 3.77 
(s, 3 H, 13-H), 5.31 (d, 3JNH,7 = 7.8 Hz, 1 H, NHc). 
HRMS (CI):    calculated found 
C35H49N4O8 [M+H]
+   653.3545 653.3559 
Melting point:   68 °C 
Optical rotation:   [∝]𝐷
20 = –68.0° (c = 1.0, CHCl3) 
HPLC: Chiralcel OD-H, n-hexane:iPrOH 80:20, 1 mL/min, 20 °C: 
tR = 10.7 min (> 99 %, broad). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 8.53 min 
([M+Na]+ = 676). 
 
Cbz-(R)-Tyr(Me)-(S,S)-Ile-(S)-Pro-Gly-OH (32) 
A solution of 652 mg (0.999 mmol) 31 in 5.0 mL DCM abs. was treated with 5.0 mL (7.40 g, 64.9 
mmol) Trifluoroacetic acid at rt. The reaction was stirred for 1 h, concentrated in vacuo and dried 
by lyophilisation. 592 mg (0.993 mmol, 99 %) of acid 32 were obtained as an off-white solid. 
Rf (32) = 0.04 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.74 (t, 3J19,18 = 7.2 Hz, 3 H, 19-H), 0.78 – 0.94 (m, 1 H, 18-
Ha), 0.84 (d, 
3J17,16 = 6.5 Hz, 3 H, 17-H), 1.23 (m, 1 H, 18-Hb), 1.65 (m, 1 H, 16-H), 1.96 – 2.07 
(m, 2 H, 22-Ha, 23-Ha), 2.10 – 2.28 (m, 2 H, 22-Hb, 23-Hb), 2.96 (m, 2 H, 8-H), 3.65 (m, 1 H, 24-
Ha), 3.76 (s, 3 H, 13-H), 3.87 (dd, 
2J26a,26b = 18.6 Hz, 
3J26a,NH = 4.0 Hz, 1 H, 26-Ha), 3.97 (m, 1 H, 
24-Hb), 4.16 (dd, 
2J26b,26a = 18.4 Hz, 
3J26b,NH = 5.9 Hz, 1 H, 26-Hb), 4.39 – 4.55 (m, 2 H, 7-H, 21-
H), 4.46 (dd, 3J15,16 ≈ 3J15,NH = 9.3 Hz, 1 H, 15-H), 5.01 (d, 2J5a,5b = 12.1 Hz, 1 H, 5-Ha), 5.06 (d, 
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2J5b,5a = 12.6 Hz, 1 H, 5-Hb), 5.56 (d, 
3JNH,7 = 8.5 Hz, 1 H, NHc), 6.78 (d, 
3J11,10 = 8.5 Hz, 2 H, 11-
H), 7.07 (d, 3J10,11 = 8.3 Hz, 2 H, 10-H), 7.20 – 7.35 (m, 6 H, 1-H, 2-H, 3-H, NHb), 7.99 (d, 3JNH,26a/b 
= 8.3 Hz, 1 H, NHa), 9.47 (br s, 1 H, COOH). 
13C-NMR (100 MHz, CDCl3): δ = 10.6 (q, C-19), 14.7 (q, C-17), 24.6 (t, C-18), 25.0 (t, C-23), 
27.9 (t, C-22), 37.0 (d, C-16), 38.2 (t, C-8), 41.8 (t, C-26), 48.4 (t, C-24), 55.2 (d, q, C-15, C-13), 
55.9 (d, C-7), 60.4 (d, C-21), 66.9 (t, C-5), 114.0 (d, C-11), 127.8 (s, C-9), 127.9 (d, C-1), 128.1 
(d, C-3), 128.5 (d, C-2), 130.3 (d, C-10), 136.2 (s, C-4), 155.8 (s, C-6), 158.5 (s, C-12), 170.9 (s, 
C-14 o. C-20 o. C-25), 172.2 (s, C-14 o. C-20 o. C-25), 172,6 (s, C-14 o. C-20 o. C-25). The signal 
of C-27 wasn’t observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C31H41N4O8 [M+H]
+   597.2919 597.2947 
Melting point:   81 °C 
Optical rotation:   [∝]𝐷
20 = –39.8° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 2.79 min 
([M+Na]+ = 619). 
 
(R)-1-(Allyloxy)but-3-en-2-yl glycinate hydrochloride (33) 
To a solution of 2.1 mL (1.66 g, 51.8 mmol) methanol in 8.8 mL ethyl acetate were added 3.6 mL 
(3.96 g, 50.4 mmol) acetyl chloride at 0 °C and the reaction was stirred for 30 min. The resulting 
HCl sol. was then transferred to 1.47 g (5.16 mmol) 26 at rt and the reaction was stirred for 1 h. 
The reaction mixture was concentrated in vacuo and the crude product was dried by lyophilisation. 
1.10 g (4.96 mmol, 96 %) of hydrochloride salt 33 were obtained as an off-white solid. 
Rf (33) = starting point (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 3.56 (d, 3J4,5 = 5.3 Hz, 2 H, 4-H), 4.00 (m, 4 H, 3-H, 9-H), 5.18 
(dd, 3J7a,6 = 10.3 Hz, 
2J7a,7b = 1.3 Hz, 1 H, 7-Ha), 5.26 (m, 2 H, 1-Ha, 1-Hb), 5.39 (d, 
3J7b,6 = 17.3 
Hz, 1 H, 7-Hb), 5.52 (dt, 
3J5,6 = 5.5 Hz, 
3J5,4 = 5.5 Hz, 1 H, 5-H), 5.82 (ddd, 
3J6,7b = 17.1 Hz, 
3J6,7a 
= 10.8 Hz, 3J6,5 = 6.3 Hz, 1 H, 6-H), 5.86 (ddt, 
3J2,1b = 17.3 Hz, 
3J2,1a = 10.8 Hz, 
3J2,3 = 5.5 Hz, 1 
H, 2-H), 8.56 (br s, 3 H, NH3). 
13C-NMR (100 MHz, CDCl3): δ = 40.7 (t, C-9), 70.8 (t, C-4), 72.3 (t, C-3), 75.7 (d, C-5), 117.6 
(t, C-1), 119.2 (t, C-7), 132.3 (d, C-6), 134.3 (d, C-2), 167.1 (s, C-8). 
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HRMS (CI):    calculated found 
C9H16NO3 [M+H]
+   186.1125 186.1130 
Melting point:   53 °C 
Optical rotation:   [∝]𝐷
20 = –6.5° (c = 1.0, CHCl3) 
 
(S)-5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-
3-yl (((9H-fluoren-9-yl)methoxy)carbonyl)glycinate (34) 
A mixture of 187 mg (0.629 mmol) Fmoc-Gly-OH and 213 mg (0.572 mmol) (3S)-7c in 6.0 mL 
DCM abs. was cooled to 0 °C before 136 mg (0.659 mmol) DCC and 7.9 mg (64.7 µmol) 4-DMAP 
were added. The reaction was allowed to warm to rt overnight. Afterwards, further 68 mg (0.229 
mmol) Fmoc-Gly-OH and 48 mg (0.233 mmol) DCC were added and stirring was continued for 
4.5 h. For workup, the reaction was filtrated through a pad of Celite® and washed with DCM. The 
filtrate was treated with water and the layers were separated. The aqueous phase was extracted 
three times with DCM, the combined organic layers were washed with sat. NaHCO3 sol. and dried 
over Na2SO4. The crude product was purified by column chromatography (silica gel, PE:EA 100:0, 
90:10, 80:20) to yield 346 mg (0.531 mmol, 93 %) of ester 34 as a colourless oil. 
Rf (34) = 0.17 (silica gel, PE:EA 80:20) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.17 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.60 (m, 1 H, 8-Ha), 1.69 – 1.77 (m, 2 H, 8-Hb, 9-Ha), 1.93 (m, 1 H, 9-Hb), 3.67 – 3.75 
(m, 2 H, 3-Ha, 4-H), 3.89 (dd, 
2J3b,3a = 9.5 Hz, 
3J3b,4 = 3.3 Hz, 1 H, 3-Hb), 3.93 (td, 
3J5,8 = 7.7 Hz, 
3J5,4 = 3.4 Hz, 1 H, 5-H), 4.00 (d, 
3J14,NH = 5.3 Hz, 2 H, 14-H), 4.24 (t, 
3J17,16 = 7.0 Hz, 1 H, 17-
H), 4.40 (d, 3J16,17 = 7.3 Hz, 2 H, 16-H), 5.21 (d, 
3J12a,11 = 10.3 Hz, 1 H, 12-Ha), 5.28 (d, 
3J12b,11 = 
17.3 Hz, 1 H, 12-Hb), 5.28 (m, 1 H, NH), 5.34 (td, 
3J10,9 ≈ 3J10,11 = 6.5 Hz, 1 H, 10-H), 5.77 (ddd, 
3J11,12b = 17.3 Hz, 
3J11,12a = 10.5 Hz, 
3J11,10 = 6.8 Hz, 1 H, 11-H), 7.31 (ddd, 
3J21,20 ≈ 3J21,22 = 7.5 
Hz, 4J21,19 = 0.9 Hz, 2 H, 21-H), 7.40 (dd, 
3J20,19 = 7.5 Hz, 
3J20,21 = 7.3 Hz, 2 H, 20-H), 7.60 (d, 
3J22,21 = 7.3 Hz, 2 H, 22-H), 7.77 (d, 
3J19,20 = 7.5 Hz, 2 H, 19-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 18.0 (q, C-1), 26.9 (q, C-7), 27.4 (q, C-7'), 28.9 
(t, C-8), 30.6 (t, C-9), 42.9 (t, C-14), 47.1 (d, C-17), 64.2 (t, C-3), 67.2 (t, C-16), 76.2 (d, C-10), 
79.1 (d, C-5), 80.7 (d, C-4), 108.6 (s, C-6), 117.9 (t, C-12), 120.0 (d, C-19), 125.1 (d, C-22), 127.1 
(d, C-21), 127.7 (d, C-20), 135.5 (d, C-11), 141.3 (s, C-23), 143.8 (s, C-18). The signals of C-13 
and C-15 weren’t observed in the 13C-NMR spectrum. 
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HRMS (CI):    calculated found 
C37H54NO7Si [M+H]
+   652.3664 652.3668 
Optical rotation:   [∝]𝐷
20 = –3.0° (c = 1.0, CHCl3) 
HPLC: Chiralcel OD-H, n-hexane:iPrOH 80:20, 0.8 mL/min, 20 °C: 
(3S)-34: tR = 25.8 min (> 99 %). 
 
(S)-5-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-
3-yl glycinate (35) 
To a solution of 156 mg (0.239 mmol) 34 in 2.0 mL ethyl acetate was added 0.25 mL (245 mg, 
1.68 mmol) Tris(2-aminoethyl)amine and the reaction was stirred at rt for 1 h. For workup, the 
reaction was diluted with EA and sat. NaHCO3 sol. was added. The layers were separated, the 
organic phase was washed two times with sat. NaHCO3 sol. and dried over Na2SO4.The crude 
product was purified by column chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5) 
to yield 90.6 mg (0.211 mmol, 88 %) of amine 35 as a colourless oil. 
Rf (35) = 0.18 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.14 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.50 (br s, 2 H, NH2), 1.60 (m, 1 H, 8-Ha), 1.67 – 1.78 (m, 2 H, 8-Hb, 9-Ha), 1.89 (m, 1 
H, 9-Hb), 3.41 (s, 2 H, 14-H), 3.66 – 3.74 (m, 2 H, 3-Ha, 4-H), 3.88 (dd, 2J3b,3a = 9.0 Hz, 3J3b,4 = 
3.0 Hz, 1 H, 3-Hb), 3.92 (td, 
3J5,8 = 7.6 Hz, 
3J5,4 = 3.4 Hz, 1 H, 5-H), 5.18 (d, 
3J12a,11 = 10.5 Hz, 1 
H, 12-Ha), 5.25 (ddd, 
3J12b,11 = 17.3 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.1 Hz, 1 H, 12-Hb), 5.31 (td, 3J10,9 ≈ 
3J10,11 = 6.4 Hz, 1 H, 10-H), 5.76 (ddd, 
3J11,12b = 17.2 Hz, 
3J11,12a = 10.5 Hz, 
3J11,10 = 6.5 Hz, 1 H, 
11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.3 (q, C-7'), 28.9 
(t, C-8), 30.6 (t, C-9), 44.1 (t, C-14), 64.2 (t, C-3), 75.3 (d, C-10), 79.2 (d, C-5), 80.7 (d, C-4), 
108.5 (s, C-6), 117.4 (t, C-12), 135.9 (d, C-11), 173.6 (s, C-13). 
HRMS (CI):    calculated found 
C22H44NO5Si [M+H]
+   430.2983 430.2980 
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(R)-1-(Allyloxy)but-3-en-2-yl ((R)-2-(((benzyloxy)carbonyl)amino)-3-(4-methoxyphenyl)-
propanoyl)-L-isoleucyl-L-prolylglycinate (36a) 
888 mg (1.65 mmol) 18a and 332 mg (1.50 mmol) 33 were dissolved in 15.0 mL MeCN abs. 
before 528 mg (1.64 mmol) TBTU, 249 mg (1.63 mmol) HOBt and 588 µL (435 mg, 3.37 mmol) 
DIPEA were added subsequently at rt. The reaction was stirred at rt overnight and concentrated in 
vacuo. The residue was redissolved in DCM and 1 M HCl sol. was added. The layers were sepa-
rated and the aqueous phase was extracted three times with DCM. The combined organic layers 
were washed with brine, sat. NaHCO3 sol. and dried over Na2SO4. After purification by column 
chromatography (silica gel, PE:EA 100:0, 80:20, 50:50), 727 mg (1.03 mmol, dr ~ 90:10, 69 %) 
of tetrapeptide 36a were obtained as an off-white solid. 
Rf (36a) = 0.04 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.61 – 0.72 (m, 4 H, 18-Ha, 19-H), 0.80 – 0.97 (m, 1 H, 18-Hb), 
0.88 (d, 3J13,12 = 6.5 Hz, 3 H, 17-H), 1.57 (m, 1 H, 16-H), 1.92 – 2.07 (m, 2 H, 22-Ha, 23-Ha), 2.13 
(m, 1 H, 23-Hb), 2.24 (m, 1 H, 22-Hb), 2.93 (m, 2 H, 8-H), 3.52 (d, 
3J31,30 = 5.3 Hz, 2 H, 31-H), 
3.65 – 3.81 (m, 2 H, 24-Ha, 26-Ha), 3.74 (s, 3 H, 13-H), 3.87 (dt, 2J24b,24a = 9.5 Hz, 3J24b,23 = 7.5 
Hz, 1 H, 24-Hb), 3.98 (m, 2 H, 32-H), 4.18 (dd, 
2J26b,26a = 18.4 Hz, 
3J26b,NH = 5.6 Hz, 1 H, 26-Hb), 
4.50 (dd, 3J15,NH ≈ 3J15,16 = 9.0 Hz, 1 H, 15-H), 4.66 – 4.76 (m, 2 H, 7-H, 21-H), 5.08 (s, 2 H, 5-
H), 5.17 (ddd, 3J34a,33 = 10.5 Hz, 
2J34a,34b ≈ 4J34a,32 = 1.3 Hz, 1 H, 34-Ha), 5.20 – 5.33 (m, 3 H, 28-
H, 34-Hb), 5.44 (dt, 
3J30,29 ≈ 3J30,31 = 5.7 Hz, 1 H, 30-H), 5.48 (m, 1 H, NHc), 5.74 – 5.90 (m, 2 H, 
29-H, 33-H), 6.76 (d, 3J11,10 = 8.8 Hz, 2 H, 11-H), 7.05 (d, 
3J10,11 = 8.3 Hz, 2 H, 10-H), 7.27 – 7.36 
(m, 6 H, 1-H, 2-H, 3-H, NHb), 7.67 (br s, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-19), 15.2 (q, C-17), 23.9 (t, C-18), 24.7 (t, C-23), 
28.4 (t, C-22), 37.4 (d, C-16), 38.8 (t, C-8), 41.4 (t, C-26), 47.9 (t, C-24), 54.8 (d, C-15), 55.1 (q, 
C-13), 55.5 (d, C-7), 59.6 (d, C-21), 67.0 (t, C-5), 71.0 (t, C-31), 72.2 (t, C-32), 74.3 (d, C-30), 
113.9 (d, C-11), 117.4 (t, C-34), 118.5 (t, C-28), 128.0 (s o. d, C-1 o. C-3 o. C-9), 128.1 (s o. d, C-
1 o. C-3 o. C-9), 128.2 (s o. d, C-1 o. C-3 o. C-9), 128.5 (d, C-2), 130.2 (d, C-10), 132.8 (d, C-29), 
134.3 (d, C-33), 136.2 (s, C-4), 155.7 (s, C-6), 158.5 (s, C-12), 168.8 (s, C-14 o. C-20 o. C-27). 
The signal of C-14/C-20/C-25/C-27 wasn’t observed in the 13C-NMR spectrum. 
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Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 0.81 (d, 3J17,16 = 6.8 Hz, 3 H, 17-H), 6.80 (d, 3J11,10 = 8.3 Hz, 2 
H, 11-H). 
HRMS (CI):    calculated found 
C38H51N4O9 [M+H]
+   707.3651 707.3642 
Melting point:   47-48 °C 
Optical rotation:   [∝]𝐷
20 = –64.7° (c = 0.5, CHCl3) 
 
(R)-1-(Allyloxy)but-3-en-2-yl ((R)-2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)-
propanoyl)-L-isoleucyl-L-prolylglycinate (36c) 
To a solution of 1.19 g (2.35 mmol) 18c and 525 mg (2.37 mmol) 33 in 19 mL acetonitrile were 
added 757 mg (2.36 mmol) TBTU. Afterwards, 0.84 mL (622 mg, 4.81 mmol) DIPEA were added 
dropwise and the reaction was stirred at rt for 5 h. For workup, the reaction was concentrated in 
vacuo and the residue was redissolved in DCM. 1 M HCl sol. was added and the layers were 
separated. The aqueous phase was extracted three times with DCM, the combined organic phases 
were washed with sat. NaHCO3 sol. and dried over Na2SO4. The crude product was purified by 
column chromatography (silica gel, PE:EA 100:0, 80:20, 50:50) to give 1.24 g (1.84 mmol, dr > 
99:1, 78 %) of tetrapeptide 36c as an off-white solid. 
Rf (36c) = 0.08 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.71 (m, 3 H, 16-H), 0.80 (m, 1 H, 15-Ha), 0.89 (d, 3J14,13 = 6.4 
Hz, 3 H, 14-H), 1.06 (m, 1 H, 15-Hb), 1.40 (s, 9 H, 1-H), 1.62 (m, 1H, 13-H), 1.99 (m, 2 H, 19-Ha, 
20-Ha), 2.13 (m, 1 H, 20-Hb), 2.25 (m, 1 H, 19-Hb), 2.93 (m, 2 H, 5-H), 3.51 (d, 
3J28,27 = 5.5 Hz, 2 
H, 28-H), 3.68 (m, 1 H, 21-Ha), 3.75 (s, 3 H, 10-H), 3.84 (m, 1 H, 23-Ha), 3.88 (m, 1 H, 21-Hb), 
3.98 (m, 2 H, 29-H), 4.16 (dd, 2J23b,23a = 18.3 Hz, 
3J23b,NH = 5.5 Hz, 1 H, 23-Hb), 4.51 (dd, 
3J12,13 ≈ 
3J12,NH = 8.8 Hz, 1 H, 12-H), 4.63 (m, 1 H, 4-H), 4.68 (m, 1 H, 18-H), 5.14 (m, 1 H, NHc), 5.22 
(m, 4 H, 25-H, 31-H), 5.43 (dt, 3J27,26 = 5.8 Hz, 
3J27,28 = 5.5 Hz, 1 H, 27-H), 5.82 (m, 2 H, 26-H, 
30-H), 6.78 (d, 3J8,7 = 8.5 Hz, 2 H, 8-H), 7.07 (d, 
3J7,8 = 8.5 Hz, 2 H, 7-H), 7.21 (m, 1 H, NHb), 
7.66 (m, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-16), 15.2 (q, C-14), 24.1 (t, C-15), 24.8 (t, C-20), 
27.7 (t, C-19), 28.3 (q, C-1), 37.5 (d, C-13), 38.4 (t, C-5), 41.3 (t, C-23), 47.8 (t, C-21), 54.8 (d, 
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C-12), 55.1 (q, C-10), 55.2 (d, C-4), 59.6 (d, C-18), 71.0 (t, C-28), 72.2 (t, C-29), 74.3 (d, C-27), 
80.1 (s, C-2), 113.9 (d, C-8), 117.4 (t, C-25 o. C-31), 118.5 (t, C-25 o. C-31), 130.2 (t, C-7), 132.7 
(d, C-26 o. C-30), 134.2 (d, C-26 o. C-30), 155.2 (s, C-3 o. C-6), 158.5 (s, C-9), 168.8 (s, C-24), 
171.1 (s, C-17 o. C-22), 171.5 (s, C-11), 171.8 (s, C-17 o. C-22). 
HRMS (CI):    calculated found 
C35H53N4O9 [M+H]
+   673.3807 673.3814 
Melting point:   53 °C 
Optical rotation:   [∝]𝐷
20 = –61.2° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 70:30, 1 mL/min, 20 °C: 
tR = 27.7 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 9.67 min 
([M+H]+ = 673). 
 
(S)-5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-
3-yl ((R)-2-(((benzyloxy)carbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-L-isoleucyl-L-
prolylglycinate (37) 
A solution of 85.5 mg (0.158 mmol) 18a in 1.5 mL MeCN abs. was treated with 61.9 mg (0.144 
mmol) 35, 51 mg (0.159 mmol) TBTU, 23 mg (0.150 mmol) HOBt and 31 µL (22.9 mg, 0.177 
mmol) DIPEA subsequently at rt. The reaction was stirred overnight concentrated in vacuo. The 
residue was redissolved in DCM and water was added. The aqueous phase was extracted three 
times with DCM, the combined organic layers were washed with brine and dried over Na2SO4. 
Purification by column chromatography (silica gel, PE:EA 100:0, 70:30, 50:50) yielded 96.3 mg 
(0.101 mmol, 70 %) tetrapeptide 37 as an off-white solid. 
Rf (37) = 0.11 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.63 – 0.75 (m, 4 H, 18-Ha, 19-H), 0.75 – 0.88 (m, 1 H, 18-Hb), 
0.86 (d, 3J13,12 = 6.5 Hz, 3 H, 17-H), 0.99 – 1.13 (m, 21 H, 38-H, 39-H), 1.34 (s, 3 H, 36-H), 1.37 
(s, 3 H, 36'-H), 1.53 – 1.62 (m, 2 H, 16-H, 32-Ha), 1.63 – 1.73 (m, 2 H, 32-Hb, 31-Ha), 1.87 (m, 1 
H, 31-Hb), 1.92 – 2.05 (m, 2 H, 22-Ha, 23-Ha), 2.12 (m, 1 H, 23-Hb), 2.25 (m, 1 H, 22-Hb), 2.94 
(m, 2 H, 8-H), 3.63 – 3.81 (m, 4 H, 24-Ha, 26-Ha, 34-H, 37-Ha), 3.75 (s, 3 H, 13-H), 3.82 – 3.90 
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(m, 1 H, 24-Hb), 3.86 (dd, 
2J37b,37a = 9.7 Hz, 
3J37b,34 = 3.4 Hz, 1 H, 37-Hb), 3.89 (td, 
3J33,32 = 7.9 
Hz, 3J33,34 = 2.9 Hz, 1 H, 33-H), 4.09 (dd, 
2J26b,26a = 18.2 Hz, 
3J26b,NH = 5.6 Hz, 1 H, 26-Hb), 4.50 
(dd, 3J15,NH ≈ 3J15,16 = 8.8 Hz, 1 H, 15-H), 4.59 – 4.70 (m, 2 H, 7-H, 21-H), 5.07 (s, 2 H, 5-H), 5.16 
(d, 3J28a,29 = 10.5 Hz, 1 H, 28-Ha), 5.21 (d, 
3J28b,29 = 17.3 Hz, 1 H, 28-Hb), 5.26 (dt, 
3J30,29 ≈ 3J30,31 
= 6.3 Hz, 1 H, 30-H), 5.47 (d, 3JNH,7 = 7.3 Hz, 1 H, NHc), 5.71 (ddd, 
3J29,28b = 17.2 Hz, 
3J29,28a = 
10.5 Hz, 3J29,30 = 6.8 Hz, 1 H, 29-H), 6.76 (d, 
3J11,10 = 8.8 Hz, 2 H, 11-H), 7.06 (d, 
3J10,11 = 8.5 Hz, 
2 H, 10-H), 7.20 (br s, 1 H, NHb), 7.27 – 7.37 (m, 5 H, 1-H, 2-H, 3-H), 7.53 (br s, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-19), 11.8 (d, C-38), 15.2 (q, C-17), 17.9 (q, C-39), 
24.0 (t, C-18), 24.8 (t, C-23), 26.9 (q, C-36), 27.3 (q, C-36'), 28.2 (t, C-22), 28.8 (t, C-32), 30.6 (t, 
C-31), 37.4 (d, C-16), 38.6 (t, C-8), 41.4 (t, C-26), 47.9 (t, C-24), 54.9 (d, C-15), 55.0 (d, C-7 o. 
C-21), 55.1 (q, C-13), 59.7 (d, C-7 o. C-21), 64.2 (t, C-37), 67.0 (t, C-5), 76.0 (d, C-30), 79.1 (d, 
C-33), 80.7 (d, C-34), 108.5 (s, C-35), 114.0 (d, C-11), 117.7 (t, C-28), 128.0 (s/d, C-1 o. C-3 o. 
C-9), 128.1 (s/d, C-1 o. C-3 o. C-9), 128.1 (s/d, C-1 o. C-3 o. C-9), 128.5 (d, C-2), 130.2 (d, C-
10), 135.5 (d, C-29), 136.2 (s, C-4), 158.6 (s, C-6), 168.8 (s, C-14 o. C-20 o. C-25 o. C-27). The 
signals of C-12 and C-14/C-20/C-25/C-27 weren’t observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C51H79N4O11Si [M+H]
+  951.5509 951.5535 
Melting point:   65 °C 
Optical rotation:   [∝]𝐷
20 = –48.9° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 26.0 min 
([M+Na]+ = 974). 
 
(S,E)-6-(Allyloxy)-2-((S)-1-(((R)-2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)-pro-
panoyl)-L-isoleucyl)pyrrolidine-2-carboxamido)hex-4-enoic acid (38c) 
A solution of 0.91 mL (646 mg, 6.38 mmol) Di-iso-propylamine in 6.5 mL THF abs. was cooled 
to –78 °C before 3.6 mL (5.76 mmol) n-BuLi (1.6 M in hexanes) were added dropwise. The cool-
ing bath was removed and the reaction was stirred at rt for 15 min. 
435 mg (3.19 mmol) zinc chloride (dried in high-vacuo) was treated with a solution of 713 mg 
(1.06 mmol) 36c in 13 mL THF abs. at rt. After cooling to –78 °C, the previously prepared LDA 
solution was added dropwise to the zinc chloride/tetrapeptide ester solution. Upon complete addi-
tion, the remaining dry ice was removed from the cooling bath and the reaction was allowed to 
warm to rt overnight. For workup, the reaction was diluted with Et2O and 1 M KHSO4 sol. was 
added. The layers were separated and the aqueous phase was extracted three times with diethyl 
ether. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. After ly-
ophilisation, 713 mg (1.06 mmol, dr > 99:1, quant.) of acid 38c were obtained as a slightly yellow 
solid. 
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Rf (38c) = 0.02 (silica gel, PE:EA 50:50 + 1 % HOAc) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.79 (t, 3J16,15 = 7.4 Hz, 3 H, 16-H), 0.88 (d, 3J14,13 = 6.5 Hz, 3 
H, 14-H), 0.98 (m, 1 H, 15-Ha), 1.37 (s, 9 H, 1-H), 1.38 (m, 1 H, 15-Hb), 1.69 (m, 1 H, 13-H), 1.89 
– 2.20 (m, 3 H, 19-Ha, 20-H), 2.40 (m, 1 H, 19-Hb), 2.49 (ddd, 2J24a,24b = 13.6 Hz, 3J24a,23 ≈ 3J24a,25 
= 5.9 Hz, 1 H, 24-Ha), 2.61 (ddd, 
2J24b,24a = 13.9 Hz, 
3J24b,23 ≈ 3J24b,25 = 5.0 Hz, 1 H, 24-Hb), 2.96 
(m, 2 H, 5-H), 3.64 (m, 1 H, 21-Ha), 3.76 (s, 3 H, 10-H), 3.86 (d, 
3J27,26 = 3.9 Hz, 2 H, 27-H), 3.91 
(d, 3J28,29 = 5.6 Hz, 2 H, 28-H), 3.94 (m, 1 H, 21-Hb), 4.40 (m, 1 H, 4-H), 4.49 (m, 1 H, 12-H), 
4.53 (td, 3J23,24 ≈ 3J23,NH = 6.4 Hz, 1 H, 23-H), 4.65 (d, 3J18,19a/b = 6.5 Hz, 1 H, 18-H), 5.15 (d, 
3J30a,29 = 10.2 Hz, 1 H, 30-Ha), 5.16 (m, 1 H, NHc), 5.23 (dd, 
3J30b,29 = 17.2 Hz, 
2J30b,30a = 1.6 Hz, 
1 H, 30-Hb), 5.54 – 5.67 (m, 2 H, 25-H, 26-H), 5.86 (ddd, 3J29,30b = 16.0 Hz, 3J29,30a = 11.0 Hz, 
3J29,28 = 5.6 Hz, 1 H, 29-H), 6.97 (d, 
3J8,7 = 8.6 Hz, 2 H, 8-H), 7.07 (d, 
3J7,8 = 8.4 Hz, 2 H, 7-H), 
7.52 (d, 3JNH,12 = 8.4 Hz, 1 H, NHb), 7.60 (m, 1 H, NHa). The signal of -COOH wasn’t observed 
in the 1H-NMR spectrum. 
13C-NMR (100 MHz, CDCl3): δ = 10.7 (q, C-16), 15.1 (q, C-14), 24.6 (t, C-15), 24.8 (t, C-20), 
27.7 (t, C-19), 28.2 (q, C-1), 35.3 (t, C-24), 37.0 (d, C-13), 38.0 (t, C-5), 48.2 (t, C-21), 52.6 (d, 
C-23), 55.0 (d, C-12), 55.2 (q, C-10), 55.6 (d, C-4), 60.5 (d, C-18), 70.3 (t, C-27), 71.1 (t, C-28), 
79.8 (s, C-2), 113.9 (d, C-8), 117.1 (t, C-30), 127.8 (d, C-25 o. C-26), 128.4 (a, C-6), 130.3 (d, C-
7), 130.5 (d, C-25 o. C-26), 134.6 (d, C-29), 155.1 (s, C-3), 158.5 (s, C-9), 170.3 (s, C-22), 172.0 
(s, C-11), 173.2 (s, C-31). The signal of C-17 wasn’t observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C35H53N4O9 [M+H]
+   673.3807 673.3816 
Melting point:   68 °C 
Optical rotation:   [∝]𝐷
20 = –33.3° (c = 1.0, CHCl3) 
HPLC: A small sample was derivatized with TMS-diazomethane for HPLC analysis. Reprosil, n-
hexane:iPrOH 70:30, 1 mL/min, 20 °C: 
tR = 32.3 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 17.6 min 
([M+Na]+ = 695). 
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Perfluorophenyl (S,E)-6-(allyloxy)-2-((S)-1-(((R)-2-((tert-butoxycarbonyl)amino)-3-(4-meth-
oxyphenyl)propanoyl)-L-isoleucyl)pyrrolidine-2-carboxamido)hex-4-enoate (39) 
To a solution of 484 mg (0.705 mmol) 38c in 7.0 mL DCM abs. were added 149 mg (0.809 mmol) 
pentafluorophenol and 149 mg (0.777 mmol) EDC·HCl at 0 °C. The reaction was allowed to warm 
to rt overnight. The reaction mixture was diluted with DCM and 1 M HCl sol. was added. The 
layers were separated, and the aqueous phase was extracted three times with DCM. The combined 
organic phases were washed with sat. NaHCO3 sol. and dried over Na2SO4. 573 mg (0.683 mmol, 
dr ~ 96:4, 97 %) of Pfp ester 39 were obtained after lyophilisation. 
Rf (39) = 0.16 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (500 MHz, 373 K, DMSO-d6): δ = 0.81 (t, 3J16,15 = 7.0 Hz, 3 H, 16-H), 0.88 (m, 1 H, 
15-Ha), 0.89 (d, 
3J14,13 = 6.7 Hz, 3 H, 14-H), 1.05 (m, 1 H, 15-Hb), 1.34 (s, 9 H, 1-H), 1.44 (m, 1 
H, 13-H), 1.73 – 2.06 (m, 5 H, 19-H, 20-H, 24-Ha), 2.40 (m, 1 H, 24-Hb), 2.73 (dd, 2J5a,5b = 13.9 
Hz, 3J5a,4 = 9.1 Hz, 1 H, 5-Ha), 2.91 (dd, 
2J5b,5a = 13.9 Hz, 
3J5b,4 = 5.4 Hz, 1 H, 5-Hb), 3.57 (m, 1 
H, 21-Ha), 3.74 (s, 3 H, 10-H), 3.88 – 3.94 (m, 5 H, 27-H, 28-H, 21-Hb), 4.20 (m, 1 H, 4-H), 4.31 
(m, 1 H, 23-H), 4.41 (t, 3J18,19 = 8.2 Hz, 1 H, 18-H), 4.47 (m, 1 H, 23-H), 5.13 (dd, 
3J30a,29 = 10.4 
Hz, 2J30a,30b = 1.4 Hz, 1 H, 30-Ha), 5.24 (d, 
3J30b,29 = 17.4 Hz, 1 H, 30-Hb), 5.59 – 5.70 (m, 2 H, 25-
H, 26-H), 5.89 (dddd, 3J29,30b = 15.9 Hz, 
3J29,30a = 10.7 Hz, 
3J29,28a = 5.4 Hz, 
3J29,28b = 2.1 Hz, 1 H, 
29-H), 6.38 (br s, 1 H, NHc), 6.81 (d, 
3J8,7 = 8.6 Hz, 2 H, 8-H), 7.14 (d, 
3J7,8 = 8.4 Hz, 2 H, 7-H), 
7.56 – 7.67 (m, 2 H, NHa, NHb). 
13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-16), 15.2 (q, C-14), 24.2 (t, C-15), 24.8 (t, C-20), 
27.7 (t, C-19), 28.2 (q, C-1), 34.5 (t, C-24), 37.5 (d, C-13), 38.2 (t, C-5), 47.9 (t, C-21), 52.2 (d, 
C-23), 54.8 (d, C-4 o. C-12), 55.1 (q, C-10), 55.2 (d, C-4 o. C-12), 59.5 (d, C-18), 70.0 (t, C-27), 
71.1 (t, C-28), 114.0 (d, C-8), 117.0 (t, C-30), 125.5 (d, C-25), 128.3 (s, C-6), 130.2 (d, C-7), 132.2 
(d, C-26), 134.6 (d, C-29), 155.1 (s, C-3), 158.6 (s, C-9), 167.6 (s, C-31), 171.2 (s, C-11 o. C-17 
o. C-22), 171.4 (s, C-11 o. C-17 o. C-22), 171.9 (s, C-11 o. C-17 o. C-22). The signals of C-2, C-
32, C-33, C-34 and C-35 weren’t observed in the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (500 MHz, 373 K, DMSO-d6): δ = 4.72 (m, 1 H, 23-H), 7.05 (d, 3J8,7 = 8.5 Hz, 2 H, 8-
H), 7.26 (d, 3J7,8 = 8.7 Hz, 2 H, 7-H). 
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13C-NMR (100 MHz, CDCl3): δ = 10.8 (q, C-16), 15.0 (q, C-14), 34.7 (t, C-24), 52.3 (d, C-23), 
114.0 (d, C-8), 125.5 (d, C-25), 132.3 (d, C-26), 134.6 (d, C-29). 
HRMS (CI):    calculated found 
C41H52F5N4O9 [M+H]
+  839.3649 839.3666 
Melting point:   53 °C 
Optical rotation:   [∝]𝐷
20 = –43.1° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.6 mL/min, tR = 23.0 min 
([M+H]+ = 839). 
 
(3S,6R,9S,14aS)-3-((E)-4-(Allyloxy)but-2-en-1-yl)-9-((S)-sec-butyl)-6-(4-methoxybenzyl)-
decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone (40) 
A solution of 90.6 mg (0.108 mmol) 39 in 0.3 mL dioxane was treated with 0.54 mL (2.16 mmol) 
HCl (4 M in dioxane) at rt. The reaction was stirred for 1 h at rt and concentrated in vacuo. The 
residue was redissolved in 25 mL chloroform and added dropwise to a vigorously stirred emulsion 
of 50 mL chloroform in 50 mL sat. NaHCO3 sol. at rt. The reaction was stirred for 4 h. The layers 
were then separated and the aqueous phase was extracted two times with DCM. The combined 
organic phases were dried over Na2SO4 and concentrated in vacuo. Purification of the crude prod-
uct was column chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5) afforded 29.0 mg 
(52.3 µmol, dr 87:13, 48 % over two steps) of cyclic peptide 40 as an off-white solid. A small 
sample was further purified by reversed phase column chromatography (silica gel C-18, 
MeCN:H2O 10:90, Gradient 90:10) to partially separate the epimers and for analytical purposes. 
Rf (40) = 0.30 (silica gel, DCM:MeOH 95:5) 
 
1H-NMR (500 MHz, CDCl3): δ = 0.71 (t, 3J14,13 = 7.4 Hz, 3 H, 14-H), 0.80 (d, 3J12,11 = 6.3 Hz, 3 
H, 12-H), 0.81 (m, 1 H, 13-Ha), 1.05 (m, 1 H, 13-Hb), 1.82 – 1.92 (m, 2 H, 11-H, 18-Ha), 1.96 (m, 
1 H, 18-Hb), 2.14 (dd, 
2J17a,17b = 12.8 Hz, 
3J17a,16 = 6.8 Hz, 1 H, 17-Ha), 2.23 (m, 1 H, 17-Hb), 2.49 
(dt, 2J22a,22b = 13.9 Hz, 
3J22a,21 ≈ 3J22a,23 = 7.3 Hz, 1 H, 22-Ha), 2.60 (dt, 2J22b,22a = 13.3 Hz, 3J22b,21 
≈ 3J22b,23 = 6.7 Hz, 1 H, 22-Hb), 2.84 (dd, 2J3a,3b = 13.6 Hz, 3J3a,2 = 5.7 Hz, 1 H, 3-Ha), 3.19 (dd, 
2J3b,3a = 13.6 Hz, 
3J3b,2 = 10.1 Hz, 1 H, 3-Hb), 3.61 (m, 1 H, 19-Ha), 3.69 (s, 3 H, 8-H), 3.76 (m, 1 
H, 19-Hb), 3.98 (d, 
3J25,24 = 4.7 Hz, 2 H, 25-H), 3.93 (ddd, 
3J26,27 = 5.7 Hz, 
4J26,28a ≈ 4J26,28b = 1.3 
Hz, 2 H, 26-H), 4.52 (dd, 3J10,11 ≈ 3J10,NH = 9.8 Hz, 1 H, 10-H), 4.63 (ddd, 3J2,3b = 10.4 Hz, 3J2,3a ≈ 
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3J2,NH = 5.7 Hz, 1 H, 2-H), 4.67 (m, 1 H, 21-H), 4.95 (d, 
3J16,17a/b = 8.8 Hz, 1 H, 16-H), 5.17 (ddt, 
3J28a,29 = 10.4 Hz, 
2J28a,28b = 1.6 Hz, 
4J28a,26 = 1.3 Hz, 1 H, 28-Ha), 5.25 (ddt, 
3J28b,29 = 17.3 Hz, 
2J28b,28a ≈ 4J28b,26 = 1.6 Hz, 1 H, 28-Hb), 5.56 – 5.66 (m, 2 H, 23-H, 24-H), 5.88 (ddd, 3J27,28b = 16.6 
Hz, 3J27,28a = 10.6 Hz, 
3J27,26 = 5.5 Hz, 1 H, 29-H), 6.22 (br s, 1 H, NHa), 6.57 (br s, 1 H, NHb), 
6.65 (d, 3J6,5 = 8.5 Hz, 2 H, 6-H), 6.86 (br s, 1 H, NHc), 7.00 (d, 
3J5,6 = 8.5 Hz, 2 H, 5-H). 
13C-NMR (125 MHz, CDCl3): δ = 11.3 (q, C-14), 15.9 (q, C-12), 21.8 (t, C-18), 24.1 (t, C-13), 
31.1 (t, C-22), 31.6 (t, C-17), 34.6 (t, C-3), 36.3 (d, C-11), 47.0 (t, C-19), 53.3 (d, C-21), 55.0 (q, 
C-8), 55.8 (d, C-10), 57.4 (d, C-2), 61.0 (d, C-16), 70.3 (t, C-25), 71.0 (t, C-26), 113.7 (d, C-6), 
117.0 (t, C-28), 127.9 (d, C-23), 128.6 (s, C-4), 130.3 (d, C-24), 130.5 (d, C-5), 134.7 (d, C-27), 
158.3 (s, C-7), 170.2 (s, C-9), 170.6 (s, C-15), 173.5 (s, C-1), 174.5 (s, C-20). 
HRMS (CI):    calculated found 
C30H43N4O6 [M+H]
+   555.3177 555.3169 
Melting point:   250 °C (decomposition) 
Optical rotation:   [∝]𝐷
20 = –76.6° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.6 mL/min, tR1 = 16.4 min 
(13 %, [M+H]+ = 555), tR2 = 17.4 min (87 %, [M+H]
+ = 555). 
 
(3S,6R,9S,14aS)-3-allyl-9-((S)-sec-butyl)-6-(4-methoxybenzyl)decahydropyrrolo[1,2-a]-
[1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone (41) 
26.5 mg (48.5 µ mol) 40 and 2.0 mg (2.39 µmol) Grubbs I were dissolved in 2.0 mL DCM abs. 
and heated to 45 °C in a sealed tube for 20 h. For workup, 8.5 µL (9.4 mg, 120 µmol) DMSO were 
added and stirring was continued for 24 h. The reaction was concentrated in vacuo and purified by 
column chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5) to yield 13.0 mg (26.8 
µmol, 55 %) of peptide 41 as an off-white solid. 
Rf (41) = 0.40 (silica gel, DCM:MeOH 95:5) 
 
1H-NMR (500 MHz, 373 K, Tetrachloroethane-d2): δ = 0.83 (t, 3J14,13 = 7.4 Hz, 3 H, 14-H), 0.88 
(d, 3J12,11 = 6.6 Hz, 3 H, 12-H), 0.96 (m, 1 H, 13-Ha), 1.27 (m, 1 H, 13-Hb), 1.87 – 1.98 (m, 2 H, 
11-H, 18-Ha), 2.01 (m, 1 H, 18-Hb), 2.18 (m, 1 H, 17-Ha), 2.28 (m, 1 H, 17-Hb), 2.48 (dt, 
2J22a,22b 
= 14.8 Hz, 3J22a,21 ≈ 3J22a,23 = 7.4 Hz, 1 H, 22-Ha), 2.62 (dt, 2J22b,22a = 14.5 Hz, 3J22b,21 ≈ 3J22b,23 = 
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6.7 Hz, 1 H, 22-Hb), 2.88 (dd, 
2J3a,3b = 14.1 Hz, 
3J3a,2 = 6.3 Hz, 1 H, 3-Ha), 3.25 (dd, 
2J3b,3a = 14.1 
Hz, 3J3b,2 = 9.1 Hz, 1 H, 3-Hb), 3.68 (m, 2 H, 19-H), 3.81 (s, 3 H, 8-H), 4.54 (dd, 
3J10,11 ≈ 3J10,NH = 
9.3 Hz, 1 H, 10-H), 4.54 (m, 1 H, 21-H), 4.63 (m, 1 H, 2-H), 4.68 (d, 3J16,17a/b = 8.8 Hz, 1 H, 16-
H), 5.18 (m, 2 H, 24-H), 5.67 (d, 3JNH,21 = 10.0 Hz, 1 H, NHa), 5.82 (m, 1 H, 23-H), 5.87 (d, 
3JNH,10 
= 10.0 Hz, 1 H, NHc), 6.29 (d, 
3JNH,2 = 10.7 Hz, 1 H, NHb), 6.84 (d, 
3J6,5 = 8.8 Hz, 2 H, 6-H), 7.16 
(d, 3J5,6 = 8.8 Hz, 2 H, 5-H). 
13C-NMR (125 MHz, 373 K, Tetrachloroethane-d2): δ = 11.0 (q, C-14), 15.7 (q, C-12), 21.6 (t, C-
18), 24.2 (t, C-13), 31.2 (t, C-17), 32.2 (t, C-22), 34.2 (t, C-3), 36.6 (d, C-11), 46.9 (t, C-19), 52.9 
(d, C-21), 55.2 (q, C-8), 55.5 (d, C-10), 56.3 (d, C-2), 61.2 (d, C-16), 114.1 (d, C-6), 118.2 (t, C-
24), 128.8 (s, C-4), 130.0 (d, C-5), 132.5 (d, C-23), 158.5 (s, C-7), 170.0 (s, C-9), 170.1 (s, C-15), 
173.0 (s, C-1), 174.4 (s, C-20). 
HRMS (CI):    calculated found 
C26H36N4O5 [M]
+   484.2686 484.2684 
Melting point:   280 °C (decomposition) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.8 mL/min, tR = 10.1 min 
([M+H]+ = 485). 
 
Methyl (S)-2-((S)-1-(((R)-2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-
L-isoleucyl)pyrrolidine-2-carboxamido)pent-4-enoate (42) 
To a solution of 1.11 g (2.20 mmol) 18c and 365 mg (2.20 mmol) methyl (S)-2-aminopent-4-
enoate hydrochloride in 11.0 mL acetonitrile abs. were added 709 mg (2.21 mmol) TBTU and 0.79 
mL (585 mg, 4.53 mmol) DIPEA slowly at rt. The reaction was stirred at rt overnight and concen-
trated in vacuo. The residue was redissolved in DCM and 1 M HCl sol. was added. The layers 
were separated and the aqueous phase was extracted three times with DCM. The combined organic 
phases were washed with sat. NaHCO3 sol. and dried over Na2SO4. The crude product was purified 
by column chromatography (silica gel, PE:EA 100:0, 80:20, 50:50) to afford 847 mg (1.37 mmol, 
dr ~ 95:5, 62 %) of product 42 as an off-white solid. 
Rf (42) = 0.12 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.77 (t, 3J16,15 = 7.0 Hz, 3 H, 16-H), 0.84 (m, 1 H, 15-Ha), 0.88 
(d, 3J14,13 = 6.7 Hz, 3 H, 14 H), 1.26 (m, 1 H, 15-Hb), 1.39 (s, 9 H, 1-H), 1.66 (m, 1 H, 13-H), 1.92 
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- 2.02 (m, 2 H, 19-Ha, 20-Ha), 2.10 (m, 1 H, 20-Hb), 2.28 (m, 1 H, 19-Hb), 2.47 (dd, 
3J24,23 ≈ 3J24,25 
= 6.0 Hz, 2 H, 24-H), 2.96 (m, 2 H, 5-H), 3.63 (m, 1 H, 21-Ha), 3.71 (s, 3 H, 28-H), 3.76 (s, 3 H, 
10-H), 3.86 (m, 1 H, 21-Hb), 4.41 (m, 1 H, 4-H), 4.49 - 4.58 (m, 2 H, 12-H, 23-H), 4.61 (d, 
3J18,19a 
= 5.3 Hz, 1 H, 18-H), 4.95 - 5.15 (m, 3 H, 26-H, NHc), 5.66 (ddt, 
3J25,26b = 16.9 Hz, 
3J25,26a = 10.0 
Hz, 3J25,24 = 7.1 Hz, 1 H, 25-H), 6.79 (d, 
3J8,7 = 8.4 Hz, 2 H, 8-H), 6.80 (m, 1 H, NHb), 7.08 (d, 
3J7,8 = 8.2 Hz, 2 H, 7-H), 7.32 (br s, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.9 (q, C-16), 15.2 (q, C-14), 24.1 (t, C-15), 24.9 (t, C-20), 
27.7 (t, C-19), 28.2 (q, C-1), 36.2 (t, C-24), 37.6 (d, C-13), 38.0 (t, C-5), 47.8 (t, C-21), 52.2 (q, 
C-28), 52.2 (d, C-23), 54.8 (d, C-12), 55.2 (q, C-10), 55.7 (d, C-4), 59.8 (d, C-18), 80.0 (s, C-2), 
114.0 (d, C-8), 118.9 (t, C-26), 128.4 (s, C-6), 130.2 (d, C-7), 132.2 (d, C-25), 155.1 (s, C-3), 158.5 
(s, C-9), 171.0 (s, C-22), 171.7 (s, C-11 o. C-17), 171.9 (s, C-27). The signal of C-11/C-17 wasn’t 
observed in the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 6.72 (d, 3J8,7 = 8.3 Hz, 2 H, 8-H), 6.97 (d, 3J7,8 = 8.3 Hz, 2 H, 7-
H). 
HRMS (CI):    calculated found 
C32H49N4O8 [M+H]
+   617.3545 617.3554 
Melting point:    44-46 °C 
Optical rotation:   [∝]𝐷
20 = –43.4° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 50:50, 1 mL/min, 20 °C: 
tR1 = 9.53 min (11 %), 
tR2 = 13.6 min (89 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 8.33 min 
([M+Na]+ = 639). 
 
(S)-2-((S)-1-(((R)-2-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)propanoyl)-L-iso-
leucyl)pyrrolidine-2-carboxamido)pent-4-enoic acid (43) 
841 mg (1.36 mmol) 42 were dissolved in 12.0 mL dioxane and cooled to 0 °C before a solution 
of 67.8 mg (1.59 mmol) LiOH·H2O in 1.50 mL water was added slowly. The cooling bath was 
removed and the reaction was stirred for 6 h. The reaction mixture was concentrated in vacuo and 
the residue was redissolved in EA. 1 M HCl sol. was added and the layers were separated. The 
aqueous phase was extracted three times with EA and the combined organic layers were dried over 
Na2SO4. After lyophilisation, 798 mg (1.32 mmol, 97 %) of acid 43 (containing 2 % iso-butylcar-
bonate at tyrosine residue) were obtained as an off-white solid. 
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Rf (43) = 0.03 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.78 (t, 3J16,15 = 7.3 Hz, 3 H, 16-H), 0.87 (d, 3J14,13 = 6.2 Hz, 3 
H, 14 H), 0.97 (m, 1 H, 15-Ha), 1.36 (m, 1 H, 15-Hb), 1.37 (s, 9 H, 1-H), 1.68 (m, 1 H, 13-H), 1.92 
(m, 1 H, 19-Ha), 2.05 (m, 2 H, 20-H), 2.44 (m, 1 H, 19-Hb), 2.53 (ddd, 
2J24a,24b = 13.9 Hz, 
3J24a,23 
≈ 3J24a,25 = 6.8 Hz, 1 H, 24-Ha), 2.62 (ddd, 2J24b,24a = 13.7 Hz, 3J24b,23 ≈ 3J24b,25 = 6.7 Hz, 1 H, 24-
Hb), 2.97 (m, 2 H, 5-H), 3.63 (m, 1 H, 21-Ha), 3.76 (s, 3 H, 10-H), 3.97 (dt, 
2J21a,21b = 8.8 Hz, 
3J21a,20 = 8.6 Hz, 1 H, 21-Hb), 4.41 (m, 1 H, 4-H), 4.49 (dd, 
3J12,13 ≈ 3J12,NH = 7.9 Hz, 1 H, 12-H), 
4.56 (dt, 3J23,24 ≈ 3J23,NH = 5.7 Hz, 1 H, 23-H), 4.69 (d, 3J18,19a = 7.2 Hz, 1 H, 18-H), 5.02 (d, 3J26a,25 
= 10.8 Hz, 1 H, 26-Ha), 5.06 (d, 
3J26b,25 = 18.3 Hz, 1 H, 26-Hb), 5.20 (d, 
3JNH,4 = 7.8 Hz, 1 H, NHc), 
5.66 (m, 1 H, 25-H), 6.79 (d, 3J8,7 = 8.6 Hz, 2 H, 8-H), 7.07 (d, 
3J7,8 = 8.3 Hz, 2 H, 7-H), 7.62 (d, 
3JNH,12 = 8.6 Hz, 1 H, NHb), 7.74 (d, 
3JNH,23 = 5.6 Hz, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 10.7 (q, C-16), 15.1 (q, C-14), 24.5 (t, C-15), 24.9 (t, C-20), 
26.9 (t, C-19), 28.2 (q, C-1), 36.5 (t, C-24), 37.0 (d, C-13), 37.9 (t, C-5), 48.3 (t, C-21), 52.7 (d, 
C-23), 55.0 (d, C-12), 55.2 (q, C-10), 55.7 (d, C-4), 60.5 (d, C-18), 79.8 (s, C-2), 113.9 (d, C-8), 
118.6 (t, C-26), 128.4 (s, C-6), 130.3 (d, C-7), 132.6 (d, C-25), 155.1 (s, C-3), 158.5 (s, C-9), 171.0 
(s, C-17 o. C-22), 172.2 (s, C-11), 173.3 (s, C-27). The signal of C-17/C-22 wasn’t observed in 
the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 3.78 (s, 3 H, 10-H), 6.73 (d, 3J8,7 = 8.2 Hz, 2 H, 8-H), 6.93 (d, 
3J7,8 = 8.8 Hz, 2 H, 7-H). 
HRMS (CI):    calculated found 
C31H47N4O8 [M+H]
+   603.3388 603.3380 
Melting point:    90 °C 
Optical rotation:   [∝]𝐷
20 = –41.4° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.6 mL/min, tR = 17.3 min 
(95 %, [M+H]+ = 603), tR2 = 19.3 min (2 %, [M+H]
+ = 689). 
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Methyl 4-((3S,6R,9S,14aS)-9-((S)-sec-butyl)-6-(4-methoxybenzyl)-1,4,7,10-tetraoxotetrade-
cahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-3-yl)butanoate (46) 
To a solution of 14.7 mg (26.5 µmol) 40 in 0.53 mL DCM abs. were added 6.44 µL pyridine and 
the reaction was cooled to –78 °C. The reaction was then treated with ozone until the mixture 
turned blue. The dissolved ozone was removed with oxygen and the reaction was allowed to warm 
to rt within 15 min. Afterwards, a solution of 35.4 mg (106 µmol) methyl 2-(triphenyl-λ5-phos-
phaneylidene)acetate in 0.53 mL DCM abs. was added and stirring was continued for 3 h. For 
workup, the reaction was diluted with Et2O and 1 M HCl sol. was added. The layers were separated 
and the aqueous phase was extracted three times with diethyl ether. The combined organic layers 
were washed with sat. NaHCO3 sol. and dried over Na2SO4. The crude product was purified by 
column chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5) to give 6.8 mg (8.36 µmol, 
E/Z = 3:1, 32 %) of unsaturated ester 45, which contained triphenylphosphine oxide as an impurity. 
6.6 mg (8.15 µmol) of this ester were then dissolved in 1.0 mL MeOH at rt before 2.0 mg palladium 
on charcoal (10 w% Pd) were added. The reaction was hydrogenated for 6.5 h and filtrated through 
a pad of Celite®. The filtrate was concentrated in vacuo and the crude product was purified by 
column chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5). 5.0 mg (6.43 µmol, 70 % 
pure, 79 %) of ester 46 were obtained as an off-white solid. 46 still contained approximately 30 
w% of triphenylphosphine oxide as an impurity. 
Rf (46) = 0.30 (silica gel, DCM:MeOH 95:5) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.72 (t, 3J14,13 = 7.2 Hz, 3 H, 14-H), 0.81 (d, 3J12,11 = 6.4 Hz, 3 
H, 12-H), 0.87 (m, 1 H, 13-Ha), 1.06 (m, 1 H, 13-Hb), 1.57 – 1.78 (m, 3 H, 22-Ha, 23-H), 1.83 – 
1.94 (m, 3 H, 11-H, 18-Ha, 22-Hb), 1.98 (m, 1 H, 18-Hb), 2.21 (m, 2 H, 17-H), 2.33 (m, 2 H, 24-
H), 2.83 (dd, 2J3a,3b = 13.5 Hz, 
3J3a,2 = 5.6 Hz, 1 H, 3-Ha), 3.19 (dd, 
2J3b,3a = 13.3 Hz, 
3J3b,2 = 10.0 
Hz, 1 H, 3-Hb), 3.67 (m, 1 H, 19-Heq), 3.65 (s, 3 H, 26-H), 3.70 (s, 3 H, 8-H), 3.78 (dd, 
2J19ax,19eq 
≈ 3J19ax,18ax = 10.2 Hz, 1 H, 19-Hax), 4.52 (dd, 3J10,11 ≈ 3J10,NH = 9.7 Hz, 1 H, 10-H), 4.58 (m, 1 H, 
21-H), 4.63 (m, 1 H, 2-H), 4.95 (d, 3J16,17a/b = 8.4 Hz, 1 H, 16-H), 6.21 (br s, 1 H, NHa), 6.54 (br s, 
1 H, NHc), 6.66 (d, 
3J6,5 = 8.6 Hz, 2 H, 6-H), 6.86 (m, 1 H, NHb), 7.01 (d, 
3J5,6 = 8.3 Hz, 2 H, 5-
H). 
13C-NMR (100 MHz, CDCl3): δ = 11.3 (q, C-14), 15.9 (q, C-12), 21.0 (t, C-23), 21.9 (t, C-18), 
24.1 (t, C-13), 27.6 (t, C-22), 31.6 (t, C-17), 33.3 (t, C-24), 34.5 (t, C-3), 36.3 (d, C-11), 47.1 (t, 
C-19), 51.6 (q, C-26), 53.7 (d, C-21), 55.1 (q, C-8), 55.7 (d, C-10), 57.1 (d, C-2), 61.0 (d, C-16), 
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113.7 (d, C-6), 128.4 (s, C-4), 130.4 (d, C-5), 158.3 (s, C-7), 170.1 (s, C-9), 170.5 (s, C-15), 173.3 
(s, C-25), 173.5 (s, C-1), 174.8 (s, C-20). 
HRMS (CI):    calculated found 
C28H41N4O7 [M]
+   545.2970 545.2952 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.8 mL/min, tR1 = 9.47 min 
([M+H]+ = 545), tR2 = 9.71 min ([M+H]
+ = 279). 
 
S-((4-(2-((3S,6R,9S,14aS)-9-((S)-sec-Butyl)-6-(4-methoxybenzyl)-1,4,7,10-tetraoxotetra-
deca-hydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-3-yl)ethyl)tetrahydrofuran-3-
yl)methyl) ethanethioate (47) 
To a suspension of 10.2 mg (18.4 µmol) 40 in 0.5 mL THF were added 2.63 µL (2.80 mg, 36.8 
µmol) thioacetic acid and 6.0 µL (6.0 µmol) BEt3 (1 M in THF) at rt. 0.1 mL air were added and 
the reaction was stirred at rt overnight before further 2.0 µL (2.13 mg, 28.0 µ mol) thioacetic acid 
and 6.0 µL (6.0 µmol) BEt3 (1 M in THF) were added. Stirring was continued for 3 h and the 
reaction was concentrated in vacuo. Purification by column chromatography (silica gel, 
DCM:MeOH 100:0, Gradient 95:5) afforded 9.5 mg (15.1 µmol, 82 %) of compound 47 as an off-
white solid. 
Rf (47) = 0.19 (silica gel, DCM:MeOH 95:5) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.72 (m, 3 H, 14-H), 0.80 (d, 3J12,13 = 6.2 Hz, 3 H, 12-H), 0.82 
(m, 1 H, 13-Ha), 1.04 (m, 1 H, 13-Hb), 1.27 (m, 2 H, 23-H), 1.71 (m, 1 H, 22-Ha), 1.80 – 1.94 (m, 
4 H, 11-H, 18-Ha, 22-Hb, 24-H), 2.01 (m, 2 H, 18-Hb, 27-H), 2.22 (m, 2 H, 17-H), 2.33 (s, 3 H, 30-
H), 2.78 – 2.87 (m, 2 H, 3-Ha, 28-Ha), 3.03 (m, 1 H, 28-Hb), 3.21 (m, 1 H, 3-Hb), 3.45 (m, 1 H, 26-
Ha), 3.57 – 3.79 (m, 4 H, 19-H, 25-H), 3.71 (s, 3 H, 8-H), 3.88 (dd, 2J26b,26a ≈ 3J26b,24/27 = 9.3 Hz, 1 
H, 26-Hb), 4.49 – 4.68 (m, 3 H, 2-H, 10-H, 21-H), 4.93 (m, 1 H, 16-H), 6.26 (m, 1 H, NHc), 6.46 
(br s, 1 H, NHa), 6.66 (d, 
3J6,5 = 8.6 Hz, 2 H, 6-H), 6.86 (m, 1 H, NHb), 7.02 (m, 2 H, 5-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.3 (q, C-14), 15.9 (q, C-12), 21.9 (t, C-18), 24.1 (t, C-13), 
27.7 (t, C-22), 29.3 (t, C-23), 30.6 (q, C-30), 31.6 (t, C-17), 31.7 (t, C-28), 34.5 (t, C-3), 36.3 (d, 
C-24), 44.5 (d, C-27), 47.1 (t, C-19), 54.0 (d, C-21), 55.1 (q, C-8), 55.7 (d, C-10), 57.2 (d, C-2), 
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61.1 (d, C-16), 72.0 (t, C-25 o. C-26), 72.6 (t, C-25 o. C-26), 113.7 (d, C-6), 128.6 (s, C-4), 130.4 
(d, C-5), 158.3 (s, C-7), 170.1 (s, C-9), 170.6 (s, C-15), 195.5 (s, C-29). The signals of C-1, C-11 
and C-20 weren’t observed in the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 2.34 (s, 3 H, 30-H), 2.64 (m, 1 H, 28-Ha), 3.36 (m, 1 H, 25-Ha), 
3.69 (s, 3 H, 8-H), 3.70 (s, 3 H, 8-H), 3.82 (m, 1 H, 26-Ha), 3.97 (m, 1 H, 25-Hb), 6.65 (d, 
3J6,5 = 
8.6 Hz, 2 H, 6-H), 6.67 (d, 3J6,5 = 8.2 Hz, 2 H, 6-H), 6.68 (d, 
3J6,5 = 8.4 Hz, 2 H, 6-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.3 (q, C-14), 11.3 (q, C-14), 11.4 (q, C-14), 15.9 (q, C-12), 
15.9 (q, C-12), 21.9 (t, C-18), 24.1 (t, C-13), 27.6 (t, C-22), 29.3 (t, C-23), 44.6 (d, C-27), 47.2 (t, 
C-19), 55.1 (q, C-8), 130.5 (d, C-5), 195.4 (s, C-29). 
HRMS (CI):    calculated found 
C32H47N4O7S [M]
+   631.3160 631.3118 
Melting point:   238 °C (decomposition) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.8 mL/min, tR = 9.88 min 
([M+H]+ = 631). 
 
S-((4-(2-((3S,6R,9S,14aS)-9-((S)-sec-Butyl)-6-(4-methoxybenzyl)-1,4,7,10-tetraoxotetra-
deca-hydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-3-yl)ethyl)tetrahydrofuran-3-
yl)methyl) benzothioate (48) 
A suspension of 10.2 mg (18.4 µmol) 40 in 0.5 mL THF was treated with 4.34 µL (5.10 mg, 36.9 
µmol) thiobenzoic acid and 6.0 µL (6.0 µmol) BEt3 (1 M in THF) at rt. 0.1 mL air were added and 
the reaction was stirred at rt overnight before further 6.0 µL (6.0 µmol) BEt3 (1 M in THF) were 
added and stirring was continued for 4 h. The reaction was concentrated in vacuo and purified by 
column chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5) to yield 8.6 mg (12.4 
µmol, 67 %) of compound 48 as an off-white solid. 
Rf (48) = 0.30 (silica gel, DCM:MeOH 95:5) 
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Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.71 (m, 3 H, 14-H), 0.80 (d, 3J12,13 = 6.2 Hz, 3 H, 12-H), 0.83 
(m, 1 H, 13-Ha), 1.04 (m, 1 H, 13-Hb), 1.31 (m, 1 H, 23-Ha), 1.58 (m, 1 H, 23-Hb), 1.76 (m, 1 H, 
22-Ha), 1.82 – 2.04 (m, 5 H, 11-H, 18-H, 22-Hb, 28-Ha), 2.10 – 2.35 (m, 3 H, 17-H, 24-H), 2.47 
(m, 1 H, 27-H), 2.85 (m, 1 H, 3-Ha), 3.14 – 3.27 (m, 2 H, 3-Hb, 28-Hb), 3.49 – 3.82 (m, 4 H, 19-
H, 25-Ha, 26-Ha), 3.69 (s, 3 H, 8-H), 3.84 – 3.95 (m, 2 H, 25-Hb, 26-Hb), 4.49 – 4.71 (m, 3 H, 2-
H, 10-H, 21-H), 5.00 (d, 3J16,17a/b = 6.4 Hz, 1 H, 16-H), 6.24 (m, 1 H, NHa), 6.42 (m, 1 H, NHc), 
6.65 (d, 3J6,5 = 7.0 Hz, 2 H, 6-H), 6.96 (m, 1 H, NHb), 7.00 (d, 
3J5,6 = 7.7 Hz, 2 H, 5-H), 7.44 (dd, 
3J32,31 ≈ 3J32,33 = 7.6 Hz, 2 H, 32-H), 7.57 (t, 3J33,32 = 7.4 Hz, 1 H, 33-H), 7.93 (d, 3J31,32 = 7.5 Hz, 
2 H, 31-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.3 (q, C-14), 15.8 (q, C-12), 21.9 (t, C-18), 23.7 (t, C-22), 
24.1 (t, C-13), 27.4 (t, C-28), 29.7 (t, C-23), 31.7 (t, C-17), 34.6 (t, C-3), 36.3 (d, C-11), 41.7 (d, 
C-27), 44.7 (d, C-24), 47.0 (t, C-19), 53.9 (d, C-21), 55.0 (q, C-8), 55.8 (d, C-10), 57.3 (d, C-2), 
61.0 (d, C-16), 70.6 (t, C-26), 72.3 (t, C-25), 113.7 (d, C-6), 127.2 (d, C-31), 128.6 (s, C-4), 128.7 
(d, C-32), 130.5 (d, C-5), 133.5 (d, C-33), 136.8 (s, C-30), 158.3 (s, C-7), 170.2 (s, C-9), 170.6 (s, 
C-15), 173.6 (s, C-1 o. C-20), 174.7 (s, C-1 o. C-20), 191.5 (s, C-29). 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 3.01 (m, 1 H, 28-Hb), 3.39 (m, 1 H, 25-Ha), 3.67 (s, 3 H, 8-H), 
3.68 (s, 3 H, 8-H), 4.00 (dt, 2J25b,25a = 8.2 Hz, 
3J25b,24 = 7.5 Hz, 1 H, 25-Hb), 6.63 (d, 
3J6,5 = 6.0 Hz, 
2 H, 6-H), 6.98 (d, 3J5,6 = 6.1 Hz, 2 H, 5-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.3 (q, C-14), 15.9 (q, C-12), 22.0 (t, C-18), 27.5 (t, C-28), 
31.6 (t, C-17), 31.7 (t, C-17), 41.8 (d, C-27), 42.2 (d, C-27), 42.3 (d, C-27), 44.8 (d, C-24), 45.2 
(d, C-24), 45.3 (d, C-24), 47.1 (t, C-19), 54.0 (d, C-21), 54.2 (d, C-21), 57.5 (d, C-2), 61.0 (d, C-
16), 71.9 (d, C-25 o. C-26), 72.0 (d, C-25 o. C-26), 72.3 (t, C-25), 72.7 (d, C-25 o. C-26), 72.7 (d, 
C-25 o. C-26), 133.6 (d, C-33), 136.7 (s, C-30), 174.8 (s, C-1 o. C-20), 174.9 (s, C-1 o. C-20), 
191.4 (s, C-29). 
Melting point:   208 °C (decomposition) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.8 mL/min, tR = 10.8 min 
([M+H]+ = 693). 
 
((4R,5R)-5-((Benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol (ent-1b)[156] 
2.99 g (74.8 mmol) Sodium hydride (60 w% in paraffin) were placed in a three-necked flask and 
25 mL n-pentane were added. The suspension was stirred for few minutes and the NaH was al-
lowed to segregate. The solvent was removed via syringe and the free NaH was dried in high-
vacuo. Afterwards, 45 mL DMF abs. were added and the suspension was cooled to –40 °C. A 
solution of 11.0 g (67.8 mmol) (-)-2,3-O-Isopropylidene-D-threitol in 60 mL DMF abs. was added 
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within 1 h at this temperature. Afterwards, a solution of 8.1 mL (8.83 g , 69.8 mmol) benzyl chlo-
ride in 60 mL DMF abs. was added slowly within 35 min and the reaction was allowed to warm 
slowly to 0 °C. After stirring at 0 °C for 1 h, the reaction was allowed to warm to rt overnight. For 
workup, a few drops of water were added and the reaction was concentrated in vacuo. The residue 
was dissolved in DCM and water was added. The layers were separated, the aqueous phase was 
extracted three times with DCM, the combined organic phases were washed with brine and dried 
over Na2SO4. The crude product was purified by column chromatography (silica gel, PE:EA 
70:30) to give 10.2 g (40.4 mmol, 60 %) of monobenzylated product ent-1b as a yellow oil. 
Rf (ent-1b) = 0.30 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.42 (s, 3 H, 11-H), 1.42 (s, 3 H, 11'-H), 2.18 (br s, 1 H, OH), 
3.56 (dd, 2J6a,6b = 9.8 Hz, 
3J6a,7 = 5.8 Hz, 1 H, 6-Ha), 3.66 – 3.71 (m, 2 H, 6-Hb, 9-Ha), 3.77 (dd, 
2J9b,9a = 11.7 Hz, 
3J9b,8 = 4.4 Hz, 1 H, 9-Hb), 3.94 (dt, 
3J8,7 = 8.4 Hz, 
3J8,9 = 4.3 Hz, 1 H, 8-H), 4.06 
(dt, 3J7,8 = 8.2 Hz, 
3J7,6 = 5.4 Hz, 1 H, 7-H), 4.59 (s, 2 H, 5-H), 7.28 – 7.38 (m, 5 H, 1-H, 2-H, 3-
H). 
13C-NMR (100 MHz, CDCl3): δ = 26.9 (q, C-11), 62.4 (t, C-9), 70.3 (t, C-6), 73.7 (t, C-5), 76.5 
(d, C-7), 79.6 (d, C-8), 109.3 (s, C-10), 127.7 (d, C-3), 127.8 (d, C-1), 128.4 (d, C-2), 137.5 (s, C-
4). 
HRMS (CI):    calculated found 
C14H20O4 [M]
+   252.1362 252.1363 
Optical rotation:   [∝]𝐷
20 = –7.6° (c = 1.0, CHCl3) 
 
(4R,5S)-4-((Benzyloxy)methyl)-5-(iodomethyl)-2,2-dimethyl-1,3-dioxolane (ent-5b)[211] 
A solution of 1.03 g (4.08 mmol) alcohol ent-1b in 12 mL toluene abs. and 2.5 mL acetonitrile 
abs. was treated with 1.13 g (4.31 mmol) triphenylphosphine and 349 mg (5.12 mmol) imidazole 
at rt. Afterwards, 1.09 g (4.30 mmol) iodine were added carefully and the reaction was heated to 
60 °C for 2 h. For workup, the reaction was diluted with Et2O and washed with sat. Na2S2O3, water 
and brine. The organic layer was dried over Na2SO4 and concentrated in vacuo. The crude product 
was purified by column chromatography (silica gel, n-pentane:Et2O 2:1) to give 1.47 g (4.06 
mmol, 99 %) of iodide ent-5b as a yellowish oil. 
Rf (ent-5b) = 0.51 (silica gel, PE:EA 70:30) 
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1H-NMR (400 MHz, CDCl3): δ = 1.42 (s, 3 H, 11-H), 1.47 (s, 3 H, 11-H’), 3.28 (dd, 2J9a,9b = 10.5 
Hz, 3J9a,8 = 5.3 Hz, 1 H, 9-Ha), 3.36 (dd, 
2J9b,9a = 10.5 Hz, 
3J9b,8 = 5.3 Hz, 1 H, 9-Hb), 3.64 (dd, 
2J6a,6b = 10.0 Hz, 
3J6a,7 = 5.0 Hz, 1 H, 6-Ha), 3.67 (dd, 
2J6b,6a = 10.0 Hz, 
3J6b,7 = 5.0 Hz, 1 H, 6-Hb), 
3.87 (dt, 3J8,7 = 7.3 Hz, 
3J8,9 = 5.3 Hz, 1 H, 8-H), 3.97 (dt, 
3J7,8 = 7.3 Hz, 
3J7,6 = 5.3 Hz, 1 H, 7-H), 
4.60 (s, 2 H, 5-H), 7.24 – 7.38 (m, 5 H, 1-H, 2-H, 3-H). 
13C-NMR (100 MHz, CDCl3): δ = 6.4 (t, C-9), 27.3 (q, C-11), 27.4 (q, C-11'), 70.5 (t, C-6), 73.6 
(t, C-5), 77.7 (d, C-8), 80.1 (d, C-7), 109.8 (s, C-10), 127.7 (d, C-2 o. C-3), 127.8 (d, C-1), 128.5 
(d, C-2 o. C-3), 137.8 (s, C-4). 
HRMS (CI):    calculated found 
C14H20O3I [M+H]
+   363.0452 363.0453 
Optical rotation:    [𝛼]𝐷
20 = +8.1° (c = 1.0, CHCl3) 
 
(S)-1-(Benzyloxy)but-3-en-2-ol (49)[212] 
To a solution of 1.91 g (5.27 mmol) ent-5b in 26 mL THF abs. was added 1.38 g (21.1 mmol) zinc 
dust and 1.51 mL (1.58 g, 26.3 mmol) acetic acid at rt. The reaction was stirred for 2 h, filtrated 
through a pad of Celite® and washed with Et2O. The filtrated was concentrated in vacuo, the resi-
due was redissolved in Et2O and sat. NaHCO3 sol. was added. The layers were separated and the 
aqueous phase was extracted three times with Et2O. The combined organic phases were dried over 
Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography 
(silica gel, PE:EA 100:0, 80:20) to yield 915 mg (5.13 mmol, er > 99:1, 97 %) allylic alcohol 49 
as a slightly yellow liquid. 
Rf (49) = 0.14 (silica gel, PE:EA 80:20) 
 
1H-NMR (400 MHz, CDCl3): δ = 2.45 (d, 3JOH,7 = 3.5 Hz, 1 H, OH), 3.39 (dd, 2J6a,6b = 9.7 Hz, 
3J6a,7 = 7.9 Hz, 1 H, 6-Ha), 3.55 (dd, 
2J6b,6a = 9.7 Hz, 
3J6b,7 = 3.4 Hz, 1 H, 6-Hb), 4.36 (m, 1 H, 7-
H), 4.58 (s, 2 H, 5-H), 5.20 (ddd, 3J9a,8 = 10.5 Hz, 
2J9a,9b ≈ 4J9a,7 = 1.5 Hz, 1 H, 9-Ha), 5.37 (ddd, 
3J9b,8 = 17.3 Hz, 
2J9b,9a ≈ 4J9b,7 = 1.5 Hz, 1 H, 9-Hb), 5.84 (ddd, 3J8,9b = 17.3 Hz, 3J8,9a = 10.5 Hz, 
3J8,7 = 5.5 Hz, 1 H, 8-H), 7.29 – 7.39 (m, 5 H, 1-H, 2-H, 3-H). 
13C-NMR (100 MHz, CDCl3): δ = 71.5 (t, C-6), 73.4 (t, C-5), 74.0 (d, C-7), 116.5 (t, C-9), 127.8 
(d, C-2 o. C-3), 127.8 (d, C-1), 128.5 (d, C-2 o. C-3), 136.5 (d, C-8), 137.8 (s, C-4). 
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HRMS (CI):    calculated found 
C11H14O2 [M]
+   178.0994 178.0992 
Optical rotation:    [𝛼]𝐷
20 = –1.3° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 95:5, 1.0 mL/min, 20 °C: 
(S)-49: tR = 8.60 min (> 99 %). 
 
(S)-1-(Benzyloxy)but-3-en-2-yl ((benzyloxy)carbonyl)glycinate (50a) 
230 mg (1.10 mmol) Cbz-Gly-OH and 178 mg (1.00 mmol) 49 were dissolved in 10.0 mL DCM 
abs. and cooled to 0 °C before 227 mg (1.10 mmol) DCC and 12.4 mg (0.101 mmol) 4-DMAP 
were added subsequently. The reaction was allowed to warm to rt overnight. For workup, the re-
action was filtrated through a pad of Celite® and washed with DCM. The filtrate was concentrated 
in vacuo. Purification by column chromatography (silica gel, PE:EA 100:0, 80:20) afforded 331 
mg (0.896 mmol, 90 %) of ester 50a as an off-white solid. 
Rf (50a) = 0.20 (silica gel, PE:EA 70:30) 
 
1H-NMR (400 MHz, CDCl3): δ = 3.58 (d, 3J6,7 = 5.5 Hz, 2 H, 6-H), 4.03 (d, 3J11,NH = 5.5 Hz, 2 H, 
11-H), 4.52 (d, 2J5a,5b = 12.3 Hz, 1 H, 5-Ha), 4.58 (d, 
2J5b,5a = 12.3 Hz, 1 H, 5-Hb), 5.13 (s, 2 H, 13-
H), 5.24 (br s, 1 H, NH), 5.27 (d, 3J9a,8 = 10.8 Hz, 1 H, 9-Ha), 5.34 (d, 
3J9b,8 = 17.3 Hz, 1 H, 9-Hb), 
5.54 (dt, 3J7,8 = 6.3 Hz, 
3J7,6 = 5.5 Hz, 1 H, 7-H), 5.82 (ddd, 
3J8,9b = 17.3 Hz, 
3J8,9a = 10.8 Hz, 
3J8,7 
= 6.3 Hz, 1 H, 8-H), 7.27 – 7.38 (m, 10 H, 1-H, 2-H, 3H, 15-H, 16-H, 17-H). 
13C-NMR (100 MHz, CDCl3): δ = 42.9 (t, C-11), 67.1 (t, C-13), 71.0 (t, C-6), 73.2 (t, C-5), 74.5 
(d, C-7), 118.7 (t, C-9), 127.6 (d, C-2 o. C-3), 127.8 (d, C-1), 128.1 (d, C-15 o. C-16 o. C-17), 
128.2 (d, C-15 o. C-16 o. C-17), 128.4 (d, C-15 o. C-16 o. C-17), 128.5 (d, C-2 o. C-3), 132.5 (d, 
C-8), 136.2 (s, C-14), 137.7 (s, C-4), 156.1 (s, C-12), 169.2 (s, C-10). 
HRMS (CI):    calculated found 
C21H24NO5 [M+H]
+   370.1649 370.1644 
Melting point:   93-95 °C 
Optical rotation:    [𝛼]𝐷
20 = +2.7° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 80:20, 1.0 mL/min, 20 °C: 
(S)-50a: tR = 15.1 min (> 99 %). 
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(S)-1-(Benzyloxy)but-3-en-2-yl (2,2,2-trifluoroacetyl)glycinate (50b) 
438 mg (2.56 mmol) TFA-Gly-OH and 457 mg (2.56 mmol) 49 were dissolved in 5.0 mL DCM 
abs. and cooled to –15 °C before a suspension of 530 mg (2.57 mmol) DCC and 31.7 mg (0.259 
mmol) 4-DMAP in 4.0 mL DCM abs. was added slowly. The reaction was allowed to warm to rt 
overnight. The precipitated urea was removed by filtration through a pad of Celite® and washed 
with DCM. 1 M HCl sol. was added to the filtrate and the layers were separated. The aqueous 
phase was extracted three times with DCM and the combined organic layers were washed with 
sat. NaHCO3 and dried over Na2SO4. Purification by column chromatography (silica gel, PE:EA 
100:0, 90:10) afforded 731 mg (2.21 mmol, 86 %) of ester 50b as a colourless oil. 
Rf (50b) = 0.50 (silica gel, PE:EA 60:40) 
 
1H-NMR (400 MHz, CDCl3): δ = 3.60 (d, 3J6,7 = 5.5 Hz, 2 H, 6-H), 4.15 (d, 3J11,NH = 5.0 Hz, 2 H, 
11-H), 4.53 (d, 2J5a,5b = 12.3 Hz, 1 H, 5-Ha), 4.58 (d, 
2J5b,5a = 12.3 Hz, 1 H, 5-Hb), 5.30 (ddd, 
3J9a,8 
= 10.8 Hz, 2J9a,9b ≈ 4J9a,7 = 1.0 Hz, 1 H, 9-Ha), 5.36 (ddd, 3J9b,8 = 17.3 Hz, 2J9b,9a ≈ 4J9b,7 = 1.1 Hz, 
1 H, 9-Hb), 5.57 (dt, 
3J7,8 = 6.5 Hz, 
3J7,6 = 5.4 Hz, 1 H, 7-H), 5.82 (ddd, 
3J8,9b = 17.2 Hz, 
3J8,9a = 
10.7 Hz, 3J8,7 = 6.4 Hz, 1 H, 8-H), 6.88 (br s, 1 H, NH), 7.28 – 7.39 (m, 5 H, 1-H, 2-H, 3-H). 
13C-NMR (100 MHz, CDCl3): δ = 41.4 (t, C-11), 70.9 (t, C-6), 73.3 (t, C-5), 75.4 (d, C-7), 115.6 
(q, 1J13,F = 287 Hz, C-13), 119.4 (t, C-9), 127.7 (d, C-3), 127.9 (d, C-1), 128.5 (d, C-2), 132.0 (d, 
C-8), 137.5 (s, C-4), 157.1 (q, 2J12,F = 37 Hz, C-12), 167.6 (s, C-10). 
HRMS (CI):    calculated found 
C15H17F3NO4 [M+H]
+   332.1104 332.1144 
Optical rotation:    [𝛼]𝐷
20 = +12.9° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 90:10, 1.0 mL/min, 20 °C: 
(S)-50b: tR = 15.3 min (> 99 %). 
GC: CP-Chirasil-Dex CB, column flow 1.25 mL/min, injector 250 °C, 180 °C, 20 min, 220 °C 
(5 °C/min), 5 min: 
(S)-50b: tR = 16.89 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 4.93 min 
([M+Na]+ = 354). 
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(R,E)-6-(Benzyloxy)-2-(((benzyloxy)carbonyl)amino)hex-4-enoic acid (51a) 
2.50 mL (1.78 g, 17.6 mmol) Di-iso-propylamine were dissolved in 17.5 mL THF abs. and cooled 
to –78 °C before 9.4 mL (15.0 mmol) n-BuLi (1.6 M in hexanes) were added dropwise. The cool-
ing bath was removed and the reaction was stirred for 10 min at rt. 822 mg (6.03 mmol) zinc 
chloride (dried in high-vacuo) were dissolved in 5.0 mL THF abs. and treated with a solution of 
1.85 g (5.01 mmol) 50a in 20 mL THF abs. at rt. The zinc chloride/ amino acid ester solution was 
cooled to –78 °C and treated with the above prepared LDA solution carefully. The remaining dry 
ice was removed and the reaction was allowed to warm to rt overnight. For workup, the reaction 
was diluted with diethyl ether and 1 M KHSO4 sol. was added. The layers were separated and the 
aqueous phase was extracted three times with Et2O. The combined organic layers were dried over 
Na2SO4 and concentrated in vacuo. Purification by column chromatography (silica gel, 
DCM:MeOH 99:1, 98:2, 95:5) gave 302 mg (0.695 mmol, 14 %) of a mixture of product and 
allylic alcohol 3 and 1.44 g (3.90 mmol, er 96:4, 78 %) of acid 51a as a slightly yellow oil. 
Rf (51a) = 0.05 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 2.54 (ddd, 2J9a,9b = 13.9 Hz, 3J9a,8 = 7.1 Hz, 3J9a,11 = 6.5 Hz, 1 
H, 9-Ha), 2.63 (ddd, 
2J9b,9a = 13.9 Hz, 
3J9b,8 = 6.3 Hz, 
3J9b,11 = 5.8 Hz, 1 H, 9-Hb), 3.96 (m, 2 H, 6-
H), 4.45 – 4.50 (m, 3 H, 5-H, 11-H), 5.10 (s, 2 H, 13-H), 5.34 (d, 3JNH,11 = 8.0 Hz, 1 H, NH), 5.62 
(dt, 3J8,7 = 15.3 Hz, 
3J8,9 = 6.9 Hz, 1 H, 8-H), 5.71 (dt, 
3J7,8 = 15.3 Hz, 
3J7,6 = 5.5 Hz, 1 H, 7-H), 
7.00 (br s, 1 H, COOH), 7.26 – 7.37 (m, 10 H, 1-H, 2-H, 3-H, 15-H, 16-H, 17-H). 
13C-NMR (100 MHz, CDCl3): δ = 34.9 (t, C-9), 53.1 (d, C-11), 67.2 (t, C-13), 70.0 (t, C-6), 72.1 
(t, C-5), 127.1 (d, C-8), 127.7 (d, C-17), 127.8 (d, C-1), 128.1 (d, C-3 o. C-15), 128.2 (d, C-3 o. 
C-15), 128.4 (d, C-2 o. C-16), 128.5 (d, C-2 o. C-16), 131.3 (d, C-7), 136.0 (s, C-14), 137.9 (s, C-
4), 155.9 (s, C-12), 175.3 (s, C-10). 
HRMS (CI):    calculated found 
C21H24NO5 [M+H]
+   370.1649 370.1654 
Optical rotation:    [𝛼]𝐷
20 = –27.2° (c = 1.0, CHCl3) 
HPLC: A small sample was derivatized with TMS-diazomethane to obtain the corresponding me-
thyl ester for HPLC analysis. Reprosil, n-hexane:iPrOH 60:40, 1.0 mL/min, 20 °C: 
(R)-51a: tR = 16.6 min (96 %), 
(S)-51a: tR = 22.2 min (4 %). 
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(R,E)-6-(Benzyloxy)-2-(2,2,2-trifluoroacetamido)hex-4-enoic acid (51b) 
To a solution of 1.8 mL (1.28 g, 12.6 mmol) Di-iso-propylamine in 13.0 mL THF abs. were added 
7.4 mL (11.8 mmol) n-BuLi (1.6 M in hexanes) dropwise at –20 °C. The cooling bath was removed 
and the reaction was stirred at rt for 15 min. A solution of 698 mg (5.12 mmol) zinc chloride (dried 
in high-vacuo) in 4.0 mL THF abs. was added to a solution of 1.41 g (4.26 mmol) 50b at rt. The 
resulting solution was cooled to –78 °C and carefully treated with the above prepared LDA solu-
tion. The reaction was allowed to warm to rt overnight and diluted with Et2O. 1 M KHSO4 sol. 
was added and the layers were separated. The aqueous phase was extracted three times with diethyl 
ether and the combined organic phases were dried over Na2SO4. The crude product was purified 
by column chromatography (silica gel, PE:EA 70:30 + 1 % HOAc) to yield 269 mg (0.543 mmol, 
13 %) of a mixture of product and allylic alcohol 49 and 1.09 g (3.29 mmol, er 99:1, rotameric 
ratio 86:14, 77 %) %) of acid 51b as an off-white solid. 
Rf (51b) = 0.45 (silica gel, PE:EA 50:50 + 1 % HOAc) 
 
Major rotamer: 
1H-NMR (400 MHz, CDCl3): δ = 2.68 (m, 2 H, 9-H), 4.02 (d, 3J6,7 = 5.3 Hz, 2 H, 6-H), 4.54 (s, 2 
H, 5-H), 4.73 (dt, 3J11,NH = 7.6 Hz, 
3J11,9 = 5.4 Hz, 1 H, 11-H), 5.60 (dt, 
3J8,7 = 15.1 Hz, 
3J8,9 = 7.5 
Hz, 1 H, 8-H), 5.73 (dt, 3J7,8 = 15.4 Hz, 
3J7,6 = 5.6 Hz, 1 H, 7-H), 7.11 (d, 
3JNH,11 = 7.6 Hz, 1 H, 
NH), 7.28 – 7.38 (m, 5 H, 1-H, 2-H, 3-H), 9.69 (br s, 1 H, COOH). 
13C-NMR (100 MHz, CDCl3): δ = 34.1 (t, C-9), 51.8 (d, C-11), 69.7 (t, C-6), 72.3 (t, C-5), 115.6 
(q, 1J13,F = 288 Hz, C-13), 125.9 (d, C-8), 127.9 (d, C-3), 128.0 (d, C-1), 128.5 (d, C-2), 131.8 (d, 
C-7), 137.2 (s, C-4), 156.9 (q, 2J12,F = 37 Hz, C-12), 172.9 (s, C-10). 
Minor rotamer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 4.52 (s, 2 H, 5-H), 6.95 (d, 3JNH,11 = 6.9 Hz, 1 H, NH). 
13C-NMR (100 MHz, CDCl3): δ = 34.2 (t, C-9), 51.9 (d, C-11), 69.8 (t, C-6), 72.3 (t, C-5), 125.7 
(d, C-8), 127.9 (d, C-3), 127.9 (d, C-1), 128.5 (d, C-2), 132.1 (d, C-7), 137.4 (s, C-4), 173.3 (s, C-
10). 
HRMS (CI):    calculated found 
C15H17F3NO4 [M+H]
+   332.1104 332.1108 
Melting point:   62 °C 
Optical rotation:    [𝛼]𝐷
20 = –61.6° (c = 1.0, CHCl3) 
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HPLC: A small sample was derivatized with TMS-diazomethane for HPLC analysis. Reprosil, n-
hexane:iPrOH 95:5, 1.0 mL/min, 20 °C: 
(S)-51b: tR = 9.16 min (1 %), 
(R)-51b: tR = 17.8 min (99 %). 
GC: A small sample was derivatized with TMS-diazomethane for GC analysis. CP-Chirasil-Dex 
CB, column flow 1.50 mL/min, injector 250 °C, 145 °C, 2 min, 180 °C (1 °C/min), 5 min, 200 °C 
(20 °C/min), 5 min: 
(S)-51b: tR = 35.74 min (1 %), 
(R)-51b: tR = 37.45 min (99 %). 
 
tert-Butyl (R,E)-6-(benzyloxy)-2-(2,2,2-trifluoroacetamido)hex-4-enoate (52) 
1.56 g (4.71 mmol) 51b were dissolved in 4.0 mL DCM abs. and cooled to 0 °C before a solution 
of 2.06 g (9.43 mmol) tert-Butyl trichloroacetimidate in 8.0 mL cyclohexane was added slowly 
within 10 min. Afterwards, 0.12 mL (134 mg (0.944 mmol) BF3*OEt2 were added dropwise and 
the reaction was stirred at 0 °C for 1 h. For workup, the reaction was diluted with ethyl acetate and 
sat. NaHCO3 sol. was added. The layers were separated and the aqueous phase was extracted three 
times with EA. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
Purification by column chromatography (silica gel, PE:EA 80:20) afforded 1.67 g (4.31 mmol, er 
98:2, 92 %) of ester 52 as a slightly yellow oil. 
Rf (52) = 0.53 (silica gel, PE:EA 70:30) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.48 (s, 9 H, 1-H), 2.57 (dt, 2J7a,7b = 13.8 Hz, 3J7a,8 = 7.2 Hz, 
3J7a,4 = 6.2 Hz, 1 H, 7-Ha), 2.70 (dt, 
2J7b,7a = 13.7 Hz, 
3J7b,8 = 7.2 Hz, 
3J7b,4 = 6.2 Hz, 1 H, 7-Ha), 
3.98 (d, 3J10,9 = 5.5 Hz, 2 H, 10-H), 4.49 (s, 2 H, 11-H), 4.54 (dt, 
3J4,NH = 7.1 Hz, 
3J4,7 = 5.6 Hz, 1 
H, 4-H), 5.57 (dt, 3J8,9 = 15.1 Hz, 
3J8,7 = 7.5 Hz, 1 H, 8-H), 5.72 (dt, 
3J9,8 = 15.3 Hz, 
3J9,10 = 5.7 
Hz, 1 H, 9-H), 6.91 (d, 3JNH,4 = 6.0 Hz, 1 H, NH), 7.27 – 7.37 (m, 5 H, 13-H, 14-H, 15-H). 
13C-NMR (100 MHz, CDCl3): δ = 28.0 (q, C-1), 34.6 (t, C-7), 52.6 (d, C-4), 69.9 (t, C-10), 72.1 
(t, C-11), 83.6 (s, C-2), 115.6 (q, 1J6,F = 288 Hz, C-6), 125.6 (d, C-8), 127.6 (d, C-15), 127.6 (d, 
C-13), 128.4 (d, C-14), 132.0 (d, C-9), 138.1 (s, C-12), 156.5 (q, 2J5,F = 37 Hz, C-5), 169.2 (s, C-
3). 
HRMS (CI):    calculated found 
C19H25F3NO4 [M+H]
+   388.1730 388.1695 
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Optical rotation:    [𝛼]𝐷
20 = –44.0° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 95:5, 1.0 mL/min, 20 °C: 
(R)-52: tR = 13.0 min (98 %), 
(S)-52: tR = 26.6 min (2 %). 
 
tert-Butyl (R)-6-Hydroxy-2-(2,2,2-trifluoroacetamido)hexanoate (53) 
A solution of 1.63 g (4.21 mmol) 52 in 17 mL MeOH was treated with 165 mg palladium on 
charcoal (10 w% Pd) and hydrogenated for 7 h. The reaction mixture was filtrated through a pad 
of Celite® and washed with MeOH. The filtrate was concentrated in vacuo and the crude product 
was dried by lyophilisation. 1.25 g (4.18 mmol, rotameric ratio 66:34, 99 %) of compound 53 were 
obtained as a colourless oil. The compound contained an unknown side product. 
Rf (53) = 0.19 (silica gel, PE:EA 70:30) 
 
Major rotamer: 
1H-NMR (400 MHz, CDCl3): δ = 1.40 (m, 2 H, 8-H), 1.48 (s, 9 H, 1-H), 1.61 (m, 2 H, 9-H), 1.76 
(m, 1 H, 7-Ha), 1.93 (m, 1 H, 7-Hb), 3.65 (t, 
3J10,9 = 6.3 Hz, 2 H, 10-H), 4.49 (dt, 
3J4,NH ≈ 3J4,7 = 
6.5 Hz, 1 H, 4-H), 7.03 (br s, 1 H, NH). 
13C-NMR (100 MHz, CDCl3): δ = 21.2 (t, C-8), 27.9 (q, C-1), 31.7 (t, C-7), 31.9 (t, C-9), 53.1 (d, 
C-4), 62.3 (t, C-10), 83.3 (s, C-2), 115.7 (q, 1J6,F = 288 Hz, C-6), 156.7 (q, 
2J5,F = 38 Hz, C-5), 
170.0 (s, C-3). 
Minor rotamer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 6.92 (br s, 1 H, NH). 
13C-NMR (100 MHz, CDCl3): δ = 31.6 (t, C-7), 170.2 (s, C-3). 
HRMS (CI):    calculated found 
C12H20F3NO4 [M]
+   299.1339 299.1336 
Optical rotation:    [𝛼]𝐷
20 = –21.1° (c = 1.0, CHCl3) 
 
TFA-(R)-Pip-OtBu (54) 
To a solution of 1.28 g (4.88 mmol) PPh3 in 175 mL THF abs. were added 0.96 mL (986 mg, 4.88 
mmol) DIAD dropwise at 0 °C. Afterwards, a solution of 908 mg (3.03 mmol) 53 in 75 mL THF 
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abs. was added dropwise within 1 h and the reaction was allowed to warm to rt overnight. The 
reaction was concentrated in vacuo and purified by column chromatography (silica gel, PE:EA 
100:0, 90:10, 80:20) to give 461 mg (1.64 mmol, rotameric ratio 74:26, 54 %) of amino acid ester 
54 as a slightly yellow liquid. The product contained appr. 6 % of tert-butyl 2-(2,2,2-trifluoroa-
cetamido)hex-5-enoate and an unknown side product. 
Rf (54) = 0.62 (silica gel, PE:EA 70:30) 
 
 
Major rotamer: 
1H-NMR (400 MHz, CDCl3): δ = 1.31 – 1.53 (m, 2 H, 6-Ha, 7-Ha), 1.47 (s, 9 H, 1-H), 1.60 – 1.79 
(m, 3 H, 5-Ha, 6-Hb, 7-Hb), 2.31 (d, 
2/3J5b,5a/6/4 = 13.9 Hz, 1 H, 5-Hb), 3.33 (ddd, 
2J8ax,8eq = 13.4 Hz, 
3J8ax,7ax = 13.4 Hz, 
3J8ax,7eq = 2.8 Hz, 1 H, 8-Hax), 3.91 (d, 
2J8eq,8ax = 13.8 Hz, 1 H, 8-Heq), 5.13 (d, 
3J4,5a = 5.8 Hz, 1 H, 4-H). 
13C-NMR (100 MHz, CDCl3): δ = 20.7 (t, C-6), 25.1 (t, C-7), 26.5 (t, C-5), 27.9 (q, C-1), 43.6 (qt, 
3J8,F = 4 Hz, C-8), 53.9 (d, C-4), 82.4 (s, C-2), 116.5 (q, 
1J10,F = 288 Hz, C-10), 156.9 (q, 
2J9,F = 36 
Hz, C-9), 168.6 (s, C-3). 
Minor rotamer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.48 (s, 9 H, 1-H), 2.98 (ddd, 2J8ax,8eq = 13.3 Hz, 3J8ax,7ax = 13.3 
Hz, 3J8ax,7eq = 3.3 Hz, 1 H, 8-Hax), 4.42 (d, 
2J8eq,8ax = 13.5 Hz, 1 H, 8-Heq), 4.58 (d, 
3J4,5a = 5.1 Hz, 
1 H, 4-H). 
13C-NMR (100 MHz, CDCl3): δ = 20.5 (t, C-6), 24.3 (t, C-7), 26.7 (t, C-5), 27.9 (q, C-1), 41.1 (t, 
C-8), 56.5 (qd, 3J4,F = 4 Hz, C-4), 82.8 (s, C-2), 168.7 (s, C-3). 
HRMS (CI):    calculated found 
C12H19F3NO3 [M+H]
+   282.1312 282.1333 
Optical rotation:    [𝛼]𝐷
20 = +47.7° (c = 1.0, CHCl3) 
 
Cbz-(S)-Phe-(R)-Pip-OtBu (55) 
A solution of 420 mg (1.49 mmol) 54 in 7.5 mL EtOH was treated with 114 mg (3.01 mmol) 
NaBH4 at 0 °C. The cooling bath was removed and the reaction was stirred at rt for 45 min. Ace-
tone was added and stirring was continued for 15 min. The reaction was concentrated in vacuo and 
the residue was dissolved in DCM and 10 w% K2CO3 sol. was added. The layers were separated 
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and the aqueous phase was extracted three times with DCM. The combined organic phases were 
dried over Na2SO4 and concentrated in vacuo. 
The crude product was redissolved in 12.0 mL MeCN and 491 mg (1.64 mmol) Cbz-(S)-Phe-OH 
were added at rt. Afterwards, 530 mg (1.65 mmol) TBTU and 300 µL (222 mg, 1.72 mmol) DIPEA 
were added slowly and the reaction was stirred at rt for 5 h. The reaction mixture was concentrated 
in vacuo and the residue was redissolved in DCM. 1 M HCl sol. was added and the layers were 
separated. The aqueous phase was extracted three times with DCM, the combined organic phases 
were washed with sat. NaHCO3 sol. and dried over Na2SO4. The crude product was purified by 
column chromatography (silica gel, PE:EA 100:0, 90:10, 80:20, 50:50) to yield 216 mg (0.463 
mmol, dr 89:11, 31 % over two steps) of a diastereomeric mixture and 284 mg (0.609 mmol, dr 
97:3, rotameric ratio 80:20, 41 % over two steps) of pure 55 as colourless oils. 
Rf (55) = 0.55 (silica gel, PE:EA 50:50) 
 
Major rotamer: 
1H-NMR (400 MHz, CDCl3): δ = 0.61 (m, 1 H, 7-Ha), 1.22 (m, 1 H, 6-Ha), 1.31 – 1.45 (m, 2 H, 
5-Heq, 7-Hb), 1.42 (s, 9 H, 1-H), 1.55 (m, 1 H, 6-Hb), 2.16 (d, 
2/3J5ax,5eq/6ax/4 = 14.3 Hz, 1 H, 5-Hax), 
3.01 (m, 2 H, 11-H), 3.14 (ddd, 2J8ax,8eq = 13.2 Hz, 
3J8ax,7ax = 13.2 Hz, 
3J8ax,7eq = 2.9 Hz, 1 H, 8-
Hax), 3.56 (d, 
2J8eq,8ax = 12.8 Hz, 1 H, 8-Heq), 4.98 (dt, 
3J10,NH = 8.0 Hz, 
3J10,11 = 6.4 Hz, 1 H, 10-
H), 5.09 (m, 2 H, 17-H), 5.11 (m, 1 H, 4-H), 5.70 (d, 3JNH,10 = 8.3 Hz, 1 H, NH), 7.13 – 7.37 (m, 
10 H, 13-H, 14-H, 15-H, 19-H, 20-H, 21-H). 
13C-NMR (100 MHz, CDCl3): δ = 20.5 (t, C-6), 24.4 (t, C-7), 26.5 (t, C-5), 28.0 (q, C-1), 40.4 (t, 
C-11), 43.6 (t, C-8), 51.5 (d, C-10), 52.9 (d, C-4), 66.7 (t, C-17), 81.6 (s, C-2), 126.9 (d, C-15), 
127.9 (d, C-19), 128.0 (d, C-21), 128.5 (d, C-14 o. C-20), 128.5 (d, C-14 o. C-20), 129.6 (d, C-
13), 136.2 (s, C-12), 136.5 (s, C-18), 155.4 (s, C-16), 169.7 (s, C-3), 171.0 (s, C-9). 
Minor rotamer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.49 (s, 9 H, 1-H), 1.71 (m, 1 H, 5-Ha), 2.27 (d, 2/3J5b,5a/6/4 = 13.7 
Hz, 1 H, 5-Hb), 2.76 (dd, 
2J11a,11b = 13.9 Hz, 
3J11a,10 = 7.6 Hz, 1 H, 11-Ha), 2.86 (m, 1 H, 8-Ha), 
4.56 (d, 2/3J8b,8a/7 = 15.0 Hz, 1 H, 8-Hb), 4.80 (d, 
3J4,5a/b = 5.0 Hz, 1 H, 4-H), 4.85 (m, 1 H, 10-H), 
5.53 (d, 3JNH,10 = 8.6 Hz, 1 H, NH (Phe)). 
13C-NMR (100 MHz, CDCl3): δ = 20.9 (t, C-6), 24.7 (t, C-7), 27.3 (t, C-5), 28.0 (q, C-1), 126.8 
(d, C-15), 128.3 (d, C-14 o. C-20), 129.5 (d, C-13). 
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HRMS (CI):    calculated found 
C27H35N2O5 [M+H]
+   467.2540 467.2554 
Optical rotation:    [𝛼]𝐷
20 = +47.3° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 90:10, 1.0 mL/min, 20 °C: 
tR1 = 24.8 min (minor), 
tR2 = 31.3 min (major). 
 
Cbz-(S)-Phe-(S)-Phe-(R)-Pip-OtBu (56) 
To a solution of 451 mg (0.967 mmol) 55 in 7.75 mL MeOH was added 45 mg palladium on 
charcoal (10 w% Pd) at rt and the reaction was hydrogenated for 5.5 h. The mixture was then 
filtrated through a pad of Celite® and washed with MeOH. The filtrate was concentrated in vacuo 
and the crude product was redissolved in 7.75 mL MeCN. 319 mg (1.07 mmol) Cbz-Phe-OH, 343 
mg (1.07 mmol) TBTU and 0.19 mL (141 mg, 1.09 mmol) DIPEA were added subsequently and 
the reaction was stirred at rt overnight. The reaction mixture was concentrated in vacuo and the 
residue was redissolved in DCM. 1 M HCl sol. was added, the layers were separated and the aque-
ous phase was extracted three times with DCM. The combined organic phases were washed with 
sat. NaHCO3 sol. and dried over Na2SO4. Purification by column chromatography (silica gel, 
PE:EA 100:0, 80:20, 50:50) gave 479 mg (0.780 mmol, dr 89:11, rotameric ratio 79:21, 81 % over 
two steps) of tripeptide 56 as an off-white solid. 
Rf (56) = 0.42 (silica gel, PE:EA 50:50) 
 
Major diastereomer/rotamer: 
1H-NMR (400 MHz, CDCl3): δ = 0.63 (ddddd, 3J24ax,23ax ≈ 3J24ax,25ax = 13.1 Hz, 2J24ax,24eq = 13.0 
Hz, 3J24ax,23eq ≈ 3J24ax,25eq = 4.1 Hz, 1 H, 24-Hax), 1.22 (m, 1 H, 23-Ha), 1.32 - 1.46 (m, 2 H, 22-Ha, 
24-Heq), 1.43 (s, 9 H, 28-H), 1.55 (m, 1 H, 23-Hb), 2.15 (d, 
2/3J22b,22a/23/21 = 13.6 Hz, 1 H, 22-Hb), 
2.95 (d, 3J15,14 = 6.5 Hz, 2 H, 15-H), 3.04 (m, 2 H, 8-H), 3.13 (ddd, 
2J25ax,25eq ≈ 3J25ax,24ax = 13.2 
Hz, 3J25ax,24eq = 2.9 Hz, 1 H, 25-Hax), 3.51 (d, 
2J25eq,25ax = 12.5 Hz, 1 H, 25-Heq), 4.44 (m, 1 H, 7-
H), 5.00 - 5.12 (m, 3 H, 5-H, 21-H), 5.16 (td, 3J14,15 = 7.4 Hz, 
3J14,NH = 6.7 Hz, 1 H, 14-H), 5.26 
(d, 3JNH,7 = 7.6 Hz, 1 H, NHb), 6.74 (d, 
3JNH,14 = 7.3 Hz, 1 H, NHa), 7.08 - 7.17 (m, 4 H, 10-H, 17-
H), 7.17 - 7.38 (m, 11 H, 1-H, 2-H, 3-H, 11-H, 12-H, 18-H, 19-H). 
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13C-NMR (100 MHz, CDCl3): δ = 20.5 (t, C-23), 24.4 (t, C-24), 26.6 (t, C-22), 28.0 (q, C-28), 
38.4 (t, C-8), 39.8 (t, C-15), 43.5 (t, C-25), 50.0 (d, C-14), 52.9 (d, C-21), 55.9 (d, C-7), 66.9 (t, 
C-5), 81.6 (s, C-27), 127.0 (d, C-12, C-19), 128.0 (d, C-3), 128.1 (d, C-1), 128.4 (d, C-2 o. C-11 
o. C-18), 128.5 (d, C-2 o. C-11 o. C-18), 128.6 (d, C-2 o. C-11 o. C-18), 129.4 (d, C-10 o. C-17), 
129.6 (d, C-10 o. C-17), 136.0 (s, C-9), 136.0 (s, C-16), 136.1 (s, C-4), 155.7 (s, C-6), 169.5 (s, C-
13), 169.8 (s, C-20), 170.4 (s, C-26). 
Minor diastereomer/rotamer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.44 (s, 9 H, 28-H), 1.49 (s, 9 H, 28-H), 1.71 (m, 1 H, 23-Hb), 
2.27 (d, 2/3J22b,22a/23/21 = 13.2 Hz, 1 H, 22-Hb), 2.74 (dd, 
2J15a,15b = 14.2 Hz, 
3J15a,14 = 7.4 Hz, 1 H, 
15-Ha), 4.36 (m, 1 H, 7-H), 4.52 (m, 1 H, 7-H), 4.64 (m, 1 H, 14-H), 4.79 (d, 
3J21,22a/b = 4.8 Hz, 1 
H, 21-H), 6.25 (br s, 1 H, Cbz-NH), 6.41 (d, 3JNH,14 = 8.0 Hz, 1 H, NH (Phe)), 6.68 (d, 
3JNH,14 = 
8.1 Hz, 1 H, NH (Phe)). 
13C-NMR (100 MHz, CDCl3): δ = 28.0 (q, C-28), 128.3 (d, C-1), 128.8 (d, C-2 o. C-11 o. C-18), 
129.2 (d, C-2 o. C-11 o. C-18), 129.3 (d, C-10 o. C-17), 129.6 (d, C-10 o. C-17). 
HRMS (CI):    calculated found 
C36H44N3O6 [M+H]
+   614.3225 614.3230 
Melting point:   66-67 °C 
Optical rotation:   [∝]𝐷
20 = +22.1° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 60:40, 1.0 mL/min, 20 °C: 
tR1 = 11.1 min (11 %), 
tR2 = 13.8 min (89 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.8 mL/min, tR = 10.9 min 
([M+H]+ = 614). 
 
tert-Butyl (R)-1-(((S,E)-2-(((benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-
propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enoyl)-L-phenylalanyl-L-phenylalanyl)-
piperidine-2-carboxylate (57) 
A solution of 245 mg (0.399 mmol) 56 in 2.0 mL MeOH was treated with 25 mg palladium on 
charcoal (10 w% Pd) and hydrogenated at rt for 5 h. The reaction mixture was filtrated through a 
pad of Celite® and washed with MeOH. The filtrate was concentrated in vacuo and the crude prod-
uct was dissolved in 3.2 mL acetonitrile at rt. 225 mg (0.399 mmol) 10, 128 mg (0.399 mmol) 
TBTU and 73 µL (54.0 mg, 0.418 mmol) DIPEA were added subsequently and the reaction was 
stirred at rt overnight. The reaction was concentrated in vacuo and the residue was redissolved in 
DCM. 1 M HCl sol. was added, the layers were separated and the aqueous phase was extracted 
three times with DCM. The combined organic layers were washed with sat. NaHCO3 sol. and dried 
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over Na2SO4. After purification by column chromatography (silica gel, PE:EA 100:0, 80:20, 
50:50), 360 mg (0.351 mmol, dr ~ 80:20, 88 % over two steps) of tetrapeptide 57 were obtained 
as an off-white solid. 
Rf (57) = 0.45 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.61 (m, 1 H, 38-Ha), 1.00 – 1.13 (m, 21 H, 18-H, 19-H), 1.33 
– 1.48 (m, 2 H, 36-Ha, 38-Hb), 1.35 (s, 3 H, 16-H), 1.38 (s, 3 H, 16-H'), 1.44 (s, 9 H, 42-H), 1.50 
– 1.76 (m, 4 H, 12-H, 37-H), 2.03 – 2.29 (m, 3 H, 11-H, 36-Hb), 2.39 (dd, 3J8,7 ≈ 3J8,9 = 6.0 Hz, 2 
H, 8-H), 2.87 – 3.03 (m, 3 H, 22-Ha, 29-H), 3.07 (dd, 2J22b,22a = 14.1 Hz, 3J22b,21 = 6.1 Hz, 1 H, 22-
Hb), 3.15 (ddd, 
2J39ax,39eq ≈ 3J39ax,38ax = 13.2 Hz, 3J39ax,38eq = 2.9 Hz, 1 H, 39-Hax), 3.51 (d, 2J39eq,39ax 
= 13.5 Hz, 1 H, 39-Heq), 3.68 (m, 1 H, 14-H), 3.73 (dd, 
2J17a,17b = 10.1 Hz, 
3J17a,14 = 5.9 Hz, 1 H, 
17-Ha), 3.85 (dd, 
2J17b,17a = 10.1 Hz, 
3J17b,14 = 3.9 Hz, 1 H, 17-Hb), 3.90 (td, 
3J13,12 = 7.9 Hz, 
3J13,14 
= 3.4 Hz, 1 H, 13-H), 4.15 (m, 1 H, 7-H), 4.64 (dt, 3J21,NH = 7.6 Hz, 
3J21,22 = 6.6 Hz, 1 H, 21-H), 
5.04 – 5.13 (m, 4 H, 5-H, 35-H, NHc), 5.15 (dt, 3J28,NH ≈ 3J28,29 = 7.3 Hz, 1 H, 28-H), 5.26 (m, 1 
H, 9-H), 5.51 (dt, 3J10,9 = 14.7 Hz, 
3J10,11 = 7.2 Hz, 1 H, 10-H), 6.61 (d, 
3JNH,21 = 7.7 Hz, 1 H, NHb), 
6.68 (d, 3JNH,28 = 7.5 Hz, 1 H, NHa), 7.09 – 7.16 (m, 4 H, 24-H, 31-H), 7.18 – 7.28 (m, 6 H, 25-H, 
26-H, 32-H, 33-H), 7.30 – 7.40 (m, 5 H, 1-H, 2-H, 3-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-18), 17.9 (q, C-19), 20.5 (t, C-37), 24.4 (t, C-38), 
26.7 (t, C-36), 27.0 (q, C-16), 27.4 (q, C-16'), 28.0 (q, C-42), 29.2 (t, C-11), 33.1 (t, C-12), 35.3 
(t, C-8), 38.2 (t, C-22), 39.8 (t, C-29), 43.5 (t, C-39), 50.0 (d, C-28), 52.9 (d, C-35), 54.1 (d, C-7), 
54.1 (d, C-21), 64.1 (t, C-17), 67.2 (t, C-5), 78.6 (d, C-13), 80.8 (d, C-14), 81.6 (s, C-41), 108.4 
(s, C-15), 124.3 (d, C-9), 127.0 (d, C-26, C-33), 128.1 (d, C-3), 128.2 (d, C-1), 128.5 (d, C-2 o. C-
25 o. C-32), 128.5 (d, C-2 o. C-25 o. C-32), 128.6 (d, C-2 o. C-25 o. C-32), 129.3 (d, C-24), 129.6 
(d, C-31), 135.0 (d, C-10), 136.0 (s, C-4), 136.1 (s, C-23, C-30), 156.1 (s, C-6), 169.3 (s, C-27), 
169.6 (s, C-40), 170.3 (s, C-34), 170.7 (s, C-20). 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.47 (s, 9 H, 42-H), 2.33 (dd, 3J8,7 ≈ 3J8,9 = 6.4 Hz, 2 H, 8-H), 
2.77 (m, 1 H, 29-Ha), 4.07 (t, 
3J7,8 = 6.2 Hz, 1 H, 7-H), 4.36 (dt, 
3J21,NH = 7.6 Hz, 
3J21,22 = 5.5 Hz, 
1 H, 21-H), 4.52 (m, 1 H, 28-H), 4.78 (d, 3J35,36a = 4.9 Hz, 1 H, 35-H), 6.43 (d, 
3JNH,21 = 7.8 Hz, 1 
H, NHb), 6.52 (d, 
3JNH,28 = 7.1 Hz, 1 H, NHa), 7.06 (m, 2 H, 24-H o. 31-H). 
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HRMS (CI):    calculated found 
C58H85N4O10Si [M+H]
+  1025.6029 1025.6059 
Melting point:   68 °C 
Optical rotation:   [∝]𝐷
20 = +9.5° (c = 1.0, CHCl3) 
 
tert-Butyl (R)-1-(((S,E)-2-(((benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-((tosyl-
oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enoyl)-L-phenylalanyl-L-phenylalanyl)piperidine-2-
carboxylate (58) 
331 mg (0.323 mmol) 57 were dissolved in 3.2 mL THF and treated with 484 µL (0.484 mmol) 
TBAF (1 M in THF) at rt. The reaction was stirred for 1.5 h and concentrated in vacuo. The residue 
was redissolved in DCM and water was added. The layers were separated and the aqueous phase 
was extracted three times with DCM. The combined organic phases were dried over Na2SO4 and 
concentrated in vacuo. The crude product was dissolved in 3.2 mL pyridine abs. and cooled to 
0 °C. Afterwards, 5.0 mg (40.9 µmol) 4-DMAP and 96.0 mg (0.504 mmol) TosCl were added and 
the reaction was allowed to warm to rt overnight. Further 36 mg (0.189 mmol) TosCl were added 
and stirring was continued for 3.5 h. For workup, the reaction was diluted with Et2O and 1 M HCl 
sol. was added. The layers were separated and the aqueous phase was extracted three times with 
Et2O. The combined organic phases were washed with 1 M HCl sol. three times and dried over 
Na2SO4. Purification of the crude product by column chromatography (silica gel, PE:EA 100:0, 
80:20, 50:50) gave 264 mg (0.258 mmol, dr ~ 78:22, 80 % over two steps) of tosylate 58 as an 
off-white solid. 
Rf (58) = 0.29 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 0.62 (m, 1 H, 41-Ha), 1.18 (m, 1 H, 40-Ha), 1.27 (s, 3 H, 16-H), 
1.33 (s, 3 H, 16-H'), 1.37 – 1.48 (m, 2 H, 39-Ha, 41-Hb), 1.44 (s, 9 H, 45-H), 1.51 – 1.60 (m, 3 H, 
12-H, 40-Hb), 1.96 – 2.18 (m, 3 H, 11-H, 39-Hb), 2.36 (m, 2 H, 8-H), 2.44 (s, 3 H, 22-H), 2.89 – 
3.04 (m, 3 H, 25-Ha, 32-H), 3.08 (dd, 
2J25b,25a = 13.9 Hz, 
3J25b,24 = 6.5 Hz, 1 H, 25-Hb), 3.15 (ddd, 
2J42ax,42eq ≈ 3J42ax,41ax = 13.1 Hz, 3J42ax,41eq = 2.5 Hz, 1 H, 42-Hax), 3.52 (d, 2J42eq,42ax = 13.3 Hz, 1 
H, 42-Heq), 3.72 – 3.82 (m, 2 H, 13-H, 14-H), 4.03 (dd, 2J17a,17b = 10.7 Hz, 3J17a,14 = 4.3 Hz, 1 H, 
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17-Ha), 4.08 (dd, 
2J17b,17a = 10.6 Hz, 
3J17b,14 = 4.1 Hz, 1 H, 17-Hb), 4.16 (m, 1 H, 7-H), 4.64 (dt, 
3J24,NH = 7.5 Hz, 
3J24,25 = 6.6 Hz, 1 H, 24-H), 4.97 – 5.32 (m, 6 H, 5-H, 9-H, 31-H, 38-H, NHc), 
5.48 (dt, 3J10,9 = 14.6 Hz, 
3J10,11 = 6.9 Hz, 1 H, 10-H), 6.59 (d, 
3JNH,24 = 7.5 Hz, 1 H, NHb), 6.70 
(d, 3JNH,31 = 7.5 Hz, 1 H, NHa), 7.05 – 7.16 (m, 4 H, 27-H, 34-H), 7.17 – 7.28 (m, 6 H, 28-H, 29-
H, 35-H, 36-H), 7.29 – 7.39 (m, 7 H, 1-H, 2-H, 3-H, 20-H), 7.78 (d, 3J19,20 = 8.2 Hz, 2 H, 19-H). 
13C-NMR (100 MHz, CDCl3): δ = 20.5 (t, C-40), 21.6 (q, C-22), 24.4 (t, C-41), 26.7 (t, C-39), 
26.7 (q, C-16), 27.2 (q, C-16'), 28.0 (q, C-45), 28.8 (t, C-11), 32.5 (t, C-12), 35.4 (t, C-8), 38.2 (t, 
C-25), 39.8 (t, C-32), 43.5 (t, C-42), 50.0 (d, C-31), 52.9 (d, C-38), 54.1 (d, C-7, 24), 67.1 (t, C-
5), 69.1 (t, C-17), 77.2 (d, C-13), 77.9 (d, C-14), 81.6 (s, C-44), 109.4 (s, C-15), 124.9 (d, C-9), 
127.0 (d, C-29), 127.0 (d, C-36), 128.0 (d, C-19), 128.2 (d, C-3), 128.2 (d, C-1), 128.5 (d, C-2 o. 
C-28 o. C-35), 128.5 (d, C-2 o. C-28 o. C-35), 128.6 (d, C-2 o. C-28 o. C-35), 129.4 (d, C-27 o. 
C-34), 129.6 (d, C-27 o. C-34), 129.9 (d, C-20), 132.7 (s, C-18), 134.2 (d, C-10), 136.0 (s, C-4), 
136.1 (s, C-26), 136.1 (s, C-33), 145.0 (s, C-21), 169.3 (s, C-30), 169.6 (s, C-23), 170.3 (s, C-37), 
170.7 (s, C-43). The signal of C-6 wasn’t observed in the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.50 (s, 9 H, 45-H), 2.78 (m, 1 H, 32-Ha), 4.36 (dt, 3J31,NH = 7.3 
Hz, 3J31,32 = 5.5 Hz, 1 H, 31-H), 4.52 (m, 1 H, 24-H), 4.78 (m, 1 H, 38-H), 6.43 (d, 
3JNH,24 = 7.7 
Hz, 1 H, NHb), 6.54 (d, 
3JNH,31 = 6.7 Hz, 1 H, NHa). 
HRMS (CI):    calculated found 
C56H71N4O12S [M+H]
+  1023.4784 1023.4785 
Melting point:   60 °C 
Optical rotation:   [∝]𝐷
20 = –2.8° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 15.6 min 
([M+H]+ = 1024). 
 
(R)-1-(((S,E)-2-(((Benzyloxy)carbonyl)amino)-7-((4S,5S)-2,2-dimethyl-5-((tosyloxy)methyl)-
1,3-dioxolan-4-yl)hept-4-enoyl)-L-phenylalanyl-L-phenylalanyl)piperidine-2-carboxylic 
acid (59) 
To a solution of 200 mg (0.195 mmol) 58 in 1.0 mL THF were added 1.0 mL HCl sol. (5 w% in 
H2O) at rt and the reaction was heated to 60 °C overnight. For workup, the reaction was diluted 
with DCM and brine was added. The layers were separated, the aqueous phase was extracted three 
times with DCM and the combined organic layers were dried over Na2SO4. The crude product was 
dissolved in 1.0 mL DCM abs. before 1.0 mL (1.48 g, 13.0 mmol) TFA was added dropwise. The 
reaction was stirred for 2 h at rt and concentrated in high-vacuo. The crude product was dissolved 
in 2.5 mL acetone and 2.8 mg (14.7 µmol) pTosOH·H2O were added. The reaction was heated to 
60 °C overnight and the reaction was concentrated in vacuo. After purification by column 
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chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5), 152 mg (0.157 mmol, 81 % over 
three steps) of acid 59 (contaminated with educt 58) were obtained as an off-white solid. 
Rf (59) = 0.08 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 0.68 (m, 1 H, 41-Ha), 1.14 – 1.45 (m, 3 H, 39-Ha, 40-Ha, 41-
Hb), 1.27 (s, 3 H, 16-H), 1.33 (s, 3 H, 16-H'), 1.47 – 1.62 (m, 3 H, 12-H, 40-Hb), 2.03 (m, 2 H, 11-
H), 2.20 (d, 2/3J39b,39a/38/40ax = 12.7 Hz, 1 H, 39-Hb), 2.35 (m, 2 H, 8-H), 2.43 (s, 3 H, 22-H), 2.89 
(dd, 2J25a,25b = 14.0 Hz, 
3J25a,24 = 7.3 Hz, 1 H, 25-Ha), 2.94 – 3.18 (m, 4 H, 25-Hb, 32-H, 42-Hax), 
3.56 (d, 2J42eq,42ax = 13.8 Hz, 1 H, 42-Heq), 3.69 – 3.82 (m, 2 H, 13-H, 14-H), 4.02 (dd, 2J17a,17b = 
10.7 Hz, 3J17a,14 = 4.5 Hz, 1 H, 17-Ha), 4.07 (dd, 
2J17b,17a = 10.6 Hz, 
3J17b,14 = 4.0 Hz, 1 H, 17-Hb), 
4.17 (m, 1 H, 7-H), 4.80 (dt, 3J24,NH = 7.4 Hz, 
3J24,25 = 6.0 Hz, 1 H, 24-H), 4.98 – 5.27 (m, 4 H, 5-
H, 9-H, 31-H, 38-H), 5.32 – 5.49 (m, 2 H, 10-H, NHc), 6.86 (d, 3JNH,24 = 7.5 Hz, 1 H, NHb), 7.06 
(d, 3J27,28 = 7.0 Hz, 2 H, 27-H), 7.10 – 7.37 (m, 15 H, 1-H, 2-H, 3-H, 20-H, 28-H, 29-H, 34-H, 35-
H, 36-H), 7.50 (d, 3JNH,31 = 7.6 Hz, 1 H, NHa), 7.77 (d, 
3J19,20 = 8.2 Hz, 2 H, 19-H). The signal of 
-COOH wasn’t observed in the 13C-NMR spectrum. 
13C-NMR (100 MHz, CDCl3): δ = 20.4 (t, C-40), 21.6 (q, C-22), 24.3 (t, C-41), 26.0 (t, C-39), 
26.6 (q, C-16), 27.2 (q, C-16'), 28.7 (t, C-11), 32.4 (t, C-12), 35.5 (t, C-8), 38.3 (t, C-25), 39.4 (t, 
C-32), 43.8 (t, C-42), 50.3 (d, C-31), 52.6 (d, C-38), 53.9 (d, C-24), 54.5 (d, C-7), 67.1 (t, C-5), 
69.1 (t, C-17), 77.2 (d, C-13), 77.9 (d, C-14), 109.4 (s, C-15), 128.8 (d, C-9), 126.9 (d, C-29), 
127.0 (d, C-36), 128.0 (d, C-19), 128.1 (d, C-3), 128.2 (d, C-1), 128.4 (d, C-2 o. C-28 o. C-35), 
128.5 (d, C-2 o. C-28 o. C-35), 129.2 (d, C-2 o. C-28 o. C-35), 129.4 (d, C-27 o. C-34), 129.5 (d, 
C-27 o. C-34), 129.9 (d, C-20), 132.6 (s, C-18), 134.0 (d, C-10), 136.0 (s, C-4), 136.1 (s, C-26, C-
33), 145.0 (s, C-21), 156.1 (s, C-6), 170.3 (s, C-30), 171.3 (s, C-23 o. C-37), 173.1 (s, C-43). The 
signal of C-23/C-37 wasn’t observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C52H63N4O12S [M+H]
+  967.4158 967.4185 
Melting point:   73 °C 
Optical rotation:   [∝]𝐷
20 = –8.9° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.8 mL/min, tR1 = 10.4 min 
(23 %, [M+H]+ = 1024), tR2 = 10.8 min (77 %, [M+H]
+ = 968). 
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tert-Butyl (R,E)-(6-(benzyloxy)-2-(2,2,2-trifluoroacetamido)hex-4-enoyl)glycinate (61b) 
To a solution of 1.46 g (4.41 mmol) 51b in 20.0 mL DCM abs. were added 931 mg (4.86 mmol) 
EDC·HCl and 67.6 mg (0.441 mmol) HOBt at 0 °C. The reaction was stirred for 10 min at this 
temperature before 740 mg (4.42 mmol) HCl·H-Gly-OtBu and 0.77 mL (570 mg, 4.41 mmol) 
DIPEA were added subsequently and the reaction was allowed to warm to rt overnight. For 
workup, the reaction was diluted with DCM and 1 M HCl sol. was added. The layers were sepa-
rated and the aqueous phase was extracted three times with DCM. The combined organic layers 
were washed with sat. NaHCO3 sol. and dried over Na2SO4. Purification by column chromatog-
raphy (silica gel, PE:EA 100:0, 90:10, 70:30) gave 1.79 g (3.78 mmol, 94 % pure, er 76:24, 86 %) 
of dipeptide 61b as a yellow oil. 
Rf (61b) = 0.25 (silica gel, PE:EA 70:30) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.46 (s, 9 H, 1-H), 2.55 (ddd, 2J7a,7b = 13.8 Hz, 3J7a,6 ≈ 3J7a,8 = 
6.4 Hz, 1 H, 7-Ha), 2.64 (ddd, 
2J7b,7a = 13.9 Hz, 
3J7b,6 ≈ 3J7b,8 = 6.8 Hz, 1 H, 7-Hb), 3.90 (dd, 2J4a,4b 
= 18.1 Hz, 3J4a,NH = 5.0 Hz, 1 H, 4-Ha), 3.96 (dd, 
2J4b,4a = 18.1 Hz, 
3J4b,NH = 5.3 Hz, 1 H, 4-Hb), 
3.97 (d, 3J10,9 = 5.3 Hz, 2 H, 10-H), 4.48 (s, 2 H, 11-H), 4.57 (td, 
3J6,7 ≈ 3J6,NH = 6.9 Hz, 1 H, 6-H), 
5.66 (dt, 3J8,9 = 15.0 Hz, 
3J8,7 = 7.3 Hz, 1 H, 8-H), 5.77 (dt, 
3J9,8 = 15.5 Hz, 
3J9,10 = 5.5 Hz, 1 H, 9-
H), 6.57 (br s, 1 H, NHa), 7.27 – 7.34 (m, 5 H, 13-H, 14-H, 15-H), 7.42 (d, 3JNH,6 = 7.8 Hz, 1 H, 
NHb). 
13C-NMR (100 MHz, CDCl3): δ = 27.9 (q, C-1), 35.4 (t, C-7), 42.1 (t, C-4), 52.8 (d, C-6), 70.0 (t, 
C-10), 72.1 (t, C-11), 82.8 (s, C-2), 115.6 (q, 1J17,F = 287 Hz, C-17), 126.3 (d, C-8), 127.6 (d, C-
15), 127.7 (d, C-13), 128.4 (d, C-14), 132.1 (d, C-9), 138.1 (s, C-12), 156.8 (q, 2J16,F = 37 Hz, C-
16), 168.3 (s, C-3 o. C-5), 169.3 (s, C-3 o. C-5). 
HRMS (CI):    calculated found 
C21H28F3N2O5 [M]
+   445.1945 445.1943 
Optical rotation:    [𝛼]𝐷
20 = –13.9° (er 96:4, c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 95:5, 1.0 mL/min, 20 °C: 
(R)-61b: tR = 21.9 min (76 %), 
(S)-61b: tR = 26.2 min (24 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 7.26 min 
([M+Na]+ = 467). 
 
5. Experimental section 
 
 
163 
tert-Butyl (R,E)-(6-(benzyloxy)-2-(((benzyloxy)carbonyl)amino)hex-4-enoyl)glycinate (61c) 
To a solution of 2.10 g (5.68 mmol) 51a in 55 mL THF abs. were added 0.64 mL (589 mg, 5.82 
mmol) NMM before 0.75 mL (786 mg, 5.76 mmol) IBCF were added dropwise at –20 °C. The 
reaction was stirred for 10 min before 953 mg (5.69 mmol) HCl·H-Gly-OtBu and further 0.64 mL 
(589 mg, 5.82 mmol) NMM were added and the reaction was allowed to warm to rt overnight. The 
reaction was then filtrated and washed with diethyl ether. The filtrate was concentrated in vacuo 
and redissolved in Et2O. 1 M HCl sol. was added and the layers were separated. The aqueous phase 
was extracted three times with Et2O. The combined organic layers were washed with sat. NaHCO3 
sol. and dried over Na2SO4. The crude product was purified by column chromatography (silica gel, 
PE:EA 90:10, 70:30). 2.47 g (5.12 mmol, er > 99:1, 90 %) of 61c were obtained as a slightly 
yellow oil. 
Rf (61c) = 0.32 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.46 (s, 9 H, 1-H), 2.55 (m, 2 H, 7-H), 3.91 (m, 2 H, 4-H), 3.96 
(m, 2 H, 10-H), 4.28 (m, 1 H, 6-H), 4.47 (s, 2 H, 11-H), 5.10 (s, 2 H, 17-H), 5.35 (d, 3JNH,6 = 6.0 
Hz, 1 H, NHb), 5.62 – 5.75 (m, 2 H, 8-H, 9-H), 6.55 (br s, 1 H, NHa), 7.26 – 7.35 (m, 10 H, 13-H, 
14-H, 15-H, 19-H, 20-H, 21-H). 
13C-NMR (100 MHz, CDCl3): δ = 28.0 (q, C-1), 35.4 (t, C-7), 42.0 (t, C-4), 54.2 (d, C-6), 67.2 (t, 
C-17), 70.2 (t, C-10), 72.1 (t, C-11), 82.4 (s, C-2), 127.6 (d, C-15 o. C-21), 127.8 (d, C-8), 127.8 
(d, C-13), 128.1 (d, C-19), 128.2 (d, C-15 o. C-21), 128.4 (d, C-14 o. C-20), 128.5 (d, C-14 o. C-
20), 131.3 (d, C-9), 136.0 (s, C-18), 138.1 (s, C-12), 156.0 (s, C-16), 168.6 (s, C-3), 170.9 (s, C-
5). 
HRMS (CI):    calculated found 
C27H35N2O6 [M+H]
+   483.2490 483.2493 
Optical rotation:    [𝛼]𝐷
20 = +0.8° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 80:20, 1.0 mL/min, 20 °C: 
(R)-61c: tR = 33.8 min (> 99 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 12.5 min 
([M+Na]+ = 505). 
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tert-Butyl (R)-(6-(benzyloxy)-2-(2,2,2-trifluoroacetamido)hexanoyl)glycinate (62c) 
To a solution of 1.60 g (3.32 mmol) 61c in 15 mL MeOH were added 163 mg palladium on char-
coal (10 w% Pd) at rt. The reaction was set under a H2-atmossphere and hydrogenated for 4 h. 
Afterwards, the reaction was filtrated through a pad of Celite® and washed with MeOH. The filtrate 
was concentrated in vacuo and redissolved in 15 mL MeOH. 0.67 mL (853 mg, 6.66 mmol) TFA-
OMe were added at 0 °C and the reaction was allowed to warm to rt overnight. The reaction mix-
ture was concentrated and redissolved in Et2O. 1 M HCl sol. was added and the layers were sepa-
rated. The aqueous phase was extracted three times with diethyl ether and the combined organic 
layers were dried over Na2SO4. Purification by column chromatography (silica gel, PE:EA 70:30) 
gave 1.32 g (2.96 mmol, er 95:5, 89 %) dipeptide 62c as a colourless oil. 
Rf (62c) = 0.48 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.47 (s, 9 H, 1-H), 1.49 (m, 2 H, 8-H), 1.62 – 1.79 (m, 3 H, 7-
Ha, 9-H), 1.94 (m, 1 H, 7-Hb), 3.48 (dt, 
2J10a,10b = 9.4 Hz, 
3J10a,9 = 6.2 Hz, 1 H, 10-Ha), 3.53 (dt, 
2J10b,10a = 9.5 Hz, 
3J10b,9 = 6.0 Hz, 1 H, 10-Hb), 3.73 (dd, 
2J4a,4b = 18.3 Hz, 
3J4a,NH = 4.8 Hz, 1 H, 4-
Ha), 3.91 (dd, 
2J4b,4a = 18.2 Hz, 
3J4b,NH = 5.7 Hz, 1 H, 4-Hb), 4.49 (s, 2 H, 11-H), 4.50 (m, 1 H, 6-
H), 6.36 (t, 3J4,NH = 4.9 Hz, 1 H, NHa), 7.25 – 7.37 (m, 6 H, 13-H, 14-H, 15-H, NHb). 
13C-NMR (100 MHz, CDCl3): δ = 22.0 (t, C-8), 28.0 (q, C-1), 28.8 (t, C-9), 32.5 (t, C-7), 42.0 (t, 
C-4), 53.1 (d, C-6), 70.0 (t, C-10), 73.0 (t, C-11), 82.7 (s, C-2), 115.7 (q, 1J17,F = 288 Hz, C-17), 
127.7 (d, C-15), 127.8 (d, C-13 o. C-14), 128.4 (d, C-13 o. C-14), 138.2 (s, C-12), 156.8 (q, 2J16,F 
= 37 Hz, C-16), 168.3 (s, C-3 o. C-5), 169.9 (s, C-3 o. C-5). 
HRMS (CI):    calculated found 
C21H30F3N2O5 [M+H]
+  447.2101 447.2104 
Optical rotation:    [𝛼]𝐷
20 = –2.1° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 90:10, 1.0 mL/min, 20 °C: 
(R)-62c: tR = 11.2 min (95 %), 
(S)-62c: tR = 13.1 min (5 %). 
 
5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-3-yl 
methyl carbonate (65) 
To a solution of 732 mg (1.97 mmol) 7c in 2.0 mL pyridine were added 0.31 mL (379 mg, 4.02 
mmol) methyl chloroformate carefully at 0 °C. The reaction was allowed to warm to rt overnight 
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before further 0.46 mL (562 mg, 5.95 mmol) methyl chloroformate were added at 0 °C and stirring 
was continued for 3 h. For workup, water was added and the layers were separated. The aqueous 
phase was extracted three times with DCM and the combined organic layers were dried over 
Na2SO4. The crude product was purified by column chromatography (silica gel, PE:EA 100:0, 
90:10) to give 795 mg (1.85 mmol, 94 %) 65 as a colourless liquid. 
Rf (65) = 0.31 (silica gel, PE:EA 90:10) 
 
Diastereomer 1: 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.14 (m, 21 H, 1-H, 2-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.62 (m, 1 H, 8-Ha), 1.70 – 1.99 (m, 3 H, 8-Hb, 9-H), 3.70 (m, 1 H, 4-H), 3.73 (dd, 2J3a,3b 
= 9.8 Hz, 3J3a,4 = 6.5 Hz, 1 H, 3-Ha), 3.76 (s, 3 H, 14-H), 3.88 (m, 1 H, 3-Hb), 3.93 (m, 1 H, 5-H), 
5.09 (dt, 3J10,11 ≈ 3J10,9 = 6.2 Hz, 1 H, 10-H), 5.21 (ddd, 3J12a,11 = 10.5 Hz, 2J12a,12b ≈ 4J12a,10 = 1.0 
Hz, 1 H, 12-Ha), 5.30 (ddd, 
3J12b,11 = 17.3 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.1 Hz, 1 H, 12-Hb), 5.79 (ddd, 
3J11,12b = 17.3 Hz, 
3J11,12a = 10.5 Hz, 
3J11,10 = 7.3 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.3 (q, C-7'), 28.7 
(t, C-8), 30.6 (t, C-9), 54.6 (q, C-14), 64.2 (t, C-3), 78.8 (d, C-10), 79.0 (d, C-5), 80.8 (d, C-4), 
108.5 (s, C-6), 117.5 (t, C-12), 135.7 (d, C-11), 155.2 (s, C-13). 
Diastereomer 2 (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 5.22 (ddd, 3J12a,11 = 10.5 Hz, 2J12a,12b ≈ 4J12a,10 = 1.1 Hz, 1 H, 12-
Ha), 5.31 (ddd, 
3J12b,11 = 17.3 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.1 Hz, 1 H, 12-Hb), 5.79 (ddd, 3J11,12b = 17.3 
Hz, 3J11,12a = 10.5 Hz, 
3J11,10 = 6.8 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 29.0 (t, C-8), 30.9 (t, C-9), 78.9 (d, C-10), 79.2 (d, C-5), 80.8 
(d, C-4), 117.8 (t, C-12), 135.8 (d, C-11), 155.2 (s, C-13). 
HRMS (CI):    calculated found 
C22H43O6Si [M+H]
+   431.2823 431.2796 
 
5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-3-yl 
ethyl carbonate (66) 
A solution of 396 mg (1.06 mmol) 7c in 1.0 mL pyridine abs. was treated with 0.20 mL (226 mg, 
2.08 mmol) ethyl chloroformate dropwise at 0 °C. The reaction was allowed to warm to rt over-
night. For workup, the reaction was diluted with Et2O and 1 M CuSO4 sol. was added. The organic 
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phase was washed three times with 1 M CuSO4 sol. and dried over Na2SO4. Purification by column 
chromatography (silica gel, PE:EA 100:0, 90:10) gave 429 mg (0.965 mmol, 91 %) of carbonate 
66 as a colourless oil. 
Rf (66) = 0.40 (silica gel, PE:EA 90:10) 
 
 
Diastereomer 1: 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.16 (m, 21 H, 1-H, 2-H), 1.30 (t, 3J15,14 = 7.2 Hz, 3 H, 
15-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 H, 7'-H), 1.61 (m, 1 H, 8-Ha), 1.71 – 1.98 (m, 3 H, 8-Hb, 9-H), 
3.70 (m, 1 H, 4-H), 3.73 (dd, 2J3a,3b = 9.8 Hz, 
3J3a,4 = 6.3 Hz, 1 H, 3-Ha), 3.88 (dd, 
2J3b,3a = 9.5 Hz, 
3J3b,4 = 3.3 Hz, 1 H, 3-Hb), 3.93 (m, 1 H, 5-H), 4.18 (q, 
3J14,15 = 7.1 Hz, 2 H, 14-H), 5.08 (dt, 
3J10,11 
≈ 3J10,9 = 6.0 Hz, 1 H, 10-H), 5.20 (ddd, 3J12a,11 = 10.5 Hz, 2J12a,12b ≈ 4J12a,10 = 1.0 Hz, 1 H, 12-Ha), 
5.30 (ddd, 3J12b,11 = 17.3 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.1 Hz, 1 H, 12-Hb), 5.79 (ddd, 3J11,12b = 17.3 Hz, 
3J11,12a = 10.5 Hz, 
3J11,10 = 6.8 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 14.2 (q, C-15), 18.0 (q, C-1), 27.0 (q, C-7), 27.4 
(q, C-7'), 28.8 (t, C-8), 30.7 (t, C-9), 63.8 (t, C-14), 64.2 (t, C-3), 78.6 (d, C-10), 79.0 (d, C-5), 
80.8 (d, C-4), 108.5 (s, C-6), 117.5 (t, C-12), 135.8 (d, C-11), 154.6 (s, C-13). 
Diastereomer 2 (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 5.21 (ddd, 3J12a,11 = 10.5 Hz, 2J12a,12b ≈ 4J12a,10 = 1.0 Hz, 1 H, 12-
Ha), 5.31 (ddd, 
3J12b,11 = 17.3 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.1 Hz, 1 H, 12-Hb), 5.80 (ddd, 3J11,12b = 17.3 
Hz, 3J11,12a = 10.5 Hz, 
3J11,10 = 6.8 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 29.1 (t, C-8), 30.9 (t, C-9), 78.7 (d, C-10), 79.2 (d, C-5), 80.9 
(d, C-4), 110.0 (s, C-6), 117.7 (t, C-12), 135.9 (d, C-11), 154.6 (s, C-13). 
HRMS (CI):    calculated found 
C23H45O6Si [M+H]
+   445.2980 445.2978 
 
(R)-5-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-
3-yl ethyl carbonate ((3R)-66) 
2.18 g (5.85 mmol) allylic alcohol (3R)-7c were dissolved in 7.5 mL pyridine abs. and cooled to 
0 °C. Afterwards, 1.12 mL (1.27 g, 11.7 mmol) Ethyl chloroformate were added carefully and the 
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reaction was allowed to warm to rt within 5 h. For workup, the reaction mixture was diluted with 
Et2O and 1 M CuSO4 sol. was added. The layers were separated, the organic phase was washed 
three times with 1 M CuSO4 sol. and dried over Na2SO4. Purification by column chromatography 
(silica gel, PE:EA 100:0, 90:10) afforded 2.41 g (5.42 mmol, 93 %) allylic carbonate (3R)-66 as a 
colourless oil. 
Rf ((3R)-66) = 0.39 (silica gel, PE:EA 90:10) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.14 (m, 21 H, 1-H, 2-H), 1.30 (t, 3J15,14 = 7.2 Hz, 3 H, 
15-H), 1.36 (s, 3 H, 7-H), 1.39 (s, 3 H, 7-H’), 1.59 (m, 1 H, 8-Ha), 1.75 – 1.93 (m, 3 H, 8-Hb, 9-
H), 3.70 (m, 1 H, 4-H), 3.72 (dd, 2J3a,3b = 9.8 Hz, 
3J3a,4 = 6.4 Hz, 1 H, 3-Ha), 3.88 (dd, 
2J3b,3a = 9.5 
Hz, 3J3b,4 = 3.2 Hz, 1 H, 3-Hb), 3.91 (m, 1 H, 5-H), 4.18 (q, 
3J14,15 = 7.2 Hz, 2 H, 14-H), 5.08 (dt, 
3J10,11 ≈ 3J10,9 = 6.2 Hz, 1 H, 10-H), 5.20 (d, 3J12a,11 = 10.5 Hz, 1 H, 12-Ha), 5.30 (d, 3J12b,11 = 17.2 
Hz, 1 H, 12-Hb), 5.80 (ddd, 
3J11,12b = 17.2 Hz, 
3J11,12a = 10.5 Hz, 
3J11,10 = 6.7 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 14.2 (q, C-15), 17.9 (q, C-1), 27.0 (q, C-7), 27.4 
(q, C-7'), 29.1 (t, C-8), 30.9 (t, C-9), 63.8 (t, C-14), 64.2 (t, C-3), 78.6 (d, C-10), 79.2 (d, C-5), 
80.9 (d, C-4), 108.5 (s, C-6), 117.5 (t, C-12), 135.9 (d, C-11), 154.6 (s, C-13). 
HRMS (CI):    calculated found 
C23H45O6Si [M+H]
+   445.2980 445.2990 
Optical rotation:   [∝]𝐷
20 = –3.5° (c = 1.0, CHCl3) 
 
5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-3-yl 
diethyl phosphate (67) 
195 mg (0.523 mmol) 7c were dissolved in 2.0 mL DCM abs. before 0.11 mL (108 mg, 1.37 mmol) 
pyridine and 7.4 mg (60.6 µmol) 4-DMAP were added. After cooling to 0 °C, 94 µL (113 mg, 
0.655 mmol) diethyl chlorophosphate were added and the reaction was allowed to warm to rt over-
night. Further 56 µL (67.2 mg, 0.389 mmol) diethyl chlorophosphate were added and stirring was 
continued for 4.5 h. For workup, the reaction was diluted with DCM and water was added. The 
layers were separated and the aqueous phase was extracted three times with DCM. The combined 
organic layers were washed with brine and dried over Na2SO4. After purification by column chro-
matography (silica gel, PE:EA 100:0, 80:20, 70:30), 199 mg (0.391 mmol, 75 %) of 67 were ob-
tained as a colourless oil. 
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Rf (67) = 0.14 (silica gel, PE:EA 70:30) 
 
Diastereomer 1: 
1H-NMR (400 MHz, CDCl3): δ = 1.03 – 1.14 (m, 21 H, 1-H, 2-H), 1.31 (dt, 3J14,13 = 7.0 Hz, 4J14,P 
= 4.8 Hz, 6 H, 14-H), 1.36 (s, 3 H, 7-H), 1.38 (s, 3 H, 7'-H), 1.50 – 2.05 (m, 4 H, 8-H, 9-H), 3.70 
(m, 1 H, 4-H), 3.74 (m, 1 H, 3-Ha), 3.86 (m, 1 H, 3-Hb), 3.92 (dt, 
3J5,8 = 7.3 Hz, 
3J5,4 = 3.4 Hz, 1 
H, 5-H), 4.09 (m, 2 H, 13-H), 5.08 (ddt, 3J10,P = 12.9 Hz, 
3J10,11 ≈ 3J10,9 = 6.5 Hz, 1 H, 10-H), 5.21 
(dd, 3J12a,11 = 10.5 Hz, 1 H, 12-Ha), 5.32 (ddd, 
3J12b,11 = 17.1 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.3 Hz, 1 H, 
12-Hb), 5.82 (ddd, 
3J11,12b = 17.3 Hz, 
3J11,12a = 10.3 Hz, 
3J11,10 = 70. Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 16.1 (dq, 3J14,P = 2 Hz, C-14), 17.9 (q, C-1), 27.0 
(q, C-7), 27.4 (q, C-7'), 28.6 (t, C-8), 32.3 (dt, 3J9,P = 7 Hz, C-9), 63.5 (dt, 
2J13,P = 3 Hz, C-13), 
64.1 (t, C-3), 78.7 (d, C-5), 79.5 (dd, 2J10,P = 7 Hz, C-10), 80.9 (d, C-4), 108.5 (s, C-6), 117.4 (t, 
C-12), 135.6 (dd, 3J11,P = 3 Hz, C-11). 
Diastereomer 2 (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 5.83 (ddd, 3J11,12b = 17.1 Hz, 3J11,12a = 10.3 Hz, 3J11,10 = 6.8 Hz, 
1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 16.1 (dq, 3J14,P = 3 Hz, C-14), 27.4 (q, C-7'), 32.3 (dt, 3J9,P = 7 
Hz, C-9), 63.6 (dt, 2J13,P = 3 Hz, C-13), 64.2 (t, C-3), 78.9 (d, C-5), 79.5 (dd, 
2J10,P = 6 Hz, C-10), 
81.0 (d, C-4), 117.6 (t, C-12), 136.7 (dd, 3J11,P = 3 Hz, C-11). 
HRMS (CI):    calculated found 
C24H50O7PSi [M+H]
+   509.3058 509.3062 
 
5-((4S,5S)-2,2-Dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)pent-1-en-3-yl 
benzoate (68) 
To a solution of 372 mg (0.998 mmol) 7c in 0.5 mL pyridine were added 0.23 mL (279 mg, 1.98 
mmol) benzoyl chloride dropwise at 0 °C. The reaction was stirred for 2 h. For workup, 60 µL 
(60.7 mg, 0.993 mmol) ethanolamine and Et2O were added and the reaction was stirred for 15 min. 
Afterwards, 1 M CuSO4 sol. was added and the layers were separated. The aqueous phase was 
extracted three times with Et2O and the combined organic layers were dried over Na2SO4. Purifi-
cation of the crude product by column chromatography (silica gel, PE:EA 100:0, 90:10, 80:20) 
afforded 474 mg (0.994 mmol, 99 %) of benzoate 68 as a colourless oil. 
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Rf (68) = 0.46 (silica gel, PE:EA 80:20) 
 
Diastereomer 1: 
1H-NMR (400 MHz, CDCl3): δ = 0.98 – 1.10 (m, 21 H, 1-H, 2-H), 1.37 (s, 3 H, 7-H), 1.39 (s, 3 
H, 7'-H), 1.61 – 2.07 (m, 4 H, 8-H, 9-H), 3.70 (m, 1 H, 4-H), 3.72 (m, 1 H, 3-Ha), 3.88 (m, 1 H, 3-
Hb), 3.96 (m, 1 H, 5-H), 5.20 (ddd, 
3J12a,11 = 10.5 Hz, 
2J12a,12b ≈ 4J12a,10 = 1.1 Hz, 1 H, 12-Ha), 5.33 
(ddd, 3J12b,11 = 17.3 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.3 Hz, 1 H, 12-Hb), 5.54 (dt, 3J10,11 ≈ 3J10,9 = 6.3 Hz, 
1 H, 10-H), 5.90 (ddd, 3J11,12b = 17.1 Hz, 
3J11,12a = 10.8 Hz, 
3J11,10 = 6.5 Hz, 1 H, 11-H), 7.43 (dd, 
3J16,15 ≈ 3J16,17 = 7.7 Hz, 2 H, 16-H), 7.55 (tt, 3J17,16 = 7.4 Hz, 4J17,15 = 1.3 Hz, 1 H, 17-H), 8.05 (dd, 
3J15,16 = 7.0 Hz, 
4J15,17 = 1.5 Hz, 2 H, 15-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-2), 17.9 (q, C-1), 26.9 (q, C-7), 27.4 (q, C-7'), 29.4 
(t, C-8), 31.0 (t, C-9), 64.2 (t, C-3), 75.1 (d, C-10), 79.3 (d, C-5), 80.9 (d, C-4), 108.5 (s, C-6), 
116.8 (t, C-12), 128.3 (d, C-16), 129.6 (d, C-15), 130.5 (s, C-14), 132.9 (d, C-17), 136.3 (d, C-11), 
165.8 (s, C-13). 
Diastereomer 2 (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.40 (s, 3 H, 7'-H), 5.21 (ddd, 3J12a,11 = 10.5 Hz, 2J12a,12b ≈ 4J12a,10 
= 1.2 Hz, 1 H, 12-Ha), 5.34 (ddd, 
3J12b,11 = 17.3 Hz, 
2J12b,12a ≈ 4J12b,10 = 1.3 Hz, 1 H, 12-Hb), 5.89 
(ddd, 3J11,12b = 17.1 Hz, 
3J11,12a = 10.8 Hz, 
3J11,10 = 6.5 Hz, 1 H, 11-H). 
13C-NMR (100 MHz, CDCl3): δ = 29.0 (t, C-8), 30.8 (t, C-9), 75.0 (d, C-10), 79.0 (d, C-5), 80.9 
(d, C-4), 117.0 (t, C-12), 136.2 (d, C-11). 
HRMS (CI):    calculated found 
C27H45O5Si [M+H]
+   477.3031 477.3024 
 
tert-Butyl (S,E)-2-((R)-6-(benzyloxy)-2-(2,2,2-trifluoroacetamido)hexanamido)-7-((4S,5S)-
2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enoate (69c) 
A solution of 2.10 mL (1.49 g, 14.7 mmol) Di-iso-propylamine in 30.0 mL THF abs. was treated 
with 8.30 mL (13.3 mmol) n-BuLi (1.6 M in hexanes) at –78 °C. The cooling bath was removed 
and the reaction was stirred at rt for 15 min. 1.70 g (3.81 mmol) 62c were dissolved in 30 mL THF 
abs. before 637 mg (4.67 mmol) zinc chloride (dried in high-vacuo) were added at rt. The resulting 
mixture was cooled to –78 °C and the above prepared LDA solution was added slowly at this 
temperature. The reaction was stirred at –78 °C for 30 min. 25.5 mg (69.7 µmol) [AllylPdCl]2 and 
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60.4 mg (230 µmol) PPh3 were dissolved in 7.50 mL THF abs. before 1.14 g (2.56 mmol) (3R)-66 
were added. The mixture was stirred at rt for 5 min. Afterwards, the catalyst/allylic substrate so-
lution was transferred to the zinc enolate at –78 °C and the reaction was allowed to warm to rt 
overnight (remaining dry ice was removed from the cooling bath). For workup, the reaction was 
diluted with diethyl ether and NH4OAc/HOAC-buffer was added. The layers were separated and 
the aqueous phase was extracted three times with Et2O. The combined organic layers were dried 
over Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatog-
raphy (silica gel, PE:EA 100:0, 90:10, 80:20, 70:30, 50:50) to obtain 196 mg (0.245 mmol, dr 
64:36, 10 %) and 1.55 g (1.93 mmol, dr 82:18, 75 %) 69c as slightly yellow oils. 
Rf (69c) = 0.11 (silica gel, PE:EA 80:20) 
 
(2S,R)-diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.15 (m, 21 H, 15-H, 16-H), 1.36 (s, 3 H, 13-H), 1.39 (s, 
3 H, 13-H'), 1.46 (s, 9 H, 1-H), 1.46 (m, 2 H, 20-H), 1.56 – 1.77 (m, 5 H, 9-H, 19-Ha, 21-H), 1.90 
(m, 1 H, 19-Hb), 2.09 (m, 1 H, 8-Ha), 2.19 (m, 1 H, 8-Hb), 2.43 (dd, 
2J5a,5b = 14.0 Hz, 
3J5a,6 = 6.2 
Hz, 1 H, 5-Ha), 2.50 (dd, 
2J5b,5a = 14.1 Hz, 
3J5b,6 = 6.4 Hz, 1 H, 5-Hb), 3.46 (m, 2 H, 22-H), 3.69 
(m, 1 H, 11-H), 3.73 (dd, 2J14a,14b = 10.0 Hz, 
3J14a,11 = 6.0 Hz, 1 H, 14-Ha), 3.86 (dd, 
2J14b,14a = 10.0 
Hz, 3J14b,11 = 3.9 Hz, 1 H, 14-Hb), 3.92 (td, 
3J10,9 = 7.7 Hz, 
3J10,11 = 3.4Hz, 1 H, 10-H), 4.44 – 4.54 
(m, 2 H, 4-H, 18-H), 4.49 (s, 2 H, 23-H), 5.28 (dt, 3J6,7 = 14.9 Hz, 
3J6,5 = 7.3 Hz, 1 H, 6-H), 5.51 
(dt, 3J7,6 = 14.6 Hz, 
3J7,8 = 7.0 Hz, 1 H, 7-H), 6.33 (d, 
3JNH,4 = 7.5 Hz, 1 H, NHa), 7.22 (d, 
3JNH,18 = 
7.6 Hz, 1 H, NHb), 7.27 – 7.36 (m, 5 H, 25-H, 26-H, 27-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-15), 17.9 (q, C-16), 21.9 (t, C-20), 27.0 (q, C-13), 
27.4 (q, C-13'), 28.0 (q, C-1), 29.1 (t, C-8, C-9), 32.7 (t, C-21), 33.0 (t, C-19), 35.4 (t, C-5), 52.5 
(d, C-4 o. C-18), 53.3 (d, C-4 o. C-18), 64.1 (t, C-14), 69.6 (t, C-22), 72.9 (t, C-23), 78.6 (d, C-
10), 80.8 (d, C-11), 82.6 (s, C-2), 108.5 (s, C-12), 123.5 (d, C-6), 127.6 (d, C-27), 127.7 (d, C-25), 
128.4 (d, C-26), 134.8 (d, C-7), 138.3 (s, C-24), 156.7 (q, 2J28,F = 37 Hz, C-28), 169.1 (s, C-3), 
170.2 (s, C-17). The signal of C-29 wasn’t observed in the 13C-NMR spectrum. 
(2R,R)-diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.38 (s, 3 H, 13-H), 1.46 (s, 9 H, 1-H), 2.56 (m, 2 H, 5-H), 5.09 
(m, 1 H, 6-H o. 7-H), 6.37 (d, 3JNH,4 = 7.2 Hz, 1 H, NHa). 
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13C-NMR (100 MHz, CDCl3): δ = 27.9 (q, C-1). 
HRMS (CI):    calculated found 
C41H68F3N2O8Si [M+H]
+  801.4692 801.4702 
Optical rotation:    [𝛼]𝐷
20 = +9.0° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 95:5, 1.0 mL/min, 20 °C: 
(2R,R)-69c: tR = 16.1 min, 
(2S,R)-69c: tR = 17.9 min. 
 
tert-Butyl (S,E)-2-((R,E)-6-(benzyloxy)-2-(2,2,2-trifluoroacetamido)hex-4-enamido)-7-((4S, 
5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)hept-4-enoate (69d) 
A solution of 1.51 mL (1.07 g, 10.6 mmol) Di-iso-propylamine in 20.0 mL THF abs. was cooled 
to –78 °C and 6.1 mL (9.76 mmol) n-BuLi (1.6 M in hexanes) were added dropwise. The cooling 
bath was removed and the reaction was stirred at rt for 15 min. 
1.25 g (2.81 mmol, er 96:4) 61b were added to a solution of 490 mg (3.60 mmol) zinc chloride 
(dried in high-vacuo) in 20.0 mL THF abs. at rt. The dipeptide/zinc chloride solution was added 
dropwise to the LDA solution at –78 °C and stirred for 30 min. 17.2 mg (47.0 µmol) [AllylPdCl]2 
and 44.6 mg (170 µmol) PPh3 were dissolved in 5.0 mL THF abs. and stirred for 5 min before 830 
mg (1.87 mmol) (3R)-66 were added and the catalyst/allyl substrate solution was transferred 
slowly to the zinc enolate at –78 °C. The remaining dry ice was removed from the cooling bath 
and the reaction was allowed to warm to rt overnight. For workup, the reaction was diluted with 
diethyl ether and NH4OAc/HOAc-buffer was added and the layers were separated. The aqueous 
phase was extracted three times with Et2O and the combined organic phases were dried over 
Na2SO4. After purification by column chromatography (silica gel, PE:EA 100:0, 90:10, 80:20, 
70:30), 1.30 g (1.63 mmol, dr 79:21, 87 %) of allylated dipeptide 69d were obtained as a slightly 
yellow oil. 
Rf (69d) = 0.51 and 0.55 (silica gel, PE:EA 70:30) 
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(2S,R)-diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.15 (m, 21 H, 15-H, 16-H), 1.36 (s, 3 H, 13-H), 1.39 (s, 
3 H, 13-H'), 1.46 (s, 9 H, 1-H), 1.65 (m, 2 H, 9-H), 2.16 (m, 2 H, 8-H), 2.47 (dd, 3J5,4 ≈ 3J5,6 = 6.1 
Hz, 2 H, 5-H), 2.51 (dt, 2J19a,19b = 13.1 Hz, 
3J19a,18 = 6.5 Hz, 1 H, 19-Ha), 2.64 (dt, 
2J19b,19a = 13.9 
Hz, 3J19b,18 = 6.8 Hz, 1 H, 19-Hb), 3.70 (m, 1 H, 11-H), 3.73 (dd, 
2J14a,14b = 10.0 Hz, 
3J14a,11 = 6.0 
Hz, 1 H, 14-Ha), 3.86 (dd, 
2J14b,14a = 9.9 Hz, 
3J14b,11 = 3.9 Hz, 1 H, 14-Hb), 3.92 (td, 
3J10,9 = 7.8 Hz, 
3J10,11 = 3.4Hz, 1 H, 10-H), 3.98 (d, 
3J22,21 = 5.3 Hz, 2 H, 22-H), 4.44 – 4.58 (m, 2 H, 4-H, 18-H), 
4.49 (s, 2 H, 23-H), 5.28 (dt, 3J6,7 = 15.0 Hz, 
3J6,5 = 7.4 Hz, 1 H, 6-H), 5.53 (dt, 
3J7,6 = 14.6 Hz, 
3J7,8 = 7.2 Hz, 1 H, 7-H), 5.63 (dt, 
3J20,21 = 14.8 Hz, 
3J20,19 = 7.3 Hz, 1 H, 20-H), 5.73 (dt, 
3J21,20 = 
15.4 Hz, 3J21,22 = 5.6 Hz, 1 H, 21-H), 6.34 (d, 
3JNH,4 = 7.5 Hz, 1 H, NHa), 7.22 (d, 
3JNH,18 = 7.3 Hz, 
1 H, NHb), 7.26 – 7.42 (m, 5 H, 25-H, 26-H, 27-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-15), 17.9 (q, C-16), 27.0 (q, C-13), 27.4 (q, C-13'), 
28.0 (q, C-1), 29.2 (t, C-8), 33.1 (t, C-9), 35.4 (t, C-5), 35.7 (t, C-19), 52.6 (d, C-4 o. C-18), 52.7 
(d, C-4 o. C-18), 64.1 (t, C-14), 69.9 (t, C-22), 72.2 (t, C-23), 78.6 (d, C-10), 80.8 (d, C-11), 82.7 
(s, C-2), 108.5 (s, C-12), 123.5 (d, C-6), 126.0 (d, C-20), 127.6 (d, C-27), 127.7 (d, C-25), 128.4 
(d, C-26), 132.2 (d, C-21), 134.9 (d, C-7), 138.1 (s, C-24), 168.4 (s, C-3), 170.2 (s, C-17). 
(2R,R)-diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.37 (s, 3 H, 13-H), 1.46 (s, 9 H, 1-H), 3.83 (d, 3J14b,11 = 3.8 Hz, 
1 H, 14-Hb), 5.10 (m, 1 H, 6-H o. 7-H), 6.34 (d, 
3JNH,4 = 7.8 Hz, 1 H, NHa). 
HRMS (CI):    calculated found 
C37H57F3N2O8Si [M+H-tBu]
+  742.3831 742.3850 
Optical rotation:    [𝛼]𝐷
20 = –1.1° (c = 1.0, CHCl3) 
HPLC: Chiralcel OD-H, n-hexane:iPrOH 80:20, 1.0 mL/min, 20 °C: 
(2S,R)-69d: tR = 3.75 min (79 %), 
(2R,R)-69d: tR = 5.45 min (21 %). 
 
tert-Butyl (S)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)-
2-((R)-6-Hydroxy-2-(2,2,2-trifluoroacetamido)hexanamido)heptanoate (71c) 
To a solution of 1.52 g (1.90 mmol) 69c in 15.0 mL THF were added 151 mg palladium on charcoal 
(10 w% Pd) at rt. The reaction was set under 20 bar H2-atmosphere for 18 h and after addition of 
5.4 µL (5.7 mg, 94.9 µmol) HOAc under 30 bar H2-atmossphere for 22 h. The reaction was then 
filtrated through a pad of Celite® and washed with Et2O. The filtrate was concentrated in vacuo. 
The crude product was purified by column chromatography (silica gel, PE:EA 70:30, 50:50) to 
yield 885 mg (1.24 mmol, dr 81:19, 65 %) and 455 mg (0.638 mmol, dr 88:12, 34 %) alcohol 71c 
as colourless oils. 
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Rf (71c) = 0.08 (silica gel, PE:EA 70:30) 
 
(2S,R)-diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.16 (m, 21 H, 15-H, 16-H), 1.29 – 1.50 (m, 4 H, 7-H, 8-
H, 9-H), 1.36 (s, 3 H, 13-H), 1.39 (s, 3 H, 13-H'), 1.46 (s, 9 H, 1-H), 1.51 – 1.77 (m, 8 H, 6-H, 9-
H, 20-H, 21-H), 1.78 – 2.01 (m, 4 H, 5-H, 19-H), 3.60 – 3.70 (m, 3 H, 11-H, 22-H), 3.74 (dd, 
2J14a,14b = 10.3 Hz, 
3J14a,11 = 5.9 Hz, 1 H, 14-Ha), 3.86 (dd, 
2J14b,14a = 10.3 Hz, 
3J14b,11 = 4.0 Hz, 1 
H, 14-Hb), 3.92 (td, 
3J10,9 = 7.9 Hz, 
3J10,11 = 3.4Hz, 1 H, 10-H), 4.46 (dt, 
3J4,NH = 7.2 Hz, 
3J4,5 = 5.5 
Hz, 1 H, 4-H), 4.52 (dt, 3J18,19 ≈ 3J18,NH = 6.8 Hz, 1 H, 18-H), 6.54 (d, 3JNH,4 = 7.7 Hz, 1 H, NHa), 
7.33 (d, 3JNH,18 = 7.2 Hz, 1 H, NHb). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-15), 17.9 (q, C-16), 21.5 (t, C-20), 25.0 (t, C-6), 26.1 
(t, C-7 o. C-8), 26.9 (q, C-13), 27.4 (q, C-13'), 28.0 (q, C-1), 29.4 (t, C-7 o. C-8), 31.7 (t, C-21), 
32.3 (t, C-5), 32.7 (t, C-19), 33.4 (t, C-9), 52.9 (d, C-4), 53.2 (d, C-18), 62.1 (t, C-22), 64.1 (t, C-
14), 79.1 (d, C-10), 81.0 (d, C-11), 82.6 (s, C-2), 108.4 (s, C-12), 115.7 (q, 1J24,F = 288 Hz, C-24), 
156.7 (q, 2J23,F = 37 Hz, C-23), 169.3 (s, C-3), 170.0 (s, C-17). 
(2R,R)-diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 6.46 (d, 3JNH,4 = 8.0 Hz, 1 H, NHa). 
13C-NMR (100 MHz, CDCl3): δ = 21.0 (t, C-20), 25.9 (t, C-7 o. C-8), 53.1 (d, C-4). 
HRMS (CI):    calculated found 
C34H64F3N2O8Si [M+H]
+  713.4379 713.4410 
Optical rotation:    [𝛼]𝐷
20 = +1.1° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 95:5, 1.0 mL/min, 20 °C: 
(2R,R)-71c: tR = 13.7 min, 
(2S,R)-71c: tR = 16.9 min. 
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tert-Butyl (S)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)-
2-((R)-1-(2,2,2-trifluoroacetyl)piperidine-2-carboxamido)heptanoate (72c) 
To a solution of 553 mg (2.11 mmol) PPh3 in 80 mL THF abs. were added 411 µL (427 mg, 2.11 
mmol) DIAD at 0 °C. Afterwards, a solution of 941 mg (1.32 mmol) 71c in 50 mL THF abs. was 
added dropwise and the reaction was allowed to warm to rt overnight. For workup, the reaction 
was concentrated in vacuo and the crude product was purified by column chromatography (silica 
gel, PE:EA 80:20). 902 mg (1.30 mmol, dr 80:20, rotameric ratio 80:20, 98 %) of dipeptide 72c 
were obtained as a slightly yellow oil. 
Rf (72c) = 0.54 (silica gel, PE:EA 70:30) 
 
Major diastereomer/rotamer: 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.16 (m, 21 H, 15-H, 16-H), 1.28 – 1.41 (m, 5 H, 6-H, 8-
H, 19-Ha), 1.36 (s, 3 H, 13-H), 1.39 (s, 3 H, 13-H'), 1.45 (s, 9 H, 1-H), 1.50 – 1.86 (m, 10-H, 5-H, 
7-H, 9-H, 20-H, 21-H), 2.31 (d, 2/3J19b,19a/18/20 = 12.8 Hz, 1 H, 19-Hb), 3.35 (ddd, 
2J22ax,22eq = 14.1 
Hz, 3J22ax,21ax = 11.4 Hz, 
3J22ax,21eq = 2.5 Hz, 1 H, 22-Hax), 3.68 (m, 1 H, 11-H), 3.75 (dd, 
2J14a,14b = 
10.2 Hz, 3J14a,11 = 5.9 Hz, 1 H, 14-Ha), 3.86 (dd, 
2J14b,14a = 10.3 Hz, 
3J14b,11 = 4.0 Hz, 1 H, 14-Hb), 
3.92 (m, 1 H, 10-H), 3.95 (m, 1 H, 22-Heq), 4.43 (dt, 
3J4,NH = 7.4 Hz, 
3J4,5 = 5.8 Hz, 1 H, 4-H), 5.14 
(d, 3J18,19ax/19eq = 5.0 Hz, 1 H, 18-H), 6.20 (d, 
3JNH,4 = 7.6 Hz, 1 H, NH). 
13C-NMR (100 MHz, CDCl3): δ = 11.9 (d, C-15), 17.9 (q, C-16), 21.5 (t, C-20), 25.0 (t, C-6), 26.1 
(t, C-7 o. C-8), 26.9 (q, C-13), 27.4 (q, C-13'), 28.0 (q, C-1), 29.4 (t, C-7 o. C-8), 31.7 (t, C-21), 
32.3 (t, C-5), 32.7 (t, C-19), 33.4 (t, C-9), 52.9 (d, C-4), 53.2 (d, C-18), 62.1 (t, C-22), 64.1 (t, C-
14), 79.1 (d, C-10), 81.0 (d, C-11), 82.6 (s, C-2), 108.4 (s, C-12), 115.7 (q, 1J24,F = 288 Hz, C-24), 
156.7 (q, 2J23,F = 37 Hz, C-23), 169.3 (s, C-3), 170.0 (s, C-17). 
Minor diastereomer/rotamer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.35 (s, 3 H, 13-H), 1.46 (s, 9 H, 1-H), 2.49 (d, 2/3J19b,19a/18/20 = 
12.8 Hz, 1 H, 19-Hb), 3.03 (m, 1 H, 22-Hax), 4.48 (m, 1 H, 4-H), 4.55 (d, 
2J22eq,22ax = 13.9 Hz, 1 H, 
22-Heq), 4.62 (m, 1 H, 4-H), 5.10 (m, 1 H, 18-H), 6.22 (m, 1 H, NH). 
13C-NMR (100 MHz, CDCl3): δ = 21.0 (t, C-20), 25.9 (t, C-7 o. C-8), 53.1 (d, C-4). 
HRMS (CI):    calculated found 
C34H62F3N2O7Si [M+H]
+  695.4273 695.4287 
Optical rotation:    [𝛼]𝐷
20 = +42.1° (c = 1.0, CHCl3) 
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HPLC: Reprosil, n-hexane:iPrOH 95:5, 1.0 mL/min, 20 °C: 
(2R,R)-72c: tR = 11.1 min (20 %), 
(2S,R)-72c: tR = 17.2 min (80 %). 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 29.5 min 
(minor, [M+Na]+ = 718), tR2 = 30.3 min (major, [M+Na]
+ = 718). 
 
tert-Butyl (S)-2-((R)-1-(((benzyloxy)carbonyl)-L-phenylalanyl)piperidine-2-carboxamido)-
7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-yl)heptanoate 
(74) 
876 mg (1.26 mmol) 72c were dissolved in 6.5 mL EtOH abs. and cooled to 0 °C before 97 mg 
(2.56 mmol) NaBH4 were added slowly. The reaction was stirred at rt for 15 min before acetone 
was added and stirring was continued for 15 min. The reaction was concentrated in vacuo and the 
residue was redissolved in DCM. 10 w% K2CO3 sol. was added and the layers were separated. The 
aqueous phase was extracted three times with DCM and the combined organic layers were dried 
over Na2SO4. The corresponding amine was then dissolved in 15.0 mL acetonitrile abs. at rt before 
421 mg (1.41 mmol) Cbz-(S)-Phe-OH, 446 mg (1.39 mmol) TBTU and 256 µL (189 mg, 1.46 
mmol) DIPEA were added subsequently. The reaction was stirred at rt overnight. For workup, the 
reaction was concentrated in vacuo and the residue was redissolved in DCM. 1 M HCl sol. was 
added and the layers were separated. The aqueous phase was extracted three times with DCM, the 
combined organic layers were washed with sat. NaHCO3 sol. and dried over Na2SO4. Purification 
by column chromatography (silica gel, PE:EA 70:30) gave 1.05 g (1.19 mmol, dr 81:19, rotameric 
ratio 70:30, 94 % over two steps) 74 as an off-white solid. 
Rf (74) = 0.30 (silica gel, PE:EA 70:30) 
 
Major diastereomer/rotamer: 
1H-NMR (500 MHz, 373 K, DMSO-d6): δ = 1.04 – 1.14 (m, 21 H, 15-H, 16-H), 1.25 – 1.35 (m, 
7 H, 6-H, 8-H, 7-H/19-Ha/20-H, 21-H), 1.30 (s, 3 H, 13-H), 1.31 (s, 3 H, 13-H'), 1.37 – 1.44 (m, 4 
H, 7-H/19-Ha/20-H, 21-H), 1.40 (s, 9 H, 1-H), 1.45 – 1.66 (m, 3 H, 5-Ha, 9-H), 1.71 (m, 1 H, 5-
Hb), 2.16 (d, 
2/3J19b,19a/18 = 10.0 Hz, 1 H, 19-Hb), 2.94 (d, 
3J25,24 = 6.9 Hz, 2 H, 25-H), 2.98 (br s, 2 
H, 22-H), 3.64 (m, 1 H, 11-H), 3.75 (dd, 2J14a,14b = 10.7 Hz, 
3J14a,11 = 4.8 Hz, 1 H, 14-Ha), 3.80 (dd, 
2J14b,14a = 10.7 Hz, 
3J14b,11 = 4.5 Hz, 1 H, 14-Hb), 3.85 (td, 
3J10,9 = 7.6 Hz, 
3J10,11 = 4.3 Hz, 1 H, 10-
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H), 4.17 (dt, 3J4,NH ≈ 3J4,5 = 7.1 Hz, 1 H, 4-H), 4.72 (br s, 1 H, 24-H), 4.96 – 5.05 (m, 3 H, 18-H, 
31-H), 7.19 – 7.36 (m, 11 H, 27-H, 28-H, 29-H, 33-H, 34-H, 35-H, NHa). The signal of NHb wasn’t 
observed in the 1H-NMR spectrum. 
13C-NMR (125 MHz, 373 K, DMSO-d6): δ = 11.1 (d, C-15), 17.2 (q, C-16), 19.4 (t, C-20), 23.7 
(t, C-6 o. C-8 o. C-21), 24.6 (t, C-6 o. C-8 o. C-21), 24.7 (t, C-6 o. C-8 o. C-21), 26.4 (q, C-13), 
26.8 (q, C-13'), 27.2 (q, C-1), 28.0 (t, C-7), 30.4 (t, C-5), 32.3 (t, C-9), 37.1 (t, C-25), 51.4 (d, C-
24), 52.4 (d, C-4), 63.4 (t, C-14), 65.1 (t, C-31), 77.3 (d, C-10), 80.0 (s, C-2), 80.6 (d, C-11), 107.2 
(s, C-12), 125.9 (d, C-29), 126.9 (d, C-33), 127.2 (d, C-27), 127.6 (d, C-35), 127.7 (d, C-28), 128.8 
(d, C-34), 136.4 (s, C-26 o. C-32), 170.4 (s, C-3 o. C-17 o. C-23). The signals of C-3/C-17/C-23, 
C-18, C-19, C-22, C-26/C-32 and C-30 weren’t observed in the 13C-NMR spectrum. 
Minor diastereomer/rotamer (selected signals): 
1H-NMR (500 MHz, 373 K, DMSO-d6): δ = 1.79 (m, 1 H, 5-Hb), 3.10 (dd, 2J25a,25b = 14.1 Hz, 
3J25a,24 = 4.9 Hz, 1 H, 25-Ha), 4.27 (m, 1 H, 24-H), 4.40 (m, 1 H, 4-H). 
HRMS (CI):    calculated found 
C49H78N3O9Si [M+H]
+  880.5502 880.5510 
Melting point:   122-124 °C 
Optical rotation:    [𝛼]𝐷
20 = +43.2° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 90:10, 1.0 mL/min, 20 °C: 
(2R,R,S)-74: tR = 21.6 min (5 %, minor rotamer), 
(2S,R,S)-74: tR = 25.2 min (25 %, minor rotamer), 
(2R,R,S)-74: tR = 30.7 min (14 %, major rotamer), 
(2S,R,S)-74: tR = 36.3 min (56 %, major rotamer). 
 
tert-Butyl (S)-2-((R)-1-(((benzyloxy)carbonyl)-L-phenylalanyl-L-phenylalanyl)piperidine-2-
carboxamido)-7-((4S,5S)-2,2-dimethyl-5-(((tri-iso-propylsilyl)oxy)methyl)-1,3-dioxolan-4-
yl)heptanoate (75) 
A solution of 770 mg (0.875 mmol) 74 in 7.5 mL MeOH was treated with 77 mg palladium on 
charcoal (10 w% Pd) at rt. A small amount of DCM was added to guarantee stirring, the reaction 
was set under H2 and hydrogenated for 22.5 h. The reaction was then filtrated through a pad of 
Celite® and washed with MeOH. The filtrated was concentrated in vacuo and the crude product 
was redissolved in 7.0 mL acetonitrile. Afterwards, 290 mg (0.969 mmol) Cbz-(S)-Phe-OH, 309 
mg (0.962 mmol) TBTU and 176 µL (130 mg, 1.01 mmol) DIPEA were added subsequently at rt. 
The reaction was stirred overnight and concentrated in vacuo. The residue was redissolved in DCM 
and 1 M HCl sol. was added. The layers were separated and the aqueous phase was extracted three 
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times with DCM. The combined organic layers were washed with sat. NaHCO3 sol. and dried over 
Na2SO4. The crude product was purified by column chromatography (silica gel, PE:EA 100:0, 
80:20, 50:50). 831 mg (0.808 mmol, dr 87:13, 92 % over two steps) of tetrapeptide 75 were ob-
tained as an off-white solid. 
Rf (75) = 0.46 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.02 – 1.14 (m, 21 H, 38-H, 39-H), 1.18 – 1.49 (m, 11 H, 22-
Ha, 23-H, 24-H, 29-H, 30-H, 31-H), 1.34 (s, 3 H, 36-H), 1.37 (s, 3 H, 36-H'), 1.41 (s, 9 H, 42-H), 
1.50 – 1.65 (m, 3 H, 28-Ha, 32-H), 1.77 (m, 1 H, 28-Hb), 2.30 (d, 2/3J22b,22a/23/21 = 13.0 Hz, 1 H, 22-
Hb), 2.88 (m, 1 H, 15-Ha), 2.96 – 3.08 (m, 3 H, 8-H, 15-Hb), 3.13 (dd, 2J25ax,25eq ≈ 3J25ax,24ax = 12.4 
Hz, 1 H, 25-Hax), 3.59 (d, 
2J25eq,25ax = 14.0 Hz, 1 H, 25-Heq), 3.64 (m, 1 H, 34-H), 3.73 (dd, 
2J37a,37b 
= 10.4 Hz, 3J37a,34 = 5.5 Hz, 1 H, 37-Ha), 3.83 (dd, 
2J37b,37a = 10.3 Hz, 
3J37b,34 = 4.1 Hz, 1 H, 37-
Hb), 3.89 (td, 
3J33,32 = 7.8 Hz, 
3J33,34 = 3.6 Hz, 1 H, 33-H), 4.35 (td, 
3J27,28 = 7.5 Hz, 
3J27,NH = 6.5 
Hz, 1 H, 27-H), 4.39 (m, 1 H, 7-H), 4.83 (dt, 3J14,NH = 7.5 Hz, 
3J14,15 = 6.3 Hz, 1 H, 14-H), 5.07 (s, 
2 H, 5-H), 5.24 (d, 3J21,22a = 4.3 Hz, 1 H, 21-H), 5.42 (d, 
3JNH,7 = 7.0 Hz, 1 H, NHc), 6.54 (br s, 1 
H, NHb), 6.92 (d, 
3JNH,27 = 7.6 Hz, 1 H, NHa), 7.09 (d, 
3J10,11 = 7.6 Hz, 2 H, 10-H), 7.17 – 7.37 (m, 
13 H, 1-H, 2-H, 3-H, 11-H, 12-H, 17-H, 18-H, 19-H). 
13C-NMR (100 MHz, CDCl3): δ = 11.8 (d, C-38), 17.9 (q, C-39), 20.2 (t, C-23), 24.7 (t, C-22), 
25.2 (t, C-24 o. C-29 o. C-31), 25.5 (t, C-24 o. C-29 o. C-31), 26.1 (t, C-24 o. C-29 o. C-31), 26.9 
(q, C-36), 27.4 (q, C-36'), 28.0 (q, C-42), 29.4 (t, C-30), 31.8 (t, C-28), 33.5 (t, C-32), 38.1 (t, C-
8), 38.2 (t, C-15), 43.9 (t, C-25), 51.1 (d, C-14), 52.6 (d, C-21), 53.0 (d, C-27), 55.6 (d, C-7), 64.1 
(t, C-37), 67.0 (t, C-5), 78.9 (d, C-33), 81.1 (s, C-41), 81.4 (d, C-34), 108.3 (s, C-35), 127.0 (d, C-
19), 127.2 (d, C-12), 128.0 (d, C-3), 128.2 (d, C-1), 128.5 (d, C-17), 128.6 (d, C-11 o. C-18), 128.7 
(d, C-11 o. C-18), 129.4 (d, C-10), 129.6 (d, C-2), 135.7 (s, C-16), 136.2 (s, C-4, C-9), 155.9 (s, 
C-6), 169.6 (s, C-26), 170.6 (s, C-20), 170.8 (s, C-13), 171.9 (s, C-40). 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.45 (s, 9 H, 42-H), 4.67 (m, 1 H, 14-H), 5.20 (d, 3J21,22a = 6.2 
Hz, 1 H, 21-H), 5.33 (d, 3JNH,7 = 8.4 Hz, 1 H, NHc), 6.64 (m, 1 H, NHb), 6.83 (m, 1 H, NHa). 
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HRMS (CI):    calculated found 
C58H87N4O10Si [M+H]
+  1027.6186 1027.6199 
Melting point:   56 °C 
Optical rotation:    [𝛼]𝐷
20 = +26.4° (c = 1.0, CHCl3) 
HPLC: Reprosil, n-hexane:iPrOH 80:20, 1.0 mL/min, 20 °C: 
tR1 = 20.2 min (13 %), 
tR2 = 26.6 min (87 %). 
 
tert-Butyl (S)-2-((R)-1-(((benzyloxy)carbonyl)-L-phenylalanyl-L-phenylalanyl)piperidine-2-
carboxamido)-7-((4S,5S)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)heptanoate (76) 
A solution of 148 mg (0.144 mmol) 75 was dissolved in 0.75 mL THF at rt. Afterwards, 0.22 mL 
(0.22 mmol) TBAF (1 M in THF) were added and the reaction was stirred for 3 h. For workup, the 
reaction was concentrated in vacuo at rt. The residue was redissolved in Et2O and water was added. 
The layers were separated and the aqueous phase was extracted three times with diethyl ether. The 
combined organic layers were dried over Na2SO4 and the crude product was purified by column 
chromatography (silica gel, PE:EA 100:0, 80:20, 50:50). 113 mg (0.130 mmol, dr 81:19, 90 %) of 
alcohol 76 were obtained as an off-white solid. 
Rf (76) = 0.13 (silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.15 – 1.67 (m, 14 H, 22-Ha, 23-H, 24-H, 28-Ha, 29-H, 30-H, 
31-H, 32-H), 1.37 (s, 3 H, 36-H), 1.38 (s, 3 H, 36-H'), 1.41 (s, 9 H, 40-H), 1.77 (m, 1 H, 28-Hb), 
2.31 (m, 1 H, 22-Hb), 2.87 (m, 1 H, 15-Ha), 2.95 – 3.09 (m, 3 H, 8-H, 15-Hb), 3.15 (dd, 2J25ax,25eq 
≈ 3J25ax,24ax = 12.8 Hz, 1 H, 25-Hax), 3.54 – 3.64 (m, 2 H, 25-Heq, 37-Ha), 3.66 (ddd, 3J35,37a = 8.0 
Hz, 3J35,37b = 4.2 Hz, 
3J35,34 = 3.7 Hz, 1 H, 34-H), 3.75 (d, 
2J37b,37a = 11.4 Hz, 1 H, 37-Hb), 3.83 (m, 
1 H, 33-H), 4.34 – 4.64 (m, 2 H, 7-H, 27-H), 4.81 (dt, 3J14,NH = 8.1 Hz, 3J14,15 = 6.0 Hz, 1 H, 14-
H), 5.07 (s, 2 H, 5-H), 5.24 (d, 3J21,22a = 4.5 Hz, 1 H, 21-H), 5.42 (m, 1 H, NHc), 6.52 (br s, 1 H, 
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NHb), 6.95 (d, 
3JNH,27 = 8.0 Hz, 1 H, NHa), 7.09 (d, 
3J10,11 = 6.5 Hz, 2 H, 10-H), 7.12 – 7.37 (m, 13 
H, 1-H, 2-H, 3-H, 11-H, 12-H, 17-H, 18-H, 19-H). The signal of -OH wasn’t observed in the 1H-
NMR spectrum. 
13C-NMR (100 MHz, CDCl3): δ = 20.2 (t, C-23), 24.7 (t, C-24 o. C-29 o. C-31), 25.2 (t, C-22), 
25.3 (t, C-24 o. C-29 o. C-31), 25.6 (t, C-24 o. C-29 o. C-31), 27.0 (q, C-36), 27.3 (q, C-36'), 28.0 
(q, C-40), 29.0 (t, C-30), 31.7 (t, C-28), 32.8 (t, C-32), 38.2 (t, C-8, C-15), 44.0 (t, C-25), 51.1 (d, 
C-14), 52.7 (d, C-21), 52.9 (d, C-27), 62.1 (t, C-37), 67.0 (t, C-5), 76.9 (d, C-33), 81.4 (d, C-34), 
81.5 (s, C-39), 108.5 (s, C-35), 127.1 (d, C-19), 127.3 (d, C-12), 128.0 (d, C-3), 128.2 (d, C-1), 
128.5 (d, C-17), 128.7 (d, C-11 o. C-18), 128.8 (d, C-11 o. C-18), 129.4 (d, C-10), 129.6 (d, C-2), 
136.2 (s, C-4, C-9), 169.6 (s, C-26), 170.6 (s, C-13 o. C-20), 170.9 (s, C-13 o. C-20), 171.8 (s, C-
38). The signals of C-6, C-7 and C-16 weren’t observed in the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 4.57 (m, 1 H, 14-H), 5.18 (m, 1 H, 21-H). 
HRMS (CI):    calculated found 
C49H67N4O10 [M+H]
+   871.4852 871.4853 
Melting point:   63-65 °C 
Optical rotation:    [𝛼]𝐷
20 = +18.5° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 18.5 min 
(81 %, [M+Na]+ = 894), tR2 = 19.4 min (19 %, [M+Na]
+ = 894). 
 
tert-Butyl (S)-2-((R)-1-(((benzyloxy)carbonyl)-L-phenylalanyl-L-phenylalanyl)piperidine-2-
carboxamido)-7-((4S,5S)-2,2-dimethyl-5-((tosyloxy)methyl)-1,3-dioxolan-4-yl)heptanoate 
(77) 
508 mg (0.494 mmol) 75 were dissolved in 5.0 mL THF at rt. Afterwards, 742 µL (0.742 mmol) 
TBAF (1 M in THF) were added and the reaction was stirred for 2 h. For workup, the reaction was 
concentrated in vacuo at rt. The residue was redissolved in DCM and water was added. The layers 
were separated and the aqueous phase was extracted three times with DCM. The combined organic 
layers were dried over Na2SO4 and the crude product was redissolved in 5.0 mL pyridine abs. at 
rt. The reaction was cooled to 0 °C before 6.9 mg (56.5 µmol) 4-DMAP and 141 mg (0.742 mmol) 
TosCl were added. The reaction was allowed to warm to rt overnight. For workup, the reaction 
was diluted with Et2O and 1 M HCl sol. was added. The layers were separated and the aqueous 
phase was extracted three times with Et2O. The combined organic phases were dried over Na2SO4 
and concentrated in vacuo. After purification by column chromatography (silica gel, PE:EA 
50:50), 415 mg (0.405 mmol, 82 % over two steps) 77 were obtained as an off-white solid. 
Rf (77) = 0.24 (silica gel, PE:EA 50:50) 
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1H-NMR (400 MHz, CDCl3): δ = 1.18 – 1.48 (m, 12 H, 22-Ha, 23-H, 24-H, 29-H, 30-H, 31-H, 
32-Ha), 1.26 (s, 3 H, 36-H), 1.32 (s, 3 H, 36-H'), 1.41 (s, 9 H, 45-H), 1.50 – 1.60 (m, 2 H, 28-Ha, 
32-Hb), 1.77 (m, 1 H, 28-Hb), 2.32 (d, 
2/3J22b,22a/21/23 = 12.4 Hz, 1 H, 22-Hb), 2.44 (s, 3 H, 42-H), 
2.87 (m, 1 H, 15-Ha), 2.98 – 3.09 (m, 3 H, 8-H, 15-Hb), 3.15 (dd, 2J25ax,25eq ≈ 3J25ax,24ax = 13.3 Hz, 
1 H, 25-Hax), 3.60 (d, 
2J25eq,25ax = 13.8 Hz, 1 H, 25-Heq), 3.68 – 3.78 (m, 2 H, 33-H, 34-H), 4.06 
(m, 2 H, 37-H), 4.33 – 4.43 (m, 2 H, 7-H, 27-H), 4.82 (dt, 3J14,NH = 7.8 Hz, 3J14,15 = 5.4 Hz, 1 H, 
14-H), 5.07 (s, 2 H, 5-H), 5.24 (d, 3J21,22a = 3.6 Hz, 1 H, 21-H), 5.40 (d, 
3JNH,7 = 6.5 Hz, 1 H, NHc), 
6.51 (br s, 1 H, NHb), 6.95 (d, 
3JNH,27 = 7.3 Hz, 1 H, NHa), 7.09 (d, 
3J10,11 = 6.9 Hz, 2 H, 10-H), 
7.12 – 7.37 (m, 15 H, 1-H, 2-H, 3-H, 11-H, 12-H, 17-H, 18-H, 19-H, 40-H), 7.79 (d, 3J39,40 = 8.2 
Hz, 2 H, 39-H). 
13C-NMR (100 MHz, CDCl3): δ = 20.3 (t, C-23), 21.6 (q, C-42), 24.7 (t, C-24 o. C-29 o. C-31), 
25.2 (t, C-22), 25.4 (t, C-24 o. C-29 o. C-31), 25.7 (t, C-24 o. C-29 o. C-31), 26.6 (q, C-36), 27.3 
(q, C-36'), 28.0 (q, C-45), 29.2 (t, C-30), 31.7 (t, C-28), 32.9 (t, C-32), 38.0 (t, C-8), 38.2 (t, C-15), 
43.9 (t, C-25), 51.1 (d, C-14), 52.7 (d, C-21), 52.9 (d, C-27), 55.7 (d, C-7), 67.0 (t, C-5), 69.2 (t, 
C-37), 77.6 (d, C-33 o. C-34), 78.1 (d, C-33 o. C-34), 81.5 (s, C-44), 109.3 (s, C-35), 127.1 (d, C-
12 o. C-19), 127.3 (d, C-12 o. C-19), 128.0 (d, C-39), 128.2 (d, C-3), 128.5 (d, C-1 o. C-2 o. C-11 
o. C-18), 128.7 (d, C-1 o. C-2 o. C-11 o. C-18), 128.8 (d, C-1 o. C-2 o. C-11 o. C-18), 129.4 (d, 
C-10), 129.6 (d, C-17), 129.8 (d, C-40), 132.7 (s, C-38), 136.2 (s, C-4, C-9), 145.0 (s, C-41), 155.9 
(s, C-6), 169.6 (s, C-26), 170.6 (s, C-20), 170.8 (s, C-13), 171.8 (s, C-43). The signals of C-1/C-
2/C-11/C-18 and C-16 weren’t observed in the 13C-NMR spectrum. 
HRMS (CI):    calculated found 
C56H73N4O12S [M+H]
+  1025.4940 1025.4942 
Melting point:   56 °C 
Optical rotation:    [𝛼]𝐷
20 = +17.8° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 14.7 min 
([M+Na]+ = 1048). 
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tert-Butyl (2S,8S,9S)-2-((R)-1-(((benzyloxy)carbonyl)-L-phenylalanyl-L-phenylalanyl)pipe-
ridine-2-carboxamido)-8,9-dihydroxy-10-(tosyloxy)decanoate (78) 
179 mg (0.175 mmol) 77 were dissolved in 2.0 mL THF and 2.0 mL HCl sol. (5 w% in H2O) were 
added at rt. The reaction was heated to 60 °C for 24 h and concentrated in vacuo. The residue was 
diluted with brine and extracted three times with DCM. The combined organic layers were dried 
over MgSO4 and concentrated in vacuo. After lyophilisation, 171 mg (0.174 mmol, 99 %) of diol 
78 were obtained as an off-white solid. 
Rf (78) = 0.14 (silica gel, PE:EA 50:50) 
 
1H-NMR (400 MHz, CDCl3): δ = 1.15 (m, 1 H, 22-Ha), 1.23 – 1.47 (m, 11 H, 23-H, 24-H, 29-H, 
30-H, 31-H, 32-Hb), 1.41 (s, 9 H, 43-H), 1.48 – 1.69 (m, 2 H, 28-Ha, 32-Hb), 1.81 (m, 1 H, 28-Hb), 
2.36 (d, 2J22b,22a = 13.5 Hz, 1 H, 22-Hb), 2.41 (s, 3 H, 40-H), 2.86 – 3.05 (m, 4 H, 8-Ha, 15-H, OH), 
3.11 (dd, 2J8b,8a = 13.9 Hz, 
3J8b,7 = 5.7 Hz, 1 H, 8-Hb), 3.20 (dd, 
2J25ax,25eq ≈ 3J25ax,24ax = 12.7 Hz, 1 
H, 25-Hax), 3.51 (m, 1 H, 33-H), 3.56 – 3.73 (m, 3 H, 25-Heq, 34-H, OH), 4.06 (dd, 2J35a,35b = 10.0 
Hz, 3J35a,34 = 6.6 Hz, 1 H, 35-Ha), 4.11 (dd, 
2J35b,35a = 10.3 Hz, 
3J35b,34 = 5.1 Hz, 1 H, 35-Hb), 4.34 
– 4.52 (m, 2 H, 7-H, 27-H), 4.78 (m, 1 H, 14-H), 5.04 (m, 2 H, 5-H), 5.21 (d, 3J21,22a = 4.2 Hz, 1 
H, 21-H), 5.41 (d, 3JNH,7 = 8.4 Hz, 1 H, NHc), 6.90 (br s, 1 H, NHb), 7.00 (d, 
3JNH,27 = 7.3 Hz, 1 H, 
NHa), 7.11 (d, 
3J17,18 = 6.6 Hz, 2 H, 17-H), 7.17 (d, 
3J10,11 = 7.0 Hz, 2 H, 10-H), 7.20 – 7.37 (m, 13 
H, 1-H, 2-H, 3-H, 11-H, 12-H, 18-H, 19-H, 38-H), 7.78 (d, 3J37,40 = 8.2 Hz, 2 H, 37-H). 
13C-NMR (100 MHz, CDCl3): δ = 20.2 (t, C-23), 21.6 (q, C-40), 24.5 (t, C-24 o. C-29 o. C-31), 
27.4 (t, C-24 o. C-29 o. C-31), 25.1 (t, C-22), 28.0 (q, C-43), 31.0 (t, C-28), 32.8 (t, C-32), 37.9 (t, 
C-8 o. C-15), 44.2 (t, C-25), 51.2 (d, C-14), 52.6 (d, C-21), 53.1 (d, C-27), 55.7 (d, C-7), 67.2 (t, 
C-5), 70.8 (t, C-35), 71.4 (d, C-33 o. C-34), 71.7 (d, C-33 o. C-34), 81.4 (s, C-42), 127.1 (d, C-12 
o. C-19), 127.3 (d, C-12 o. C-19), 127.9 (d, C-37), 128.1 (d, C-3), 128.2 (d, C-1 o. C-2 o. C-11 o. 
C-18), 128.5 (d, C-1 o. C-2 o. C-11 o. C-18), 128.7 (d, C-1 o. C-2 o. C-11 o. C-18), 128.8 (d, C-1 
o. C-2 o. C-11 o. C-18), 129.4 (d, C-10), 129.4 (d, C-17), 129.8 (d, C-38), 132.8 (s, C-36), 135.4 
(s, C-16), 136.3 (s, C-4, C-9), 144.9 (s, C-39), 169.3 (s, C-26), 171.3 (s, C-13), 171.7 (s, C-41). 
The signals of C-6, C-8/C-15, C-20, C-24/C-29/C-31 and C-30 weren’t observed in the 13C-NMR 
spectrum. 
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HRMS (CI):    calculated found 
C53H69N4O12S [M+H]
+  985.4627 985.4643 
Melting point:   58-60 °C 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR = 18.2 min 
([M+H]+ = 986). 
 
(S)-2-((R)-1-(((Benzyloxy)carbonyl)-L-phenylalanyl-L-phenylalanyl)piperidine-2-carbox-
amido)-7-((4S,5S)-2,2-dimethyl-5-((tosyloxy)methyl)-1,3-dioxolan-4-yl)heptanoic acid (80) 
Method A: 
To a solution of 25 mg (24.4 µmol) 77 in 0.25 mL DCM abs. were added 6.1 µL (4.43 mg, 43.8 
µmol) triethylamine and 7.24 µL (8.89 mg, 40.0 µmol) TMSOTf at 0 °C. The cooling bath was 
removed and the reaction was stirred at rt for 2 h. For workup, the reaction was diluted with DCM 
and water was added. The layers were separated and the aqueous phase was extracted three times 
with DCM. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. Pu-
rification by column chromatography (silica gel, DCM:MeOH 100:0, Gradient 95:5) gave 11.5 
mg (11.9 µmol, 49 %) 80 as an off-white solid. 
Method B: 
500 mg (0.488 mmol) 77 were dissolved in 2.5 mL THF before 2.5 mL aq. HCl (5 w%) were 
added at rt. The reaction was heated to 60 °C overnight. For workup, the reaction was diluted with 
DCM and brine was added. The layers were separated and the aqueous phase was extracted three 
times with DCM. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
The crude product was redissolved in 2.5 mL DCM abs. and 2.5 mL (3.73 g, 32.7 mmol) TFA 
were added dropwise at rt. The reaction was stirred for 2 h at rt and concentrated in vacuo. The 
crude product was then treated with 4.8 mg (25.2 µmol) pTosOH·H2O in 5.0 mL acetone at 60 °C 
overnight. The reaction mixture was then concentrated in vacuo and purified by column chroma-
tography (silica gel, DCM:MeOH 100:0, Gradient 95:5). 373 mg (0.385 mmol, 79 % over three 
steps) of acid 80 were obtained as an off-white solid. 
Rf (80) = 0.35 (silica gel, DCM:MeOH 95:5) 
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Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.17 – 1.37 (m, 9 H, 22-Ha, 24-H, 29-H, 30-H, 31-H), 1.27 (s, 
3 H, 36-H), 1.33 (s, 3 H, 36-H'), 1.37 – 1.49 (m, 3 H, 23-Ha, 32-H), 1.54 – 1.68 (m, 2 H, 23-Hb, 
28-Ha), 1.83 (m, 1 H, 28-Hb), 2.20 (m, 1 H, 22-Hb), 2.44 (s, 3 H, 42-H), 2.82 (m, 1 H, 25-Ha), 2.91 
(dd, 2J15a,15b = 12.9 Hz, 
3J15a,14 = 5.7 Hz, 1 H, 15-Ha), 2.95 (m, 1 H, 8-Ha), 3.02 (m, 1 H, 8-Hb), 
3.05 (dd, 2J15b,15a = 13.5 Hz, 
3J15b,14 = 4.3 Hz, 1 H, 15-Hb), 3.48 (d, 
2J25b,25a = 12.4 Hz, 1 H, 25-Hb), 
3.68 – 3.81 (m, 2 H, 33-H, 34-H), 4.05 (m, 2 H, 37-H), 4.38 – 4.50 (m, 2 H, 7-H, 27-H), 4.92 (m, 
1 H, 14-H), 5.04 (m, 2 H, 5-H), 5.18 (br s, 1 H, 21-H), 5.39 (d, 3JNH,7 = 7.5 Hz, 1 H, NHc), 6.98 – 
7.06 (m, 2 H, NHb, NHa), 7.11 – 7.38 (m, 17-H, 1-H, 2-H, 3-H, 10-H, 11-H, 12-H, 17-H, 18-H, 
19-H, 40-H), 7.79 (d, 3J39,40 = 8.3 Hz, 2 H, 39-H). 
13C-NMR (100 MHz, CDCl3): δ = 19.9 (t, C-23), 21.6 (q, C-42), 24.7 (t, C-24 o. C-29 o. C-31), 
24.7 (t, C-22), 25.4 (t, C-24 o. C-29 o. C-31), 25.6 (t, C-24 o. C-29 o. C-31), 26.6 (q, C-36), 27.3 
(q, C-36'), 29.0 (t, C-30), 31.5 (t, C-28), 32.8 (t, C-32), 38.0 (t, C-8), 38.2 (t, C-15), 43.7 (t, C-25), 
50.9 (d, C-14), 52.1 (d, C-21, C-27), 55.8 (d, C-7), 67.3 (t, C-5), 69.2 (t, C-37), 77.6 (d, C-33 o. 
C-34), 78.1 (d, C-33 o. C-34), 109.3 (s, C-35), 127.1 (d, C-12), 128.0 (d, C-39), 128.3 (d, C-3), 
128.6 (d, C-1 o. C-2 o. C-11 o. C-18), 128.6 (d, C-1 o. C-2 o. C-11 o. C-18), 129.4 (d, C-10), 129.5 
(d, C-17), 129.9 (d, C-40), 132.7 (s, C-38), 136.0 (s, C-9), 145.0 (s, C-41), 171.0 (s, C-20), 174.6 
(s, C-43). The signals of C-1/C-2/C-11/C-18, C-4, C-6, C-12, C-13, C-19 and C-26 weren’t ob-
served in the 13C-NMR spectrum. 
 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 4.68 (m, 1 H, 27-H), 5.49 (m, 1 H, NHc). 
HRMS (CI):    calculated found 
C52H65N4O12S [M+H]
+  969.4314 969.4326 
Melting point:   74 °C 
Optical rotation:    [𝛼]𝐷
20 = +18.0° (c = 1.0, CHCl3) 
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LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.8 mL/min, tR = 10.4 min 
([M+H]+ = 970). 
 
Perfluorophenyl (S)-2-((R)-1-(((benzyloxy)carbonyl)-L-phenylalanyl-L-phenylalanyl)pipe-
ridine-2-carboxamido)-7-((4S,5S)-2,2-dimethyl-5-((tosyloxy)methyl)-1,3-dioxolan-4-yl)hep-
tanoate (81) 
To a solution of 53.5 mg (55.2 µmol) 80 in 0.55 mL DCM abs. were added 12.7 mg (69.0 µmol) 
pentafluorophenol and 13.7 mg (71.5 µmol) EDC·HCl at 0 °C. The reaction was allowed to warm 
to rt overnight. Cat. amounts of EDC·HCl were then added and stirring was continued for 2 h. For 
workup, the reaction was diluted with DCM and 1 M HCl sol. was added. The layers were sepa-
rated and the aqueous phase was extracted three times with DCM. The combined organic phases 
were washed with sat. NaHCO3 sol. and dried over Na2SO4. 61.4 mg (54.1 µmol, dr 76:24, 98 %) 
of Pfp ester 81 were obtained as an off-white solid. 
Rf(81) = 0.32 (major) & 0.38 (minor, silica gel, PE:EA 50:50) 
 
Major diastereomer: 
1H-NMR (400 MHz, CDCl3): δ = 1.13 – 1.54 (m, 13 H, 22-Ha, 23-H, 24-H, 29-H, 30-H, 31-H, 
32-H), 1.26 (s, 3 H, 36-H), 1.32 (s, 3 H, 36-H'), 1.74 (m, 1 H, 28-Ha), 1.97 (m, 1 H, 28-Hb), 2.36 
(d, 2/3J22b,22a/21/23 = 12.5 Hz, 1 H, 22-Hb), 2.44 (s, 3 H, 42-H), 2.88 (m, 1 H, 15-Ha), 2.94 – 3.07 (m, 
3 H, 8-H, 15-Hb), 3.11 (m, 1 H, 25-Ha), 3.58 (d, 
2J25b,25a = 13.0 Hz, 1 H, 25-Hb), 3.69 – 3.81 (m, 2 
H, 33-H, 34-H), 4.02 (dd, 2J37a,37b = 10.9 Hz, 
3J37a,34 = 4.0 Hz, 1 H, 37-Ha), 4.07 (dd, 
2J37b,37a = 10.6 
Hz, 3J37b,34 = 3.2 Hz, 1 H, 37-Hb), 4.38 (br s, 1 H, 7-H), 4.70 – 4.80 (m, 2 H, 14-H, 27-H), 5.06 (m, 
2 H, 5-H), 5.19 (m, 1 H, NHc), 5.33 (d, 
3J21,22a = 4.9 Hz, 1 H, 21-H), 6.50 (br s, 1 H, NHb), 7.09 – 
7.39 (m, 18 H, 1-H, 2-H, 3-H, 10-H, 11-H, 12-H, 17-H, 18-H, 19-H, 40-H, NHa), 7.78 (d, 
3J39,40 = 
8.2 Hz, 2 H, 39-H). 
13C-NMR (100 MHz, CDCl3): δ = 20.2 (t, C-23), 21.6 (q, C-42), 24.6 (t, C-24 o. C-29 o. C-31), 
25.0 (t, C-22), 25.4 (t, C-24 o. C-29 o. C-31), 25.6 (t, C-24 o. C-29 o. C-31), 26.6 (q, C-36), 27.2 
(q, C-36'), 29.0 (t, C-30), 31.0 (t, C-28), 32.8 (t, C-32), 37.9 (t, C-8, C-15), 44.1 (t, C-25), 51.1 (d, 
C-14), 52.5 (d, C-27), 52.5 (d, C-21), 67.1 (t, C-5), 69.1 (t, C-37), 77.6 (d, C-33 o. C-34), 78.1 (d, 
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C-33 o. C-34), 109.3 (s, C-35), 127.1 (d, C-3 o. C-12 o. C-19), 127.2 (d, C-3 o. C-12 o. C-19), 
127.5 (d, C-3 o. C-12 o. C-19), 128.0 (d, C-39), 128.3 (d, C-1 o. C-2 o. C-11 o. C-17 o. C-18), 
128.5 (d, C-1 o. C-2 o. C-11 o. C-17 o. C-18), 128.7 (d, C-1 o. C-2 o. C-11 o. C-17 o. C-18), 128.9 
(d, C-1 o. C-2 o. C-11 o. C-17 o. C-18), 129.3 (d, C-10), 129.6 (d, C-1 o. C-2 o. C-11 o. C-17 o. 
C-18), 129.8 (d, C-40), 132.7 (s, C-38), 145.0 (s, C-41), 169.0 (s, C-13 o. C-20 o. C-26 o. C-43), 
170.3 (s, C-13 o. C-20 o. C-26 o. C-43), 170.7 (s, C-13 o. C-20 o. C-26 o. C-43), 171.4 (s, C-13 
o. C-20 o. C-26 o. C-43). The signals of C-4, C-6, C-7, C-9, C-16, C-44, C-45, C-46 and C-47 
weren’t observed in the 13C-NMR spectrum. 
Minor diastereomer (selected signals): 
1H-NMR (400 MHz, CDCl3): δ = 1.33 (s, 3 H, 36-H'), 4.86 (br s, 1 H, 14-H), 5.04 (s, 2 H, 5-H), 
5.31 (m, 1 H, 21-H). 
13C-NMR (100 MHz, CDCl3): δ = 128.2 (d, C-1 o. C-2 o. C-11 o. C-17 o. C-18), 128.5 (d, C-1 o. 
C-2 o. C-11 o. C-17 o. C-18), 128.8 (d, C-1 o. C-2 o. C-11 o. C-17 o. C-18), 129.9 (d, C-1 o. C-2 
o. C-11 o. C-17 o. C-18). 
HRMS (CI):    calculated found 
C58H64F5N4O12S [M+H]
+  1135.4156 1135.4153 
Melting point:   58 °C 
Optical rotation:    [𝛼]𝐷
20 = +22.4° (c = 1.0, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.6 mL/min, tR1 = 16.3 min 
(24 %, [M+Na]+ = 1158), tR2 = 16.7 min (76 %, [M+Na]
+ = 1158). 
 
((4S,5S)-5-(5-((3S,6S,9S,15aR)-6,9-Dibenzyl-1,4,7,10-tetraoxotetradecahydro-2H-pyrido-
[1,2-a][1,4,7,10]tetraazacyclododecin-3-yl)pentyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-
methylbenzenesulfonate (60) 
A solution of 330 mg (0.291 mmol) 81 in 70 mL dioxane was added dropwise to a vigorously 
stirred suspension of 332 mg palladium on charcoal (10 w% Pd) in 450 mL dioxane and 11.0 mL 
EtOH at 85 °C within 6 h. During the course of the reaction, H2 was bubbled through the reaction 
mixture. After complete addition, the reaction was stirred for further 1 h at 85 °C. After cooling to 
rt, the mixture was filtrated through a pad of Celite® and washed with chloroform. The filtrate was 
concentrated in vacuo and purified by column chromatography (silica gel, PE:EA 100:0, 80:20, 
50:50, then DCM:MeOH 95:5). 84 mg (82.3 µmol, 80 % pure, dr > 99:1, 28 %) of cyclic tetrapep-
tide 60 were obtained as an off-white solid. A small sample was further purified by reversed phase 
column chromatography (silica gel C-18, MeCN:H2O 50:50, Gradient 90:10) for analytical pur-
poses. 
Rf (60) = 0.38 (silica gel, DCM:MeOH 95:5) 
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1H-NMR (500 MHz, CDCl3): δ = 1.17 – 1.33 (m, 6 H, 19-Ha, 24-H, 25-H, 26-Ha), 1.31 (s, 3 H, 
31-H), 1.37 (s, 3 H, 31-H'), 1.42 (m, 1 H, 26-Hb), 1.47 – 1.59 (m, 4 H, 17-Ha, 23-Ha, 27-H), 1.67 
– 1.81 (m, 3 H, 18-Ha, 19-Hb, 23-Hb), 1.98 (m, 1 H, 17-Hb), 2.09 (m, 1 H, 18-Hb), 2.46 (s, 3 H, 37-
H), 3.01 (ddd, 2J20ax,20eq ≈ 3J20ax,19ax = 13.2 Hz, 3J20ax,19eq = 2.7 Hz, 1 H, 20-Hax), 3.07 (dd, 2J10a,10b 
= 14.0 Hz, 3J10a,9 = 7.1 Hz, 1 H, 10-Ha), 3.21 (dd, 
2J3a,3b = 13.7 Hz, 
3J3a,2 = 6.8 Hz, 1 H, 3-Ha), 3.24 
(dd, 2J10b,10a = 13.9 Hz, 
3J10b,9 = 7.6 Hz, 1 H, 10-Hb), 3.62 (dd, 
2J3b,3a = 13.9 Hz, 
3J3b,2 = 10.7 Hz, 1 
H, 3-Hb), 3.74 – 3.83 (m, 3 H, 2-H, 28-H, 29-H), 3.94 (d, 2J20eq,20ax = 13.9 Hz, 1 H, 20-Heq), 4.07 
(dd, 2J32a,32b = 10.7 Hz, 
3J32a,29 = 4.4 Hz, 1 H, 32-Ha), 4.11 (dd, 
2J32b,32a = 10.6 Hz, 
3J32b,29 = 4.3 Hz, 
1 H, 32-Hb), 4.18 (dt, 
3J22,NH ≈ 3J22,23 = 8.6 Hz, 1 H, 22-H), 5.02 (d, 3J16,17a = 6.3 Hz, 1 H, 16-H), 
5.35 (dt, 3J9,NH = 10.0 Hz, 
3J9,10 = 7.7 Hz, 1 H, 9-H), 6.39 (d, 
3JNH,2 = 6.0 Hz, 1 H, NHb), 6.42 (d, 
3JNH,22 = 10.1 Hz, 1 H, NHa), 7.10 (d, 
3J5,6 = 6.6 Hz, 2 H, 5-H), 7.19 – 7.31 (m, 8 H, 6-H, 7-H, 12-
H, 13-H, 14-H), 7.36 (d, 3J35,34 = 7.9 Hz, 2 H, 35-H), 7.43 (d, 
3JNH,9 = 10.4 Hz, 1 H, NHc), 7.81 (d, 
3J34,35 = 8.5 Hz, 2 H, 34-H). 
13C-NMR (125 MHz, CDCl3): δ = 19.2 (t, C-18), 21.7 (q, C-37), 24.0 (t, C-17), 25.1 (t, C-19 o. 
C-24 o. C-26), 25.2 (t, C-19 o. C-24 o. C-26), 25.6 (t, C-19 o. C-24 o. C-26), 26.7 (q, C-31), 27.3 
(q, C-31'), 29.0 (t, C-23, C-25), 32.8 (t, C-27), 35.2 (t, C-3), 36.6 (t, C-10), 44.0 (t, C-20), 49.9 (d, 
C-9), 50.9 (d, C-16), 53.6 (d, C-22), 62.6 (d, C-2), 69.1 (t, C-32), 77.8 (d, C-28 o. C-29), 78.1 (d, 
C-28 o. C-29), 109.3 (s, C-30), 126.7 (d, C-14), 126.9 (d, C-7), 128.0 (d, C-34), 128.6 (d, C-5, C-
12), 128.9 (d, C-6), 129.1 (d, C-13), 129.9 (d, C-35), 132.6 (s, C-33), 136.9 (s, C-4), 136.9 (s, C-
11), 145.1 (s, C-36), 171.4 (s, C-21), 173.3 (s, C-8), 173.6 (s, C-15), 175.7 (s, C-1). 
HRMS (CI):    calculated found 
C44H57N4O9S [M+H]
+   817.3841 817.3886 
Melting point:   80 °C 
Optical rotation:    [𝛼]𝐷
20 = –51° (c = 0.1, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 50:50, Gradient 90:10, 0.8 mL/min, tR = 10.6 min 
([M+H]+ = 818). 
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(3S,6S,9S,15aR)-6,9-Dibenzyl-3-((S)-6-Hydroxy-6-((S)-oxiran-2-yl)hexyl)octahydro-2H-pyr-
ido[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10(3H,12H)-tetraone (83) 
To a solution of 12.5 mg (15.3 µmol) 60 in 1.0 mL THF was added 1.0 mL aq. HCl (5 w%) at rt 
and the reaction was stirred at rt overnight. The reaction was concentrated in vacuo and the residue 
was redissolved in DCM. Brine was added and the layers were separated. The aqueous phase was 
extracted three times with DCM and the combined organic layers were dried over Na2SO4. The 
crude product was dissolved in 3.0 mL MeOH abs. and cooled to 0 °C before 12.0 µL (12.1 mg, 
79.5 µmol) DBU were added. The reaction was stirred at 0 °C for 4 h. For workup, the reaction 
was filtrated through a pad of Celite® and washed with EA:MeOH 90:10. The filtrate was concen-
trated in vacuo and purified by reversed phase column chromatography (silica gel C-18, 
H2O:MeCN 90:10, Gradient 10:90). 5.7 mg (9.42 µmol, 62 % over two steps) of epoxyalcohol 83 
were obtained as an off-white solid. 
Rf (83) = 0.25 (silica gel, EA:MeOH 95:5) 
 
1H-NMR (500 MHz, CDCl3): δ = 1.19 – 1.26 (m, 3 H, 19-Ha, 24-H), 1.30 – 1.38 (m, 2 H, 25-H), 
1.45 – 1.59 (m, 6 H, 17-Ha, 18-Ha, 23-Ha, 26-H, 27-Ha), 1.72 (m, 1 H, 19-Hb), 1.79 (m, 1 H, 23-
Hb), 1.93 – 1.99 (m, 2 H, 17-Hb, 27-Hb), 2.09 (m, 1 H, 18-Hb), 2.72 (dd, 2J30a,30b = 4.9 Hz, 3J30a,29 
= 2.7 Hz, 1 H, 30-Ha), 2.83 (dd, 
2J30b,30a = 5.0 Hz, 
3J30b,29 = 4.1 Hz, 1 H, 30-Hb), 2.96 (m, 1 H, 29-
H), 3.01 (ddd, 2J20ax,20eq ≈ 3J20ax,19ax = 13.6 Hz, 3J20ax,19eq = 2.6 Hz, 1 H, 20-Hax), 3.08 (dd, 2J10a,10b 
= 14.0 Hz, 3J10a,9 = 7.1 Hz, 1 H, 10-Ha), 3.20 (dd, 
2J3a,3b = 13.6 Hz, 
3J3a,2 = 6.0 Hz, 1 H, 3-Ha), 3.25 
(dd, 2J10b,10a = 14.0 Hz, 
3J10b,9 = 8.0 Hz, 1 H, 10-Hb), 3.44 (m, 1 H, 28-H), 3.65 (dd, 
2J3b,3a = 13.2 
Hz, 3J3b,2 = 10.7 Hz, 1 H, 3-Hb), 3.73 (dt, 
3J2,NH = 11.1 Hz, 
3J2,3 = 6.0 Hz, 1 H, 2-H), 3.95 (d, 
2J20eq,20ax = 13.6 Hz, 1 H, 20-Heq), 4.17 (dt, 
3J22,NH ≈ 3J22,23 = 9.4 Hz, 1 H, 22-H), 5.01 (d, 3J16,17a = 
5.4 Hz, 1 H, 16-H), 5.35 (dt, 3J9,NH = 10.0 Hz, 
3J9,10 = 7.8 Hz, 1 H, 9-H), 6.43 – 6.47 (m, 2 H, NHa, 
NHb), 7.10 (d, 
3J5,6 = 6.6 Hz, 2 H, 5-H), 7.20 – 7.31 (m, 8 H, 6-H, 7-H, 12-H, 13-H, 14-H), 7.46 
(d, 3JNH,9 = 10.4 Hz, 1 H, NHc). 
13C-NMR (125 MHz, CDCl3): δ = 19.2 (t, C-18), 24.0 (t, C-17), 25.0 (t, C-19 o. C-24 o. C-26), 
25.1 (t, C-19 o. C-24 o. C-26), 25.2 (t, C-19 o. C-24 o. C-26), 29.0 (t, C-23, C-25), 34.1 (t, C-27), 
35.2 (t, C-3), 36.5 (t, C-10), 43.9 (t, C-20), 45.1 (t, C-30), 49.9 (d, C-9), 50.9 (d, C-16), 53.6 (d, 
C-22), 55.3 (d, C-29), 62.8 (d, C-2), 71.4 (d, C-28), 126.7 (d, C-7 o. C-14), 126.9 (d, C-7 o. C-14), 
5. Experimental section 
 
 
188 
128.5 (d, C-6 o. C-13), 128.6 (d, C-6 o. C-13), 128.9 (d, C-5), 129.1 (d, C-12), 136.9 (s, C-4 o. C-
11), 137.0 (s, C-4 o. C-11), 171.4 (s, C-21), 173.3 (s, C-8), 173.6 (s, C-15), 175.8 (s, C-1). 
HRMS (CI):    calculated found 
C34H45N4O6 [M+H]
+   605.3334 605.3331 
Melting point:   95 °C 
Optical rotation:    [𝛼]𝐷
20 = –77° (c = 0.1, CHCl3) 
LCMS: Luna, MeCN:H2O + 0.1 % HCOOH 10:90, Gradient 90:10, 0.8 mL/min, tR = 9.76 min 
([M+H]+ = 605). 
 
Trapoxin A[41] 
To a solution of 3.9 mg (6.45 µmol) 83 in 2.0 mL DCM abs. were added 5.8 mg (13.7 µmol) DMP 
at rt. The reaction was stirred for 2 h, filtrated through a pad of Celite® and washed with DCM. 
The filtrate was concentrated in vacuo. Purification by reversed phase column chromatography 
(silica gel C-18, H2O:MeCN 90:10, Gradient 10:90) yielded 1.7 mg (2.82 µmol, 44 %) trapoxin A 
as an off-white solid (after lyophilisation). 
Rf (trapoxin A) = 0.36 (silica gel, EA:MeOH 95:5) 
 
1H-NMR (500 MHz, CDCl3): δ = 1.16 – 1.31 (m, 5 H, 19-Ha, 24-H, 25-H), 1.48 – 1.58 (m, 4 H, 
17-Ha, 23-Ha, 26-H), 1.69 – 1.81 (m, 3 H, 18-Ha, 19-Hb, 23-Hb), 1.97 (m, 1 H, 17-Hb), 2.09 (m, 1 
H, 18-Hb), 2.25 (dt, 
2J27a,27b = 17.5 Hz, 
3J27a,26 = 7.2 Hz, 1 H, 27-Ha), 2.41 (dt, 
2J27b,27a = 17.5 Hz, 
3J27b,26 = 7.3 Hz, 1 H, 27-Hb), 2.86 (dd, 
2J30a,30b = 5.7 Hz, 
3J30a,29 = 2.5 Hz, 1 H, 30-Ha), 3.00 (dd, 
2J30b,30a = 6.0 Hz, 
3J30b,29 = 4.7 Hz, 1 H, 30-Hb), 3.01 (m, 1 H, 20-Hax), 3.08 (dd, 
2J10a,10b = 13.9 Hz, 
3J10a,9 = 7.3 Hz, 1 H, 10-Ha), 3.20 (dd, 
2J3a,3b = 13.4 Hz, 
3J3a,2 = 6.2 Hz, 1 H, 3-Ha), 3.25 (dd, 
2J10b,10a 
= 13.9 Hz, 3J10b,9 = 8.2 Hz, 1 H, 10-Hb), 3.42 (dd, 
3J29,30b = 4.7 Hz, 
3J29,30a = 2.5 Hz, 1 H, 29-H), 
3.64 (dd, 2J3b,3a = 13.4 Hz, 
3J3b,2 = 10.9 Hz, 1 H, 3-Hb), 3.73 (dt, 
3J2,NH = 11.0 Hz, 
3J2,3 = 5.7 Hz, 1 
H, 2-H), 3.95 (d, 2J20eq,20ax = 13.9 Hz, 1 H, 20-Heq), 4.16 (dt, 
3J22,NH ≈ 3J22,23 = 8.4 Hz, 1 H, 22-H), 
5.01 (d, 3J16,17a = 6.0 Hz, 1 H, 16-H), 5.35 (dt, 
3J9,NH = 10.2 Hz, 
3J9,10 = 7.8 Hz, 1 H, 9-H), 6.38 (d, 
3JNH,2 = 5.4 Hz, 1 H, NHb), 6.43 (d, 
3JNH,22 = 10.1 Hz, 1 H, NHa), 7.10 (d, 
3J5,6 = 6.3 Hz, 2 H, 5-
H), 7.21 – 7.31 (m, 8 H, 6-H, 7-H, 12-H, 13-H, 14-H), 7.45 (d, 3JNH,9 = 10.1 Hz, 1 H, NHc). 
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13C-NMR (125 MHz, CDCl3): δ = 19.2 (t, C-18), 22.7 (t, C-26), 24.0 (t, C-17), 25.1 (t, C-19), 25.2 
(t, C-24), 28.6 (t, C-25), 28.9 (t, C-23), 35.2 (t, C-3), 36.2 (t, C-27), 36.5 (t, C-10), 43.9 (t, C-20), 
46.1 (t, C-30), 50.0 (d, C-9), 50.9 (d, C-16), 53.4 (d, C-29), 53.5 (d, C-22), 62.8 (d, C-2), 126.7 (d, 
C-14), 127.0 (d, C-7), 128.5 (d, C-6 o. C-13), 128.6 (d, C-6 o. C-13), 128.9 (d, C-5), 129.1 (d, C-
12), 136.9 (s, C-4, C-11), 171.4 (s, C-21), 173.3 (s, C-8), 173.6 (s, C-15), 175.7 (s, C-1), 207.6 (s, 
C-28). 
HRMS (CI):    calculated found 
C34H43N4O6 [M+H]
+   603.3177 603.3182 
Melting point:   130-132 °C 
Optical rotation:    [𝛼]𝐷
22 = –81.7° (c = 0.425, MeOH) 
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 Macrocyclic histone deacetylase inhibitors (HDACi) are important natural products to 
study the epigenetic function of histone-modifying enzymes. The influence of these inhibitors on 
the development of histone research can be emphasized by the fact that the first human HDAC 
was isolated through affinity chromatography using a modified HDAC inhibitor.[33] These inhibi-
tors are promising lead structures for the development of new anticancer agents, while some 
HDACi already have received approval by the FDA for this purpose. Additionally, synthetic in-
hibitors have been the focus of many recent studies. However, naturally occurring inhibitors often 
show higher biological activity and isoform selectivity due to their more sophisticated structural 
diversity. 
 This dissertation described the first total synthesis of the two natural HDACi trapoxin A 
and Cyl-1 along with derivatives thereof. The first targeted HDACi was trapoxin A, a cyclic 
tetrapeptide first isolated from Helicoma ambiens RF-1023 in 1990.[41] Trapoxin A shows detrans-
formation activity against sis oncogene-transformed NIH3T3 fibroblast cells and inhibits HDAC1 
activity in the nanomolar range. The configuration of its peptide backbone made several peptide 
modification reactions feasible. For instance, the non-proteinogenic (R)-pipecolinic acid was in-
troduced via ester enolate Claisen rearrangement (scheme 6.1). Dipeptide 62c was subjected to 
Pd-catalyzed allylic alkylation to access the second unusual amino acid, (2S,9S)-2-amino-9,10-
epoxy-8-oxodecanoic acid (Aoe). With dipeptide 69c at hand, hydrogenative debenzylation and 
subsequent Mitsunobu cyclization afforded the corresponding pipecolinic acid moiety in 72c. 
 
 
Scheme 6.1: Synthesis of pipecolinic acid-containing dipeptide 72c. 
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 The synthesis of trapoxin A was carried on by coupling to linear tetrapeptide 75 (scheme 
6.2). Replacement of the TIPS-group by a tosylate was necessary in order to selectively cleave the 
tert-butyl ester in 77. Following activation of the carboxylic acid as Pfp ester and subsequent cy-
clization under hydrogenative conditions gave cyclic 60. Installation of the α-epoxyketone moiety 
finally afforded the natural product trapoxin A. 
 
 
Scheme 6.2: Synthesis of trapoxin A. 
 
 The natural HDACi Cyl-1 called for a different synthetic approach. The non-proteinogenic 
Aoe moiety was introduced via chelate enolate Claisen rearrangement of precursor 9 (scheme 6.3). 
Subsequent incorporation into linear tetrapeptide 20 followed by activation and macrolactamiza-
tion made the cyclic precursor 22 accessible. Transformation of the Aoe side chain in accordance 
to the synthesis of trapoxin finally gave the natural product Cyl-1 after 17 steps (longest linear 
synthesis) in 2.5 % total yield. 
 To provide synthetic access to the presented natural products, various linear tetrapeptides 
bearing different protective groups, side chain functionalities and C-terminal amino acids were 
synthesized. The challenging macrocyclization towards the 12-membered ring system generally 
needed evaluation of the optimal ring closing position. Furthermore, synthetic strategies have been 
developed that allowed not only for the synthesis of the natural products but also several deriva-
tives from a common precursor. 
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Scheme 6.3: Synthesis of Cyl-1. 
 
 Access to derivatives of Cyl-1 was gained after unprecedented peptide enolate Claisen re-
arrangement of chiral allyl ester 36c (scheme 6.4). The obtained carboxylic acid was activated as 
Pfp ester, Boc-deprotected and cyclized under biphasic ring closure conditions to Cyl-1 derivative 
40. Intramolecular olefin metathesis afforded allylglycine-containing macrocycle 41, whose low 
solubility prevented further modifications. Macrocycle 41 was modified instead in manifold ways 
giving rise to derivatives of the natural product (scheme 6.5). For instance, thiol-ene click reactions 
with different thiols afforded tetrahydrofuran derivatives 47 and 48 in good yields. 
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Scheme 6.4: Peptide ester enolate Claisen rearrangement towards Cyl-1 derivatives. 
 
 
Scheme 6.5: Modifications of 40 to access several derivatives of natural Cyl-1. 
 
The presented methods could be used in succeeding studies to target the structurally similar 
natural product Cyl-2,[48] which contains a pipecolinic acid moiety instead of proline. Therefore, 
the developed synthetic route towards (R)-configured pipecolinic acid should easily be adaptable 
to synthesize the (S)-enantiomer accordingly. Derivatives of trapoxin A should be accessible by 
altering the allylic substrates utilized in Pd-catalyzed allylic alkylation. 
 The reported cytotoxicity profiles of both the natural products and their precursors/deriva-
tives need to be complemented by HDAC inhibitory activities. Their selectivity profiles towards 
the different HDAC isoforms need to be evaluated and the influence of different side chains on 
both activity and selectivity needs assessment. Especially Cyl-1 needs to undergo intense biolog-
ical testing since no inhibitory data have been reported so far. 
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8.1 Crystallographic data 
Crystal structure of tripeptide 74 
 
 
chemical structure of 74 (major diastereomer) 
 
 
 
X-ray structure of 74 (major diastereomer) 
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1) Crystal data and structure refinement for 74. 
Empirical formula  C49 H77 N3 O9 Si 
Formula weight  880.22 
Temperature  142(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  I2 
Unit cell dimensions a = 12.849(3) Å α= 90°. 
 b = 8.804(3) Å β= 90.86(2)°. 
 c = 44.542(13) Å γ = 90°. 
Volume 5038(2) Å3 
Z 4 
Density (calculated) 1.161 mg/m3 
Absorption coefficient 0.101 mm-1 
F(000) 1912 
Crystal size 0.14 x 0.08 x 0.025 mm3 
Theta range for data collection 0.914 to 25.910°. 
Index ranges -15<=h<=11, -10<=k<=10, -54<=l<=54 
Reflections collected 30742 
Independent reflections 9570 [R(int) = 0.3489] 
Completeness to theta = 25.242° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8620 and 0.7383 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9570 / 472 / 570 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.1370, wR2 = 0.2258 
R indices (all data) R1 = 0.4137, wR2 = 0.3414 
Absolute structure parameter -0.1(6) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.446 and -0.444 e.Å-3 
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2) Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 74. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
_____________________________________________________________________________ 
 x y z U(eq) 
_____________________________________________________________________________ 
Si 2025(4) 5257(7) 5353(2) 43(2) 
O(1) 3529(10) 1713(15) 4303(3) 44(3) 
O(2) 3260(10) 687(16) 4776(3) 51(4) 
O(3) 2287(9) 4278(15) 5048(3) 43(4) 
O(4) 5828(9) 6497(14) 3295(3) 42(4) 
O(5) 4945(8) 8660(14) 3396(3) 30(3) 
O(6) 4984(9) 7513(14) 2644(3) 33(3) 
O(7) 3155(8) 3173(13) 2369(3) 33(4) 
N(1) 4195(10) 5690(17) 2908(3) 32(4) 
N(2) 4863(10) 3498(16) 2512(3) 25(4) 
N(3) 3140(9) 624(16) 2759(3) 25(3) 
C(1) 4018(13) 6690(20) 3157(4) 28(4) 
C(2) 3417(12) 5820(20) 3398(4) 28(4) 
C(3) 3041(15) 6820(20) 3656(4) 40(5) 
C(4) 2429(13) 5900(20) 3889(4) 34(5) 
C(5) 3104(14) 4820(20) 4067(4) 42(5) 
C(6) 2514(14) 3970(20) 4318(4) 37(5) 
C(7) 3202(14) 2920(20) 4496(5) 37(4) 
O(8) 3625(8) 2510(13) 3080(3) 33(3) 
C(8) 2693(15) 2070(20) 4758(4) 36(4) 
C(9) 2834(14) 2860(20) 5058(4) 38(5) 
O(9) 2236(9) 1002(14) 3180(3) 41(4) 
C(11) 3493(15) -1000(20) 4355(5) 43(5) 
C(10) 3837(14) 480(20) 4499(5) 44(4) 
C(14) 1578(15) 7410(20) 4888(5) 52(6) 
C(13) 1338(17) 7020(20) 5209(5) 53(5) 
C(12) 4972(12) 550(20) 4573(4) 42(5) 
C(15) 1540(20) 8410(30) 5412(6) 89(8) 
C(16) 3247(16) 5710(30) 5570(6) 68(6) 
C(17) 4111(16) 6220(30) 5367(6) 77(7) 
C(18) 3649(15) 4490(30) 5773(6) 71(7) 
C(19) 1141(15) 4100(30) 5588(5) 51(5) 
C(20) 279(15) 3310(30) 5406(5) 59(7) 
C(21) 688(17) 5040(30) 5842(5) 69(7) 
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C(22) 5055(14) 7280(20) 3287(4) 31(4) 
C(23) 5853(14) 9490(20) 3526(5) 40(4) 
C(24) 6653(15) 9730(20) 3289(5) 51(6) 
C(25) 6270(14) 8630(20) 3802(4) 48(6) 
C(26) 5379(15) 10960(20) 3623(5) 51(6) 
C(27) 4685(13) 6190(20) 2670(4) 24(4) 
C(28) 4830(12) 5040(20) 2409(4) 24(4) 
C(29) 5820(12) 5420(20) 2227(4) 32(4) 
C(30) 6780(12) 5030(20) 2414(5) 39(5) 
C(31) 6770(13) 3380(20) 2503(4) 36(5) 
C(32) 5772(12) 3020(20) 2687(4) 32(5) 
C(33) 3972(13) 2660(20) 2478(4) 21(4) 
C(34) 3996(11) 964(18) 2554(4) 19(3) 
C(35) 3830(12) 90(20) 2263(4) 24(4) 
C(36) 4657(12) 460(20) 2040(4) 31(4) 
C(37) 5656(13) -150(20) 2083(5) 36(5) 
C(38) 6463(15) 240(30) 1886(5) 51(6) 
C(39) 6256(16) 1240(20) 1659(5) 51(6) 
C(40) 5316(17) 1870(30) 1612(5) 54(6) 
C(41) 4548(16) 1500(20) 1809(5) 45(6) 
C(42) 3066(13) 1450(20) 3007(4) 24(4) 
C(43) 2138(17) 1890(30) 3462(5) 65(6) 
C(44) 1136(15) 1380(20) 3599(5) 41(5) 
C(45) 223(18) 2060(30) 3512(5) 64(7) 
C(46) -684(18) 1630(30) 3660(5) 62(7) 
C(47) -631(17) 620(30) 3892(5) 53(6) 
C(48) 269(17) 10(30) 3986(6) 68(7) 
C(49) 1182(15) 390(30) 3841(5) 50(6) 
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3) Bond lengths [Å] and angles [°] for 74. 
 
Si-O(3)  1.647(14) 
Si-C(19)  1.86(2) 
Si-C(16)  1.87(2) 
Si-C(13)  1.89(2) 
O(1)-C(7)  1.43(2) 
O(1)-C(10)  1.45(2) 
O(2)-C(8)  1.42(2) 
O(2)-C(10)  1.46(2) 
O(3)-C(9)  1.43(2) 
O(4)-C(22)  1.21(2) 
O(5)-C(22)  1.32(2) 
O(5)-C(23)  1.49(2) 
O(6)-C(27)  1.232(19) 
O(7)-C(33)  1.236(18) 
N(1)-C(27)  1.32(2) 
N(1)-C(1)  1.44(2) 
N(1)-H(1)  0.8800 
N(2)-C(33)  1.370(19) 
N(2)-C(28)  1.43(2) 
N(2)-C(32)  1.46(2) 
N(3)-C(42)  1.33(2) 
N(3)-C(34)  1.47(2) 
N(3)-H(3)  0.8800 
C(1)-C(22)  1.53(2) 
C(1)-C(2)  1.54(2) 
C(1)-H(1A)  1.0000 
C(2)-C(3)  1.53(2) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.54(2) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-C(5)  1.50(2) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(6)  1.55(2) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-C(7)  1.50(2) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.54(3) 
C(7)-H(7)  1.0000 
O(8)-C(42)  1.220(18) 
C(8)-C(9)  1.52(2) 
C(8)-H(8)  1.0000 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
O(9)-C(42)  1.38(2) 
O(9)-C(43)  1.49(2) 
C(11)-C(10)  1.52(2) 
C(11)-H(11A)  0.9800 
C(11)-H(11B)  0.9800 
C(11)-H(11C)  0.9800 
C(10)-C(12)  1.49(2) 
C(14)-C(13)  1.51(3) 
C(14)-H(14A)  0.9800 
C(14)-H(14B)  0.9800 
C(14)-H(14C)  0.9800 
C(13)-C(15)  1.54(3) 
C(13)-H(13)  1.0000 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
C(16)-C(18)  1.49(3) 
C(16)-C(17)  1.51(3) 
C(16)-H(16)  1.0000 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(18)-H(18A)  0.9800 
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C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-C(21)  1.53(3) 
C(19)-C(20)  1.53(3) 
C(19)-H(19)  1.0000 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
C(23)-C(26)  1.49(3) 
C(23)-C(24)  1.50(3) 
C(23)-C(25)  1.54(3) 
C(24)-H(24A)  0.9800 
C(24)-H(24B)  0.9800 
C(24)-H(24C)  0.9800 
C(25)-H(25A)  0.9800 
C(25)-H(25B)  0.9800 
C(25)-H(25C)  0.9800 
C(26)-H(26A)  0.9800 
C(26)-H(26B)  0.9800 
C(26)-H(26C)  0.9800 
C(27)-C(28)  1.55(2) 
C(28)-C(29)  1.56(2) 
C(28)-H(28)  1.0000 
C(29)-C(30)  1.52(2) 
C(29)-H(29A)  0.9900 
C(29)-H(29B)  0.9900 
C(30)-C(31)  1.51(2) 
C(30)-H(30A)  0.9900 
C(30)-H(30B)  0.9900 
C(31)-C(32)  1.56(2) 
C(31)-H(31A)  0.9900 
C(31)-H(31B)  0.9900 
C(32)-H(32A)  0.9900 
C(32)-H(32B)  0.9900 
C(33)-C(34)  1.53(2) 
C(34)-C(35)  1.52(2) 
C(34)-H(34)  1.0000 
C(35)-C(36)  1.50(2) 
C(35)-H(35A)  0.9900 
C(35)-H(35B)  0.9900 
C(36)-C(41)  1.38(3) 
C(36)-C(37)  1.40(2) 
C(37)-C(38)  1.41(3) 
C(37)-H(37)  0.9500 
C(38)-C(39)  1.36(3) 
C(38)-H(38)  0.9500 
C(39)-C(40)  1.34(3) 
C(39)-H(39)  0.9500 
C(40)-C(41)  1.37(3) 
C(40)-H(40)  0.9500 
C(41)-H(41)  0.9500 
C(43)-C(44)  1.50(3) 
C(43)-H(43A)  0.9900 
C(43)-H(43B)  0.9900 
C(44)-C(45)  1.37(3) 
C(44)-C(49)  1.38(3) 
C(45)-C(46)  1.40(3) 
C(45)-H(45)  0.9500 
C(46)-C(47)  1.36(3) 
C(46)-H(46)  0.9500 
C(47)-C(48)  1.34(3) 
C(47)-H(47)  0.9500 
C(48)-C(49)  1.39(3) 
C(48)-H(48)  0.9500 
C(49)-H(49)  0.9500 
 
O(3)-Si-C(19) 108.1(9) 
O(3)-Si-C(16) 110.9(9) 
C(19)-Si-C(16) 109.9(11) 
O(3)-Si-C(13) 104.4(9) 
C(19)-Si-C(13) 110.8(10) 
C(16)-Si-C(13) 112.5(11) 
C(7)-O(1)-C(10) 105.9(15) 
C(8)-O(2)-C(10) 109.0(15) 
C(9)-O(3)-Si 122.4(12) 
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C(22)-O(5)-C(23) 120.6(14) 
C(27)-N(1)-C(1) 120.1(16) 
C(27)-N(1)-H(1) 119.9 
C(1)-N(1)-H(1) 119.9 
C(33)-N(2)-C(28) 117.2(13) 
C(33)-N(2)-C(32) 124.5(14) 
C(28)-N(2)-C(32) 117.6(13) 
C(42)-N(3)-C(34) 118.1(14) 
C(42)-N(3)-H(3) 121.0 
C(34)-N(3)-H(3) 121.0 
N(1)-C(1)-C(22) 110.5(15) 
N(1)-C(1)-C(2) 108.7(15) 
C(22)-C(1)-C(2) 110.6(15) 
N(1)-C(1)-H(1A) 109.0 
C(22)-C(1)-H(1A) 109.0 
C(2)-C(1)-H(1A) 109.0 
C(3)-C(2)-C(1) 113.8(16) 
C(3)-C(2)-H(2A) 108.8 
C(1)-C(2)-H(2A) 108.8 
C(3)-C(2)-H(2B) 108.8 
C(1)-C(2)-H(2B) 108.8 
H(2A)-C(2)-H(2B) 107.7 
C(2)-C(3)-C(4) 111.9(16) 
C(2)-C(3)-H(3A) 109.2 
C(4)-C(3)-H(3A) 109.2 
C(2)-C(3)-H(3B) 109.2 
C(4)-C(3)-H(3B) 109.2 
H(3A)-C(3)-H(3B) 107.9 
C(5)-C(4)-C(3) 113.0(15) 
C(5)-C(4)-H(4A) 109.0 
C(3)-C(4)-H(4A) 109.0 
C(5)-C(4)-H(4B) 109.0 
C(3)-C(4)-H(4B) 109.0 
H(4A)-C(4)-H(4B) 107.8 
C(4)-C(5)-C(6) 113.5(15) 
C(4)-C(5)-H(5A) 108.9 
C(6)-C(5)-H(5A) 108.9 
C(4)-C(5)-H(5B) 108.9 
C(6)-C(5)-H(5B) 108.9 
H(5A)-C(5)-H(5B) 107.7 
C(7)-C(6)-C(5) 112.8(15) 
C(7)-C(6)-H(6A) 109.0 
C(5)-C(6)-H(6A) 109.0 
C(7)-C(6)-H(6B) 109.0 
C(5)-C(6)-H(6B) 109.0 
H(6A)-C(6)-H(6B) 107.8 
O(1)-C(7)-C(6) 108.5(16) 
O(1)-C(7)-C(8) 103.0(16) 
C(6)-C(7)-C(8) 116.6(16) 
O(1)-C(7)-H(7) 109.5 
C(6)-C(7)-H(7) 109.5 
C(8)-C(7)-H(7) 109.5 
O(2)-C(8)-C(9) 107.0(15) 
O(2)-C(8)-C(7) 103.7(16) 
C(9)-C(8)-C(7) 113.3(17) 
O(2)-C(8)-H(8) 110.9 
C(9)-C(8)-H(8) 110.9 
C(7)-C(8)-H(8) 110.9 
O(3)-C(9)-C(8) 108.8(15) 
O(3)-C(9)-H(9A) 109.9 
C(8)-C(9)-H(9A) 109.9 
O(3)-C(9)-H(9B) 109.9 
C(8)-C(9)-H(9B) 109.9 
H(9A)-C(9)-H(9B) 108.3 
C(42)-O(9)-C(43) 113.4(14) 
C(10)-C(11)-H(11A) 109.5 
C(10)-C(11)-H(11B) 109.5 
H(11A)-C(11)-H(11B) 109.5 
C(10)-C(11)-H(11C) 109.5 
H(11A)-C(11)-H(11C) 109.5 
H(11B)-C(11)-H(11C) 109.5 
O(1)-C(10)-O(2) 106.2(15) 
O(1)-C(10)-C(12) 110.9(16) 
O(2)-C(10)-C(12) 108.4(16) 
O(1)-C(10)-C(11) 108.3(16) 
O(2)-C(10)-C(11) 108.6(16) 
C(12)-C(10)-C(11) 114.1(17) 
C(13)-C(14)-H(14A) 109.5 
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C(13)-C(14)-H(14B) 109.5 
H(14A)-C(14)-H(14B) 109.5 
C(13)-C(14)-H(14C) 109.5 
H(14A)-C(14)-H(14C) 109.5 
H(14B)-C(14)-H(14C) 109.5 
C(14)-C(13)-C(15) 110(2) 
C(14)-C(13)-Si 114.1(16) 
C(15)-C(13)-Si 112.1(15) 
C(14)-C(13)-H(13) 106.8 
C(15)-C(13)-H(13) 106.8 
Si-C(13)-H(13) 106.8 
C(10)-C(12)-H(12A) 109.5 
C(10)-C(12)-H(12B) 109.5 
H(12A)-C(12)-H(12B) 109.5 
C(10)-C(12)-H(12C) 109.5 
H(12A)-C(12)-H(12C) 109.5 
H(12B)-C(12)-H(12C) 109.5 
C(13)-C(15)-H(15A) 109.5 
C(13)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 
C(13)-C(15)-H(15C) 109.5 
H(15A)-C(15)-H(15C) 109.5 
H(15B)-C(15)-H(15C) 109.5 
C(18)-C(16)-C(17) 108.9(19) 
C(18)-C(16)-Si 116.0(17) 
C(17)-C(16)-Si 111.9(18) 
C(18)-C(16)-H(16) 106.5 
C(17)-C(16)-H(16) 106.5 
Si-C(16)-H(16) 106.5 
C(16)-C(17)-H(17A) 109.5 
C(16)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 
C(16)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 
C(16)-C(18)-H(18A) 109.5 
C(16)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(16)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
C(21)-C(19)-C(20) 111.0(18) 
C(21)-C(19)-Si 111.0(16) 
C(20)-C(19)-Si 113.0(16) 
C(21)-C(19)-H(19) 107.1 
C(20)-C(19)-H(19) 107.1 
Si-C(19)-H(19) 107.1 
C(19)-C(20)-H(20A) 109.5 
C(19)-C(20)-H(20B) 109.5 
H(20A)-C(20)-H(20B) 109.5 
C(19)-C(20)-H(20C) 109.5 
H(20A)-C(20)-H(20C) 109.5 
H(20B)-C(20)-H(20C) 109.5 
C(19)-C(21)-H(21A) 109.5 
C(19)-C(21)-H(21B) 109.5 
H(21A)-C(21)-H(21B) 109.5 
C(19)-C(21)-H(21C) 109.5 
H(21A)-C(21)-H(21C) 109.5 
H(21B)-C(21)-H(21C) 109.5 
O(4)-C(22)-O(5) 127.3(17) 
O(4)-C(22)-C(1) 121.9(18) 
O(5)-C(22)-C(1) 110.7(15) 
O(5)-C(23)-C(26) 102.5(14) 
O(5)-C(23)-C(24) 109.6(17) 
C(26)-C(23)-C(24) 111.9(19) 
O(5)-C(23)-C(25) 109.4(16) 
C(26)-C(23)-C(25) 109.4(17) 
C(24)-C(23)-C(25) 113.5(17) 
C(23)-C(24)-H(24A) 109.5 
C(23)-C(24)-H(24B) 109.5 
H(24A)-C(24)-H(24B) 109.5 
C(23)-C(24)-H(24C) 109.5 
H(24A)-C(24)-H(24C) 109.5 
H(24B)-C(24)-H(24C) 109.5 
C(23)-C(25)-H(25A) 109.5 
C(23)-C(25)-H(25B) 109.5 
H(25A)-C(25)-H(25B) 109.5 
C(23)-C(25)-H(25C) 109.5 
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H(25A)-C(25)-H(25C) 109.5 
H(25B)-C(25)-H(25C) 109.5 
C(23)-C(26)-H(26A) 109.5 
C(23)-C(26)-H(26B) 109.5 
H(26A)-C(26)-H(26B) 109.5 
C(23)-C(26)-H(26C) 109.5 
H(26A)-C(26)-H(26C) 109.5 
H(26B)-C(26)-H(26C) 109.5 
O(6)-C(27)-N(1) 123.0(19) 
O(6)-C(27)-C(28) 120.3(18) 
N(1)-C(27)-C(28) 116.6(17) 
N(2)-C(28)-C(27) 112.6(16) 
N(2)-C(28)-C(29) 110.5(15) 
C(27)-C(28)-C(29) 111.0(14) 
N(2)-C(28)-H(28) 107.5 
C(27)-C(28)-H(28) 107.5 
C(29)-C(28)-H(28) 107.5 
C(30)-C(29)-C(28) 109.1(16) 
C(30)-C(29)-H(29A) 109.9 
C(28)-C(29)-H(29A) 109.9 
C(30)-C(29)-H(29B) 109.9 
C(28)-C(29)-H(29B) 109.9 
H(29A)-C(29)-H(29B) 108.3 
C(31)-C(30)-C(29) 110.5(15) 
C(31)-C(30)-H(30A) 109.5 
C(29)-C(30)-H(30A) 109.5 
C(31)-C(30)-H(30B) 109.5 
C(29)-C(30)-H(30B) 109.5 
H(30A)-C(30)-H(30B) 108.1 
C(30)-C(31)-C(32) 109.8(15) 
C(30)-C(31)-H(31A) 109.7 
C(32)-C(31)-H(31A) 109.7 
C(30)-C(31)-H(31B) 109.7 
C(32)-C(31)-H(31B) 109.7 
H(31A)-C(31)-H(31B) 108.2 
N(2)-C(32)-C(31) 108.7(15) 
N(2)-C(32)-H(32A) 109.9 
C(31)-C(32)-H(32A) 109.9 
N(2)-C(32)-H(32B) 109.9 
C(31)-C(32)-H(32B) 109.9 
H(32A)-C(32)-H(32B) 108.3 
O(7)-C(33)-N(2) 123.2(16) 
O(7)-C(33)-C(34) 117.4(14) 
N(2)-C(33)-C(34) 119.2(14) 
N(3)-C(34)-C(35) 109.3(13) 
N(3)-C(34)-C(33) 108.8(14) 
C(35)-C(34)-C(33) 107.7(15) 
N(3)-C(34)-H(34) 110.3 
C(35)-C(34)-H(34) 110.3 
C(33)-C(34)-H(34) 110.3 
C(36)-C(35)-C(34) 111.2(14) 
C(36)-C(35)-H(35A) 109.4 
C(34)-C(35)-H(35A) 109.4 
C(36)-C(35)-H(35B) 109.4 
C(34)-C(35)-H(35B) 109.4 
H(35A)-C(35)-H(35B) 108.0 
C(41)-C(36)-C(37) 116.0(18) 
C(41)-C(36)-C(35) 125.0(17) 
C(37)-C(36)-C(35) 118.7(17) 
C(36)-C(37)-C(38) 120(2) 
C(36)-C(37)-H(37) 119.9 
C(38)-C(37)-H(37) 119.9 
C(39)-C(38)-C(37) 119(2) 
C(39)-C(38)-H(38) 120.7 
C(37)-C(38)-H(38) 120.7 
C(40)-C(39)-C(38) 123(2) 
C(40)-C(39)-H(39) 118.4 
C(38)-C(39)-H(39) 118.4 
C(39)-C(40)-C(41) 117(2) 
C(39)-C(40)-H(40) 121.4 
C(41)-C(40)-H(40) 121.4 
C(40)-C(41)-C(36) 125(2) 
C(40)-C(41)-H(41) 117.7 
C(36)-C(41)-H(41) 117.7 
O(8)-C(42)-N(3) 126.2(18) 
O(8)-C(42)-O(9) 121.7(18) 
N(3)-C(42)-O(9) 112.1(15) 
O(9)-C(43)-C(44) 105.5(15) 
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O(9)-C(43)-H(43A) 110.6 
C(44)-C(43)-H(43A) 110.6 
O(9)-C(43)-H(43B) 110.6 
C(44)-C(43)-H(43B) 110.6 
H(43A)-C(43)-H(43B) 108.8 
C(45)-C(44)-C(49) 122(2) 
C(45)-C(44)-C(43) 119(2) 
C(49)-C(44)-C(43) 119(2) 
C(44)-C(45)-C(46) 118(2) 
C(44)-C(45)-H(45) 121.2 
C(46)-C(45)-H(45) 121.2 
C(47)-C(46)-C(45) 120(2) 
C(47)-C(46)-H(46) 120.0 
C(45)-C(46)-H(46) 120.0 
C(48)-C(47)-C(46) 122(2) 
C(48)-C(47)-H(47) 118.9 
C(46)-C(47)-H(47) 118.9 
C(47)-C(48)-C(49) 119(2) 
C(47)-C(48)-H(48) 120.4 
C(49)-C(48)-H(48) 120.4 
C(44)-C(49)-C(48) 119(2) 
C(44)-C(49)-H(49) 120.4 
C(48)-C(49)-H(49) 120.4 
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4) Anisotropic displacement parameters (Å2x 103) 74. The anisotropic displacement factor expo-
nent takes the form: -2π2[ h2 a*2U11 + …  + 2 h k a* b* U12] 
_____________________________________________________________________________ 
 U
11
 U
22
  U
33
 U
23
 U
13
 U
12
 
_____________________________________________________________________________ 
Si 33(3)  55(4) 43(4)  -12(3) 9(3)  3(3) 
O(1) 49(8)  42(7) 40(7)  -7(6) 13(6)  5(6) 
O(2) 53(7)  54(8) 47(8)  0(6) 13(6)  11(6) 
O(3) 45(8)  44(7) 40(8)  0(6) 12(6)  6(6) 
O(4) 27(6)  43(8) 55(10)  -5(7) 2(6)  6(5) 
O(5) 20(6)  36(6) 33(8)  0(6) 5(5)  2(5) 
O(6) 43(8)  27(6) 29(8)  2(6) 5(6)  -6(6) 
O(7) 21(6)  35(8) 43(9)  3(6) -1(6)  2(5) 
N(1) 31(8)  38(9) 28(7)  0(6) 9(5)  -8(7) 
N(2) 18(5)  27(6) 29(9)  6(6) 4(5)  -7(5) 
N(3) 20(6)  29(8) 28(7)  -5(6) 2(5)  -20(6) 
C(1) 22(7)  35(9) 27(7)  1(6) 0(5)  0(6) 
C(2) 18(8)  40(11) 26(8)  3(7) 0(6)  3(7) 
C(3) 36(10)  51(11) 32(9)  -2(7) 8(7)  -1(8) 
C(4) 29(9)  45(11) 30(9)  -4(8) 9(7)  -1(8) 
C(5) 40(10)  53(12) 32(10)  0(8) 11(8)  7(8) 
C(6) 38(10)  47(10) 26(9)  -15(7) 4(7)  0(7) 
C(7) 34(9)  44(8) 31(8)  -7(6) 7(6)  1(7) 
O(8) 28(7)  31(7) 41(9)  -10(6) 6(6)  -18(5) 
C(8) 32(9)  46(8) 31(8)  -5(6) 4(6)  -3(6) 
C(9) 44(11)  45(9) 26(9)  0(7) 7(8)  7(8) 
O(9) 41(7)  45(9) 38(7)  -15(6) 17(6)  -27(6) 
C(11) 41(11)  49(9) 39(13)  -1(8) 15(9)  -2(8) 
C(10) 38(8)  46(8) 50(9)  -1(7) 13(7)  -2(7) 
C(14) 44(13)  46(14) 65(12)  4(9) 2(9)  4(11) 
C(13) 43(11)  56(9) 61(11)  5(8) 7(9)  14(8) 
C(12) 40(7)  39(13) 46(13)  4(10) 10(7)  2(7) 
C(15) 100(20)  78(13) 86(17)  -11(11) 0(14)  15(12) 
C(16) 46(9)  72(14) 85(13)  -19(10) -6(8)  8(8) 
C(17) 46(11)  80(17) 106(17)  -18(13) -6(10)  -15(11) 
C(18) 37(12)  78(15) 96(16)  -14(12) -19(11)  -2(10) 
C(19) 42(9)  67(12) 45(10)  4(8) 10(7)  5(8) 
C(20) 48(11)  88(15) 41(13)  11(11) 13(9)  -13(11) 
C(21) 69(13)  91(17) 47(12)  -3(11) 10(9)  13(12) 
8. Appendix 
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C(22) 26(7)  41(8) 28(11)  -1(7) 6(7)  1(6) 
C(23) 33(9)  51(9) 35(10)  -8(7) 0(7)  -8(7) 
C(24) 38(9)  70(15) 46(11)  -10(9) 3(8)  -18(9) 
C(25) 28(10)  74(13) 43(11)  -1(9) 1(8)  -1(9) 
C(26) 53(12)  50(10) 48(14)  -8(9) 4(10)  -11(8) 
C(27) 14(8)  31(7) 27(8)  3(6) 0(6)  -1(6) 
C(28) 19(7)  29(7) 24(8)  3(5) 6(6)  -7(5) 
C(29) 30(7)  30(10) 36(9)  -9(8) 13(6)  -15(7) 
C(30) 19(7)  51(10) 47(12)  -7(9) 18(7)  -6(7) 
C(31) 19(7)  50(10) 38(12)  -11(8) -1(7)  -8(7) 
C(32) 25(7)  34(10) 36(10)  -2(8) -2(6)  -6(6) 
C(33) 17(6)  28(7) 17(10)  3(6) 7(6)  -3(5) 
C(34) 7(7)  28(7) 23(7)  5(5) -5(5)  -2(5) 
C(35) 15(7)  32(9) 26(7)  -1(6) -3(5)  0(7) 
C(36) 22(7)  44(11) 27(8)  -7(7) 0(6)  -15(7) 
C(37) 28(7)  47(12) 35(11)  -3(9) 2(6)  -7(7) 
C(38) 32(8)  72(14) 49(12)  3(10) 11(7)  -11(8) 
C(39) 49(10)  61(14) 44(13)  -3(9) 7(8)  -17(9) 
C(40) 53(9)  71(14) 38(11)  8(10) 7(8)  -12(9) 
C(41) 45(9)  52(12) 38(10)  4(9) 4(7)  -7(8) 
C(42) 26(8)  23(9) 22(7)  1(6) -1(6)  -12(6) 
C(43) 60(10)  82(14) 52(10)  -31(9) 24(8)  -27(9) 
C(44) 43(8)  45(12) 36(10)  -22(8) 13(7)  -15(7) 
C(45) 55(9)  80(15) 57(13)  8(12) 16(8)  -1(9) 
C(46) 50(10)  81(16) 57(14)  -3(12) 12(9)  -3(9) 
C(47) 52(9)  65(15) 42(13)  -20(10) 18(8)  -9(9) 
C(48) 56(9)  86(16) 61(13)  14(12) 19(9)  -4(10) 
C(49) 44(9)  62(13) 44(11)  -10(10) 13(8)  -2(9) 
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8.2 NMR-spectra of natural products 
NMR-spectra of trapoxin A and data comparison[41] 
 
 
 
1H-NMR spectrum (200 MHz, CDCl3) of isolated trapoxin A 
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1H-NMR spectrum (500 MHz, CDCl3) of synthesized trapoxin A 
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Data comparison of 1H-NMR for trapoxin A: 
 isolated synthesized 
No. δ [ppm] J [Hz] δ [ppm] J [Hz] 
1 7.46 d, 10 7.45 d, 10 
2 7.27 s 7.21 – 7.37 m 
3 7.11 m 7.10 d, 6.3 
4 6.46 m 6.43 + 6.38 d, 10.1 + d, 5.4 
5 5.36 q, 9 5.35 q, 8.6 
6 5.02 d, 5 5.01 d, 4.8 
7 4.17 q, 9 4.16 q, 7.9 
8 3.96 d, 9 3.95 d, 12 
9 3.43 dd, 2.4, 4.6 3.42 dd, 2.5, 4.7 
10 2.98 dd, 4.6, 5.8 2.99 dd, 4.7, 6.0 
11 2.86 dd, 2.4, 5.8 2.86 dd, 2.5, 5.7 
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13C-NMR spectrum (50 MHz, CDCl3) of isolated trapoxin A 
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13C-NMR spectrum (125 MHz, CDCl3) of synthesized trapoxin A 
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Data comparison of 13C-NMR for trapoxin A: 
No. δ (isolated) [ppm] δ (synthesized) [ppm] 
1 208.24 207.57 
2 176.35 175.70 
3 174.22 173.60 
4 173.95 173.32 
5 172.05 171.43 
6 137.44 136.92 
7 129.56 129.07 
8 129.35 128.86 
9 129.04 128.56 + 128.54 
10 127.43 126.96 
11 127.18 126.70 
12 63.07 62.78 
13 53.82 53.48 
14 53.69 53.40 
15 51.20 50.93 
16 50.23 49.96 
17 46.38 46.11 
18 44.20 43.95 
19 36.80 36.54 
20 36.49 36.22 
21 35.45 35.19 
22 29.18 28.89 
23 28.82 28.57 
24 25.40 25.16 
25 25.39 25.06 
26 24.17 23.96 
27 22.94 22.72 
28 19.43 19.20 
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HH-COSY spectrum of synthesized trapoxin A 
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HSQCed spectrum of synthesized trapoxin A 
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HMBC spectra of synthesized trapoxin A 
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NMR-spectra of Cyl-1 and data comparison[47] 
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1H-NMR spectrum (500 MHz, CDCl3) of synthesized Cyl-1 
 
 
 
Data comparison of 1H-NMR for Cyl-1: 
 isolated synthesized 
No. δ [ppm] J [Hz] δ [ppm] J [Hz] 
1 3.41 2.5, 4.5 3.41 2.5, 4.5 
2 2.99 4.5, 6.0 2.99 4.5, 5.8 
3 2.86 2.5, 6.0 2.86 2.5, 5.8 
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13C-NMR spectrum (125 MHz, CDCl3) of synthesized Cyl-1 
 
 
 
Data comparison of 13C-NMR for Cyl-1: 
No. δ (isolated) [ppm] δ (synthesized) [ppm] 
1 207.4 207.5 
2 53.5 53.4 
3 46.2 46.1 
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HH-COSY spectrum of synthesized Cyl-1 
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HSQCed spectrum of synthesized Cyl-1 
 
 
 
 
 
 
 
 
 
 
